<SEC-DOCUMENT>0001193125-14-072014.txt : 20140227
<SEC-HEADER>0001193125-14-072014.hdr.sgml : 20140227
<ACCEPTANCE-DATETIME>20140227123708
ACCESSION NUMBER:		0001193125-14-072014
CONFORMED SUBMISSION TYPE:	SUPPL
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20140227
DATE AS OF CHANGE:		20140227
EFFECTIVENESS DATE:		20140227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SUPPL
		SEC ACT:		
		SEC FILE NUMBER:	333-182260
		FILM NUMBER:		14647628

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>SUPPL
<SEQUENCE>1
<FILENAME>d685450dsuppl.htm
<DESCRIPTION>SUPPLEMENT
<TEXT>
<HTML><HEAD>
<TITLE>SUPPLEMENT</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed pursuant to General Instruction II.L of Form F-10 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>File No.333-182260 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS
SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(To Base Shelf Prospectus dated July&nbsp;3, 2012) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g685450g61u08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>US$13,300,000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Common Shares </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into a purchase
agreement dated February&nbsp;27, 2014 (the &#147;<B>Purchase Agreement</B>&#148;) with Lincoln Park Capital Fund, LLC (&#147;<B>Lincoln Park</B>&#148;), relating to our common shares. In accordance with the terms of the Purchase Agreement, we may
offer and sell our common shares to Lincoln Park up to an aggregate offering amount of US$26,000,000, subject to an aggregate maximum of US$13,300,000 under this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The common shares offered to Lincoln Park include, subject to an aggregate maximum amount of US$13,300,000 under this prospectus supplement: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">600,962 of our common shares that Lincoln Park is purchasing for gross proceeds of US$1,000,000.77 as an initial purchase, at a purchase price of US$1.664 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">up to US$24,999,999.23 of our common shares that may be sold from time to time after the initial purchase, at our sole discretion, to Lincoln Park over the next 30 months in accordance with the Purchase Agreement;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">292,793 common shares to be issued to Lincoln Park as initial commitment shares (the &#147;<B>Initial Commitment Shares</B>&#148;), in consideration for entering into the Purchase Agreement, valued at US$1.5539989 per
common share for a total of US$455,000 aggregate value issued under this prospectus supplement; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">up to 292,793 additional common shares, valued at US$1.5539989 per common share, that we may issue to Lincoln Park on a pro rata basis as additional commitment shares (the &#147;<B>Additional Commitment
Shares</B>&#148;), upon each purchase by Lincoln Park under the Purchase Agreement (including the initial purchase of US$1,000,000.77) for a total of up to US$26,000,000 aggregate value of common shares purchased. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus also cover the resale of these common shares by Lincoln Park to the public. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common shares are listed on the Nasdaq Capital Market (&#147;<B>NASDAQ</B>&#148;) under the symbol &#147;ONCY&#148; and on the Toronto Stock Exchange
(&#147;<B>TSX</B>&#148;) under the symbol &#147;ONC&#148;. On February&nbsp;26, 2014, the last reported sale price of our common shares was US$1.73 per common share on NASDAQ and C$1.93 per common share on the TSX. None of our common shares issued
pursuant to the Purchase Agreement will be offered for sale or sold by us or Lincoln Park on the TSX or to purchasers in Canada. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lincoln Park will not
engage in any transactions that stabilize the price of our common shares. No underwriter or dealer involved in the distribution, no affiliate of such an underwriter or dealer and no person or company acting jointly or in concert with such an
underwriter or dealer has over-allotted, or will over-allot, securities in connection with the distribution or effect any other transactions that are intended to stabilize or maintain the market price of the securities. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investing in our common shares is speculative and bears certain risks. See &#147;<A HREF="#stoc685450_8">Risk Factors</A>&#148; beginning on page S-11 of
this prospectus supplement and on page 7 of the accompanying prospectus and the risk factors discussed or referred to in our Annual Information Form and Annual MD&amp;A which are incorporated by reference into this prospectus supplement and the
accompanying prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This offering is made by a Canadian issuer that is permitted under a multi-jurisdictional disclosure system adopted by
the United States and Canada to prepare this prospectus supplement and the accompanying prospectus in accordance with Canadian disclosure requirements. Prospective investors should be aware that such requirements are different from those applicable
to issuers in the United States. Financial statements incorporated herein by reference have been prepared in accordance with International Financial Reporting Standards (&#147;IFRS&#148;) as issued by the International Accounting Standards Board
(&#147;IASB&#148;), and may not be comparable to financial statements of United States companies. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prospective investors should be aware that the
acquisition, holding or disposition of the common shares may have tax consequences both in the United States and in Canada. Such consequences for investors who are resident in, or citizens of, the United States may not be described fully herein.
Prospective investors should read the tax discussion contained in this prospectus supplement under the heading &#147;Certain US Federal Income Tax Considerations&#148; and should consult their own tax advisor with respect to their own particular
circumstances. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The enforcement by investors of civil liabilities under the US federal securities laws may be affected adversely by the fact that
we are governed by the laws of Canada, that some or all of our officers and directors are residents of Canada, and that a substantial portion of our assets and the assets of said persons are located outside the United States. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NEITHER THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION (THE &#147;SEC&#148;) NOR ANY STATE SECURITIES REGULATOR HAS APPROVED OR DISAPPROVED OF THE
SECURITIES OFFERED HEREBY OR DETERMINED IF THIS PROSPECTUS SUPPLEMENT OR THE ACCOMPANYING PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENCE. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The date of this prospectus supplement is February&nbsp;27, 2014 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Prospectus Supplement </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#stoc685450_1">IMPORTANT NOTICE ABOUT INFORMATION IN THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#stoc685450_2">FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#stoc685450_3">PRESENTATION OF FINANCIAL INFORMATION</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#stoc685450_4">CURRENCY AND EXCHANGE RATE INFORMATION</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#stoc685450_5">PROSPECTUS SUPPLEMENT SUMMARY</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#stoc685450_6">THE OFFERING</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#stoc685450_7">RECENT DEVELOPMENTS</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#stoc685450_8">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#stoc685450_9">DOCUMENTS INCORPORATED BY REFERENCE</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#stoc685450_10">DOCUMENTS FILED AS PART OF THE REGISTRATION STATEMENT</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#stoc685450_11">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#stoc685450_12">CONSOLIDATED CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#stoc685450_13">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#stoc685450_14">TRADING PRICE AND VOLUME</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#stoc685450_15">PRIOR SALES</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#stoc685450_16">CERTAIN U.S. FEDERAL INCOME TAX CONSIDERATIONS</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#stoc685450_17">LEGAL MATTERS AND INTEREST OF EXPERTS</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#stoc685450_18">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Base Prospectus </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="97%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_1">ABOUT THIS PROSPECTUS AND OTHER MATTERS</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_2">SPECIAL NOTICE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_3">DOCUMENTS INCORPORATED BY REFERENCE</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_4">ENFORCEABILITY OF CIVIL LIABILITIES</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_5">THE CORPORATION</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_6">OUR BUSINESS</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_7">CONSOLIDATED CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_8">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_9">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_10">DESCRIPTION OF SHARE CAPITAL</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_11">PRIOR SALES</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_12">TRADING PRICE AND VOLUME</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_13">DESCRIPTION OF SUBSCRIPTION RECEIPTS</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_14">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_15">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_16">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_17">CERTAIN INCOME TAX CONSIDERATIONS</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_18">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_19">AUDITOR</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_20">REGISTRAR AND TRANSFER AGENT</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_21">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_22">DOCUMENTS FILED AS PART OF THE REGISTRATION STATEMENT</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stoc685450_1"></A>IMPORTANT NOTICE ABOUT INFORMATION IN THIS PROSPECTUS SUPPLEMENT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offering and also adds to and
updates information contained in the accompanying prospectus and the documents incorporated by reference herein and therein. The second part is the accompanying prospectus, which provides more general information. If the description of the common
shares varies between this prospectus supplement and the accompanying prospectus, investors should rely on the information in this prospectus supplement. Before you invest, you should carefully read this prospectus supplement, the accompanying
prospectus, all information incorporated by reference herein and therein, as well as the additional information described under &#147;Where You Can Find Additional Information&#148; on page S-24 of this prospectus supplement. These documents contain
information you should consider when making your investment decision. This prospectus supplement may add, update or change information contained in the accompanying prospectus. To the extent that any statement that we make in this prospectus
supplement is inconsistent with statements made in the accompanying prospectus or any documents incorporated by reference therein filed prior to the date of this prospectus supplement, the statements made in this prospectus supplement will be deemed
to modify or supersede those made in the accompanying prospectus and such documents incorporated by reference therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should rely only on the
information contained or incorporated by reference in this prospectus supplement and the accompanying prospectus. We have not, and Lincoln Park has not, authorized any other person to provide you with different information. If anyone provides you
with different or inconsistent information, you should not rely on it. We are offering to sell, and seeking offers to buy, our common shares only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement
and the offering of the common shares in certain jurisdictions may be restricted by law. You should assume that the information contained in this prospectus supplement and the accompanying prospectus, as well as information we have previously filed
with the United States Securities and Exchange Commission (the &#147;<B>SEC</B>&#148;) and with the securities regulatory authority in each of the provinces and territories of Canada, except Qu&eacute;bec, that is incorporated by reference herein
and in the accompanying prospectus, is accurate only as of its respective date. Our business, financial condition, results of operations and prospects may have changed since those dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities
offered by this prospectus supplement by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain statistical information and other data relating to the pharmaceutical and biotechnology industry included in this prospectus supplement and the
prospectus are derived from recognized industry reports published by industry analysts, industry associations and/or independent consulting and data compilation organizations. Market data and industry forecasts used throughout this prospectus
supplement and the prospectus were obtained from various publicly available sources. Although the Corporation believes that these independent sources are generally reliable, the accuracy and completeness of the information from such sources is not
guaranteed and has not been independently verified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is deemed to be incorporated by reference into the prospectus solely for
the purposes of this offering. Other documents are also incorporated or deemed to be incorporated by reference into this prospectus supplement and into the prospectus. See &#147;Documents Incorporated by Reference.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this prospectus supplement, &#147;Oncolytics,&#148; the &#147;Corporation,&#148; &#147;we,&#148; &#147;us,&#148; and &#147;our&#148; refer to Oncolytics
Biotech Inc. and its subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stoc685450_2"></A>FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus contain certain information that may constitute &#147;forward-looking information&#148; and
&#147;forward-looking statements&#148; (&#147;<B>forward-looking information</B>&#148;) within the meaning of applicable Canadian securities laws and the United States Private Securities Litigation Reform Act of 1995, respectively. Forward-looking
information typically contains statements with words such as &#147;anticipate&#148;, &#147;believe&#148;, &#147;expect&#148;, &#147;plan&#148;, &#147;estimate&#148;, &#147;intend&#148;, &#147;may&#148; or similar words suggesting future outcomes.
Forward-looking information in this prospectus supplement includes, but is not limited to, statements with respect to: clinical trial study timing, product development timing, our ability to attract and retain business partners, future levels of
government funding, competition from other biotechnology companies, our ability to obtain the capital required for research, product development, operations and marketing and the intended uses for the proceeds of this offering. This forward-looking
information is subject to various risks and uncertainties, including those discussed below, that could cause actual results and experience to differ materially from the anticipated results or other expectations expressed. Our statements of
&#147;belief&#148;, &#147;estimates&#148;, &#147;expectations&#148; and other similar statements are based primarily upon our results derived to date from our research and development program with animals and early stage human results and upon which
we believe we have a reasonable scientific basis to expect the particular results to occur. It is not possible to predict, based upon studies in animals or early stage human results, whether a new therapeutic will be proved to be safe and effective
in humans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that the particular results expected by us will occur. Forward-looking information is provided for the purpose of
assisting you in understanding our current views of future outcomes, and may not be appropriate for other purposes. Readers are cautioned not to place undue reliance on this forward-looking information, which is provided as of the date of this
prospectus unless otherwise stated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of the assumptions, risks and factors which could cause future outcomes to differ materially from those set
forth in the forward-looking information contained herein include, but are not limited to: (i)&nbsp;the assumption that we will be able to obtain sufficient and suitable financing to support operations, clinical trials and commercialization of
products, (ii)&nbsp;the risk that we may not be able to capitalize on partnering and acquisition opportunities, (iii)&nbsp;the assumption that we will obtain favourable clinical trial results in the expected timeframe, (iv)&nbsp;the assumption that
we will be able to adequately protect proprietary information and technology from competitors, (v)&nbsp;the risks relating to the uncertainties of the regulatory approval process, (vi)&nbsp;the impact of competitive products and pricing and the
assumption that we will be able to compete in the targeted markets, and (vii)&nbsp;the risk that we may be unable to retain key personnel or maintain third party relationships, including relationships with key collaborators. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By its nature, forward-looking information involves numerous assumptions, inherent risks and uncertainties, both general and specific, that contribute to the
possibility that the predictions, forecasts, projections or other forward-looking statements will not occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#147;Risk Factors&#148; beginning on
page S-11 in this prospectus supplement and on page 7 of the accompanying prospectus and the risk factors discussed or referred to in our Annual Information Form and the Annual MD&amp;A which are incorporated by reference into this prospectus
supplement and the accompanying prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as required by law, we undertake no obligation to publicly update any forward-looking information,
whether as a result of new information, future events or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stoc685450_3"></A>PRESENTATION OF FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all financial information included and incorporated by reference in this prospectus supplement is prepared in accordance with
IFRS. Since January&nbsp;1, 2011, we have prepared our financial statements in accordance with IFRS. Prior to the adoption of IFRS, we followed Canadian Generally Accepted Accounting Principles (&#147;<B>Canadian GAAP</B>&#148;). While IFRS has many
similarities to Canadian GAAP, some of our accounting policies have changed as a result of our transition to IFRS. The most significant accounting policy changes that have had an impact on the results of our operations are discussed in more detail
in our management&#146;s discussion and analysis dated March&nbsp;13, 2013, for the year ended December&nbsp;31, 2012, which is incorporated herein by reference. Further, our financial statements incorporated by reference in this prospectus
supplement and the prospectus and in the documents incorporated by reference herein and therein may not be comparable to financial statements prepared in accordance with United States generally accepted accounting principles. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stoc685450_4"></A>CURRENCY AND EXCHANGE RATE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>In this prospectus supplement, unless otherwise specified or the context otherwise requires, all dollar amounts are expressed in United States dollars.</B>
All references to &#147;US$&#148; and &#147;$&#148; are to the lawful currency of the United States and all references to &#147;C$&#148; are to the lawful currency of Canada. In this prospectus supplement, where applicable, and unless otherwise
indicated, amounts are converted from United States dollars to Canadian dollars and vice versa by applying the noon rate of exchange of the Bank of Canada on February&nbsp;26, 2014. The following table sets forth: (i)&nbsp;the rates of exchange for
Canadian dollars, expressed in U.S. dollars, in effect at the end of the periods indicated; (ii)&nbsp;the average rates of exchange in effect during such periods; (iii)&nbsp;the high rates of exchange in effect during such periods; and (iv)&nbsp;the
low rates of exchange in effect during such periods, such rates, in each case, based on the noon rates of exchange for conversion of one Canadian dollar to U.S. dollars as reported by the Bank of Canada. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014<BR>(Through<BR>February&nbsp;26,<BR>2014)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Low</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.9430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.9710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.9839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.8952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">High</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.0583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.0418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.0697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.9422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Average<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.0110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.9996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.0299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.9100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">End</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.9833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.0051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.9402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.8995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note: </B></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The average of the inverse of the noon buying rate on the last day of each month during the applicable period. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;26, 2014, the inverse of the noon exchange rate quoted by the Bank of Canada for Canadian dollars was C$1.00 = $0.8995. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stoc685450_5"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights certain information about us, this offering and selected information contained elsewhere in or incorporated by reference into this
prospectus supplement or the prospectus. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in the common shares. For a more complete understanding of the Corporation
and this offering, we encourage you to read and consider carefully the more detailed information in this prospectus supplement and the prospectus, including the information incorporated by reference in this prospectus supplement and the prospectus,
and the information included in any free writing prospectus that the Corporation has authorized for use in connection with this offering, including the information under the heading &#147;Risk Factors&#148; in this prospectus supplement on page
S-11. All capitalized terms used in this summary refer to those definitions contained elsewhere in this prospectus supplement and/or the prospectus, as applicable. </I></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Oncolytics Biotech Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Business
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We focus on the discovery and development of oncolytic viruses for the treatment of cancers that have not been successfully treated with conventional
therapeutics. Recent scientific advances in oncology, virology, and molecular biology have created opportunities for new approaches to the treatment of cancer. The product candidate we are presently developing may represent a novel treatment for
Ras-mediated cancers. This product candidate can be used as an alternative to existing cytotoxic or cytostatic therapies or as an adjuvant therapy to conventional chemotherapy, radiation therapy, or surgical resections. It could also potentially be
used to treat certain cellular proliferative disorders for which no current therapy exists. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our technologies are based primarily on discoveries made in
the Department of Microbiology and Infectious Diseases at the University of Calgary in the 1990s. Oncolytics was formed in 1998 to explore the natural oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an
activated Ras pathway. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead product candidate, REOLYSIN<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> may represent a novel treatment for
certain tumour types and some cellular proliferative disorders. This lead product is a virus that is able to replicate specifically in, and hence kill, certain tumour cells both in tissue culture as well as in a number of animal models without
damaging normal cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">REOLYSIN, is developed from the reovirus. This virus has been demonstrated to replicate specifically in tumour cells bearing an
activated Ras pathway. Activating mutations of Ras occur in approximately thirty per cent of all human tumours directly, but considering its central role in signal transduction, activation of the Ras pathway has been shown to play a role in
approximately two-thirds of all tumours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The functionality of REOLYSIN is based upon the finding that tumours bearing an activated Ras pathway are
deficient in their ability to activate the anti-viral response mediated by the host cellular protein, Protein Kinase R (&#147;<B>PKR</B>&#148;). Since PKR is responsible for preventing reovirus replication, tumour cells lacking the activity of PKR
are susceptible to reovirus infections. As normal cells do not possess Ras activations, these cells are able to thwart reovirus infections by the activity of PKR. In a tumour cell with an activated Ras pathway, reovirus is able to freely replicate
and hence kill the host tumour cell. The result of this replication is progeny viruses that are then free to infect surrounding cancer cells. This cycle of infection, replication and cell death is believed to be repeated until there are no longer
any tumour cells carrying an activated Ras pathway available. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following schematic illustrates the molecular basis of how the reovirus kills cancer cells. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g685450g34w23.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have been issued over 360 patents including 47 U.S. and 14 Canadian patents as well as issuances in other jurisdictions.
We have an extensive patent portfolio covering the oncolytic reovirus that we use in our clinical trial program including a composition of matter patent that expires in 2028. Our patent portfolio also includes methods for treating proliferative
disorders using modified adenovirus, herpes simplex virus, parapoxvirus and vaccinia virus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oncolytics Biotech Inc. was incorporated pursuant to the provisions of the <I>Business Corporations Act </I>(Alberta) on April&nbsp;2, 1998 as 779738 Alberta
Ltd. On April&nbsp;8, 1998, we amended our articles and changed our name to Oncolytics Biotech Inc. On July&nbsp;29, 1999, we further amended our articles by removing the private company restrictions and subdividing our 2,222,222 common shares
issued and outstanding into 6,750,000 common shares. On February&nbsp;9, 2007, we further amended our articles to permit our shareholder meetings to be held at any place in Alberta or at any other location as determined by our directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our head office and principal place of business is located at 210, 1167 Kensington Crescent N.W., Calgary, Alberta T2N 1X7. Our registered office is located
at 3700, 400 &#150; 3<SUP STYLE="font-size:85%; vertical-align:top">rd</SUP> Avenue S.W., Calgary, Alberta, T2P 4H2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have two direct wholly-owned
subsidiaries: Oncolytics Biotech (Barbados) Inc., which is incorporated pursuant to the laws of Barbados and Valens Pharma Ltd., which is incorporated pursuant to the laws of the Province of Alberta; and two indirect wholly-owned subsidiaries:
Oncolytics Biotech (U.S.), Inc., which is incorporated pursuant to the laws of Delaware, and Oncolytics Biotech (U.K.) Ltd., which is incorporated pursuant to the laws of England and Wales, both of which are wholly-owned direct subsidiaries of
Oncolytics Biotech (Barbados) Inc. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stoc685450_6"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Issuer: </B></P></TD>
<TD>Oncolytics Biotech Inc. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Offering: </B></P></TD>
<TD>The common shares offered to Lincoln Park include, subject to an aggregate maximum of US$13,300,000 under this prospectus supplement: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="right">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">600,962 common shares that Lincoln Park is purchasing for gross proceeds of US$1,000,000.77 as an initial purchase, at a purchase price of US$1.664 per common share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="right">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">up to US$24,999,999.23 of our common shares that may be sold from time to time after the initial purchase, at our sole discretion, to Lincoln Park over the next 30&nbsp;months in accordance with the Purchase Agreement;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="right">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">292,793 common shares to be issued to Lincoln Park as Initial Commitment Shares, in consideration for entering into the Purchase Agreement; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="right">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">up to 292,793 common share that we may issue to Lincoln Park on a pro rata basis, as Additional Commitment Shares, upon each purchase by Lincoln Park under the Purchase Agreement (including the initial purchase of
US$1,000,000.77) up to a total of US$26,000,000 of common shares purchased. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; padding-bottom:3pt; margin-top:-2pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Common shares outstanding before this offering<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP> </B></P></TD>
<TD>84,803,818 common shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; padding-bottom:3pt; margin-top:-2pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Common shares outstanding immediately after this offering<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>: </B></P></TD>
<TD>Up to 101,014,404 after issuance of up to 16,210,586 common shares, assuming a sales price of US$1.664 per common share for the remaining US$24,999,999.23 that may be sold from time to time after the initial purchase, which was the closing price
on NASDAQ on February 26, 2014, including up to 585,586 common shares to be issued to Lincoln Park as a fee for its commitment to purchase our common shares, subject to an aggregate maximum of US$13,300,000 under this prospectus supplement. Actual
number of common shares issued and outstanding will vary depending on the actual sales prices and aggregate dollar amount sold under this offering. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds: </B></P></TD>
<TD>We intend to use the net proceeds from this offering, if any, for general corporate purposes. See &#147;Use of Proceeds&#148;. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Listing Symbols: </B></P></TD>
<TD>Our common shares are listed on the NASDAQ under the symbol &#147;ONCY&#148; and on the TSX under the symbol &#147;ONC&#148;. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Risk Factors: </B></P></TD>
<TD>You should carefully read and consider the information set forth in &#147;Risk Factors&#148; beginning on page S-11 of this prospectus supplement and page 7 of the prospectus before investing in our common shares. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Tax Considerations </B></P></TD>
<TD>Purchasing our common shares may have tax consequences in the United States. This prospectus supplement and the accompanying prospectus may not describe these consequences fully for all investors. Investors should read the tax discussion in this
prospectus supplement and consult their tax advisor. See &#147;Certain U.S. Federal Income Tax Considerations.&#148; Potential investors that are United States taxpayers should be aware that we may be considered a &#147;passive foreign investment
company&#148; (&#147;<B>PFIC</B>&#148;). For more information on tax considerations related to our PFIC status, see &#147;Certain U.S. Federal Income Tax Considerations &#150; Passive Foreign Investment Company Rules&#148;. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note: </B></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">On a non-diluted basis. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stoc685450_7"></A>RECENT DEVELOPMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Purchase Agreement with Lincoln Park </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
February&nbsp;27, 2014, we entered into a Purchase Agreement with Lincoln Park, which provides that, upon the terms and subject to the conditions and limitations set forth therein, we have the right to sell to Lincoln Park up to US$26,000,000
(including the initial purchase of US$1,000,000.77) worth of our common shares at our discretion as described below, subject to an aggregate maximum of US$13,300,000 under this prospectus supplement. As consideration for entering into the Purchase
Agreement, we agreed to issue 292,793 common shares to Lincoln Park, or the Initial Commitment Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are filing this prospectus supplement with
regard to the offering of up to US$13,300,000 worth of our common shares, which consists of (i)&nbsp;600,962&nbsp;shares that Lincoln Park is purchasing as the initial purchase under the Purchase Agreement for gross proceeds of US$1,000,000.77, or
the initial purchase, at a purchase price of US$1.664 per common share, (ii)&nbsp;a portion of the additional common shares with an aggregate offering price of up to US$24,999,999.23 which we may sell from time to time, in our sole discretion, to
Lincoln Park over the next 30 months subject to the conditions and limitations in the Purchase Agreement, (iii)&nbsp;the 292,793 Initial Commitment Shares having an aggregate value of US$455,000 and (iv)&nbsp;a portion of the up to an additional
292,793 common shares that we may issue to Lincoln Park on a pro rata basis, as Additional Commitment Shares, upon each purchase by Lincoln Park under the Purchase Agreement up to a total of US$26,000,000 worth of our common shares (including the
initial purchase of US$1,000,000.77) purchased. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the Initial Purchase of US$1,000,000.77 worth of our common shares, under the Purchase
Agreement, on any business day and as often as every other business day over the 30-month term of the Purchase Agreement, we have the right, in our sole discretion, subject to the conditions and limitations in the Purchase Agreement, to direct
Lincoln Park to purchase up to 100,000 common shares (each a &#147;<B>Regular Purchase</B>&#148;). Such amount of the Regular Purchase may be increased to up to 150,000 common shares, provided that the closing sale price of the common shares is not
below US$2.00 on the applicable purchase date, and up to 200,000 common shares, provided that the closing sale price of the common shares is not below US$3.50 on the applicable purchase date; however, Lincoln Park&#146;s obligation under each
Regular Purchase shall not exceed $1,000,000, which may be increased upon the mutual agreement of us and Lincoln Park. The purchase price for common shares to be purchased by Lincoln Park in a Regular Purchase will be the lower of (i)&nbsp;the
lowest sale price on the purchase date, as reported by NASDAQ, and (ii)&nbsp;the arithmetic average of the three lowest closing sale prices for our common shares during the 12 consecutive business days prior to the purchase date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We can also accelerate the amount of our common shares to be purchased under certain circumstances in an amount up to the lesser of (i)&nbsp;200% of the
number of common shares purchased pursuant to the applicable Regular Purchase and (ii)&nbsp;30% of the trading volume on such accelerated purchase date, if the closing sale price of our common shares equals or exceeds US$1.50 on such purchase date,
as reported by NASDAQ (each an &#147;<B>Accelerated Purchase</B>&#148;). The purchase price for the common shares in an Accelerated Purchase is the lower of (i)&nbsp;the closing sale price for our common shares on the date of sale, and (ii)&nbsp;95%
of the volume weighted average price of our common shares on NASDAQ on the date of sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no upper limit on the price per share that Lincoln Park
must pay for our common shares under the Purchase Agreement, but in no event will shares be sold to Lincoln Park on a day the closing sale price for our common shares is less than the floor price of US$1.00 per common share. The purchase price will
be equitably adjusted for any reorganization, recapitalization, non-cash dividend, stock split, or other similar transaction occurring during the business days used to compute the purchase price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no trading volume requirements or restrictions under the Purchase Agreement, but there are limitations on the number of common shares we can direct
Lincoln Park to purchase, as described herein. We will control the timing and amount of any sales of our common shares to Lincoln Park. We may at any time, in our sole discretion terminate the Purchase Agreement without fee, penalty or cost, upon
one business days&#146; notice. We will issue 292,793 Initial Commitment Shares to Lincoln Park as consideration for entering into the Purchase Agreement, and we may issue up to 292,793 Additional Commitment Shares as an additional commitment fee on
a pro rata basis as Lincoln Park purchases up to US$26,000,000 worth of our common shares (including the initial purchase of US$1,000,000.77) in our discretion under the Purchase Agreement. By way of example only, if we elect, at our sole
discretion, to require Lincoln Park to purchase US$100,000 worth of our common shares, then we would issue </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approximately 1,126 Additional Commitment Shares as a pro rata additional commitment fee, which is the product of US$100,000, the amount we have elected to sell, divided by US$26,000,000, the
total amount we can sell to Lincoln Park under the Purchase Agreement, multiplied by 292,793, the maximum number of Additional Commitment Shares under the Purchase Agreement. The Additional Commitment Shares will only be issued pursuant to this
formula if, as and when we elect to sell our common shares to Lincoln Park. Lincoln Park may not assign or transfer its rights or obligations under the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Purchase Agreement limits our sales of common shares to Lincoln Park to 16,952,283 common shares, or 19.99% of our total outstanding common shares as of
the date of the Purchase Agreement (the &#147;<B>Exchange Cap</B>&#148;), unless and until we have obtained shareholder approval of the transactions contemplated by the Purchase Agreement under applicable NASDAQ rules, provided that such limitation
shall not apply to the extent that the average price of all sales of common shares to Lincoln Park under the Purchase Agreement exceed a &#147;base price&#148; of $0.0619, such that the sales to Lincoln Park are considered to be at least &#147;at
market&#148; under applicable NASDAQ rules. None of our common shares issued pursuant to the Purchase Agreement will be offered for sale or sold by us or Lincoln Park on the TSX. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Purchase Agreement also prohibits us from directing Lincoln Park to purchase any common shares if those common shares, when aggregated with all of our
other common shares then beneficially owned by Lincoln Park and its affiliates, would result in Lincoln Park and its affiliates having beneficial ownership, at any single point in time, of more than 9.99% of our then total outstanding common shares
(approximately 8,531,938 shares as of the date of this prospectus supplement), as calculated pursuant to Section&nbsp;13(d) of the Exchange Act, and Rule 13d-3 thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of common shares ultimately offered for sale by Lincoln Park under this prospectus supplement is dependent upon the number of common shares
purchased by Lincoln Park under the Purchase Agreement. The following table sets forth the amount of proceeds we would receive from Lincoln Park from the sale of shares that are registered in this offering at varying purchase prices (without
accounting for certain fees and expenses), assuming the completion of the initial purchase and the sale by us of additional common shares at the average prices set forth in the table and the issuance by the Corporation of the related Initial and
Additional Commitment Shares, in the aggregate amount of the US$13,300,000 in common shares qualified by this prospectus supplement: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:224.10pt; font-size:8pt; font-family:Times New Roman"><B>Assumed&nbsp;Average&nbsp;Purchase&nbsp;Price for Additional Purchase Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Registered<BR>Shares to be<BR>Issued if Full<BR>Purchase</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of<BR>Outstanding<BR>Shares<BR>After&nbsp;Giving<BR>Effect to the<BR>Issuance to<BR>Lincoln Park</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Proceeds from the<BR>Sale of Shares to<BR>Lincoln&nbsp;Park<BR>Under&nbsp;the<BR>Purchase<BR>Agreement</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">US$1.00</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,655,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">12,612,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">US$1.50</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,785,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.39</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">12,612,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">US$1.664</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,022,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.64</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">12,612,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">US$2.00</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,849,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">12,612,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">US$3.50</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,368,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.90</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">12,612,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Events of default under the Purchase Agreement include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effectiveness of the registration statement, of which this prospectus supplement and accompanying prospectus are a part, lapses for any reason (including, without limitation, the issuance of a stop order), or this
prospectus supplement and accompanying prospectus or the Canadian prospectus supplement and accompanying prospectus related to the offering hereby are unavailable for sale by us to Lincoln Park of our common shares offered hereby and thereby,
respectively, and such lapse or unavailability continues for a period of 10 consecutive business days or for more than an aggregate of 30 business days in any 365-day period; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension by our principal market of our common shares from trading for a period of one business day; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the de-listing of our common shares from The NASDAQ Capital Market, provided our common shares are not immediately thereafter trading on the New York Stock Exchange, The NASDAQ Global Market, The NASDAQ Global Select
Market, the NYSE MKT, the NYSE Arca, the OTC Bulletin Board or OTC Markets (or nationally recognized successor to any of the foregoing); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the transfer agent&#146;s failure for three business days to issue to Lincoln Park our common shares after the applicable payment therefor; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any breach of the representations or warranties or covenants contained in the Purchase Agreement or any related agreements which has had or which could have a material adverse effect on us, subject to a cure period of
five business days; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any participation or threatened participation in insolvency or bankruptcy proceedings by or against us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if at any time we are not eligible to transfer our common shares electronically; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if at any time the Exchange Cap is reached (to the extent the Exchange Cap is applicable) and we have not obtained shareholder approval of the transactions contemplated by the Purchase Agreement under applicable NASDAQ
rules. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lincoln Park does not have the right to terminate the Purchase Agreement upon any of the events of default set forth above. During
an event of default, all of which are outside the control of Lincoln Park, our common shares cannot be sold by us or purchased by Lincoln Park under the terms of the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This offering will terminate on the date that all common shares offered by this prospectus supplement have been sold or, if earlier, the expiration or
termination of the Purchase Agreement. We have the right to terminate the Purchase Agreement at any time, at no cost to us. In the event of bankruptcy proceedings by or against us, the Purchase Agreement will automatically terminate without action
of any party. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>REO 018 Study </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;21,
2013, the Corporation announced positive top line data from the first endpoint in its double-blinded randomized Phase III clinical study examining REOLYSIN in combination with carboplatin and paclitaxel in second-line patients with
platinum-refractory, taxane-na&iuml;ve head and neck cancers (the &#147;<B>REO 018 Study</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The REO 018 study enrolled 167 patients. The
efficacy analysis was performed on an intent-to-treat basis of the 118 patients with loco-regional head and neck cancer with or without metastatic disease. In the intent-to-treat patient population, PFS, progression at first post-treatment scan,
cycles of therapy received, and tumour shrinkage at first post-treatment scan were analyzed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The analysis showed a median PFS of 94 days (13.4 weeks) in
the test arm (n=62), versus 50 days (7.1 weeks) in the control arm (n=56). The test arm maintained a PFS benefit over the control arm through five cycles of therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A number of patients on study received additional treatments with other agents following discontinuation of study treatment in accordance with the clinical
practices of individual enrolling centres. Thirty of the 118 patients in the loco-regional group received at least one therapy with other agents after study therapy was discontinued. A greater number of patients in the control arm received
post-discontinuation therapy versus the test arm. This imbalance created a &#147;confounding,&#148; or distorting, effect on OS (Pazdur; <I>The Oncologist </I>2008, 13:19-21), as such additional therapy can extend the patients&#146; lifespan beyond
that expected from receiving the study therapy. Eighty-eight loco-regional patients did not receive additional therapy and an analysis of these patients showed a median OS of 150 days (21.4 weeks) in the test arm (n=50) versus 115 days (16.4 weeks)
in the control arm (n=38). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients were evaluated for progression at the first scheduled post-treatment scan (performed at six weeks,
post-cycle two of therapy). Of 62 patients on the test arm, 32.3% had progressed, compared with 51.8% of the 56 patients on the control arm (p=0.04). The patients were also evaluated for the total cycles of therapy received. The patients on the test
arm had received a median of four cycles of therapy, versus a median of two cycles on the control arm. The same proportion of patients from each arm remained on study at five cycles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Of 86 patients with measurable disease at the first post-treatment scan, the test arm (n=48) had a statistically significant increase in tumour shrinkage over
the control arm (n= 38; p=0.049). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>REO 16 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
October&nbsp;28, 2013, the Corporation announced a poster presentation containing updated efficacy data from a Phase 2 study examining the use of REOLYSIN<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in combination with carboplatin and
paclitaxel in patients with stage IV non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumors (REO 016) was made at International Association for the Study of Lung Cancer (IASLC) conference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The poster presentation included new efficacy data that correlated a number of molecular abnormalities with best response, progression free survival (PFS) and
one-year survival. Current data in these patients demonstrates that 20 of 36 evaluable patients (56%)&nbsp;survived a year or more. There were 13 patients with only EGFR mutations or amplifications, of whom nine (69.2%)&nbsp;survived a year or
longer. Four of four (100%)&nbsp;patients with BRAF and EGFR amplification survived a year or longer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The chart below summarizes key findings for the 36
evaluable patients: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:43.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Molecular <BR>Abnormality</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number of <BR>patients</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:48.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Best Response</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:57.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number <BR>progression free <BR>at six months</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:47.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number <BR>surviving one <BR>year</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">BRAF mutation, EGFR amplification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2PR, 1SD, 1PD</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">EGFR amplification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5PR, 5SD</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">EGFR mutation, EGFR amplification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1PR, 1SD, 1PD</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">KRAS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3PR, 8SD</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">KRAS, EGFR amplification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6SD, 1PD</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Total</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">36</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11 PR, 11 SD</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(30%&nbsp;response&nbsp;rate)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">14 (38%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">20 (56%)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Partial response (PR), stable disease (SD), progressive disease (PD) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients received REOLYSIN (3 x 1010 TCID50) intravenously daily on days one to five, in combination with paclitaxel at initial doses of paclitaxel 175 mg/m2
and carboplatin AUC 5, on day one of each 21-day cycle. Overall, 37 patients received 209 cycles (per patient median four, range one to 18). The study treatment was found to be well tolerated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stoc685450_8"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prospective purchasers of common shares should consider carefully the risk factors set out herein and contained in and incorporated by reference in the
accompanying base shelf prospectus. Discussions of certain risks affecting the Corporation in connection with its business are set forth under &#147;Risk Factors&#148; in the accompanying prospectus and in our Annual Information Form, our Annual
MD&amp;A and our other disclosure documents filed with the various securities regulatory authorities which are incorporated by reference in this prospectus supplement and the accompanying prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Volatility of Market Price of common shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market
price of the common shares may be volatile. The volatility may affect the ability of holders of common shares to sell the common shares at an advantageous price. Market price fluctuations in the common shares may be due to the Corporation&#146;s
operating results failing to meet the expectations of securities analysts or investors in any quarter, downward revision in securities analysts&#146; estimates, governmental regulatory action, adverse change in general market conditions or economic
trends, acquisitions, dispositions or other material public announcements by the Corporation or its competitors, along with a variety of additional factors, including, without limitation, those set forth under &#147;Forward-Looking Statements&#148;
in this prospectus supplement. In addition, the market price for securities in the stock markets, including NASDAQ and the TSX, recently experienced significant price and trading fluctuations. These fluctuations have resulted in volatility in the
market prices of securities that often has been unrelated or disproportionate to changes in operating performance. These broad market fluctuations may adversely affect the market price of the common shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Corporation will have broad discretion over the use of the net proceeds from this offering and the Corporation May Not Use These Proceeds in a Manner
Desired by the Corporation&#146;s Shareholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management will have broad discretion with respect to the use of the net proceeds, if any, from this
offering and investors will be relying on the judgment of management regarding the application of these proceeds. Management could spend most of the net proceeds from this offering in ways that the Corporation&#146;s shareholders may not desire or
that do not yield a favorable return. You will not have the opportunity, as part of your investment in the common shares, to influence the manner in which the net proceeds of this offering are used. At the date of this prospectus supplement, the
Corporation intend to use the net proceeds from this offering as described under the heading &#147;Use of Proceeds&#148;. However, the Corporation&#146;s needs may change as the business and the industry the Corporation addresses evolve. As a
result, the proceeds to be received in this offering may be used in a manner significantly different from the Corporation&#146;s current expectations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Corporation Does Not Currently Intend to Pay any Cash Dividends on its common shares in the Foreseeable Future; Therefore, the Corporation&#146;s
Shareholders May Not be Able to Receive a Return on their common shares Until They Sell Them </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Corporation has never paid or declared any cash
dividends on its common shares. The Corporation does not anticipate paying any cash dividends on its common shares in the foreseeable future because, among other reasons, the Corporation currently intends to retain any future earnings to finance its
business. The future payment of dividends will be dependent on factors such as cash on hand and achieving profitability, the financial requirements to fund growth, the Corporation&#146;s general financial condition and other factors the board of
directors of the Corporation may consider appropriate in the circumstances. Until the Corporation pays dividends, which it may never do, its shareholders will not be able to receive a return on their common shares unless they sell them. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We Expect to be Treated as a &#147;Passive Foreign Investment Company&#148; for the Current Taxable Year and for the Foreseeable Future </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, a foreign corporation will be a passive foreign investment company (&#147;<B>PFIC</B>&#148;) if, for any tax year, (a)&nbsp;75% or more of its gross
income for such tax year is passive income or (b)&nbsp;50% or more of the value of its assets either produce passive income or are held for the production of passive income, based on the quarterly average of the fair market value of such assets.
Based on current business plans and financial projections, we expect that we will be a PFIC for the current taxable year and for the foreseeable future. If we are treated as PFIC for any taxable year, a U.S. investor may be subject to materially
adverse tax treatment with respect to their common shares. For a more detailed discussion of the tax consequences of PFIC classification for a U.S. investor, see &#147;Certain U.S. Federal Income Tax Considerations.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stoc685450_9"></A>DOCUMENTS INCORPORATED BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is deemed to be incorporated by reference into the prospectus solely for the purposes of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are incorporating by reference in this prospectus supplement certain information contained in documents filed by us with certain securities regulatory
authorities in Canada and the SEC. This means that we are disclosing important information to you by referring you to those documents. The information incorporated by reference is deemed to be part of this prospectus supplement, except for any
information superseded by information contained directly in this prospectus supplement or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may obtain copies of the documents incorporated by reference in this prospectus supplement on request without charge from our Corporate Secretary at 210,
1167 Kensington Crescent N.W., Calgary, Alberta T2N 1X7 Telephone: (403)&nbsp;670-7377, as well as through the sources described below under &#147;Where You Can Find Additional Information&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following documents are specifically incorporated by reference in and form an integral part of the prospectus and this prospectus supplement: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">our annual information form, which is comprised of our Annual Report on Form 20-F dated March&nbsp;22, 2013, for the year ended December&nbsp;31, 2012 (the &#147;<B>Annual Information Form</B>&#148;); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">our management information circular dated April&nbsp;4, 2013, relating to the annual general meeting of shareholders held on May&nbsp;9, 2013; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">our audited consolidated financial statements, together with the notes thereto, as at December&nbsp;31, 2012 and 2011, which comprise the consolidated statements of financial position as at December&nbsp;31, 2012 and
2011, and the consolidated statements of loss and comprehensive loss, changes in equity, and cash flows for the years ended December&nbsp;31, 2012 and 2011; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">our management&#146;s discussion and analysis of financial condition and results of operations dated March&nbsp;13, 2013, for the year ended December&nbsp;31, 2012 (the &#147;<B>Annual MD&amp;A</B>&#148;);
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">our management&#146;s discussion and analysis of financial condition and results of operations dated November&nbsp;6, 2013, for the nine months ended September&nbsp;30, 2013; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top">our unaudited interim condensed consolidated financial statements, together with the notes thereto, as at and for the nine months September&nbsp;30, 2013. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any documents of the type referred to above, any material change reports (excluding confidential material change reports), and any business acquisition
reports filed by us with the securities regulatory authorities in Canada after the date of this prospectus supplement and prior to the termination of this offering will be deemed to be incorporated by reference in this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When new documents of the type referred to in the paragraphs above are filed by us with the securities regulatory authorities in Canada during the currency of
this prospectus supplement, such documents will be deemed to be incorporated by reference in this prospectus supplement and the previous documents of the type referred to in the paragraphs above and all material change reports, unaudited interim
consolidated financial statements (and management&#146;s discussion and analysis relating thereto) and certain prospectus supplements filed by us with the securities regulatory authorities in Canada before the commencement of our financial year in
which the new documents are filed will no longer be deemed to be incorporated by reference in this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, to the extent that
any document or information incorporated by reference into this prospectus supplement is included in any report on Form 6-K, Form 40-F, Form 20-F, Form 10-K, Form 10-Q or Form 8-K (or any respective successor form) that is filed with or furnished to
the SEC after the date of this prospectus supplement until the date that all common shares offered hereunder are sold, such document or information shall be deemed to be incorporated by reference as an exhibit to the registration statement of which
this prospectus supplement forms a part. In addition, we may incorporate by reference into this prospectus supplement other information from documents that we file with or furnish to the SEC pursuant to Section&nbsp;13(a) or 15(d) of the Exchange
Act, if and to the extent expressly provided therein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Any statement contained in this prospectus supplement or in a document incorporated or deemed to be
incorporated by reference in this prospectus supplement shall be deemed to be modified or superseded for purposes of this prospectus supplement to the extent that a statement contained herein or in any other subsequently filed document which also is
or is deemed to be incorporated by reference herein modifies or supersedes such statement. The modifying or superseding statement need not state that it has modified or superseded a prior statement or include any other information set forth in the
document that it modifies or supersedes. The making of a modifying or superseding statement shall not be deemed an admission for any purposes that the modified or superseded statement, when made, constituted a misrepresentation, an untrue statement
of a material fact or an omission to state a material fact that is required to be stated or that is necessary to make a statement not misleading in light of the circumstances in which it was made. Any statement so modified or superseded shall not be
deemed, except as so modified or superseded, to constitute a part of this prospectus supplement. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stoc685450_10"></A>DOCUMENTS FILED AS PART OF THE REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the documents specified in this prospectus supplement and in the prospectus under &#147;Documents Incorporated by Reference&#148;, the Purchase
Agreement described in this prospectus supplement, the consents of auditors and legal counsel, powers of attorney, and the form of the placement agent agreement with Bayridge&nbsp;Securities, LLC have been or will be filed with the SEC and form part
of the registration statement of which this prospectus supplement forms a part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stoc685450_11"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because it is uncertain whether the Corporation will sell shares to Lincoln Park beyond the initial US$1,000,000.77 purchase or how many such shares will be
sold or the prices at which the shares will be sold, the net proceeds to the Corporation from the sale of shares to Lincoln Park pursuant to this prospectus supplement cannot be determined at this time. Assuming the Corporation sells additional
shares and issues the related Additional Commitment Shares for no cash consideration such that the full US$13,300,000 in shares qualified by this prospectus supplement are issued, the estimated net proceeds of the offering will be approximately
US$12.5&nbsp;million after estimated expenses of US$100,000 payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming estimated net proceeds of approximately US$12.5&nbsp;million, we
intend to use approximately US$12.5&nbsp;million of the estimated net proceeds from this offering for working capital and other general corporate purposes. Working capital and other general corporate purposes may include funding ongoing operations
and/or capital requirements, discretionary capital programs and potential future acquisitions. Although, the Corporation intends to expend the net proceeds from the offering as set forth above, there may be circumstances where for sound business
reasons, a reallocation of funds may be deemed prudent or necessary, and may vary materially from that set forth above. Pending the uses described above, we plan to invest the net proceeds from this offering in short- and intermediate-term, interest
bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stoc685450_12">
</A>CONSOLIDATED CAPITALIZATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than as described in this prospectus supplement and in the accompanying prospectus, there have been no material
changes in our consolidated share and loan capital, on a consolidated basis, since the date of our most recently filed unaudited financial statements as at and for the nine months ended September&nbsp;30, 2013. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stoc685450_13"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to this prospectus supplement and the accompanying prospectus, we are offering up to US$13,300,000 of our common shares that may be issued by us
directly to Lincoln Park under the Purchase Agreement. This prospectus supplement and the accompanying prospectus also cover the resale of these common shares by Lincoln Park to the public. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We entered into the Purchase Agreement with Lincoln Park on February&nbsp;27, 2014. In consideration for entering into the Purchase Agreement, we will issue
292,793 of our common shares to Lincoln Park as Initial Commitment Shares, all of which are covered by this prospectus supplement. The Purchase Agreement provides that, upon the terms and subject to the conditions set forth therein, Lincoln Park is
irrevocably committed to purchase an aggregate of up to US$26,000,000 worth of our common shares (including the initial purchase of US$1,000,000.17) over the 30-month term of the Purchase Agreement, subject to an aggregate maximum of US$13,300,000
under this prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Purchase Agreement provides that, from time-to-time over the term of the Purchase Agreement, on any business
day, and as often as other business day, and at our sole discretion, we may require Lincoln Park to purchase up to 100,000 of our common shares in a Regular Purchase. Such amount of the Regular Purchase may be increased to up to 150,000 common
shares, provided that the closing sale price of the common shares is not below US$2.00 on the applicable purchase date, and up to 200,000 common shares, provided that the closing sale price of the common shares is not below US$3.50 on the applicable
purchase date; however, Lincoln Park&#146;s obligation under each Regular Purchase shall not exceed $1,000,000, which may be increased upon the mutual agreement of us and Lincoln Park. We can also accelerate the amount of our common shares to be
purchased under certain circumstances in an Accelerated Purchase in an amount up to the lesser of (i)&nbsp;200% of the number of common shares purchased pursuant to the applicable Regular Purchase and (ii)&nbsp;30% of the trading volume on such
accelerated purchase date, provided that the closing sale price of our common shares equals or exceeds US$1.50 on such purchase date, as reported by NASDAQ. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Purchase Agreement limits our sales of common shares to Lincoln Park to the Exchange Cap, which is 16,952,283 common shares, or 19.99% of our total
outstanding common shares as of the date of the Purchase Agreement, unless and until we have obtained shareholder approval of the transactions contemplated by the Purchase Agreement under applicable NASDAQ rules, provided that such limitations shall
not apply to the extent that the average price of all sales of common shares to Lincoln Park under the Purchase Agreement exceed a &#147;base price&#148; of $0.0619, such that the sales to Lincoln Park are considered to be at least &#147;at
market&#148; under applicable NASDAQ rules. None of our common shares issued pursuant to the Purchase Agreement will be offered for sale or sold by us or Lincoln Park on the TSX or to purchasers resident in Canada. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Purchase Agreement also prohibits us from directing Lincoln Park to purchase any common shares if those common shares, when aggregated with all of our
other common shares then beneficially owned by Lincoln Park and its affiliates, would result in Lincoln Park and its affiliates having beneficial ownership, at any single point in time, of more than 9.99% of our then total outstanding common shares
(as calculated pursuant to Section&nbsp;13(d) of the Exchange Act and Rule 13d-3 thereunder). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may suspend the sale of common shares to Lincoln Park
pursuant to this prospectus supplement for certain periods of time for certain reasons, including if this prospectus supplement is required to be supplemented or amended to include additional material information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This offering will terminate on the date that all common shares offered by this prospectus supplement have been sold or, if earlier, the expiration or
termination of the Purchase Agreement. We have the right to terminate the Purchase Agreement at any time, at no cost to us. In the event of bankruptcy proceedings by or against us, the Purchase Agreement will automatically terminate without action
of any party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offering has been approved by NASDAQ. The TSX has accepted notice of the offering and the Corporation is relying on the section 602(g)
exemption under the TSX Company Manual. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately prior to the date of the Purchase Agreement, Lincoln Park beneficially owned none of our common
shares. Josh Scheinfeld and Jonathan Cope, the Managing Members of Lincoln Park Capital, LLC, the manager of Lincoln Park, are deemed to be beneficial owners of all of the common shares owned by Lincoln Park. Messrs. Cope and Scheinfeld have shared
voting and investment power over the common shares being offered under this prospectus supplement filed with the SEC in connection with the transactions contemplated under the Purchase Agreement. Lincoln Park Capital, LLC is not a licensed broker
dealer or an affiliate of a licensed broker dealer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lincoln Park is an &#147;underwriter&#148; within the meaning of Section&nbsp;2(a)(11) of the
Securities Act. Lincoln Park has informed us that it will use a broker-dealer unaffiliated with Lincoln Park to effectuate all sales, if any, of the common shares that it may purchase from us pursuant to the Purchase Agreement. Such sales will be
made on NASDAQ at prices and at terms then prevailing or at prices related to the then current market price. Each such unaffiliated broker-dealer will be an underwriter within the meaning of Section&nbsp;2(a)(11) of the Securities Act. Lincoln Park
has informed us that each such broker-dealer will receive commissions from Lincoln Park that will not exceed customary brokerage commissions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We know of no existing arrangements between Lincoln Park and any other shareholder, broker, dealer, underwriter,
or agent relating to the sale or distribution of our common shares offered by this prospectus supplement. At the time a particular offer of our common shares is made, a prospectus supplement, if required, will be distributed that will set forth the
names of any agents, underwriters, or dealers and any compensation from the selling shareholder, and any other required information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into
an agreement with Bayridge Securities, LLC, a registered broker-dealer and FINRA member, pursuant to which Bayridge&nbsp;Securities, LLC agreed to act as the placement agent in connection with the Purchase Agreement with Lincoln Park. Bayridge
Securities, LLC will receive US$10,000 as compensation in connection with its services and expense reimbursement up to US$5,000, upon receipt of written confirmation from the Financial Industry Regulatory Authority, Inc., or FINRA, to the effect
that FINRA&#146;s Corporate Finance Department has determined not to raise any objection with respect to the fairness or reasonableness of the terms of the Purchase Agreement or the transactions contemplated thereby. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will pay all of the expenses incident to the registration, offering, and sale of our common shares to Lincoln Park. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify Lincoln Park, Bayridge Securities, LLC and certain other persons against certain liabilities in connection with the offering of our
common shares offered hereby, including liabilities arising under the Securities Act to the extent permissible by law or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons, we have been
advised that in the opinion of the SEC this indemnification is against public policy as expressed in the Securities Act and is therefore, unenforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lincoln Park represented to us that at no time prior to the date of the Purchase Agreement has Lincoln Park or its agents, representatives or affiliates
engaged in or effected, in any manner whatsoever, directly or indirectly, any short sale (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of our common shares or any hedging transaction. Lincoln Park agreed that during the
term of the Purchase Agreement, it and its agents, representatives and affiliates will not enter into or effect, directly or indirectly, any of the foregoing transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have advised Lincoln Park that it is required to comply with Regulation M promulgated under the Exchange Act, to the extent applicable to this offering.
With certain exceptions, Regulation M precludes the selling shareholder, any affiliated purchasers, and any broker-dealer or other person who participates in the distribution from bidding for or purchasing, or attempting to induce any person to bid
for or purchase any security which is the subject of the distribution until the entire distribution is complete. Regulation M also prohibits any bids or purchases made in order to stabilize the price of a security in connection with the distribution
of that security. All of the foregoing may affect the marketability of the shares offered by this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent for our
common shares is Computershare Trust Company of Canada at its principal office in Calgary, Alberta. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our outstanding common shares are listed and posted
for trading on the TSX under the symbol &#147;ONC&#148; and on NASDAQ under the symbol &#147;ONCY&#148;. The TSX has conditionally approved the listing of up to 16,952,283 of our common shares in connection with this prospectus supplement, subject
to us fulfilling the listing conditions set out in the conditional approval letter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stoc685450_14"></A>TRADING PRICE AND VOLUME </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our outstanding common shares are listed and posted for trading on NASDAQ under the trading symbol &#147;ONCY&#148; and on the TSX under the trading symbol
&#147;ONC&#148;. The following table sets forth the market price ranges and the aggregate volume of trading of the common shares on NASDAQ and the TSX for the periods indicated: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NASDAQ</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TSX</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:22.65pt; font-size:8pt; font-family:Times New Roman"><B>Period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Close</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Volume</B><br><B>(Shares)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B><br><B>(C$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B><br><B>(C$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Close</B><br><B>(C$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Volume</B><br><B>(Shares)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,203,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,360,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,461,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,532,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,343,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,199,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,160,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,527,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,595,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">993,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,151,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,019,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,088,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,050,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">August</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,057,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">912,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,190,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,864,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,269,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,665,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,758,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,936,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,457,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,096,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,358,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,673,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February (1 to 26)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,521,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">764,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stoc685450_15"></A>PRIOR SALES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the twelve month period preceding the date of this prospectus supplement, the Corporation issued an aggregate of 8,093,533 common shares, the
particulars of which are set forth in the following table: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:43.95pt; font-size:8pt; font-family:Times New Roman"><B>Date of Issue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;common<BR>shares Issued</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Issue&nbsp;Price&nbsp;per<BR>common share<BR>or&nbsp;Exercise&nbsp;Price</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&nbsp;2, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">C$2.00</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&nbsp;2, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">C$2.13</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&nbsp;2, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">C$2.22</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&nbsp;2, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">C$2.25</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February&nbsp;8, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">C$2.22</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February&nbsp;26, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>C$4.09&nbsp;($4.00)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;4, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">C$1.65</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;5, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">C$1.65</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the twelve month period preceding the date of this prospectus supplement, the Corporation granted options exercisable
for an aggregate of 1,866,000 common shares, the particulars of which are set forth in the following table: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:47.50pt; font-size:8pt; font-family:Times New Roman"><B>Date of Grant</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number and Type of<BR>Securities Issued</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February&nbsp;15, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,000&nbsp;options</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">C$</TD>
<TD VALIGN="bottom" ALIGN="right">4.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May&nbsp;9, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000&nbsp;options</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">C$</TD>
<TD VALIGN="bottom" ALIGN="right">2.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;11, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,416,000&nbsp;options</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">C$</TD>
<TD VALIGN="bottom" ALIGN="right">1.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February&nbsp;3, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,000&nbsp;options</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">C$</TD>
<TD VALIGN="bottom" ALIGN="right">1.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stoc685450_16"></A>CERTAIN U.S. FEDERAL INCOME TAX CONSIDERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a general summary of certain U.S. federal income tax considerations applicable to a U.S. Holder (as defined below) arising from and relating
to the acquisition, ownership and disposition of common shares acquired pursuant to this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This summary is for general information
purposes only and does not purport to be a complete analysis or listing of all potential U.S. federal income tax considerations that may apply to a U.S. Holder arising from and relating to the acquisition, ownership and disposition of common shares.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, this summary does not take into account the individual facts and circumstances of any particular U.S. Holder that may affect the U.S.
federal income tax considerations applicable to such U.S. Holder. Except as specifically set forth below, this summary does not discuss applicable tax reporting requirements. Accordingly, this summary is not intended to be, and should not be
construed as, legal or U.S. federal income tax advice with respect to any particular U.S. Holder. Except as specifically set forth below, this summary does not discuss applicable tax reporting requirements. This summary does not address the U.S.
state and local, U.S. federal estate and gift, U.S. federal alternative minimum tax, or non-U.S. tax consequences to U.S. Holders relating to the acquisition, ownership, and disposition of common shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each U.S. Holder should consult its own tax advisor regarding the U.S. federal, U.S. state and local, and non-U.S. tax consequences relating to the
acquisition, ownership, and disposition of common shares. No ruling from the U.S. Internal Revenue Service (the &#147;<B>IRS</B>&#148;) has been requested, or will be obtained, regarding the U.S. federal income tax considerations applicable to U.S.
Holders as discussed in this summary. This summary is not binding on the IRS, and the IRS is not precluded from taking a position that is different from, and contrary to, the positions taken in this summary. In addition, because the authorities on
which this summary is based are subject to various interpretations, the IRS and the U.S. courts could disagree with one or more of the positions taken in this summary. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Authorities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This summary is based on the Internal
Revenue Code of 1986, as amended (the <B>&#147;Code</B>&#148;), Treasury Regulations (whether final, temporary, or proposed), U.S. court decisions, published IRS rulings, published administrative positions of the IRS, and the Convention Between
Canada and the United States of America with Respect to Taxes on Income and on Capital, signed September&nbsp;26, 1980, as amended (the &#147;<B>Canada-U.S. Tax Convention</B>&#148;), that are applicable and, in each case, as in effect, as of the
date of this prospectus supplement. Any of the authorities on which this summary is based could be changed in a material and adverse manner at any time, and any such change could be applied on a retroactive or prospective basis and could affect the
U.S. federal income tax considerations described in this summary. This summary does not discuss the potential effects, whether adverse or beneficial, of any proposed legislation that, if enacted, could be applied on a retroactive or prospective
basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this summary, a
&#147;<B>U.S. Holder</B>&#148; is a beneficial owner of common shares acquired pursuant to this prospectus supplement that is (a)&nbsp;an individual who is a citizen or resident of the U.S. for U.S. federal income tax purposes, (b)&nbsp;a
corporation, or other entity classified as a corporation for U.S. federal income tax purposes, that is created or organized in or under the laws of the U.S. or any state in the U.S., including the District of Columbia, (c)&nbsp;an estate if the
income of such estate is subject to U.S. federal income tax regardless of the source of such income, or (d)&nbsp;a trust if (i)&nbsp;such trust has validly elected to be treated as a U.S. person for U.S. federal income tax purposes or (ii)&nbsp;a
U.S. court is able to exercise primary supervision over the administration of such trust and one or more U.S. persons have the authority to control all substantial decisions of such trust. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Holders Subject to Special U.S. Federal Income Tax Rules Not Addressed </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This summary does not address the U.S. federal income tax considerations applicable to U.S. Holders that are subject to special provisions under the Code,
including: (a)&nbsp;U.S. Holders that are tax-exempt organizations, qualified retirement plans, individual retirement accounts, or other tax-deferred accounts; (b)&nbsp;U.S. Holders that are financial institutions, underwriters, insurance companies,
real estate investment trusts, or regulated investment companies or that are broker-dealers, dealers, or traders in securities or currencies that elect to apply a mark-to-market accounting method; (c)&nbsp;U.S. Holders that have a &#147;functional
currency&#148; other than the U.S. dollar; (d)&nbsp;U.S. Holders that own common shares as part of a straddle, hedging transaction, conversion transaction, constructive sale, or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
arrangement involving more than one position; (e)&nbsp;U.S. Holders that acquired common shares in connection with the exercise of employee stock options or otherwise as compensation for
services; (f)&nbsp;U.S. Holders that hold common shares other than as a capital asset within the meaning of Section&nbsp;1221 of the Code; or (g)&nbsp;U.S. Holders that own or will own, directly, indirectly, or by attribution, 10% or more, by voting
power or value, of our outstanding shares. The summary also does not address the U.S. federal income tax considerations applicable to U.S. Holders who are (a)&nbsp;certain U.S. expatriates or former long-term residents of the U.S.; (b)&nbsp;persons
that have been, are, or will be a resident or deemed to be a resident in Canada for purposes of the <I>Income Tax Act</I> (Canada) (the &#147;<B>Tax Act</B>&#148;); (c)&nbsp;persons that use or hold, will use or hold, or that are or will be deemed
to use or hold common shares in connection with carrying on a business in Canada; (d)&nbsp;persons whose common shares constitute &#147;taxable Canadian property&#148; under the Tax Act; or (e)&nbsp;persons that have a permanent establishment in
Canada for the purposes of the Canada-U.S. Tax Convention. U.S. Holders and others that are subject to special provisions under the Code, including U.S. Holders described immediately above, should consult their own tax advisors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an entity or arrangement that is classified as partnership (or &#147;pass-through&#148; entity) for U.S. federal income tax purposes holds common shares,
the U.S. federal income tax consequences applicable to such partnership (or &#147;pass-through&#148; entity) or arrangement and the partners of such partnership (or owners of such &#147;pass-through&#148; entity) or arrangement generally will depend
on the activities of the partnership (or &#147;pass-through&#148; entity) or arrangement and the status of such partners (or owners). Partners of entities or arrangements that are classified as partnerships (and owners of &#147;pass-through&#148;
entities) for U.S. federal income tax purposes should consult their own tax advisor regarding the U.S. federal income tax consequences relating to the acquisition, ownership, and disposition of common shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Passive Foreign Investment Company Rules </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we were a
&#147;passive foreign investment company&#148; under the meaning of Section&nbsp;1297 of the Code (a &#147;<B>PFIC</B>&#148;) for any year during a U.S. Holder&#146;s holding period, then certain potentially adverse rules will affect the U.S.
federal income tax consequences to a U.S. Holder resulting from the acquisition, ownership and disposition of common shares. In addition, in any year in which we are classified as a PFIC, such holder may be required to file an annual report with the
IRS containing such information as Treasury Regulations and/or other IRS guidance may require. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PFIC Status </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We generally will be a PFIC if, for any tax year, (a)&nbsp;75% or more of our gross income for such tax year is passive income (the &#147;<B>income
test</B>&#148;) or (b)&nbsp;50% or more of the value of our assets either produce passive income or are held for the production of passive income, based on the quarterly average of the fair market value of such assets (the &#147;<B>asset
test</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the PFIC income test and asset test described above, if we own, directly or indirectly, 25% or more of the total value
of the outstanding shares of another corporation, we will be treated as if we (a)&nbsp;held a proportionate share of the assets of such other corporation and (b)&nbsp;received directly a proportionate share of the income of such other corporation.
In addition, for purposes of the income test and asset test, &#147;passive income&#148; does not include any interest, dividends, rents, or royalties that are received or accrued by us from a &#147;related person,&#148; to the extent such items are
properly allocable to the income of such related person that is not passive income. Under certain attribution rules, if we are a PFIC, U.S. Holders will be deemed to own their proportionate share of any of our subsidiaries which is also a PFIC (a
&#147;<B>Subsidiary PFIC</B>&#148;), and will be subject to U.S. federal income tax on (i)&nbsp;a distribution on the shares of a Subsidiary PFIC and (ii)&nbsp;a disposition or deemed disposition of shares of a Subsidiary PFIC, both as if the holder
directly held the shares of such Subsidiary PFIC, even though such U.S. Holder had not received the proceeds of those distributions or dispositions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
believe we were a PFIC for one or more prior taxable years, and based on current business plans and financial projections, we expect that we will be a PFIC for the current taxable year and for the foreseeable future. The determination of whether we
were (or a Subsidiary PFIC was), or will be, a PFIC for a tax year depends, in part, on the application of complex U.S. federal income tax rules, which are subject to differing interpretations. In addition, whether we (or a Subsidiary PFIC) will be
a PFIC for any tax year depends on our assets and income (and each Subsidiary PFIC&#146;s assets and income) over the course of each such tax year and, as a result, cannot be predicted with certainty as of the date of this prospectus supplement.
Accordingly, there can be no assurance that the IRS will not challenge any determination made by us (or a Subsidiary PFIC) concerning our PFIC status or that we (and each Subsidiary PFIC) were not, or will not be, a PFIC for any tax year. Each U.S.
Holder should consult its own tax advisor regarding our PFIC status and the status of each Subsidiary PFIC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Default PFIC Rules </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are a PFIC, the U.S. federal income tax consequences to a U.S. Holder of the acquisition, ownership, and disposition of common shares will depend on
whether such U.S. Holder is eligible to make and actually makes an election to treat us (and/or a Subsidiary PFIC) as a &#147;qualified electing fund&#148; or &#147;QEF&#148; (a &#147;<B>QEF Election</B>&#148;) or has made a &#147;mark-to-market
election&#148; (a &#147;<B>Mark-to-Market Election</B>&#148;) with respect to common shares. A U.S. Holder that does not make either a QEF Election or a Mark-to-Market Election will be referred to in this summary as a &#147;<B>Non-Electing U.S.
Holder</B>&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Non-Electing U.S. Holder will be subject to the default PFIC rules with respect to (a)&nbsp;any gain recognized on the sale or other
taxable disposition (including a pledge) of common shares and (b)&nbsp;any &#147;excess distribution&#148; received on the common shares. A distribution generally will be an &#147;excess distribution&#148; to the extent that such distribution
(together with all other distributions received in the current tax year) exceeds 125% of the average distributions received during the shorter of the three preceding tax years or a U.S. Holder&#146;s holding period for the common shares). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any gain recognized on the sale or other taxable disposition of common shares of a PFIC (including an indirect disposition of offered shares of a Subsidiary
PFIC), and any excess distribution received on such common shares (or a distribution by a Subsidiary PFIC to its shareholder that is deemed to be received by a U.S. Holder) must be ratably allocated over a Non-Electing U.S. Holder&#146;s holding
period for the common shares. The amount of any such gain or excess distribution allocated to the tax year of disposition or distribution of the excess distribution and to years before the first taxable year in which the entity became a PFIC, if
any, would be taxed as ordinary income. The amounts allocated to any other tax year would be subject to U.S. federal income tax at the highest tax rate applicable to ordinary income in each such year, and an interest charge generally applicable to
the underpayments of tax would be imposed in respect of the tax attributable to each such year. A Non-Electing U.S. Holder that is not a corporation must treat any such interest paid as &#147;personal interest,&#148; which is not deductible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a Non-Electing U.S. Holder holds common shares during any tax year which we are a PFIC, such Non-Electing U.S. Holder&#146;s common shares will be treated
as equity in a PFIC, regardless of whether we cease to be a PFIC in one or more subsequent years. A Non-Electing U.S. Holder may terminate this deemed PFIC status with respect to common shares if we cease to be a PFIC and the Non-Electing
U.S.&nbsp;Holder makes a &#147;deemed sale&#148; election with respect to its common shares. If such election is made, the U.S. Holder will be deemed to have sold such common shares on the last day of the last tax year for which we were a PFIC, and
such U.S. Holder will recognize gain from such deemed sale (which will be taxed as discussed above). After the deemed sale election, a Non-Electing U.S. Holder&#146;s common shares with respect to which the deemed sale election was made will not be
treated as shares in a PFIC unless we subsequently become a PFIC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>QEF Election </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A U.S. Holder that makes a timely and effective QEF Election for the first tax year in which its holding period of its common shares begins, generally, will
not be subject to the default PFIC rules discussed above with respect to its common shares. However, a U.S. Holder that makes a timely and effective QEF Election will be subject to U.S. federal income tax on such U.S. Holder&#146;s pro rata share of
(a)&nbsp;our net capital gain, which will be taxed as long-term capital gain to such U.S. Holder, and (b)&nbsp;and our ordinary earnings, which will be taxed as ordinary income to such U.S. Holder. Generally, &#147;net capital gain&#148; is the
excess of (a)&nbsp;net long-term capital gain over (b)&nbsp;net short-term capital loss, and &#147;ordinary earnings&#148; are the excess of (a)&nbsp;&#147;earnings and profits&#148; over (b)&nbsp;net capital gain. A U.S. Holder that makes a QEF
Election will be subject to U.S. federal income tax on such amounts for each tax year in which we are a PFIC, regardless of whether such amounts are actually distributed to such U.S. Holder by us. However, for any tax year in which we are a PFIC and
have no net income or gain, U.S. Holders that have made a QEF Election would not have any income inclusions as a result of the QEF Election. If a U.S. Holder that made a QEF Election has an income inclusion, such a U.S. Holder may, subject to
certain limitations, elect to defer payment of current U.S. federal income tax on such amounts, subject to an interest charge. If such U.S. Holder is not a corporation, any such interest paid will be treated as &#147;personal interest,&#148; which
is not deductible. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A U.S. Holder that makes a QEF Election generally (a)&nbsp;may receive a tax-free distribution from us to the
extent that such distribution represents our &#147;earnings and profits&#148; that were previously included in income by the U.S. Holder because of such QEF Election and (b)&nbsp;will adjust such U.S. Holder&#146;s tax basis in the common shares to
reflect the amount included in income or allowed as a tax-free distribution because of such QEF Election. In addition, a U.S. Holder that makes a QEF Election generally will recognize capital gain or loss on the sale or other taxable disposition of
common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The procedure for making a QEF Election, and the U.S. federal income tax consequences of making a QEF Election, will depend on whether
such QEF Election is timely. A QEF Election will be treated as &#147;timely&#148; if such QEF Election is made for the first year in the U.S. Holder&#146;s holding period for the common shares in which we were a PFIC. A U.S. Holder may make a timely
QEF Election by filing the appropriate QEF Election documents at the time such U.S. Holder files a U.S. federal income tax return for such year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A QEF
Election will apply to the tax year for which such QEF Election is made and to all subsequent tax years, unless such QEF Election is invalidated or terminated or the IRS consents to revocation of such QEF Election by the U.S. Holder. If a U.S.
Holder makes a QEF Election and, in a subsequent tax year, we cease to be a PFIC, the QEF Election will remain in effect (although it will not be applicable) during those tax years in which we are not a PFIC. Accordingly, if we become a PFIC in
another subsequent tax year, the QEF Election will be effective and the U.S. Holder will be subject to the QEF rules described above during a subsequent tax year in which we qualify as a PFIC. The QEF Election is made on a shareholder-by-shareholder
basis and, once made, can be revoked only with the consent of the IRS. A U.S. Holder generally makes a QEF Election by attaching an appropriately completed IRS Form 8621 (Return by a Shareholder of a Passive Foreign Investment Company or Qualified
Electing Fund), including the information provided in a PFIC annual information statement, to a timely filed U.S. federal income tax return for the tax year to which the election relates. Retroactive QEF Elections generally may be made only by
filing a protective statement with such return and if certain other conditions are met or with the consent of the IRS. In order to comply with the requirements of a QEF Election, a U.S. Holder must receive certain information from us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will make available to U.S. Holders, upon their written request, information as to our status as a PFIC and the status of any Subsidiary PFIC in which we
own more than 50% of such Subsidiary PFIC&#146;s total aggregate voting power, and for each year we are a PFIC, provide to a U.S. Holder, upon written request, all information and documentation that a U.S. Holder making a QEF Election with respect
to us and such more than 50% owned Subsidiary PFIC is required to obtain for U.S. federal income tax purposes. We may elect to provide such information to U.S. Holders through our website. Because we may hold 50% or less of the aggregate voting
power of one or more Subsidiary PFICs at any time, U.S.&nbsp;Holders should be aware that there can be no assurance that we will satisfy record keeping requirements that apply to a QEF, or that we will supply U.S. Holders with information that such
U.S. Holders require to report under the QEF rules, in the event that we are a PFIC and a U.S.&nbsp;Holder wishes to make a QEF Election with respect to any such Subsidiary PFIC. With respect to Subsidiary PFICs for which we do not or the U.S.
Holders do not obtain the required information, U.S. Holders will continue to be subject to the rules discussed above that apply to Non-Electing U.S. Holders with respect to the taxation of gains and excess distributions. Each U.S. Holder should
consult its own tax advisor regarding the availability of, and procedure for making, a QEF Election with respect to us and any Subsidiary PFIC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mark-to-Market Election </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A U.S. Holder may make a
Mark-to-Market Election only if the common shares are marketable stock. The common shares generally will be &#147;marketable stock&#148; if the common shares are regularly traded on (a)&nbsp;a national securities exchange that is registered with the
SEC, (b)&nbsp;the national market system established pursuant to section 11A of the Securities and Exchange Act of 1934, or (c)&nbsp;a foreign securities exchange that is regulated or supervised by a governmental authority of the country in which
the market is located, provided that (i)&nbsp;such foreign exchange has trading volume, listing, financial disclosure, and other requirements and the laws of the country in which such foreign exchange is located, together with the rules of such
foreign exchange, ensure that such requirements are actually enforced and (ii)&nbsp;the rules of such foreign exchange effectively promote active trading of listed stocks. If such stock is traded on such a qualified exchange or other market, such
stock generally will be &#147;regularly traded&#148; for any calendar year during which such stock is traded, other than in de minimis quantities, on at least 15 days during each calendar quarter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A U.S. Holder that makes a Mark-to-Market Election with respect to its common shares generally will not be
subject to the default PFIC rules discussed above. A U.S. Holder that makes a Mark-to-Market Election will include in ordinary income, for each tax year in which we are a PFIC, an amount equal to the excess, if any, of (a)&nbsp;the fair market value
of the common shares, as of the close of such tax year over (b)&nbsp;such U.S. Holder&#146;s adjusted tax basis in such common shares. A U.S. Holder that makes a Mark-to-Market election will be allowed a deduction in an amount equal to the excess,
if any, of (a)&nbsp;such U.S. Holder&#146;s adjusted tax basis in the common shares, over (b)&nbsp;the fair market value of such common shares as of the close of such tax year (but only to the extent of the net amount of previously included income
as a result of the Mark-to-Market Election for prior tax years). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A U.S. Holder that makes a Mark-to-Market Election generally also will adjust such U.S.
Holder&#146;s tax basis in the common shares to reflect the amount included in gross income or allowed as a deduction because of such Mark-to-Market Election. In addition, upon a sale or other taxable disposition of common shares, a U.S. Holder that
makes a Mark-to-Market Election will recognize ordinary income or loss (not to exceed the excess, if any, of (a)&nbsp;the amount included in ordinary income because of such Mark-to-Market Election for prior tax years over (b)&nbsp;the amount allowed
as a deduction because of such Mark-to-Market Election for prior tax years). Any distributions we made would be subject to the rules discussed below under &#147;U.S. Federal Income Tax Consequences of the Acquisition, Ownership, and Disposition of
common shares&#151;Distributions on common shares&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Mark-to-Market Election applies to the tax year in which such Mark-to-Market Election is made
and to each subsequent tax year, unless the common shares cease to be &#147;marketable stock&#148; or the IRS consents to revocation of such election. Each U.S. Holder should consult its own tax advisor regarding the availability of, and procedure
for making, a Mark-to-Market Election. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although a U.S. Holder may be eligible to make a Mark-to-Market Election with respect to the common shares, no
such election may be made with respect to the stock of any Subsidiary PFIC that a U.S. Holder is treated as owning because such stock is not marketable. Hence, the Mark-to-Market Election will not be effective to eliminate the interest charge
described above with respect to deemed dispositions of Subsidiary PFIC stock or distributions from a Subsidiary PFIC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other PFIC Rules </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The IRS has issued proposed Treasury Regulations that, subject to certain exceptions, would cause a U.S. Holder that had not made a timely QEF Election to
recognize gain (but not loss) upon certain transfers of common shares that would otherwise be tax-deferred (e.g., gifts and exchanges pursuant to corporate reorganizations). However, the specific U.S. federal income tax consequences to a U.S. Holder
may vary based on the manner in which common shares are transferred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In any year in which we are classified as a PFIC, a U.S. Holder will be required to
file an annual report with the IRS containing such information as Treasury Regulations and/or other IRS guidance may require. A failure to satisfy such reporting requirements may result in an extension of the time period during which the IRS can
assess a tax. U.S. Holders should consult their own tax advisors regarding the requirements of filing such information returns under these rules, including the requirement to file an IRS Form 8621. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain additional adverse rules will apply with respect to a U.S. Holder if we are a PFIC, regardless of whether such U.S. Holder makes a QEF Election. For
example, a U.S. Holder that uses common shares as security for a loan will, except as may be provided in Treasury Regulations, be treated as having made a taxable disposition of such common shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Special rules also apply to the amount of foreign tax credit that a U.S. Holder may claim on a distribution from a PFIC. Subject to such special rules,
foreign taxes paid with respect to any distribution in respect of stock in a PFIC are generally eligible for the foreign tax credit. The rules relating to distributions by a PFIC and their eligibility for the foreign tax credit are complicated, and
a U.S. Holder should consult with its own tax advisor regarding the availability of the foreign tax credit with respect to distributions by a PFIC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
PFIC rules are complex, and each U.S. Holder should consult its own tax advisor regarding the PFIC rules and how the PFIC rules may affect the U.S. federal income tax consequences of the acquisition, ownership, and disposition of common shares. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Federal Income Tax Consequences of the Acquisition, Ownership, and Disposition of common shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following discussion is subject to the rules described above under the heading &#147;Passive Foreign Investment Company Rules&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Distributions on common shares </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the PFIC rules
discussed above, a U.S. Holder that receives a distribution, including constructive distribution, with respect to common shares will be required to include the amount of such distribution in gross income as a dividend (without reduction for any
Canadian income tax withheld from such distribution) to the extent of our current or accumulated &#147;earnings and profits,&#148; as computed for U.S. federal income tax purposes. A dividend generally will be taxed to a U.S. Holder at ordinary
income tax rates. To the extent that a distribution exceeds our current and accumulated &#147;earnings and profits,&#148; such distribution will be treated first as a tax-free return of capital to the extent of a U.S. Holder&#146;s tax basis in the
common shares and thereafter as gain from the sale or exchange of such common shares. See &#147;Sale or Other Taxable Disposition of common shares&#148; below. However, we do not intend to maintain the calculations of earnings and profits in
accordance with U.S. federal income tax principles, and each U.S. Holder should therefore assume that any distribution by us with respect to the common shares will constitute ordinary dividend income. Dividends received on common shares generally
will not be eligible for the &#147;dividends received deduction&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to applicable limitations, dividends paid with respect to the common
shares to non-corporate U.S. Holders, including individuals, generally will be eligible for the preferential tax rates applicable to long-term capital gains for dividends, provided certain holding period and other conditions are satisfied, including
that we not be classified as a PFIC in the tax year of distribution or in the preceding tax year. Since we expect to be classified as a PFIC for the foreseeable future, dividends received on common shares generally are expected not to be considered
&#147;qualified dividend income,&#148; and thus are not expected to be eligible for the preferential tax rates applicable to long-term capital gains for the foreseeable future. The dividend rules are complex, and each U.S. Holder should consult its
own tax advisor regarding the application of such rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sale or Other Taxable Disposition of common shares </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the PFIC rules discussed above, upon the sale or other taxable disposition of common shares, a U.S. Holder generally will recognize capital gain or
loss in an amount equal to the difference between (i)&nbsp;the amount of cash plus the fair market value of any property received and (ii)&nbsp;such U.S. Holder&#146;s tax basis in such common shares sold or otherwise disposed of. While gain or loss
recognized on such sale or other disposition generally would be long-term capital gain or loss if, at the time of the sale or other disposition, the common shares have been held for more than one year, the PFIC rules discussed above may render such
gain ordinary income. Preferential tax rates apply to long-term capital gain of a U.S. Holder that is an individual, estate, or trust. There are currently no preferential tax rates for long-term capital gain of a U.S. Holder that is a corporation.
Deductions for capital losses are subject to significant limitations under the Code. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Foreign Tax Credit </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the PFIC rules discussed above, a U.S. Holder that pays (whether directly or through withholding) Canadian income tax with respect to dividends paid
on the common shares generally will be entitled, at the election of such U.S. Holder, to receive either a deduction or a credit for such Canadian income tax paid. This election is made on a year-by-year basis and applies to all foreign taxes paid
(whether directly or through withholding) by a U.S. Holder during a year. Complex limitations apply to the foreign tax credit, including the general limitation that the credit cannot exceed the proportionate share of a U.S. Holder&#146;s U.S.
federal income tax liability that such U.S. Holder&#146;s &#147;foreign source&#148; taxable income bears to such U.S. Holder&#146;s worldwide taxable income for the same tax year. In applying this limitation, a U.S. Holder&#146;s various items of
income and deduction must be classified, under complex rules, as either &#147;foreign source&#148; or &#147;U.S. source&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, dividends paid
by a foreign corporation should be treated as foreign source for this purpose, and gains recognized on the sale of stock of a foreign corporation by a U.S. Holder should be treated as U.S. source for this purpose, except as otherwise provided in an
applicable income tax treaty, and if an election is properly made under the Code. However, the amount of a distribution with respect to the common shares that is treated as a &#147;dividend&#148; may be lower for U.S. federal income tax purposes
than it is for Canadian federal income tax purposes, resulting in a reduced foreign tax credit allowance to a U.S. Holder. In addition, this limitation is calculated separately with respect to specific categories of income. The foreign tax credit
rules are complex, and each U.S. Holder should consult its own tax advisor regarding the foreign tax credit rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Receipt of Foreign Currency </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amount of any distribution paid in foreign currency to a U.S. Holder in connection with the ownership of common shares, or on the sale, exchange or other
taxable disposition of our common shares, generally will be equal to the U.S. dollar value of such foreign currency based on the exchange rate applicable on the date of actual or constructive receipt (regardless of whether such foreign currency is
converted into U.S. dollars at that time). If the foreign currency received is not converted into U.S. dollars on the date of receipt, a U.S. Holder will have a tax basis in the foreign currency equal to its U.S. dollar value on the date of receipt.
A U.S. Holder that receives foreign currency and converts such foreign currency into U.S. dollars at a conversion rate other than the rate in effect on the date of receipt may have a foreign currency exchange gain or loss, which generally would be
treated as U.S. source ordinary income or loss for foreign tax credit purposes. Each U.S. Holder should consult its own tax advisor regarding the U.S. federal income tax consequences of receiving, owning, and disposing of foreign currency. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Additional Tax on Passive Income </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Individuals, estates
and certain trusts whose income exceeds certain thresholds will be required to pay a 3.8% Medicare surtax on &#147;net investment income&#148; including, among other things, dividends and net gain from dispositions of property (other than property
held in certain trades or businesses). U.S. Holders should consult their own tax advisors regarding the effect, if any, of this tax on their ownership and disposition of common shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Information Reporting; Backup Withholding Tax </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under U.S.
federal income tax law and Treasury Regulations, certain categories of U.S. Holders must file information returns with respect to their investment in, or involvement in, a foreign corporation. For example, recently enacted legislation generally
imposes new U.S. return disclosure obligations (and related penalties) on U.S. Holders that hold certain specified foreign financial assets in excess of certain threshold amounts. The definition of specified foreign financial assets includes not
only financial accounts maintained in foreign financial institutions, but also, unless held in accounts maintained by a financial institution, any stock or security issued by a non-U.S. person, any financial instrument or contract held for
investment that has an issuer or counterparty other than a U.S. person and any interest in a foreign entity. U.S. Holders may be subject to these reporting requirements unless their common shares are held in an account at certain financial
institutions. Penalties for failure to file certain of these information returns are substantial. U.S. Holders should consult their own tax advisors regarding the requirements of filing information returns, including the requirement to file an IRS
Form 8938. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments made within the U.S., or by a U.S. payor or U.S. middleman, of dividends on, and proceeds arising from certain sales or other taxable
dispositions of the common shares may be subject to information reporting and backup withholding tax, at the current rate of 28%, if a U.S. Holder (a)&nbsp;fails to furnish such U.S. Holder&#146;s correct U.S. social security or other taxpayer
identification number (generally on Form W-9), (b)&nbsp;furnishes an incorrect U.S. taxpayer identification number, (c)&nbsp;is notified by the IRS that such U.S. Holder has previously failed to properly report items subject to backup withholding
tax, or (d)&nbsp;fails under certain circumstances to certify, under penalty of perjury, that such U.S. Holder has furnished its correct U.S. taxpayer identification number and that the IRS has not notified such U.S. Holder that it is subject to
backup withholding tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Any amounts withheld under the U.S. backup withholding tax rules generally will be
allowed as a credit against a U.S. Holder&#146;s U.S. federal income tax liability, if any, or will be refunded, if such U.S. Holder furnishes required information to the IRS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The discussion of reporting requirements set forth above is not intended to constitute a complete description of all reporting requirements that may apply to
a U.S. Holder. A failure to satisfy certain reporting requirements may result in an extension of the time period during which the IRS can assess a tax, and under certain circumstances, such an extension may apply to assessments of amounts unrelated
to any unsatisfied reporting requirement. Each U.S. Holder should consult its own tax advisor regarding the information reporting and backup withholding tax rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stoc685450_17"></A>LEGAL MATTERS AND INTEREST OF EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The auditors of the Corporation are Ernst&nbsp;&amp; Young LLP, Chartered Accountants, 1000, 440 &#150;
2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> Avenue S.W., Calgary, Alberta, T2P 5E9. Ernst&nbsp;&amp; Young LLP is independent of the Corporation in accordance with the Rules of Professional Conduct as outlined by the Institute of
Chartered Accountants of Alberta. Ernst&nbsp;&amp; Young LLP is registered with the U.S. Public Corporation Accounting Oversight Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain legal
matters relating to this offering will be passed upon on our behalf by Norton Rose Fulbright Canada LLP with respect to certain Canadian legal matters and by Dorsey&nbsp;&amp; Whitney LLP with respect to certain U.S. legal matters and on behalf of
the Lincoln Park by Baker&nbsp;&amp; McKenzie LLP with respect to certain Canadian legal matters and by Greenberg Traurig, LLP with respect to certain U.S. legal matters. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stoc685450_18"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a public company and file annual, quarterly and special reports, proxy statements and other information with the Canadian securities regulatory
authorities and the SEC. You may read and copy, for a fee, any document we file at the SEC&#146;s public reference room at 100 F Street, Washington, D.C. 20549. You can request copies of these documents by writing to the SEC and paying a fee for the
copying cost. Please call the SEC at 1-800-SEC-0330 for more information about the operation of the public reference room. Our SEC filings are also available to the public at the SEC&#146;s website at http://www.sec.gov. These documents are also
available through the Internet on the Canadian System for Electronic Document Analysis and Retrieval (SEDAR) which can be accessed at http://www.sedar.com. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BASE SHELF PROSPECTUS</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;3, 2012</TD></TR>
</TABLE> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g685450g72m57.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Cdn. $150,000,000 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Common Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Subscription Receipts </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Units </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may from time to time during the 25-month period that this prospectus (the
&#147;<B>Prospectus</B>&#148;), including any amendments, remains valid, sell under this Prospectus up to Cdn. $150,000,000 (or the equivalent in other currencies or currency units) in one or more offerings, aggregate initial offering price of our
common shares (&#147;<B>Common Shares</B>&#148;), subscription receipts (&#147;<B>Subscription Receipts</B>&#148;), warrants to purchase Common Shares (&#147;<B>Warrants</B>&#148;) and/or units comprised of one or more of the other securities
described in this Prospectus in any combination, (&#147;<B>Units</B>&#148; and, together with the Common Shares, Subscription Receipts and Warrants, the &#147;<B>Securities</B>&#148;). We may offer Securities in such amounts and, in the case of the
Subscription Receipts, Warrants and Units, with such terms, as we may determine in light of market conditions. We may sell the Subscription Receipts and Warrants in one or more series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prospective purchasers should note that we are development stage entity and that an investment in the Securities should be considered highly speculative
due to various risk factors listed on pages 8 to 16 of the Corporation&#146;s AIF. Prospective investors should carefully review these risk factors prior to investing in the Securities of the Corporation.&nbsp;In particular, prospective purchasers
should note the following risks namely, all of our potential products, including REOLYSIN<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, are in the research and development stage and will require further development and testing before
they can be marketed commercially; any failure or delay in clinical trials for our products, including REOLYSIN<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, may cause us to incur additional costs or delay or prevent the
commercialization of our products and could severely harm our business; pharmaceutical products are subject to intense regulatory approval processes; we have limited manufacturing experience and intend to rely on third parties to commercially
manufacture our products, if and when developed; and we have no operating revenues and a history of losses. For detailed description of &#147;</B><B><I><A HREF="#basetoc685450_9">Risk Factors</A></I></B><B>&#148; see page&nbsp;8 of this
Prospectus.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We are permitted, as a foreign issuer in the United States, under a multi-jurisdictional disclosure system adopted by the United
States and Canada, to prepare this Prospectus in accordance with Canadian disclosure requirements. You should be aware that such requirements are different from those of the United States. We have prepared our financial statements incorporated
herein by reference in accordance with International Financial Reporting Standards (&#147;IFRS&#148;) issued by the International Accounting Standards Board&nbsp;and adopted by the Accounting Standards Board of Canada&nbsp;and they are subject to
Canadian auditing and auditor independence standards. Thus, they may not be comparable to the financial statements of United States companies.</B> </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>You should be aware that the purchase of the Securities described herein may have tax consequences both in the
United States and Canada. Such consequences for investors who are resident in, or citizens of, the United States may not be described fully herein. You should read the tax discussion contained in the applicable Prospectus Supplement with respect to
a particular offering of securities. See &#147;</B><B><I>Certain Income Tax Considerations</I></B><B>&#148; at page 13 of this Prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Your
ability to enforce civil liabilities under United States federal securities laws may be affected adversely by the fact that we are incorporated under the laws of Canada, the majority of our officers and directors and some of the experts named in
this Prospectus are residents of Canada, and a substantial portion of our assets and the assets of said persons are located outside the United States.&nbsp;See &#147;</B><B><I>Enforceability of Civil Liabilities</I></B><B>&#148; at page 4 of this
Prospectus.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NEITHER THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION (THE &#147;SEC&#148;) NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR
DISAPPROVED THE SECURITIES OFFERED HEREBY, OR PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENCE. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The specific variable terms of any offering of Securities will be set forth in a supplement to this Prospectus relating to such Securities (each, a
&#147;<B>Prospectus Supplement</B>&#148;) including where applicable: (i)&nbsp;in the case of the Common Shares, the number of Common Shares offered, the currency (which may be Canadian dollars or any other currency), the issue price and any other
specific terms; (ii)&nbsp;in the case of Subscription Receipts, the number of Subscription Receipts offered, the currency (which may be Canadian dollars or any other currency), the issue price, the terms and procedures for the exchange of the
Subscription Receipts and any other specific terms; (iii)&nbsp;in the case of Warrants, the designation, the number of Warrants offered, the currency (which may be Canadian dollars or any other currency), number of Common Shares that may be acquired
upon exercise of the Warrants, the exercise price, dates and periods of exercise, adjustment procedures and any other specific terms; and (iv)&nbsp;in the case of Units, the designation, the number of Units offered, the offering price, the currency
(which may be Canadian dollars or any other currency), terms of the Units and of the securities comprising the Units and any other specific terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All
shelf information permitted under applicable laws to be omitted from this Prospectus will be contained in one or more Prospectus Supplements that will be delivered to purchasers together with this Prospectus.&nbsp;Each Prospectus Supplement will be
incorporated by reference into this Prospectus for the purposes of securities legislation as of the date of the Prospectus Supplement and only for the purposes of the distribution of the Securities to which the Prospectus Supplement
pertains.&nbsp;You should read this Prospectus and any applicable Prospectus Supplement before you invest in the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our outstanding securities
are listed for trading on the Toronto Stock Exchange under the trading symbol &#147;ONC&#148; and on the NASDAQ Capital Market under the trading symbol &#147;ONCY&#148;.&nbsp;Unless otherwise specified in any applicable Prospectus Supplement, the
Subscription Receipts, Warrants and Units will not be listed on any securities exchange.&nbsp;<B>There is no market through which the Subscription Receipts, Warrants or Units may be sold and purchasers may not be able to resell the Subscription
Receipts, Warrants or Units purchased under this Prospectus.&nbsp;This may affect the pricing of these securities in the secondary market, the transparency and availability of trading prices, the liquidity of the securities, and the extent of issuer
regulation.&nbsp;See the &#147;</B><B><I>Risk Factors</I></B><B>&#148; section of the applicable Prospectus Supplement.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may sell the Securities to
or through underwriters, dealers, placement agents or other intermediaries or directly to purchasers or through agents.&nbsp;See detailed discussion on &#147;<I>Plan of Distribution</I>&#148; at page&nbsp;12 of this Prospectus.&nbsp;The Prospectus
Supplement relating to a particular offering of Securities will identify each person who may be deemed to be an underwriter with respect to such offering and will set forth the </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
terms of the offering of such Securities, including, to the extent applicable, the initial public offering price, the proceeds that we will receive, the underwriting discounts or commissions and
any other discounts or concessions to be allowed or re-allowed to dealers.&nbsp;The lead underwriter or underwriters with respect to Securities sold to or through underwriters, if any, will be named in the related Prospectus Supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to applicable securities legislation, in connection with any offering of Securities under this Prospectus, the underwriters, if any, may over-allot or
effect transactions which stabilize or maintain the market price of the Securities offered at a level above that which might otherwise prevail in the open market.&nbsp;These transactions, if commenced, may be discontinued at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>You should rely only on the information contained in this Prospectus.&nbsp;We have not authorized anyone to provide you with information different from
that contained in this Prospectus.&nbsp;No underwriters have been involved in the preparation of this Prospectus or performed any review of the contents of this Prospectus. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our head office and principal place of business is located at 210, 1167 Kensington Crescent N.W., Calgary, Alberta, T2N&nbsp;1X7.&nbsp;Our registered office
is located at 3300, 421 &#150; 7th&nbsp;Avenue S.W., Calgary, Alberta, T2P&nbsp;4K9. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="92%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_1">ABOUT THIS PROSPECTUS AND OTHER MATTER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_2">SPECIAL NOTICE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_3">DOCUMENTS INCORPORATED BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_4">ENFORCEABILITY OF CIVIL LIABILITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_5">THE CORPORATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_6">OUR BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_7">CONSOLIDATED CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_8">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_9">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_10">DESCRIPTION OF SHARE CAPITAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_11">PRIOR SALES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_12">TRADING PRICE AND VOLUME</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_13">DESCRIPTION OF SUBSCRIPTION RECEIPTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_14">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_15">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_16">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_17">CERTAIN INCOME TAX CONSIDERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_18">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_19">AUDITOR</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_20">REGISTRAR AND TRANSFER AGENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_21">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#basetoc685450_22">DOCUMENTS FILED AS PART OF THE REGISTRATION STATEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="basetoc685450_1"></A>ABOUT THIS PROSPECTUS AND OTHER MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this Prospectus and any Prospectus Supplement, unless otherwise indicated, references to &#147;<B>we</B>&#148;, &#147;<B>us</B>&#148;,
&#147;<B>our</B>&#148;, &#147;<B>issuer</B>&#148;, &#147;<B>Oncolytics</B>&#148; or the &#147;<B>Corporation</B>&#148; are to Oncolytics Biotech Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
this Prospectus and in any Prospectus Supplement, unless otherwise specified or the context otherwise requires, all references to &#147;dollars&#148;, &#147;Cdn.$&#148; or &#147;$&#148; are to Canadian dollars and all references to &#147;US$&#148;
are to United States dollars. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all financial information included and incorporated by reference in this Prospectus and any
Prospectus Supplement is determined using International Financial Reporting Standards (&#147;<B>IFRS</B>&#148;).&nbsp;Since January&nbsp;1, 2011, we prepare our financial statements in accordance with IFRS.&nbsp;Prior to the adoption of IFRS, we
followed Canadian Generally Accepted Accounting Principles (&#147;<B>Canadian GAAP</B>&#148;).&nbsp;While IFRS has many similarities to Canadian GAAP, some of our accounting policies have changed as a result of our transition to IFRS.&nbsp;The most
significant accounting policy changes that have had an impact on the results of our operations are discussed in more detail in our management&#146;s discussion and analysis dated March&nbsp;14, 2012, for the year ended December&nbsp;31, 2011, which
is incorporated herein by reference.&nbsp;Since IFRS differ from United States generally accepted accounting principles (&#147;<B>U.S. GAAP</B>&#148;), our financial statements incorporated by reference in this Prospectus and any Prospectus
Supplement and in the documents incorporated by reference in this Prospectus and in any applicable Prospectus Supplement may not be comparable to financial statements prepared in accordance with U.S. GAAP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Prospectus provides you with a general description of the Securities that the Corporation may offer.&nbsp;Each time the Corporation sells Securities
under this Prospectus, the Corporation will provide a Prospectus Supplement that will contain specific information about the terms of that offering of Securities.&nbsp;The Prospectus Supplement also may add, update or change information contained in
this Prospectus.&nbsp;Before investing, investors should read both this Prospectus and any applicable Prospectus Supplement together with additional information described under the heading &#147;<I>Documents Incorporated by Reference</I>&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>You should rely only on the information contained in or incorporated by reference in this Prospectus or any applicable Prospectus Supplement. The
Corporation has not authorized anyone to provide you with different or additional information.&nbsp;The Corporation is not making an offer of these Securities in any jurisdiction where the offer is not permitted by law.&nbsp;You should not assume
that the information contained in or incorporated by reference in this Prospectus or any applicable Prospectus Supplement is accurate as of any date other than the date of the applicable document. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="basetoc685450_2"></A>SPECIAL NOTICE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Prospectus contains certain forward-looking information within the meaning of Canadian securities laws.&nbsp;Forward-looking information typically
contains statements with words such as &#147;anticipate&#148;, &#147;believe&#148;, &#147;expect&#148;, &#147;plan&#148;, &#147;estimate&#148;, &#147;intend&#148;, &#147;may&#148; or similar words suggesting future outcomes.&nbsp;Forward-looking
information in this Prospectus and any applicable Prospectus Supplement includes, but is not limited to, statements with respect to: clinical trial study timing, product development timing, our ability to attract and retain business partners, future
levels of government funding, competition from other biotechnology companies, our ability to obtain the capital required for research, product development, operations and marketing.&nbsp;This forward-looking information is subject to various risks
and uncertainties, including those discussed below, that could cause actual results and experience to differ materially from the anticipated results or other expectations expressed.&nbsp;Our statements of &#147;belief&#148;, &#147;estimates&#148;,
&#147;expectations&#148; and other similar statements are based primarily upon our results derived to date from our research and development program with animals and early stage human results and upon which we believe we have a reasonable scientific
basis to expect the particular results to occur.&nbsp;It is not possible to predict, based upon studies in animals or early stage human results, whether a new therapeutic will be proved to be safe and effective in humans.&nbsp;There can be no
assurance that the particular results expected by us will occur.&nbsp;Forward-looking information is provided for the purpose of assisting you in understanding our current views of future outcomes, and may not be appropriate for other
purposes.&nbsp;Readers are cautioned not to place undue reliance on this forward-looking information, which is provided as of the date of this Prospectus unless otherwise stated, and we will not undertake any obligation to publicly update or revise
any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of the
assumptions, risks and factors which could cause future outcomes to differ materially from those set forth in the forward-looking information contained herein include, but are not limited to: (i)&nbsp;the assumption that we will be able to obtain
sufficient and suitable financing to support operations, clinical trials and commercialization of products, (ii)&nbsp;the risk that we may not be able to capitalize on partnering and acquisition opportunities, (iii)&nbsp;the assumption that we will
obtain favourable clinical trial results in the expected timeframe, (iv)&nbsp;the assumption that we will be able to adequately protect proprietary information and technology from competitors, (v)&nbsp;the risks relating to the uncertainties of the
regulatory approval process, (vi)&nbsp;the impact of competitive products and pricing and the assumption that we will be able to compete in the targeted markets, and (vii)&nbsp;the risk that we may be unable to retain key personnel or maintain third
party relationships, including relationships with key collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By its nature, forward-looking information involves numerous assumptions, inherent
risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections or other forward-looking statements will not occur.&nbsp;<B>Prospective investors should carefully consider the
information contained under the heading &#147;</B><B><I>Risk Factors</I></B><B>&#148; in our AIF (as defined below) and all other information included in or incorporated by reference in this Prospectus before making investment decisions with regard
to our Securities.</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="basetoc685450_3"></A>DOCUMENTS INCORPORATED BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information has been incorporated by reference in this Prospectus from documents filed with securities commissions or similar authorities in Canada and
filed with, or furnished to, the SEC.</B>&nbsp;Copies of the documents incorporated herein by reference may be obtained on request without charge from our Corporate Secretary at 210, 1167 Kensington Crescent N.W., Calgary, Alberta, T2N&nbsp;1X7
telephone (403)&nbsp;670-7377, and are available electronically at www.sedar.com.&nbsp;Disclosure documents filed with, or furnished to, the SEC are available through the SEC&#146;s Electronic Document Gathering and Retrieval System (EDGAR) at
www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed the following documents with the securities commissions or similar regulatory authorities in certain of the provinces of
Canada and such documents are specifically incorporated by reference in, and form an integral part of, this Prospectus, provided that such documents are not incorporated by reference to the extent that their contents are modified or superseded by a
statement contained in this Prospectus or in any subsequently filed document that is also incorporated by reference in this Prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Annual Information Form, which is comprised of our Annual Report on Form&nbsp;20-F dated March&nbsp;23, 2012, for the year ended December&nbsp;31, 2011 (the &#147;<B>AIF</B>&#148;); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our management information circular dated May&nbsp;14, 2012, relating to the annual general meeting of shareholders held on June&nbsp;20, 2012; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our audited consolidated financial statements, together with the notes thereto, as at December&nbsp;31, 2011 and 2010, which comprise the consolidated statements of financial position as at December&nbsp;31, 2011 and
2010 and January&nbsp;1, 2010, and the consolidated statements of loss and comprehensive loss, changes in equity, and cash flows for the years ended December&nbsp;31, 2011 and 2010; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our management&#146;s discussion and analysis of financial condition and results of operations dated March&nbsp;14, 2012, for the year ended December&nbsp;31, 2011; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our unaudited interim condensed consolidated financial statements, together with the notes thereto, as at and for the period ended March&nbsp;31, 2012; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our management&#146;s discussion and analysis of financial condition and results of operations dated May&nbsp;9, 2012, as at and for the period ended March&nbsp;31, 2012; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our material change report dated February&nbsp;10, 2012, concerning the offering closed February&nbsp;8, 2012 of Common Shares for aggregate gross proceeds of approximately Cdn.&nbsp;$21,276,150. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any documents of the type required by National Instrument&nbsp;44-101&#151;<I>Short Form Prospectus Distributions&nbsp;</I>of the Canadian Securities
Administrators to be incorporated by reference in a short form prospectus, including any annual information form, comparative annual consolidated financial statements and the auditors&#146; report thereon, comparative interim consolidated financial
statements, management&#146;s discussion and analysis of financial condition and results of operations, material change report (except a confidential material change report), business acquisition report and information circular, if filed by us with
the securities commissions or similar authorities in the provinces of Canada after the date of this Prospectus shall be deemed to be incorporated by reference in this Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any similar document filed by the Corporation with, or furnished by the Corporation to, the SEC pursuant to pursuant to section&nbsp;13(a), 13(c), 14 or 15(d)
of the United&nbsp;States Securities Exchange Act of 1934, as amended (the&nbsp;&#147;<B>Exchange Act</B>&#148;), after the date of this Prospectus shall be deemed to be incorporated by reference in this Prospectus and filed as exhibits to the
registration statement of which this Prospectus forms a part (in&nbsp;the case of any Report on Form&nbsp;6-K, if and to the extent provided in such&nbsp;report). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Any statement contained in this Prospectus or in a document incorporated or deemed to be
incorporated by reference herein will be deemed to be modified or superseded for purposes of this Prospectus to the extent that a statement contained in this Prospectus or in any other subsequently filed document which also is, or is deemed to be,
incorporated by reference into this Prospectus modifies or supersedes that statement.&nbsp;The modifying or superseding statement need not state that it has modified or superseded a prior statement or include any other information set forth in the
document that it modifies or supersedes.&nbsp;The making of a modifying or superseding statement shall not be deemed an admission for any purposes that the modified or superseded statement when made, constituted a misrepresentation, an untrue
statement of a material fact or an omission to state a material fact that is required to be stated or that is necessary to make a statement not misleading in light of the circumstances in which it was made.&nbsp;Any statement so modified or
superseded shall not be deemed, except as so modified or superseded, to constitute part of this Prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon a new annual information form and
related audited annual financial statements and management&#146;s discussion and analysis being filed by us with, and where required, accepted by, the securities commission or similar regulatory authority in each of the provinces of British
Columbia, Alberta, Manitoba and Ontario during the term of this Prospectus, the previous annual information form, the previous audited annual financial statements and related management&#146;s discussion and analysis, all unaudited interim financial
statements and related management&#146;s discussion and analysis, material change reports and business acquisition reports filed prior to the commencement of our financial year in which the new annual information form and related audited annual
financial statements and management&#146;s discussion and analysis are filed shall be deemed no longer to be incorporated into this Prospectus for purposes of future offers and sales of Securities under this Prospectus.&nbsp;Upon new interim
financial statements and related management&#146;s discussion and analysis being filed by us with the securities commission or similar regulatory authority in each of the provinces of British Columbia, Alberta, Manitoba and Ontario during the term
of this Prospectus, all interim financial statements and related management&#146;s discussion and analysis filed prior to the new interim consolidated financial statements and related management&#146;s discussion and analysis shall be deemed no
longer to be incorporated into this Prospectus for purposes of future offers and sales of Securities under this Prospectus.&nbsp;Upon a new information circular relating to an annual general meeting of holders of Common Shares being filed by us with
the securities commission or similar regulatory authority in each of the provinces of British Columbia, Alberta, Manitoba and Ontario during the term of this Prospectus, the information circular for the preceding annual general meeting of holders of
Common Shares shall be deemed no longer to be incorporated into this Prospectus for purposes of future offers and sales of Securities under this Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One or more Prospectus Supplements containing the specific variable terms for an issue of the Securities and other information in relation to such Securities
will be delivered to purchasers of such Securities together with this Prospectus and will be deemed to be incorporated by reference into this Prospectus as of the date of the Prospectus Supplement solely for the purposes of the offering of the
Securities covered by any such Prospectus Supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="basetoc685450_4"></A>ENFORCEABILITY OF CIVIL LIABILITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a corporation incorporated under the&nbsp;<I>Business Corporations Act</I>&nbsp;(Alberta) (the &#147;<B>ABCA</B>&#148;).&nbsp;The majority of our
officers and directors and some of the experts named in this Prospectus, are residents of Canada or otherwise reside outside the United States, and all, or a substantial portion of their assets and a substantial portion of our assets, are located
outside the United States.&nbsp;We have appointed an agent for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
service of process in the United States, but it may be difficult for holders of Securities who reside in the United States to effect service within the United States upon those directors,
officers and experts who are not residents of the United States.&nbsp;It may also be difficult for holders of Securities who reside in the United States to realize in the United States upon judgments of courts of the United States predicated upon
our civil liability and the civil liability of our directors, officers and experts under the United States federal securities laws.&nbsp;We have been advised by our Canadian counsel, McCarthy T&eacute;trault LLP, that a judgment of a United States
court predicated solely upon civil liability under United States federal securities laws, would probably be enforceable in Canada if, the United States court in which the judgment was obtained, has a basis for jurisdiction in the matter that would
be recognized by a Canadian court for the same purposes.&nbsp;We have also been advised by McCarthy T&eacute;trault LLP, however, that there is substantial doubt whether an action could be brought in Canada in the first instance on the basis of
liability predicated solely upon United States federal securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We filed with the SEC, concurrently with our registration statement on
Form&nbsp;F-10, an appointment of agent for service of process on Form&nbsp;F-X.&nbsp;Under the Form&nbsp;F-X, we appointed&nbsp;CT Corporation System&nbsp;as our agent for service of process in the United States in connection with any investigation
or administrative proceeding conducted by the SEC or similar authorities in United States, and any civil suit or action brought against or involving us in a United States court arising out of or related to or concerning the offering of the
Securities under this Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="basetoc685450_5"></A>THE CORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oncolytics Biotech Inc. was incorporated pursuant to the ABCA on April&nbsp;2, 1998 as 779738 Alberta Ltd.&nbsp;On April&nbsp;8, 1998, we amended our articles
of incorporation (the &#147;<B>Articles</B>&#148;) and changed our name to Oncolytics Biotech Inc.&nbsp;On July&nbsp;29, 1999, we further amended our Articles by removing the private company restrictions included therein and subdivided our 2,222,222
Common Shares issued and outstanding into 6,750,000 Common Shares.&nbsp;On February&nbsp;9, 2007,&nbsp;we further amended our Articles to permit shareholder meetings to be held at any place in Alberta or at any other location as determined by our
board of directors (the &#147;<B>Board</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our head office and principal place of business is located at 210, 1167 Kensington Crescent N.W.,
Calgary, Alberta, T2N&nbsp;1X7.&nbsp;Our registered office is located at 3300, 421 &#150; 7th&nbsp;Avenue S.W., Calgary, Alberta, T2P&nbsp;4K9. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
two direct wholly-owned subsidiaries, namely: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Oncolytics Biotech (Barbados) Inc., which is incorporated pursuant to the laws of Barbados; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Valens Pharma Ltd., which is incorporated pursuant to the laws of the Province of Alberta. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also have two
indirect wholly-owned subsidiaries, namely: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Oncolytics Biotech (U.S.), Inc., which is incorporated pursuant to the laws of Delaware; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Oncolytics Biotech (U.K.) Ltd., which is incorporated pursuant to the laws of England and Wales. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Both
Oncolytics Biotech (U.S.), Inc. and Oncolytics Biotech (U.K.) Ltd. are wholly-owned direct subsidiaries of Oncolytics Biotech (Barbados) Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following schematic illustrates our corporate structure: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g685450g55t09.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="basetoc685450_6"></A>OUR BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We focus on the discovery and development of oncolytic viruses for the treatment of cancers that have not been successfully treated with conventional
therapeutics.&nbsp;Recent scientific advances in oncology, virology, and molecular biology have created opportunities for new approaches to the treatment of cancer.&nbsp;The product we are presently developing may represent a novel treatment for
Ras-mediated cancers.&nbsp;The product may be useful as an alternative to existing cytotoxic or cytostatic therapies, or as an adjuvant therapy to conventional chemotherapy, radiation therapy, or surgical resections.&nbsp;It could also potentially
be used to treat certain cellular proliferative disorders for which no current therapy exists. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our technologies are based primarily on discoveries made
in the Department of Microbiology and Infectious Diseases at the University of Calgary in the 1990s.&nbsp;Oncolytics was formed in 1998 to explore the natural oncolytic capability of the reovirus, a virus that preferentially replicates in cells with
an activated Ras pathway. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The lead product being developed by us may represent a novel treatment for certain tumour types and some cellular proliferative
disorders.&nbsp;This lead product is a virus that is able to replicate specifically in, and hence kill, certain tumour cells both in tissue culture as well as in a number of animal models without damaging normal cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our potential product for human use, REOLYSIN<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, is developed from the reovirus.&nbsp;This virus has
been demonstrated to replicate specifically in tumour cells bearing an activated Ras pathway.&nbsp;Activating mutations of Ras occur in approximately 30% of all human tumours directly, but considering its central role in signal transduction,
activation of the Ras pathway has been shown to play a role in approximately 2/3 of all tumours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The functionality of REOLYSIN<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> is based upon the finding that tumours bearing an activated Ras pathway are deficient in their ability to activate the anti-viral response mediated by the host cellular protein, Protein Kinase R
(&#147;<B>PKR</B>&#148;).&nbsp;Since PKR is responsible for preventing reovirus replication, tumour cells lacking the activity of PKR are susceptible to reovirus infections.&nbsp;As normal cells do not possess Ras activations, these cells are able
to thwart reovirus infections by the activity of PKR.&nbsp;In a tumour cell with an activated Ras pathway, reovirus is able to freely replicate and hence kill the host tumour cell.&nbsp;The result of this replication is progeny viruses that are then
free to infect surrounding cancer cells.&nbsp;This cycle of infection, replication and cell death is believed to be repeated until there are no longer any tumour cells carrying an activated Ras pathway available. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following schematic illustrates the molecular basis of how we believe the reovirus may kill certain cancer
cells: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g685450g89q14.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For both non-cancer cells and cancer cells with an activated Ras pathway, virus binding, entry, and production of viral
genes all proceed normally.&nbsp;In the case of normal cells however, the viral genes cause the activation of the anti-viral response that is mediated by the host cell&#146;s PKR, thus blocking the replication of the reovirus.&nbsp;In cells with an
activated Ras pathway, the activation of PKR is prevented or reversed by an element of the Ras signal transduction pathway, thereby allowing the replication of the reovirus in these cancer cells.&nbsp;The end result of this replication is the death
of the cancer cell.&nbsp;The action of the Ras pathway in allowing reovirus replication to ensue can be mimicked in non-cancerous cells by treating these cells with the chemical 2-aminopurine (2-AP) which prevents the activation of PKR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="basetoc685450_7"></A>CONSOLIDATED CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise described below, there has been no material change in the share and loan capital of the Corporation on a consolidated basis since
March&nbsp;31, 2012, the date of the most recently filed unaudited interim consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;25, 2012, the Corporation
issued 4,405,000 Common Shares at a price of $4.20 per Common Share by way of a bought deal financing by way of a Prospectus Supplement to a base shelf prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="basetoc685450_8"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in an applicable Prospectus Supplement relating to an offering of Securities, our present intention is to use the net proceeds we
receive from the sale of Securities to fund our core </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
activities.&nbsp;Our key focus is on the progression of our clinical trial program which includes the trials currently underway or which may commence during the period that this Prospectus is
valid.&nbsp;The determination of the size of such trials, their geographic locations, and the disease indications being tested are continually assessed and may change as further information is received. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Funding for our manufacturing program also remains an important activity, as sufficient capacity to produce and provide GMP (good manufacturing practice)
compliant product is required if we are successful in our clinical program and our product is approved for commercial sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Continually developing our
intellectual property portfolio to expand and protect our core assets, our potential products, and the other necessary overhead costs for administrative, marketing and general activities would generally conclude the allocation of net proceeds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">More specific allocations would be included in an applicable Prospectus Supplement relating to a specific offering of Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All expenses relating to the offering of Securities and any compensation paid to underwriters, dealers or agents, as the case may be, will be paid out of the
Corporation&#146;s general fund, unless otherwise stated in the applicable Prospectus Supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="basetoc685450_9"></A>RISK
FACTORS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>An investment in the Securities involves a high degree of risk.&nbsp;Prospective investors should note that there is no
market through which the Subscription Receipts, Warrants or Units may be sold and purchasers may not be able to resell the Subscription Receipts, Warrants or Units purchased under this Prospectus.&nbsp;This may affect the pricing of these securities
in the secondary market, the transparency and availability of trading prices, the liquidity of the securities, and the extent of issuer regulation. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prospective investors should consider carefully the risks incorporated by reference in this Prospectus (including in subsequently filed documents incorporated
by reference) and those described in any Prospectus Supplement before purchasing the Securities offered hereby.&nbsp;Discussions of certain risks affecting the Corporation in connection with its business are provided under the heading &#147;Risk
Factors&#148; in our AIF filed with the various securities regulatory authorities, which is incorporated by reference in this Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="basetoc685450_10"></A>DESCRIPTION OF SHARE CAPITAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Authorized Capital </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our authorized capital consists of
an unlimited number of Common Shares.&nbsp;The following is a summary of the provisions attached to our Common Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of our Common Shares are entitled to one vote per share at meetings of shareholders, to receive such dividends as declared by our Board and to
receive our remaining property and assets upon dissolution or wind up.&nbsp;Our Common Shares are not subject to any future call or assessment and there are no pre-emptive, conversion or redemption rights attached to such shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As at July&nbsp;3, 2012, we have&nbsp;76,582,751&nbsp;Common Shares issued and outstanding.&nbsp;After giving effect to the exercise of all our Common Share
purchase warrants and options, we would have&nbsp;84,395,717<B>&nbsp;</B>Common Shares issued and outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="basetoc685450_11"></A>PRIOR SALES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as disclosed below, no other Common Shares or securities exchangeable or convertible into Common Shares have been issued during the twelve month period
preceding the date of this Prospectus: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;27, 2011, 81,000 stock options were granted with an exercise price of $4.31. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;9, 2011, 225,000 stock options were granted with an exercise price ranging between $3.81 and $4.72. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;14, 2011, 907,000 stock options were granted with an exercise price of $3.89. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;23, 2012, 30,000 stock options were granted with an exercise price of $4.27. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;25, 2012, the Corporation issued 4,405,000 Common Shares at a price of $4.20 per Common Share by way of a bought deal financing by way of a
Prospectus Supplement to a base shelf prospectus.&nbsp;In connection with the offering, the underwriters exercised in full their over-allotment option to purchase an additional 660,750 shares at a price of $4.20 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the period from July&nbsp;3, 2011 to July&nbsp;3, 2012, 302,683 stock options were exercised for proceeds of $896,994. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="basetoc685450_12"></A>TRADING PRICE AND VOLUME </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our outstanding Common Shares are listed and posted for trading on the Toronto Stock Exchange under the trading symbol &#147;ONC&#148; and on NASDAQ under the
trading symbol &#147;ONCY&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the market price ranges and the aggregate volume of trading of the Common Shares on the
Toronto Stock Exchange and NASDAQ for the periods indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Toronto Stock Exchange</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NASDAQ Capital Market</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Close</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Volume</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Close</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Volume</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:22.65pt; font-size:8pt; font-family:Times New Roman"><B>Period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Cdn.$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Cdn.$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Cdn.$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Shares)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(US$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(US$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(US$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Shares)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>2011</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,071,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,549,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">August</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,643,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,957,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,195,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,546,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">775,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,012,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">730,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,565,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,142,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,767,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>2012</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,089,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,534,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,405,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,188,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,623,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,798,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,195,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,497,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,169,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,606,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,070,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,329,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="basetoc685450_13"></A>DESCRIPTION OF SUBSCRIPTION RECEIPTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description of the terms of Subscription Receipts sets forth certain general terms and provisions of Subscription Receipts in respect of which a
Prospectus Supplement may be filed.&nbsp;The particular terms and provisions of Subscription Receipts offered by any Prospectus Supplement, and the extent to which the general terms and provisions described below may apply thereto, will be described
in the Prospectus Supplement filed in respect of such Subscription Receipts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subscription Receipts may be offered separately or in combination with one
or more other Securities.&nbsp;The Subscription Receipts will be issued under a subscription receipt agreement (the &#147;<B>Subscription Agreement</B>&#148;).&nbsp;A copy of the Subscription Agreement will be filed by us with the applicable
securities commission or similar regulatory authorities after it has been entered into by us and will be available electronically at www.sedar.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Subscription Agreement, original purchasers of Subscription Receipts will have a contractual right of rescission against Oncolytics, following
the issuance of the underlying Common Share or other securities to such purchasers upon the surrender or deemed surrender of the Subscription Receipts, to receive the amount paid for the Subscription Receipts in the event that this Prospectus or a
Prospectus Supplement and any amendment thereto, contains a misrepresentation or is not delivered to such purchaser, provided such remedy for rescission is exercised within 180&nbsp;days from the closing date of the offering of Subscription
Receipts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The description of general terms and provisions of Subscription Receipts described in any Prospectus Supplement will include, where applicable:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of Subscription Receipts offered; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the price at which the Subscription Receipts will be offered; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if other than Canadian dollars, the currency or currency unit in which the Subscription Receipts are denominated; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the procedures for the exchange of the Subscription Receipts into Common Shares or other securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of Common Shares or other securities that may be obtained upon exercise of each Subscription Receipt; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the designation and terms of any other Securities with which the Subscription Receipts will be offered, if any, and the number of Subscription Receipts that will be offered with each Security; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms applicable to the gross proceeds from the sale of the Subscription Receipts plus any interest earned thereon; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the material tax consequences of owning such Subscription Receipts; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other material terms, conditions and rights (or limitations on such rights) of the Subscription Receipts. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We reserve the right to set forth in a Prospectus Supplement specific terms of the Subscription Receipts that are not within the options and parameters set
forth in this Prospectus.&nbsp;In addition, to the extent that any particular terms of the Subscription Receipts described in a Prospectus Supplement differ from any of the terms described in this Prospectus, the description of such terms set forth
in this Prospectus shall be deemed to have been superseded by the description of such differing terms set forth in such Prospectus Suppleme </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="basetoc685450_14"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description of the terms of Warrants sets forth certain general terms and provisions of Warrants in respect of which a Prospectus Supplement may
be filed.&nbsp;The particular terms and provisions of Warrants offered by any Prospectus Supplement, and the extent to which the general terms and provisions described below may apply thereto, will be described in the Prospectus Supplement filed in
respect of such Warrants.&nbsp;Warrants may be offered separately or in combination with one or more other Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The description of general terms
and provisions of Warrants described in any Prospectus Supplement will include, where applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the designation and aggregate number of Warrants offered; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the price at which the Warrants will be offered; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if other than Canadian dollars, the currency or currency unit in which the Warrants are denominated; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the designation and terms of the Common Shares that may be acquired upon exercise of the Warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date on which the right to exercise the Warrants will commence and the date on which the right will expire; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of Common Shares that may be purchased upon exercise of each Warrant and the price at which and currency or currencies in which that amount of securities may be purchased upon exercise of each Warrant;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the designation and terms of any Securities with which the Warrants will be offered, if any, and the number of the Warrants that will be offered with each Security; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date or dates, if any, on or after which the Warrants and the related Securities will be transferable separately; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the minimum or maximum amount, if any, of Warrants that may be exercised at any one time; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the Warrants will be subject to redemption or call, and, if so, the terms of such redemption or call provisions; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other material terms, conditions and rights (or limitations on such rights) of the Warrants. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We reserve
the right to set forth in a Prospectus Supplement specific terms of the Warrants that are not within the options and parameters set forth in this Prospectus.&nbsp;In addition, to the extent that any particular terms of the Warrants described in a
Prospectus Supplement differ from any of the terms described in this Prospectus, the description of such terms set forth in this Prospectus shall be deemed to have been superseded by the description of such differing terms set forth in such
Prospectus Supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="basetoc685450_15"></A>DESCRIPTION OF UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue Units comprised of one or more of the other Securities described in this Prospectus in any combination.&nbsp;Each Unit will be issued so that the
holder of the Unit is also the holder of each Security included in the Unit.&nbsp;Thus, the holder of a Unit will have the rights and obligations of a holder of each included Security.&nbsp;The unit agreement, if any, under which a Unit is issued
may provide that the Securities comprising the Unit may not be held or transferred separately, at any time or at any time before a specified date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The particular terms and provisions of Units offered by any Prospectus Supplement, and the extent to which the
general terms and provisions described below may apply thereto, will be described in the Prospectus Supplement filed in respect of such Units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
particular terms of each issue of Units will be described in the related Prospectus Supplement.&nbsp;This description will include, where applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the designation and aggregate number of Units offered; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the price at which the Units will be offered; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if other than Canadian dollars, the currency or currency unit in which the Units are denominated; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms of the Units and of the Securities comprising the Units, including whether and under what circumstances those securities may be held or transferred separately; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of Securities that may be purchased upon exercise of each Unit and the price at which and currency or currency unit in which that amount of Securities may be purchased upon exercise of each Unit;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any provisions for the issuance, payment, settlement, transfer or exchange of the Units or of the Securities comprising the Units; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other material terms, conditions and rights (or limitations on such rights) of the Units. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We reserve the
right to set forth in a Prospectus Supplement specific terms of the Units that are not within the options and parameters set forth in this Prospectus.&nbsp;In addition, to the extent that any particular terms of the Units described in a Prospectus
Supplement differ from any of the terms described in this Prospectus, the description of such terms set forth in this Prospectus shall be deemed to have been superseded by the description of such differing terms set forth in such Prospectus
Supplement with respect to such Units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="basetoc685450_16"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also may sell Securities directly to purchasers or
through agents, subject to obtaining any applicable exemptions from registration requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The distribution of Securities may be effected from time
to time in one or more transactions at a fixed price or prices, which may be changed, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an
accompanying Prospectus Supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the sale of Securities, underwriters may receive compensation from us or from purchasers of
Securities for whom they may act as agents in the form of discounts, concessions or commissions.&nbsp;Underwriters, dealers, placement agents or other intermediaries that participate in the distribution of Securities may be deemed to be underwriters
and any discounts or commissions received by them from us and any profit on the resale of Securities by them may be deemed to be underwriting discounts and commissions under applicable securities legislation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If so indicated in the applicable Prospectus Supplement, we may authorize dealers or other persons acting as our agents to solicit offers by certain
institutions to purchase the Securities directly from us pursuant to contracts providing for payment and delivery on a future date.&nbsp;These contracts will be subject only to the conditions set forth in the applicable Prospectus Supplement or
supplements, which will also set forth the commission payable for solicitation of these contracts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Prospectus Supplement relating to any offering of Securities will also set forth the terms of the offering of
the Securities, including, to the extent applicable, the initial offering price, the proceeds to us, the underwriting discounts or commissions, and any other discounts or concessions to be allowed or reallowed to dealers.&nbsp;Underwriters with
respect to any offering of Securities sold to or through underwriters will be named in the Prospectus Supplement relating to such offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of
Warrants resident in the United States who acquire Common Shares pursuant to the exercise of Warrants in accordance with their terms and under this Prospectus and any applicable Prospectus Supplement may have a right of action against the
Corporation for any misrepresentation in this Prospectus or any applicable Prospectus Supplement.&nbsp;However, the existence and enforceability of such a right of action is not without doubt. By contrast, holders of Warrants resident in Canada who
may acquire Common Shares pursuant to the exercise of Warrants in accordance with their terms and who will be deemed to acquire such Common Shares under applicable Canadian prospectus exemptions, will not have any such right of action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under agreements which may be entered into by us, underwriters, dealers, placement agents and other intermediaries who participate in the distribution of
Securities may be entitled to indemnification by us against certain liabilities, including liabilities under applicable securities legislation.&nbsp;The underwriters, dealers, placement agents and other intermediaries with whom we enter into
agreements may be customers of, engage in transactions with or perform services for us in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any offering of Subscription
Receipts, Warrants or Units will be a new issue of securities with no established trading market. Unless otherwise specified in the applicable Prospectus Supplement, the Subscription Receipts, Warrants or Units will not be listed on any securities
exchange.&nbsp;<B>Unless otherwise specified in the applicable Prospectus Supplement, there is no market through which the Subscription Receipts, Warrants or Units may be sold and purchasers may not be able to resell Subscription Receipts, Warrants
or Units purchased under this Prospectus or any Prospectus Supplement.&nbsp;This may affect the pricing of the Subscription Receipts, Warrants or Units in the secondary market, the transparency and availability of trading prices, the liquidity of
the securities, and the extent of issuer regulation.</B>&nbsp;Certain dealers may make a market in the Subscription Receipts, Warrants or Units, as applicable, but will not be obligated to do so and may discontinue any market making at any time
without notice.&nbsp;No assurance can be given that any dealer will make a market in the Subscription Receipts, Warrants or Units or as to the liquidity of the trading market, if any, for the Subscription Receipts, Warrants or Units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to applicable securities legislation, in connection with any offering of Securities under this Prospectus, the underwriters, if any, may over-allot or
effect transactions which stabilize or maintain the market price of the Securities offered at a level above that which might otherwise prevail in the open market.&nbsp;These transactions, if commenced, may be discontinued at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="basetoc685450_17"></A>CERTAIN INCOME TAX CONSIDERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The applicable Prospectus Supplement may describe certain Canadian federal income tax consequences which may be applicable to a purchaser of Securities
offered thereunder, and may also include a discussion of certain United States federal income tax consequences to the extent applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="basetoc685450_18"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in the Prospectus Supplement, certain legal matters relating to the offering of the Securities will be passed upon for us by
McCarthy T&eacute;trault LLP and Dorsey &amp;Whitney LLP.&nbsp;In addition, certain legal matters in connection with any offering of Securities will be passed upon for any underwriters, dealers or agents by counsel to be designated at the time of
the offering by such underwriters, dealers or agents with respect to matters of Canadian and United States law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The partners and associates of McCarthy T&eacute;trault LLP, as a group, beneficially own, directly or
indirectly, less than 1% of our securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="basetoc685450_19"></A>AUDITOR </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our auditors are Ernst&nbsp;&amp; Young LLP, Chartered Accountants, Calgary, Alberta, Canada. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our consolidated financial statements as at December&nbsp;31, 2011 and 2010 and January&nbsp;1, 2010 incorporated by reference into this Prospectus have been
audited by Ernst&nbsp;&amp; Young LLP, independent registered chartered accountants, as indicated in their report dated March&nbsp;14,&nbsp;2012 and are incorporated herein in reliance upon the authority of said firm as experts in accounting and
auditing in giving said report. Ernst&nbsp;&amp; Young LLP has been our auditors since inception in 1998. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP has advised that
they are independent with respect to the Corporation within the meaning of the Rules of the Professional Conduct of the Institute of Chartered Accountants of Alberta. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="basetoc685450_20"></A>REGISTRAR AND TRANSFER AGENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our registrar and transfer agent is Computershare Trust Company of Canada at its principal office in Calgary, Alberta. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="basetoc685450_21"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form&nbsp;F-10 relating to the Securities.&nbsp;This Prospectus, which constitutes a part of the
registration statement, does not contain all of the information contained in the registration statement, certain items of which are contained in the exhibits to the registration statement as permitted by the rules and regulations of the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file annual and quarterly financial information and material change reports and other material with the SEC and with the securities commissions or similar
regulatory authorities in Canada.&nbsp;Under a multi-jurisdictional disclosure system adopted by the United States and Canada, documents and other information that we file with the SEC may be prepared in accordance with the disclosure requirements
of Canada, which are different from those of the United States.&nbsp;As a foreign private issuer, the Corporation is exempt from the rules under the Exchange Act prescribing the furnishing and content of proxy statements, and the Corporation&#146;s
officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section&nbsp;16 of the Exchange Act.&nbsp;In addition, the Corporation is not required to publish financial
statements as promptly as U.S.&nbsp;companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may read and copy any document that we have filed with the SEC at the SEC&#146;s public reference
rooms in Washington, D.C. and Chicago, Illinois.&nbsp;You may also obtain copies of those documents from the public reference room of the SEC at 100F Street, N.E., Washington, D.C. 20549 by paying a fee.&nbsp;You should call the SEC at
1-800-SEC-0330 or access its website at&nbsp;<U>www.sec.gov</U>&nbsp;for further information about the public reference rooms.&nbsp;You may read and download some of the documents we have filed with the SEC&#146;s Electronic Data Gathering and
Retrieval system (EDGAR) at www.sec.gov.&nbsp;You may read and download any public document that we have filed with the securities commissions or similar regulatory authorities in Canada at&nbsp;www.sedar.com. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="basetoc685450_22"></A>DOCUMENTS FILED AS PART OF THE REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following documents have been filed with the SEC as part of the registration statement of which this Prospectus is a part insofar as required by the
SEC&#146;s Form F-10: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the documents listed under &#147;Documents Incorporated by Reference&#148; in this Prospectus; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the consent of our auditors Ernst&nbsp;&amp; Young LLP; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the consent of our Canadian counsel McCarthy T&eacute;trault LLP; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">powers of attorney from our directors and officers; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Form F-X&#151;Appointment of Agent for Service of Proceeds and Undertaking. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g685450g34w23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g685450g34w23.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``@&!@<&!0@'!P<*"0@*#18.#0P,#1L3%!`6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`80"80,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/?Z`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`:X<H0C!6[%
MAD#\,B@#F-.US5[_`$>\U!$M";:1T,.QAO"]<-N.,_2M'%)V,U*35S=TK48]
M6TNWOHE*I,N[:>H/<?G4-6=BXNZN7*0PH`*`"@"M8F\-HOV\0BYR=PA)*XSQ
MC//3%-VZ"5[:EFD,*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`
M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H
M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`\VL
MH]0_X1'4YK29C$E[(9X%`!DCXW@-U!Q6[MS*YSJ_*['57NIP6/@F2_TA5\F.
MW'D!1PO8?EW^E9I7E9FK=H70ZTTV^CO+.YCGC6)0?.Q([F<$<$Y[YP<T-H$G
M>Y6\/I_;NAO?7CR?:;F23!#$-;X8@*O]W&`??O1+W79"C[RNS/:XO=3\"6^J
MN[M>6;&1BC%1,J.0P..H*C]*K12L3=N%S?L1#J5Y/J$3N8&C6*(JY`/&2PP?
M]H#/7Y34/30T6KN<_'/<'X72S_:IQ.JRGS?,.\XE8<GK5_;,]?9E_4].6Q\-
M:I>1W5TT\MMO+-,W#*,@CT_"DG>2135HMBZJ\B0>&YDFE5WNH8WQ(P#*5)((
MS@]!UH74'T(-8N)+#4;N;4X9VT^0J(+RW<_Z+P!@J#QSSGOG'M1'5:"D[/78
MZT$$`@Y!Z&LS46@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`:ZED*ARA/\`$N,C
M\Z`*&E:-;Z-%)%:R2F.1B[+(V[YCU/3/:FY7W)C%1V&6>@V-C%<P0J_V6XW;
M[=FS&,]<#M]!3<FP44A=/T2WTX(L<UQ)''_JHY92RQ_0?XYH<K@HI#AHUNGV
M@0/+!'<,6ECC;"L3U/J"?;%+F8<J+D=M!#;+;1Q*D"KL"`<`>E*X[6T(K.PA
MT_3HK&US%%$NU2,$CWY[TV[N[!*RLBFOAZT716TD23?8VSE=PS@DDC./4YI\
MSO<7*K6+KV,4M@]E.6FA="C;\9*D8QP!2OK<=M+&</#%EY%K$\UU)]E=7B9Y
MB2N`0`/0<_H/2GS,GD18N-%M[GSDDEF,$[!I8=_R.1C\1T'`(S0I6&XIFD!@
M8'%24%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!
M0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!4U+[8-/E:P*_:4`9
M%8<-@YV_B./QIJU]1.]M!VGWL6HV$-W#G9(N<'JI[@^X.1^%#5G8$[JY9I#,
MNTO9K[5[D0D"QM1Y3'',DO?!]%''U)]*IJR)3NS4J2@H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`
MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`
M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@!K,J(79@JJ,DGH!0!PEA<:GJ=Q>R:#
M/)!'-.9""$$48(')+*Q+-C<0.!D9YK9V7Q&";=^4M3V7BFSA>6ZU2>Z3!R;0
M(K)QUV%/F_`@TDXO9#M-;LUO"%Y:W?AVW6V`4P#RY%!_C'4_CG=^-3--,NFT
MXZ&[4%A0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`
M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0
M`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`4KVZO()%
M6VTYKI2,EA*J8/IS320FVMD8.NWU_/9QVESIS6=M<2".20S*VX8)V?+TW$!<
M^]7%):HSDW:S1K>&H(H/#>GB+!#PK(3_`'F8;B?S)J9?$RX*T4:M24</`7TC
MQ9>_V="TYGN2CVJ$`L/*5RP)(`VLQ'/]_%:[QU,5[LM#HTU/4&D56T&Z120"
MQFAX]_OU%EW-+OL:M24%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!
M0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`
M%`!0!7OK.'4+*:TG7,4J[3CJ/<>XZTT[.XFKJQQNBZQ-X9CFTO5")HK:0JK(
MP\Q0>0=I.64@Y!&2.16DH\VJ,HRY-&:<OC2RE0IIXWS$<-<'R8T]R6P?P&34
M\C6Y7M%T$\'Z8T<,^KW#&2YO6+*[#!V9SG';<>?IM':G-]`IKJ=169H%`!0`
M4`%`%>SNUO8#*B,@$CQD-C.48J>GNIIM6$G<L4AA0`4`%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!
M0`4`%`!0`4`%`&9?ZU!91W2HK2W$.Q1$!R[O]P#ZFJ4;DN5ANFZ-%;VI-Y'%
M<7DK&2>5D!RY],]AP!["AR[`HVW+;:98.I5K*`@C!'EBE=CLC%MM1.@6UUIU
MP&E:S`:WR>9(68*O/JI.T_AZU37-J0GRJQTE0:&#XCGECMIXX#<B?[-))%Y1
M91O'3[HR3TX/&,YJXD3&W48DU>_96N09+%##L>106_>9X!QG&W\_4T+9">[*
M=U,8M`2.T>\\W[$TD6'D^^`,<\DG/\/3&::WU$]%H:;W2R:H\%P;F-2$>V,8
M<!QU/3OGJ#VQ4VLBKZZE2R22":RD225?,U"Z61=YV;"TK`E>@YV$'W'K38EH
M1V*3O_9YFN+O,EQ<1R@S.,IN?9GGCHN#[^]-@N@D,UT8;."YNKB*$I*@F`8L
M6#X7)'.=N",]>>M&G0->I+<"X5KV1;BY+Q7$'E?O&`Q\F[Y1P1][(Z=:2!W+
MNFQJFLZMN:;>9@4#.Y788X^0#Q]X-^1%)[(I;LUZDH*`"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`(O/B^T_9]W[W;OVX[9QF@+]"6@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`
M"@`H`*`"@`H`*`"@`H`*`"@`H`*`.:M5O]2U2^U+3KN&VMGVP(9(#)YNPMEA
M\PP,L1WSBK=DK,S5VVT='&'6-0[!G`&Y@,`GUQVJ#0@M+Q+PW`16'D2F)L]R
M`#_6FU82=S-U7P\NH),Z7MRDS<H#(3&K`@CY?3('%-2L3*-R[I.H?VE8),R&
M.928YHSUC<<,/S_2DU9E1=T7J0PH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"
M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@#*OI;UM46UM;J.!6MFDR\>[#!E&>HXYJE:UV2[WLBE%?2-<Q7THCAD;3
ME=@V=JDM^9^E.W0F_4E74+\V]\J#SI;>Z$2A5"NR%$<X!.-P#''T]:+(=WJ5
MYM8O)%F:UN(PB6'VI6>$ABP)X(SQTHY5U%S/H6QJ-S!<W"330^7Y$4R,RD;2
MS%2,#KT&.^>*5D.[1:TJYFN%NUG8,T$YC#;0"1@'D#OS2:L.+-"D4%`!0`4`
M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`8^MW$LGDZ3:.5N;S(9
MQUBB'WW^O8>YJHJVK(D^B-*&*"RM8X8PL4$2A5'0`#I4[E;%:;7-)M_]=J=H
MA'8S*#^6:?*^PN9+J8FC^(=,C?43]H:027CNOE1/)D87GY0?2K<7H1&2U-/^
MWT;_`%6FZE(/^O5E_P#0L5/*7S>1GQS:G'K4E[9:'<B"X3$\<LD29<?=8?,>
M<<'Z#TJM+6;)UO=(T/MNN,/ETBVC'K+>=/R0U-H]QWEV*TFI:K'_`*VYT:WQ
MUW3LV/Y4[(+OR*LFM2KQ)XHT6(CC$<6X_C^\I\ODR>;S1'_:X?IXI#<<>39`
M_CT-%O(.;S%^VK)Q_;NLS'L(=/QG_P`A<T6\@OYL-ZM_RW\22#N?)*9_\=%'
MW!]X>6#UM?$CGL/M!7]=XH^X/O#[(KG_`)`NN2MZRW^W`^OFT7\T%O)_U\P_
MLT-_S+=^Q]9=0!_7S":+^86\@_LH'KX8E8>C7P(_(M1?S#E\@_L<'D>%8@/]
MJ\&?THOYAR^0?V/_`-2M!_X&?_6HOYAR^0?V/_U*T'_@9_\`6HOYAR^0?V/_
M`-2M!_X&?_6HOYAR^0?V0!U\*Q$?[-X"?UQ1?S#E\@&E`#`\,S`>@O\``'_C
MU%_,.7R#^S@O`\.:BO\`USU$`?\`HT47\PMY!]F"?*-)\01>JQW^1^?FT7\T
M%O)_U\Q-H4?ZOQ)&!WW[L?J<_K1]P?>+YNT_\?GB2/V^R[__`&F:/N#[P_M+
M;C_BHK]?^NNFX_\`:8HMY!?S_`3^VRO_`#-5FIQ_RWL]O_LPHY?(.;S)TUN[
M?_5ZUH,W3@.5_P#9S2Y5V8^9]T6X]0UEON6VF7/;]U>,#^J&BR'>1+_:.K)]
M_09&_P"N5S&?YD4K+N.[[!_;CK_K=&U*/_MDK_\`H+&CE\PYO(/^$ETY>)OM
M4!]);25?U*XHY6+G0^/Q'HLK;5U6U#?W6E"G\C1ROL/GCW+\-S!<#,,\<@_V
M&!_E4VL.Y+0,*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`*,^FQW.IQ7<HC=8XFC
M$;QYZD'.>W3TIWLK$VN[EF2VMYBQE@C<LNQMR@Y7T/M2O8=D,%A9JK*+2$*V
M-P$8P<=,_2G=A9"_8[7!'V:+!39]P?=]/I[47860-96KA@UM$P9-C`H#E?0^
MWM1=A9#HK>"WWF&!(RW+;%`W$#'/X"E<+6&65TE]90W4:LJ2J&`;&1]<4VK.
MP)W5RQ2&%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`UF6-2SL%4=23@"@#.F\
M0Z/;ML?4K<O_`'$<,WY#)JN5]B>:*ZD0\0PR?\>MC?W([%+9E!_%\"CE%S=A
M?[0UB3_4Z)Y8[&XN57]%W467<+R[%*XU6^BR+G5M%L?8L9"/S9?Y4TET3$Y-
M;M%4:BL_!\1WMQGM8V.<_B$;^=.UN@K^9&+.":<S_P!FZ[=S,H0M+-Y.5ZX/
MSKQR>U.]NJ"WDR5=&+,"OA6RS_>N[G>1_P".M2YO,.7R+T.GZO%CR8='M/\`
MKG`SX_5:5T4E+R*FD6.J2R:C_P`3@Q8NW#>5;KR<+S\V['TIMK30F*>NII_V
M)*W^MUK47/?$BH/_`!U14\WD5R^8?\(Y8M_KI+R8_P#32\E/Z;L4<S'R(!X8
MT3.6TV&0^L@W_P`\T<TNX<D>Q9CT;2X?]5IEHG^[`H_I2YGW#E2Z%J."*'_5
M1(G&/E4"D5:Q)0`4`-=O+C9\$[1G"C)/TH`56W*&P1D9P1@B@!:`"@`H`*`"
M@`H`*`"@`H`*`"@`H`*`"@`H`@DLK27_`%EK"_\`O(#3NQ614D\/Z-+]_2;,
MGU\A<_GBGS/N+ECV(O\`A&-''W+3RO\`KE(Z8_(BCF8<D0_X1^!/]3>ZA$.P
M6\<@?@Q-','*']CWL?\`J->O5]I%B<?JN?UHNNP<K[C)--U=A@ZE:7`'\-Q9
M9_DPHNNPK2[F?+H-R_,NBZ'.?55:)OP.TU7,N[)Y7V1&=,FAY70[R$CO9:F?
MT!91^E%_,+6Z?B'FW$'*W'B"V]I+=)P/R#']:/N#5=P&NRPG'_"069_V;VR>
M$_GD?RHY?(.:W4O0:SJ4F/*BTR^!Z&VO<'\BO]:7*AJ3+/\`;5S%Q<Z)?1GU
MC"2C_P`=;/Z4N5=&/F?5!_PDVE)Q/-);'N+B!XL?BP`HY6'.B[;:E87F/LU[
M;S9Z>7(&_E2::*33V+5(84`%`!0`4`%`!0`4`%`'-:U]I-UJODS7*^58+)"(
MI&`\T%^@'4\)Q[CUJXVT,Y7U%O)+FUN[P037#6Q%N[-EG*`LP<KWZ!"0.@-"
ML#NF2.CFZTR-+RYEMW>7S&WLN5V\9(YQGH:.X=4,TS[0DNE.T]P[.DJ3"1V(
M./ND@\`\=>IH=M05]"+3(IH[*P>":=/]&=;B-F;:N!QP?NMN],9&?2FP6R+$
M68M,L1-->.]TJ^9^]?AM@R,CE>1T&.:74.B(;5KB[M[`W$URI;3<RXD:,^:-
MO7&.?O4.R!7=K]A8I[F9[6.ZNKB#?:1-&R*?FDYW@X[_`'>#_C1HM@N^ITM0
M:!0`4`%`!0`4`%`#)9HH(R\LBQH.K.<"@-C+?Q+I(8I#<FZ<<;;5&F/_`(Z#
M5<K)YT']K7\W_'IH=P1_>N'6(?EDM^E%EU8<SZ(I76IW\.1>:KI&G#NN3*_T
MY*_RII+HB6VMVD5/M*7(S_:>M:A[6D'E)_WT%'_H5.UNB%>_5CDTKS'#)X85
MSV?4;H.?KCYZ+^8<OD:$-AK2KLCFTZP3TM[8N?S)`_2E=%6D3?V+<R\W.MWT
MGM&4B'_CJY_6ES=D'*^K#_A&=);_`%UN]R>YN)GES_WT31S,.1%VWTVPM,?9
MK*WAQT\N)5_D*3;9226Q:I#"@`H`R/$HOET.>;39FBNH!YJ;0#NQU!!Z\9_'
M%5&U]2)WMH<1X.UC6-;UXPF816HD-U<>4N-QX`&?0D#CZUK.*BC*G*4F>G5@
M=!G:](\.@WLD<CQND18.AP1BG'<F6B,NXGN;629[>\DET]GB+RN2_EYW;L$8
M.W[F>>,G\*6I+NMMBP`[W=E";^62WDCF+.C%`>5V\YSQDX.><=30/JM2G;WE
MW-%:0W%ZUOOM$*2E22TN2&'!&6'R\$'.3Q3:2$FQ]P\D(\0M'<SK<*X,2[B<
M*8X^0/KD?G270'I<=K$[65K+%#=W#2K$9XV+]3NSP1][']WH!UHBKA)V))V*
MZKJ;BYE5_LB-"`YQT?D#IUQ^)H6R'U9)%/(YQ=3RQ1_8XVC=21EN=Y]V'R\?
MXTO0/4I2S7YM+R6>::.YBM(9`B-@++@[@`.O(''O5:$ZV.H!!`(.169J+0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`A`(P1D4`4I]&
MTNZSY^G6LA/=H5)_/%-2:)Y4^A5_X1G3$_X]TGM3V,%Q)'C\`<4^9AR+H+_8
MUW%_Q[:Y?)[2[)1^JY_6CF787*ULRC<:!>R_ZU-(OO>>SV-^8)_E34D)Q?D5
M?[(N[?[FD31$#[VGZFP!_P"`MM%.Z[_@+E:Z?B'VN]MNM[J]LH_Y^K%9U'XQ
MC/ZT63"[7<EA\1W._8M_H]TPXV-(ULY_!MU'*@YWY&BFM7:*&GT6ZV'H]NZ3
M+^AS^E3RKN5S/L.7Q-I0(6>X:U;TN8FBQ_WT`*.5ASHT8+JWNEW6\\<R^L;A
MA^E3:Q2:>Q-0,*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`(;BZM[./S+F>.%/[T
MCA1^M%K[";2W,W_A([.7BQAN;X^MO"2O_?1POZU7*UN3SKH1S7^L>69#;66G
M1#^.[GW$?@O'_CU.R"\C,:^CN6*MKU[?-_SSTR#"_P#?2@_^A4[6Z$WOU'1:
M89&WV_AI"_:;4[C>WUQ\Y_E1?S"W9&HFGZQ(@674X;5!QLM+<#`^KD_RJ;KL
M5:7<7_A&[.3_`(_)[R\/I/<-M_[Y&%_2CF?0.1=2[:Z7I]C_`,>EC!`?6.,`
M_G2;;W*44MBW2&%`!0`4`%`!0`4`%`!0`8XP:`,/P[X<AT`WQBP?M$Q=<#[J
M?PK^&35RES$0ARW-RH+(+RU2]M);:0L$D7:Q7KBFG;435U8F`P`,Y]Z0Q:`"
M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`(IK:"X7;/#'*OHZ@C]:+V%8SG\,Z.6+1V2V['
M^*W8Q'_QTBJYF+DB-.ASQ@BVUF^C'3;*RS+C_@8)_6CF\A<O9F=/X;NF;<UM
MI-VW]\P-;R?]]*3_`"JE)$N#\B'[+J-F!LMM6ME!X^S7BW*C_@,G./PHNF%F
MNX?V]=VAVRZG"#_=U"RDMR/^!CY?THY4^@<S74T;?7KN1=W]FK<QCK)8W23#
MZX.TTG%=RE)]B8>)=-3`NGELV]+J%H_U(Q^M+E8<ZZFE;W=M=IOMKB*9?6-P
MP_2IM8I-/8FH&%`!0`4`%`!0`4`8QU34KG(L=)=$_P">MX_E+]=HRWY@55DM
MV1=O9&9/?>9(8KOQ`\LO>VTJ')!]"1N;]156[(F_=_<+;:>YD\VR\.QQOVN-
M2FWR?7'S-^HH;[L$NR-+^R]2N0/MNLR(.\=G&(A^9RWZBINELBK-[LDA\.:3
M#()6M%GE_P">EP3*WYMFCF8^1(U%4*H50`!T`[5)0M`!0`4`%`!0`4`%`!0`
M4`%`!0!0U#5K?3BD;!Y;F3_5V\0W2/\`0=A[GBFE<ER2,6]U&\,@BOK\6#N,
MK9V2^=<,/<X./P'XU:2Z$-OJ0KI370R/#\L^?^6FIWI)/OM&[\L"B]NH<M^@
MX^'77D^&]%..R3LI_`^7Q1S>8<GDB-H38?,UKJNE`?\`+2WF^TPCW*\X'_`1
M1OYAMY%^VUF[@MQ<3&+4K#_G[LQ\R?[T?/XX_*DXK;8:DUYF[;7,%Y;I<6TJ
MRPN,JZG(-0U;0M.^Q+0,*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`
MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@!"`1@
MC(H`S[C0=)NFWRZ?`9/[ZH%;\QS34FB7%/H5_P"P!$,6>IW]N.RF;S5_)PU/
MF[H7+;9F=<>&KIGWF+3+MO[S0&WD_P"^T/\`2J4D2X,B\G5;(Y6+5;=1_P`\
M9TNT'X/\WY4:,+-"IXCNX'"27EC(?[EW')9/]/F!&:.5!SM?U8U(]?D"!KC2
MKI4/_+2WVSI^:$G]*GE\RN;NBQ;^(-)N7\N._B63_GG(?+?_`+Y;!HY6AJ29
MI`Y&14E!0`4`9MUH=G?7337GFSJ<8A>0^4O_``$<'\<U2DUL2XI[EV"WAM8A
M%;PI%&.BHH4#\!4WN4E;8EH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`,S5=1E
MMC%9V2++J%QD1(WW5`ZNWHH_7I5)7U9,G;1;F/9VTT\\UOIUPQ;=MOM48`N[
M#JB>F/R7W-4W;<A+HOO-^PTRTTR(I:Q!2W+N3EW/JS'DFH;;W-$DMBY2&%`!
M0!DWFB(\YO-/D^Q7_>1!\LGLZ]&'OU]ZI2Z,EQZHR(9+BVNIKFSM_)OHOFOM
M.4_+,/\`GK'[^_?H>:K1[D:K5'36EW!?6D5S;R!X9%W*PK-JVAHG=71/0,*`
M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H
M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`:Z)(A1T#*>H89!H`S
M)/#>DNYDCLQ;R?W[=C"?S4BJYF3R(KW'AZ>1-B:F\L?_`#SO84N%_4`_K34O
M(3CYF;_85_9<P64:^^G7;P'_`+]ME?UI\R9/*UL.BU2^L94^UW=W%""-POK'
M=QWQ)$=N?K19/8+M;FQ_PDVA_P#05M?^_@J>678OGCW-6I*"@`H`*`"@`H`0
MD#KQ0`M`!0`4``((R#D4`%`!0`4`%`#))$AB>61@J("S$]@*`V.31[FY5)$9
MH]0UEOE;^*WM5]/0X(_X$WM6FB^1EJ_5G4VMK#96L5M;H$AB7:JCL*S;N:)6
M5D34#*NH7T>G6,EU(K,J8&U>I)(`'YD4TKNPF[*Y:I#"@`H`RM:LI9(X[ZR`
M_M"T^>/_`*:+_%&?8C]<547T9,EU12TNYB@U.(VY_P")?JR&>$'C9*!EE]LC
MG'J&IM:>A,79Z=3HJ@T"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`
MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`BN&E2VE:!`\JJ2BDX#'L,T(3,F351<
MZ/)>+!%/!MC(5^['!.1STR/Q],55K.Q-[JY)/J=W&^HE((3%9*2Q+G<W[L,,
M#'OBA):#;>H^74YXY+A([;S6CMEG15/+$DC'Z46"Y9T^\6]M!,DB2#)&Y`1T
M/<'D'VI-6&G=&=9ZC<2I9V]K:6\/G02R`;CM0HZKC`'3YJ;7<E-[(T].NOMV
MF6EYLV>?"DNW.<;@#C]:35G8I.ZN6:0PH`*`,?Q(3)I0M!P;R:.W/^ZS#=_X
M[NJH[W(GM833E%QKVIW6!M@V6D7L``S8_%@/^`T/1)`M6V2-JS6FHFUU&(01
MRMBWG!RC_P"R3_"WL>#VHM=:#YK.S-&>XAM8C+/,D48ZL[!0/Q-3N5>QS6J:
MW8WTVG112.;3[6CRW)C81#&2HW$8.6"^U:*+5S-R3L=369H%`!0`4`<?=+]B
ML]2C48_LN]2\B]D;#,/IS(*T6MO,R>B?D=A69J%`!0`4`%`!0`4`%`!0`4`%
M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`
M4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`R65((7ED)"(
MI9B`3@#V%`;%:.SLYM.$,<0%K)^\"@D9R=V?S.:=VF*RL2?8K?\`?YCS]H&)
M022&XQ_+BBX61#'I%G%G8CY,8CW&5R=H.0,DYX/>B[#E2+,%O%;1E(E(!)8Y
M)))/4DGFE<$K$,6FVL#1M'&5,2,B'>W`8@D=>Y`_*G=A9(FM[>*TMHK>%=D4
M2A$7).`.@YI;@E;0EH&%`!0!D:W_`,?.CY^[]N7/_?M\?KBJCU)ET#0>!J7]
M[[=+G],?IBB70(]2]J"VQTZX^UQK);B,M(K#((`S26^@W:VIQ/A[P]#KUI;W
MM\)&MXU"J&D8M*P^\=Q.54'Y0%QG&:UE+ET1C"/,KLZ.X\):5+;M%#$]LQ&-
MT3G]0>&'L0:A39HX(Q](U6_T&273-262[CBE$,31#=("1E1CNI`.#VP0?6J:
M4M41%N.C-Z*ZUF[E4I816<&1DW$FZ0CV5>!_WU46BC2\F:U24%`'+:MMW>*<
MXQ_9J?GME_7I^E:+H92^UZ'2P9%O'G.=HSGZ5F:HDH`*`"@`H`*`"@`H`*`"
M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`*VH_\@R[_
M`.N+_P`C36XGL94,]W$]C;I*XCN;9/+(4'RV7&[MW4Y&?0U6A*OHAEUJEY:W
M%Z,M)B.1K?8%9#M`R"!\P8'\#FA),3;18N[J[A=H[:Z20/:F19)-H"/N4+R!
MC#9/;^&DDAMM;#++4)[JXMX&>:'(EWF14W;U91MR!M/4GCKCV-#5@3N0QWE]
M=75A;_:VA$\5QET13NV.H1QD'J#GTYIV2%=MI$,>K:A'8VUV9?/:?2VNC&4&
M%D4)TP,X.\\<]*=E>WF',[7\C:TZ22179[R.Y0@%"F.!]14,I%ZD4%`&1XC4
MII/VI02UG*EQ@#LK`M_X[FJCO8F>UR.QE2SUS4X6=5BG5+R-B>,$!&Y^J@_\
M"H>J0EHV4O$&NV-UI-U9V<S7+.`DKP(SI&A(#DL`0,+FJC%IW8I235D7/"DT
M1T86D;H7M7:-MIR",DJP]BI!S[TI[CAM8W*@LXZW==2^(DKQ<P6T0);L74%?
M_:K#ZJ:TV@9+69V-9FH4`%`''7#?;;/4'!_Y"M\MK%CO&N%8_3"R&M5HUY&6
MZ?F=C61J%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!
M0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`
M%`!0`4`%`!0`4`%`!0`A4,I#`$>AH`A6WQ=>=O\`E5-J(``%YY/X\?E[T[BL
M2"-%D,@10Y&"P')I#`11JK*L:@-U`'6@!/)B\L1^6GECHNT8'X4!84Q1DY**
M2!C)':@`6*-2"L:@C@8'2@`CBCB7;&BHN<X48%`;#Z`"@!KHLD;1NH9&!!!Z
M$4`<9/8;X4L9K=+J]T9_,ACD4-]HMSQCGJ<<?[RCUK5/KW,;=.QUEA<6UW80
MSVA4V[KE-HP`/3';Z5F[IZFJ::T.5U?1#H5RVL:9-);6X_U\<6/E!/4*>&'/
MW?R(K12YM&92CRZH5H/%VJKY0N5L[4CEY(A'(P^BLQ'YK1[B':;+4&DWOAUE
MN[8B^C6,12P)&$*H"2#'ZG))()).>N:5U+0?*XZHZ"RO;?4+5+FUE$D3=".W
ML?0^U0U8M--718I#,G6KR55CTVQ;%_=_*I'_`"R3^*0_3MZG%5%=63)]$4])
MMXKG4HWMAC3M+0VUM_MOP';WP!MSZEJ;T7J3%7>FR.BJ#0*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`,W5=->\6*XM9!#?VYS#(1P?56]5/?\^U4G;<F2
MOJC%M)YHKR>?3X/+N_O7NENP!)_YZ1GID^O0]\&J?9D+1Z?<6+_4[76H+2RM
MG;?-=1K/"RE9(U7YR&4\C[N/QI)..HVU+1'25!H%`$45O#`TC11)&96WN57&
MYO4^IXH%:QF76N!IVLM*C%[>CAMI_=Q>[MV^@YJE'JR7+HC*MX9KR::UL;DS
M3RG;?ZF!C&/^6<?O].!]:K;5DK71'46UM#9VT=M;QB.&)0JJ.PK.]S1*VB):
M!A0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`
M4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`4=0TJUU((9@R31\QS1MM
MDC/L?Z=*:;0G%,QKW2[[<IO+.+55C^Y<0MY%RGX\`_@1]*M-=-"&GUU*XOFM
M/E_MC4;0?W+^R,@'_`P!G_OHT6OT%>W4<=:D/'_"36G_``"P;=^'S'^5'+Y!
MS>8QA]O^5AJ^K!OX67[+`?KPN1^=&WD&_=FA!HMU<PK#>-%9V(Z65EE01Z,_
M!/T`%+F2V&HM[FY!!%;0I#!&L42#"H@P`/I4&BT)*`&--'&P5Y%5L%L$X.!U
M-`$+ZA91('DO($4KO!:0`%?7Z>].S%=(?)=VT,:O+<1(C\JS.`#]/S%*S"Z0
MIN(1+Y1F029QMW#.>N,4#N(;NV6<P&XB$JKN*%QN`]<>E%A76Q!#J5M=^0UI
M>6\D;N5.'R6PI.![]#]*=FMPNGL2Q7UG-*(HKJ%Y""0JR`D@=3BBS070Z.[M
MI7"17$3N1D!7!./6E9A=$U`PH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H
M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"
M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@"EJFHKI5@]
MX]M//''RRPJ"P'K@D<4TKNPF[*YPVE>-+K5O$-EIT+.MLUP[F1P`[IR54@<#
M'3WQ6K@DKF$:C<DCT:L3H"@`H`S[R"X.I65S!&LBQK(C@MMQNQ@_^._K36UB
M6G>Y4T[3KFV?3&FC7_1K22%]K`_,Q0C'_?!_,53:U$DU8CT^PU'3X[6,PPSQ
M_8XK>16DQL9`03T.5.?KQ0VF"31.^G3M;W-J0")KD3"7/0;@WYC&!]!2OU"W
M0;'9WO\`:L$SQ1+#%+*?D8`;6R0P&,Y]<GK[475@L[C;33[N.UT>*2)0;*4E
MR'SE?+=,C\6!^E#:U!)V0U+&6TM[1Y4`2UEGED(.?E8/C&.?XA^5.]PM8CT/
MSX9K2*>V&YK1561)@X"KCM@8!SUYZ42%'0Z*H-`H`*`"@`H`*`"@`H`*`"@`
MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`
M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@!`0>AS0`M`!0`4`%
M`!0`Q9$8L%=3M.TX/0^E`#Z`"@`H`XY_!J67B^RU?3E5;?>3-#TV$J>5]L]N
MW\M>>\;,R]G:2:.QK(U"@`H`*`"@`H`*`"@`H`*`&1Q1Q;O+C5-QR=HQDT!L
M/H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`
MH`*`"@`H`Q+?49=EK%!:01F>YN(B`Q"J49^>!SG:2>G6JL0F$&JWMS/8(D4*
MB82^;ECU1@IQQ^-%D@4F[#EUBY>PEOTL\VPA>5"S@?=Z`X)/(SVXQWHY5>P<
MSM<5M1OUN;2V,%N'NA(R-YC$*%`(R,>]%D%WL01^()DMH;JYMD6"6SDN<1ME
ME*`$CGKG/'TI\O1!S=67/[0N8DS<6PC+NB1'<,,S'IP3TZY[^E*R'=E"*5K>
M?4#-##,QU.)#Q@+F.(!@.>1FGV)VOZE_^TIO[3CM1%'LD\Q1\^2"O3...1VZ
MBE;0J^MBK::O>2V5B7A1KB[4NHCZ!0`3P2.>1QFFXI,2D[(V8'D>WC>:+RI2
MH+)NW;3W&>]06B2@"K?ZC:Z9`LUV[(A;:-J,Y)^B@GL::5]A-I;C[.\@O[2.
MZMGWPR9VMM(SSCH>>U#5M&"=]43TAA0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`
M4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`%1-.
MM8S&4C(,<C2+\YX9L[CU[Y/YT[L5D0S6NGV2V\CHR".7;&59^&D8#!P>A)'7
MBB[8K)$BZ39QI-&L3".;=N3S&V_-UP,X7/MBB['RH<]M:+<VI=6\U`RQ'+<`
MCG]!WHU"R$32[.-856'Y84:-%+$@*>HP3ST'6B[#E17DL--AABTZ1)"DYQ&K
M2.Q!4;AALY7&,CD>U.[W%9;$ZZ7:*''EL=\BRL3(Q)=0`#R?]D?E2NQV0)I5
MG'<+.D;"17:1?WC8#-][`SCG.2.F>:+L.5#?['L1!%"(W5(FWQD2N&0^QSD#
MD\#BCF8N5%U$6-`BC"@8%(HY_P`3Z_=Z+]E6UM1*TK=7!PW^P,?Q'_.:N$4]
MS.<G'8G;1&U6)'UN5Y&SN%O#(4CC..Q&"QYZD_@*7-;8?+?<KW5M=>&=,DFT
MIC/:0J6-K,<[!U+*W7CJ0<Y[8IIJ3U$TX+0M>&M4N-6TOS[F/#!RJR!2JRKV
M8`_E^%*2Y7H.#NC9J2PH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`.:75KN.TN6FF(FC,+
M[QL,1C:3&Y2!T(SPW(Q^-797,^9V%O[PSQWL1N59(;^U"$8^4&2,G]2>M"5@
M;N2S76H6D-[(UR98K.=&+E%RT6`74X&,J"3D8Z4))CNT6C<727&F!I6Q<2/O
M4J,@;&91T[8%+34>NA5MKRY_LZWN+G4&#73^6H$:`@C?]TG@$X!^;/0^M-K6
MR$F[:L;:73WJZ#/)())#)(&88Y(1QVXH:M<2=['0U!H%`!0`4`8/B;4;.QAL
MQ<S*K?:8G"'DD!QD^P'7/M5Q39$VD;P.1D5!94U2XAM-*NIYR!$D3%L]^.E-
M:L3=D5?#M];WNBVP@DWM#&D<@((*L%'4&G)68HNZ-6I*"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`
MH`*`"@`H`C\F(*ZB)-K_`'AM&&^OK0`>3%L*>6FT@`C:,&@+"XC11'A0&X"^
MOM0`U1YN3+"%*L0N<'(]:!%?S8_[1^P?9TV>4)L^^['3'ZT^EPZV+7E1C'[M
M>"2..AI#'T`%`!0`4`9FK:%9ZR(OM0<&(G#1G!(/52?0\?E51DX[$N*9E:M-
M>^%;*%[&19[,RB,0S@DQ#!/#@YQQC!SUZU2M)ZDN\%H365E)XCTV&ZUAQ)%*
MI*VL8*(.H!/.6/IS@>G>DWRNR!+F5Y&KIFEVVDVGV:U5@NXL68Y9C[GOV'X5
M+;9:2BK(NTAA0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`<QI=FDDL4MO'(D\%]<!Y,,%,
M?FR?+Z$=..QYK1LSBNQ)8QSFZDD-K/");/:^0V[>#_$W=N?O=^U)@AB:6B0Z
M*\EI([*P-QPS$-Y6W)'U`YZ47W"VQ(5N;<LSVLLUJ;R1I4"EB4*_*=O<9[?3
MTHT#5"7EK<JSFPMYHP+0*B]#]_)4$]"5SBA-=0:?0U=,BCCA=HA.%=MV)4V8
M.`.%P,=/3WJ66B]2&%`!0`4`%`!0!G:O>RZ=!!<J%\A9E6?(Z(>,CZ$@_0&G
M%7T)D[:FC2*"@"H=2LQ>2VAG59HE#N"<8')Z_04[.UQ75[#1JU@T#S+=QM&A
MP2#GL#_(@T68<R'2ZG90`>9=1C='Y@`.25_O#':BS"Z0_P"VVWF(@F4LX#+C
MD8/0Y]\''K18+H;)J5G$T@DN43RU+L6.!@'!.>^#P?2BS"Z0Q;^WEFB$5Y"5
M)=2O4L5ZX.>W?ZT6"Z$AUG3KC/E7D38C\TX/\'K1RM"4DPM]2M[PVKV]U&8Y
ME)"%?F?@'CGC&>>.]%K`FF3+?6K#(G3;L,@).`5'5@>X]_>BS'="6]_:74FR
M"X21MH?"GJI[CU%%F@33+-(84`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!
M0`4`%`!0`4`%`!0`4`%`!0!%;VT5K&8X5*J69R,D\DDD\^I)-%[B2L2T#"@`
MH`*`"@`H`*`"@`H`*`"@"&[MH[VSFM9AF.9"C#V(Q0M!-75C/T2^+Z-&;R15
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M5V^G`QSCGMZ47'9CK+3I[:>Q=VC*V]I]G;!/)^7D<=/E_6AL$K6-2I*"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`*][%<2V<B6EQ]GG(^23:&`/N#VIK3<3O;0\D>Y
MU=O&EI9:J=KF^B>2-!M1VRHW8'7(`YKHTY;HY;RYK,]CKF.L*`"@`H`*`"@`
MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`
M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H
M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`SM1T6TU&ZL[J1=MQ:
M2*\<@'.`<E3[4U)K0EQ3U-&D4%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`
M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!1O=7L-.8)<W2)
M(?NQCYG;Z*.3^5-1;V$Y);E4:Q>S_P#'GHETZ_WIRL(_(G=^E/E2W9/,^B%\
MWQ"_(M-/B'HUP[G]$%'NC]X/,\0IR;73I!Z"=T/_`*":/=#WA#JVH0<W>AW`
M7^];2+*/RX;]*++HQ<S6Z+%GK>GWLODQ7`6X[PR@QR#_`("V#2<6AJ29H4B@
MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`
M"@`H`*`"@`H`0D*"2<`=30!G0-J$VJ_:$FA;2WA4H`IW$G/?/T[=*K1+S)5[
M^1/>C4/D^P-;#KO\\,?IC!^M)6ZC=^A4V^(?^>FF_P#?$G^-/W1>\&WQ#_ST
MTW_OB3_&CW0]XOVOVH0#[68C-DY,0(7VZTG;H-7ZD](84`%`!0`4`%`!0`4`
M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!!=W=O8
MVKW-S*L42#)9J$KZ(3:6K,I1JFM?,7DTRP/15XN)![G^`?K]*O2).LO(T+'2
M[+35(M+=(RWWGZLWU8\G\:EMO<I)+8N4AA0`4`%`%:]T^SU&+RKRVCF4=-PY
M'N#U!^E--K832>YF&VU/1OGLY'U"S'6WE;,J#_8<_>^C?G3T>Y-G'8TK&_M]
M1MA/;/N7.U@1AD8=5([$>E)JVY2:>Q:I#"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`BGMX;J!X)XUEB<89'&0
M?PHV!JY471=/73H]/6W"VT>"%0E.1W.W'-/F=[D\JM8R+"PT>]2Z=M/N8%MW
M*DO+)SC\?TJVVB4HOH0_\4I_TW_\CT>\+W"U9:AX=T]V>VDF0L,'*3-_,&DU
M)[C3BMB[_P`)-I/_`#\2?]^)/_B:7*RN=&E!/'<P)-$28W&5)!''T-3L4G<D
MH`*`"@`H`*`"@`H`*`"@`H`*`"@!KNL:[F(`'>@!D-Q%.\R1MEH7V.,$8;`.
M/R8'\:+6%<(;B*<RB)LF)S&_!&&P#CGZBBU@O<EH&1)<1/<R6RM^]B569<$8
M#9P??[I_*BPK]"6@84`%`!0`4`10W$4[S)&V6A?8XP1AL`X_)@?QHM85R6@8
MR.5)5+1L&`8J<>H."/S%`#Z`"@`H`*`&22)#$\DC!$0%F8]`!WH#8Q=/@?6;
MA-6O4(MU.ZRMV'W1VD8?WCV]![U;TT1"][5F[4%A0!C>))KBWTV)[:X:%_M,
M2$J!R"X!!_/M51W(FVEH*\+Z?%%%)JDSK-,Q)D`:5\C[B;1QTSTZ9Z=C?H&W
M4I:;-J,FD:S#!.[7,%R\5N9V!8?*I`)[G+'K3=KH2O9EK1+V.>ZN8";N&>-5
M+VMT2Q3K\P;)R#[''';-*2L.+-NI+"@#&U.SFM)SJVFIFX4?OX1TN$';_>'8
M_A5)WT9#5M4:=I=0WMI%=6[AXI5#*P]*EJVA2=U=$U`PH`*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`*,NJVL.JP
MZ<S-Y\J,XPIQP0,?K^AIV=KD\R3L$^LZ5:S-#<:E:0RK]Y'G56'U!-'*PYDN
MI'_PD.B_]!BQ_P#`E/\`&GRR[!S1[A_PD.B_]!BQ_P#`E/\`&CEEV#FCW+-I
MJ%E?[_L=Y!<;,;O*D#[<],XZ=*336XTT]BS2&%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`4-2),^G1_\`+-[D;_P1F'_CRK374E]#+:2Z@NM5N+68;DOX@82H(D!B
MB!&>H//%5IHF3JKV)(+B2&^GA1M@GU$HSXZ#R0W'N2`*+:#O9DG]J2+>?8IY
MA&K7#Q)<8`W816`YXSEB/^`&E;2X<VMBI-?-9:O*7GRKVULCW84;4^>;YB/<
M\>@SS3M="O9F@][/%KB6\K-]G=@D;(%*EMA)5^X/<$<8I6T*O9V'74DX\06,
M*71BA>"5V3`PQ5HQW]F-"V!_$BO:WEV]HD\]XH,TS0JJQ`$$.X^7W(`Z\#%%
MD)-V&6NH7EU;Z6/M`4SRRQR.J*20N[!'8'Y?I3:2N";=B/\`M6\CL[::1RT2
M^8L[QJNX;7VJQ4]5X.<<\T65Q<SL31SF&]U-%E\MIKY4&`"Q/V=#A<\9XSSQ
M@&CHA[-_UT(K>^N[M=&8WGE^<)/,*J,/M'^>E%DKB3;L3VVH7,MQ#`\@4/<S
MIO"CHA.U1[XY_P"`FE9#3>PU+V]FN;:W\_8K2S1F14&6"=",\`]CQU!IV07>
MQH:1<2W6EP33$&0@AB!C)!(S^E2U9E1=T7:0PH`QM='VR2RTK.$NY"TP]8D&
M6'XG:/QJHZ:D2ULC8````&`*DL6@`SV[T`5+_3X-1B6*XW[%<.`K%>0<@_F*
M:=MA-7W&W>F07JV_FM('MVWQR(Y5U.,'D>H)!H3L#5R.+1;.!+I(Q*%N6#N/
M-;[W'S`YR#P.:.9BY4B>VL(;:9YP7DG=0K22-EMHS@>PY/2ANXTK%JD,*`"@
M#%TQ?L&M7^FCB%P+J`?W=Q(<?]]#/_`JIZJY"T;1M5)84`%`!0`4`%`!0`4`
M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!GG%`!0`4`-,:&19
M"BEU!4-CD`XR,_@/RH`:T,3-EHD)]2HH`3[/!_SQC_[Y%%PL'V>#_GC'_P!\
MBBX6'I&D>=B*N>N!B@!U`!0`4`%`!0`4`%`#)9!%&78,0.RC)-`;$5I=Q7L)
MEBW##%&5A@JP.""*;5A)W"2\@BO(+1WQ-,K,@QUVXS_/]#1;2X75[$$NKVD%
MU+;RLZ-$$+L4.U0Q(4D^Y!HLQ<R6A?I%!0!%/`EQ&$?/#*X(Z@@Y'\J-A6N-
M:...X1UM@SR-AI%4?+@'DGK[=^M`#_(BPP\I,,<L-HY/O0.Q$L,%Q:*DUJJQ
MMSY,BJ<?AR*>PMT.CCBD1F:U$9;*$.HR5!QVSQW_`!H`<(($D#B*,2`8#!1D
M#TI!8142X2&:6WVN!N59`"R$_3.#]#1L`&UMVB,301F,G.TH,9^E%PLA5MH%
M(VPQC!+#"C@GJ:`L1SQV=O`T\L,2QP`R9V#Y<<DC\J>H:(2."*>$F>S1"S;F
M1PK<@\$XXS1L%KDGV6WPH\B/"-O4;!PWJ/?WI7"R'>1"%*^4FTG)&T8SZT#L
M'D1?+^Z3Y!A?E'`]J`L.2-(UVHBHOHHP*`'4`%`&+,ZQ^*_-D.%AL&8?0N,_
M^@BJ^R1]HDGUIK:TBN);7"RPM*@#Y.57=M/'!QGUZ4<MQ\UD61?-%I\MY=PB
M%(P7PK[LKC.>@Y]J5M;(=]+LS7NI+37IY9K=!(]O!&JH^=Q:1@,G`QUJK71-
M[,M3ZP;6Z\B6W`VO$KL'R%60E5;I_>4BDHC<K$<6N&>VDDCMU+Q&3>AD(PJC
M(8''<%2/9A1RV%S`=;ECC=Y+/I;K<($<L2I.#GY>,=>,]Z.4.82+6+B>Y00P
MVTD!@:;>DY.<,0,?+[?K[4<M@YFPBUNXE2/;I^Z26(3HBRYRA`Z\<')(_#K1
MRH.9]BQ_:CB_M[9K<()BRC=*-ZD+GE0#P<=<_A1;0?-K8JVFN75XMJ8[",?:
MHGDCW3]"I`(;Y>.O49H<4A*3?0CCNQ>ZQH=ZB&,W%K-N0]0/W9Y^A_G3M9-!
M>[3.@J"PH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`*%YJ1L[M(6AR)(G=&W8W,N/DZ=3GCZ&FE<ENQ7N=1%E-J$AM`9;>VBE8J_W
MP2XQTXQM/YTTKV!NUQU]JMQI]A+<S6D8,2O(R^?@%5]#CEB.<8_&A*[!R:5Q
MT``\37Y``S:6Y/O\\U'V4"^)D-WK4MM<7B)9K(EIY9<^;@D/Z#';ZT*(G*Q5
MUJ]DFT75X981%-;;<%'W!@<$$'`QW%.*LT*3T9-I1$VL:D$0P6\82)K1\<-R
M2^!P`00..N#0]$AQW97L9I-*BMK>^8S:;=JOE2OSY3L,[&/]TD\'MT]*'KL)
M>[H]B:]5IO#UK8Q/)')-`"'C4DKA00>`?XMOYFA:.XW\-C3TJ]_M'2[:[V[6
MD0%E_NL.&'X$$5+5G8J+NKERD,S+C3;R6=Y8=9NH,GY45(RBCTP5S^M4FNQ+
M3[E:2]U31QOU!4O;(?>N($*R1CU9.<CW'Y463V%=QW-F*5)HDEB</&X#*P.0
M0>]3L6/H`*`"@`H`@NIS;6SRK"\S#HB#))H2N)NQ2LO/>T(MU-N_F%G:YA^^
M3R<`,,=?Z53$MM"IJ4%S.SW\*2^;:SHT47E\NJ\-CZAG'XBFK+033W'_`&#[
M9KE^9TD%K+#`,;<+(5+D@\>Z_P"<TKV2"UVS<J2PH`*`,_4/-%]I9C$NT7#>
M9LR1M\I_O8XQNV]>]-;,E[HS;&*XCDTZ1OMA8S3++O,A^3YMN0?HN#5/J2KZ
M$=M#(9='>Y%YE5E5B3(#NW`KNQ[`]:'UL"Z7$=KC^S3`Z7Q=WN@A_>#I(2F2
M!NSMQMY`QGVHZAK;[RQ`ADU6RN)Q=?-9#D>8!NR,Y`XS]:'M8:W0:=]I$6G"
M]$_E?92&W[L^9D?>[YQTS[]\4.VM@5]+E<07DB,MP;PD63;<-(/FW';G'\6W
M&>^:>@K,U9VNV\/%H0_VLP#C&'SCG&>_7\:G2Y6O*9^KPRS6.IQVJS/`]@Z[
M`&),F#M`'7/7/X9IK1JY,MG8WH8UCA5$+E0.-[%C^)/-0:(DH`*`"@`H`*`"
M@#&U+%MKVF73`>5,'M),],MAE_52/QJEJFB'HTRV=*MFMQ;G>8EC,2*6^ZI&
M"!^'&>M*['RHGDM8IK-K29?,A=#&RMW4C&.*5^H[:6*JZ+:C)=II6**FZ20D
MX5MR_B#SFGS,7*A?LME?0WL+$R^8?*F).""!P/;&<C'KFB[063)/[,M5DN'2
M/8UQ&(WV\9`!`^G!Q^`HNQV0G]F0!E8-(K)&(E(;!"@Y'ZBBX6&)H]K')YB>
M8K[7#$-C=N;<2?QHYF+E0O\`9-N!;;&EC:V3RT9'P=G'RGU'`_*BX<J$72+9
M+A9E:4,DC2J/,.`Q!!X_&CF8<J'6^E6UJ+80[U^SJR1_-G`;K]>@HO<:BD9U
MA;QCQ$88,_9]-M1`,G.&<AB/P55_.J;T]24O>]#?J"PH`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`(+BT@NG@:9`Q@D\Q/9L$9_4T
MT[":N17&FV]R]PTF[_2(UBD`/5020/\`QYOS^E%[`TF-O-*M[[/GF0[HFA?:
MY7<K=0<4)V$XIDT5I'%<O<`L9'C6,DG.0N2/_0F_.BX[6(9M*MIFN6??FYVB
M3#==O3Z47L'*A+C2;:Z2Y27>5N=OF8;&<=/I0FT+E3)6L(6O$O!N6X5/+WJ<
M;E]".A_I1?2P[:W#^S[=M/-A*AFMBFPK(<Y7THOK<+*UA8K**&5)$+Y2,1*"
M>`HHN"5@L[**Q21(2VV21I"&.?F8Y./3GM0W<$K%FD,*`"@#$TI?[-U:[TE>
M+<J+FV']U2<,H]@W/_`JIZJY$='8VZDL*`"@`H`*`,W7[B6T\/ZA<0.4EC@9
MD8=B!51U:)D[19I5)04`%`!0`4`,:6-'5&=59ON@G!-`$8G#SH$DB:,HS<-\
MQP0,CVZY_"F*X&\MA$\IN(A&GWFWC"_4]NHI6871"UVXU:VM5V&&:WDESWRK
M(!SZ?.?RIVTN%];%F2>&(@22HA/0,P&:0[V#SXO,$?FIO(R%W#)'KB@!J75O
M)+Y4<\;R8W;5<$X]<46%="_:8,.?/CQ'PYW#Y?KZ46"Y%]L3[7#$"K),A:-U
M.02,9'Y']#3MH%]2U2&%`!0`4`%`!0`4`5=2L4U'3YK5V*;Q\KCJC#D,/<$`
MTT[.XFKJQ6T?47NXGM[M1'J%L0DZ#H3V8?[)ZC\NU-JVPHN^C-.I*,J\O+LZ
MC)9VIA1HX!,&E;`;)8>AX&T9Z?>'-4DK7);=[(I17<T6I7-K!M5KB[?YF;'W
M8T.!P>?PZ`T[:$WL[#;[4]3MQ?`36X>TL%NOEC)5FR^1DGH=GZT)(&VKDUSJ
M=[::C+9L\;[S#Y;D;0GF%Q@]>Z8'NW>A)-7&VT[$OG:D;ZWLFN(4,D,SED3<
M05=`O7`SA^>/_K+2UPUO8BTJ_O+^[M9'F1(I+&&=H@G\39SSGVIM)!%MF]4%
ME'5=273;4,J&6XD.R"$=9'/0>P]3V%-*Y+=A-(L&T^Q"2OYES(QEGD_O.>I^
MG8>P%#=V$59%^D4%`!0`4`%`!0`4`%`!0`4`5Y[CRI;>)1EYGP/8`$D_ICZD
M4[";L.6Y@>=[=)XS.@RR!@64>I%*P71FZ=J=Q=2::)?+`N;1YGVJ1AE:,<<]
M/G-4TE<E-NQHB\MMC.+F+8B[F;>,`>I]JFS*NA3=VPWYN(AL4,WSCY0>A/H*
M+!="K<P-,85FC,H&2@8;@/I^(_.BP7(SJ%F+QK,W,0N%4,8RX#8Y[?@:=GN%
MU>P?VA9>4\OVR#RX\;G\P87(R,GMQS19A="RW]G"H:6[AC4KO!:0#*^OT]Z+
M,+I#C=6ZM&IN(PT@!0%QEL],>M*P714M-14VD\][+%$L4\D>\G:N%8@=3Z"F
MUV$GIJ6'U"SCN8K9[J)9I5W(A<98>WYT68[K8(KN/[-')+<0'<#\R-\K8].:
M+!<66_L[<`S7<,8V[\O(!\OK]*+,+I$X(8`J00>012&+0`4`%`!0`4`%`!0`
M4`%`!0`4`%`&/J9%MK>D79X1F>V8_P"^,K^J`?C5+9HAZ-,V*DL*`"@`H`*`
M,GQ1_P`BMJG_`%[O_*JA\2(G\+-:I+"@`H`*`"@#/U6SGN8H)+1E6Z@E5XV;
MH/X6_P#'2?TIIVW)DK[$4^GM]NMS%%N@CLY8#DCJQ3`Y_P!P_G33T!K4BAL9
MK6QTZ*.SCWHH68C;D'9MR,\'IC/)QVHO=L5K)":7875M_8_FQ;?LMBUO)\P.
M&_=X_#Y#^8H;6H135B#5@[ZA>B.W\^'[*BSA90I`#,P^]P.">1^F`::V%+<F
MLK61KN26:TD:.207$3M)@("H&TIGAATZ8QWI-C2U&6VE7$4.GQB,1&%9E9E(
M^7=T(IM@HO0;#I<CZ6D4UG+'<1K&AD2XRV5((*9)&`1G!QZ8HOJ+ET+-O!<M
M/IJ7)!F@#RR,H`'.5&0.,G<3Z9!I::V&D]+FQ4EA0`4`%`!0`4`%`!0!FZGI
M1NY([NUF^S:A""(Y@,@C^ZP[J?TZBFG;0EJ^J([/6@TZV6I1?8KX\!&/R2^Z
M-W^G4>E-QZH%+HS0FM+>X>-YK>*1XSE&=`2I]L]*F]AV3&R6-I,C)+:PNK-O
M(:,$%O7ZT[L+(5K.V;=NMXCN4(V4'*CL?;VI7860/96LBNKVT+B10KAD!W`=
M`?44[L+(5;2W39MMXEV*57"`;0>H'M2N%D(MG:QO&Z6T2O$NU&"`%1Z#T%%V
M%D4[_6H;6;[);QM=WY'RV\74>['HH]S5*-]1.5M$-T_2Y4N3J.HR+/?LNT;?
MN0K_`'4'\SU-#?1`H]6:M24%`!0`4`%`!0`4`%`!0`4`%`%&[C*ZE8W')52\
M;>VX<'\U`_&FMK$O=%.TL[Z/5+>XEAB6.**:,K&PQ\SHP(&/]GN>IIMJPDG>
MY`NC736=K;,1&4L)K5G4YVL^S!'_`'R?TI\R%RNUB_\`8FN;J&2>%8T2W>%T
M!R&W;<@?[(V_K2O8JUS/M-$O89;9Y9U?"^1/DGYHE.8_QX.?]]J;DB5%EVWL
MKF'6))T)2WD+-(A8,K-QM9>ZG&<]J5U8I)IDH@GCUN>Y$:M!+;QQYW<@JSG&
M/?>/R-+I8+:W*EK875GIFEP)!%YMO&L<S9`(PFW*G!XS^.*;:;8DFD@TW3KF
MU&D^=&N;.Q:W?:P.6/EXQ_WP?S%#:U!)JQ#:Z3>VT>F>7^[FMX(89F#@HZH?
MF!4_B5(YR><4VUJ)1:L2BPO8U*I%'\\T[%BPW*'.1C@\>O>BZ'9C[*RN[:73
M':)"(;/R)`'^Z?EZ>OW32;3N"35A-/T^YLFM9&0/Y<+Q,@(R,MN!'\C^%#:8
M)-"6VE36TD/RJRI:R1G!X#,P8`>PQC\J+W!1L:.G0O;:9:V\F`\42HV/4#%)
MZLI:(M4AA0!'+/#`,RRI&/\`:8"BP;%;^V=+_P"@E:?]_E_QI\K%S+N21:A9
M3G$-Y!(?]B0&BS"Z+-(84`%`!0`4`%`!0!5U"QBU&PEM)20KCAEZJ1R&'N"`
M::=G<35U8S;;6FL2MIKA6VG'RI<'B&;W!Z*?]D_A3Y;ZQ)4K:2([[Q=8:5JP
MLK\-%'(@>*X'S(P/KCIS]::@VKH3FD[,VK:Z@O(5FMIDFB;HR,"*BUBT[[$U
M`PH`R?%'_(K:I_U[O_*JA\2(G\+-:I+"@`H`*`"@`H`*`"@`H`B>WADD61X4
M9U^ZS*"1]#1<+$M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`$%W9VU];M!=0)-$>
MJN,BFG;832>YFC2;ZQ_Y!FI-Y8Z6]V#*@]@V=P_,T[I[HGE:V8HU'5K?BZT9
MI`.KVDRN/R;::++HPNUNA?[?B'#Z?J2'T^QNW_H(-'*/F\@_X2"$_<L-28^G
MV*0?S`%'*',']IZE-Q:Z),H_O74J1C\@6/Z462ZBN^B&G3M4OAC4-2\B/O#9
M`IGZN?F_+%%TMD%F]V:%EI]IIL/DV=ND*9R=HY8^I/4GW-)MO<I)+8LTAA0`
M4`%`!0`4`%`!0`4`%`!0`4`%`%2:X2/4((BTN]HW954?*P&W.??ICZFGT%?4
MKPZQ;W<:;$G19K8W$3%0-Z<9QSU&X=?6GRV$I)A;ZK&\UK;10SRB2W682$#H
M>F?>BP)]!J:O;0:7#<?Z1+%Y2N7*Y8+TW-_];GVHY7>P<R2'SZF@N;RU,,ZB
M"$.TJ`<`@]/?BA+J%^@]=2A6$E1+((X5E<A<E5(XSZG`/`_J*5@N,FUNVA,I
MV2R)"J.[HH*A6Z-UY'':GRL.9(NW%Q':P^9(3C(4`#)))P`/Q(J4KC;L9VI:
MKY%E<"-)!/&T:LF/F`=@`1V]?Q%4EJ)NR-&W4);QJHD`"C`D8LP^I)))_&I*
M1+0`4`%`!0!C2ZQ/=S/;Z-;K<-&2LEQ(=L*'TR.6/L/SJN5+<CFOHB">RB5T
M76]>=GD^["LHMD/L`#N/XDT[]D#7\S)8M,\-0P-=+;V#1K]Z9]KX^K'/\Z5Y
M;!:*U+`.A_8_M8-A]F''F_)L_/I1[VP_=M<BN8?#C1QFZCTTI-Q&9!'\_P!,
M]?PH7-T$U'J0PZ+I,N\Z7=R6S(<$V=R<*?0KDK^E/F?4.5=![2:UI8W2A=4M
MAU,:A)U'^[]UOPP:6C\@]Y>9IV5[;ZA:K<6L@>)N_0@]P1V/M2:MHRDT]BQ2
M&%`!0`4`%`#7C21"DB*Z$8*L,@T`<%K7@235]<S:PV^G6$:@;D49<]20H_+G
M'2MHU++4PE3N]-#H=`\)V'AXE[=YI)F&&=W.#_P$<?GFHE-R-(P4=C>J"QKI
MOC9"2`PQE3@CZ&@#'F\-P7$+PS7^H21.-K*URQ!'I5<UB.1,ECT-(Y%?^T-0
M;:0<-<L0?K1S#Y?,FU35[31H8YKUFCA=]GF!20I[9QTZ4E%O8')1W+-K=V][
M`LUK/'-$>C(P(I-6&FGL34#"@"CJ&K6NG%(Y"\EQ)_JX(EWR/]!Z>YXII-DN
M214#Z]>C*1V^FQGIYG[Z3\@0H_,T_=0O>?D.&BSR<W.M7\A]$98A_P".@']:
M.;L@Y7U8?\(Y8G_62WTA[%[Z;C_QZCF8^1!_PC\*_P"JO]1C],7CMC\&)HY@
MY?,0Z?J]N,VNLF4#HEW"K9_X$NT_SHNNPK26S&G6;JPXU>P:&,=;F`^9$/<\
M!E_$8]Z.5/8.9K=&O%+'-$LL3J\;#*LIR"/8U.Q8^@#+F\0Z3#*T37L;R+]Y
M8P9"OUVYQ5<K)YDB>RU;3]1++:7<4KKU0-\P^HZBDTUN-23V+M(84`%`!0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!5FM#)
M?070DP84=0NW.=V/\!3OI85M;E6WT?[/'9(L^1:VC6JY7J#MY//7Y!^M/F$H
MV'6^EM:RVSQW'^IMQ;D%/O`8P>O!XHN"5BK)H)DLEL1?$1K;^5M*`XYX8#/!
M[?RQ3YM;BY=+%R337>YN91<8%S"(G79W&[D'/^UTJ;CL)'I9A5Q%.5,D*Q.=
MN?NC`8>AP?<<#\2X<MB.31(VANH4EV1SPI``%SL5<@=_>GS!REV[M!>6XB9R
MK*RNK+V92"#^8I)V&U<K7&EBY\YGEQ+*8\L%X"HVX#&?4G\Z$[":N:(Z<TB@
MH`*`"@#*\022#3DMXI#$;J:.W+KU56;!Q[XS51W)EM8T+>WAM+>.WMXUCBC4
M*JKT`J=RDK:&)XI.'T,XSC4XO_06JX=2)]/4C-A<#4-9U,QF"WFM?+$9(S(P
M!^<@=/0=Z+JR0K.[91\,7T5];6&EW2M$(+6.2.)QQ<<9W#U`/;UY[<5)6U%!
MWLF:/BPE8=)(4L1J4!P.IYJ8=1SZ>I'IC?VCXNO;]0;?[+$+1X&QO8YW!FQQ
MC'3DT/2-@6LKG2U!H8KQBP\4P-#\J:A&XF0="Z`$/]<$@_A5;Q(VEH;5264+
MS36NYA(+^[@P,;87"K]>AYIIV):N0?V&_P#T&-2_[^K_`/$T^;R#E\P_L-_^
M@QJ7_?U?_B:.;R#E\P_L-_\`H,:E_P!_5_\`B:.;R#E\P_L-_P#H,:E_W]7_
M`.)HYO(.7S#^PW_Z#&I?]_5_^)HYO(.7S#^PW_Z#&I?]_5_^)HYO(.7S#^PW
M_P"@QJ7_`']7_P")HYO(.7S#^PW_`.@QJ7_?U?\`XFCF\@Y?,/[#?_H,:E_W
M]7_XFCF\@Y?,/[#?_H,:E_W]7_XFCF\@Y?,P?%FAW<FC_9;2?4+Z:>15$;N"
MB@'.YN!CIZ]ZN$E>[,YQ=K(I^&_`-]I\RW5UJDEL_>.U;D^Q)X_#!IRJ)Z)"
MA2:U;/0*Q-REJUZVG:9/<HF^10%C7^\Y(51^9%-*[L*3LKC-,TM+!&ED;SKV
M7F>X8?,Y_H!V':ANXE&Q0\7-)%HZ30S312+/&`8I&3@N`0<'GBJAN*>PV)YO
M^$H>RMIY9K!K?=.#*S>4^>,-G()';/O1]FXOM61G^&[QM2T*/3TO97O)-[3R
MM.Q>)/,9002<YP./3J>P+DK.XH.ZL7O%,9T_PK*]O<7,;PM'MD%P^[EU!R<Y
M/!/6E#60YZ1T".X=O%-M%IER]Q:"-_M@,ID2,X^3!).&)[>E%O=U"_O:'1U!
MH8+6XT+58'M?EL+V7RY81]V.0CY64=LD8(]P:N_,B+<KT'WP?5=6.E!V2SAC
M$ET4.#)N)VIGL."3^`[TEHK@]78M3RQ:0EE;6MI&$GE\E$4[%4[2W8>BFDM=
MQ_#HB%[6Q\0V,=PT;Q2J6$<H^66%@2#AAZ$'V-.[BQ64E<ET6[GN;22.ZP;J
MUE:"5@,!B,88?4$'\:)*VPXNZU-*I*"@`H`*`"@`H`*`"@`H`CGF2VMY)Y#B
M.-2['&<`#)H#86*19H4E3[KJ&'T-&P#Z`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`,^^U(V-S#&T(:.5'*OOQ\ZC(7&.XS^5-*Y+=BM>:B;&2^G:SC,UO
M9"=B'Y8`L=N<=!@X^O:FE<3=KDM[J-W8V<LTEM#O17<#SN&5>0.F<D>V!ZT)
M)C;:0D#!_$4L@&-UG&?_`!YZ.@+XAUQJ<L5U)!%;J[(\:!6<@N'/WAP>!_0^
MG(D%^@D6J7%QODALBUL#(HD,@`RA(Y'7!(QTHM8+LKKKSQPK-<6RJDEJ+E`D
MFX]0-IR!C[PYHY1<Q+<:K<V=L9KFR,*"0*9"VY54@G<=N2`#Q^(/3H))[#<F
MMR6*<G5X-NTI=6ID.QMRY4KR#WR).O?%'0.II5)04`%`!0!5U&Q34;&2V=RF
M[!5UZHP.58>X(!IIV8FKJQGVFM-!(MEK(6UN^BR'B*?W5O7_`&3S3<>J)4K:
M,FU?2YM3DL6CNDA6UN%N`&B+EB,C'WA@<T1=AR5[%R[@EN+*6!)%1Y$*[F3<
M!D8Z9'\Z2T8WL8[>&%DT*SL'NL7-D!]GNHX]K1D=#C)S[C/-5S:W)Y-+$^H:
M1>ZC;V*27T(DMITG+BW.'9>1QOX%)-('%NP^ZT9Y-6@U.UN5M[I$\N;]WN69
M/0C(Z'H<T*6EF-QUNBS?ZK9Z8J_:)?WC\1Q(-TDA]%4<FDDV-R2*NFVUU<7K
M:K?Q^5*4\N"#.?)3.3D_WC@9],`4VTE9"2;=V:]244-2UG3M'B\R_NXX0>BD
MY9OH!R::BWL2Y*.YRL?Q#@OM8@L[...WMF?]Y<W;A0%')P,]3VR>_2M/9V5V
M9^U3=D=/_P`)#HO_`$&+'_P)3_&HY9=C3FCW#_A(=%_Z#%C_`.!*?XT<LNP<
MT>X?\)#HO_08L?\`P)3_`!HY9=@YH]P_X2'1?^@Q8_\`@2G^-'++L'-'N'_"
M0Z+_`-!BQ_\``E/\:.678.:/</\`A(=%_P"@Q8_^!*?XT<LNP<T>X?\`"0Z+
M_P!!BQ_\"4_QHY9=@YH]P_X2'1?^@Q8_^!*?XT<LNP<T>X?\)#HO_08L?_`E
M/\:.678.:/</^$AT7_H,6/\`X$I_C1RR[!S1[A_PD.B_]!BQ_P#`E/\`&CEE
MV#FCW-!'61%=&#(PR&!R"/6I**>L63ZAI4]M$X24X:-CT#J0RY_$"G%V9,E=
M6$TO5(M2@/!BN8CMG@;[T;>A]O0]Z&K!%W*?BBUNKW2EM[2U>>0S1N0K*,!6
M!/WB/2J@TGJ*:;5D:P;RX-R0,#C/EC`/TZX_6H+.0L/#E]'H5K+%$;'6[-G,
M;LRE9%+EMC;2<J0?P-:N2OY&*@[>9HZXFI:MX6>W72Y4O)3'F+S(R%VNK'G=
MC'!J8V4MRI7<;6)+NRO;;6(=8TZV9C,!'>6Q9074=&&3C</KTH335F-IIW1O
M*25!(*G'0]J@LP+SR?$5_'8HBS6%K)ON7/*LX!Q&/7DY/I@#O5KW5<S?O.PR
M*&T\-ZX=D*6VGWZ*@95PJ2J3@'TW`_F*-9(-(/R-+5+&:]EL#&4"P7'FOERI
MQL9>,#K\WMTJ4[%-7L6)9;32[$R2-';VT*_0`4:MCT2*6@13?9;B[GC:)[V=
MIQ&PP47`50??:H/XTY=A1[FM4E!0`4`%`!0`4`%`!0`4`9GB*7R?#>HL/O&!
MU7ZD8'ZFJCNB9:19?@B$%O'$.B*%_(5)2T)*`"@`H`*`"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`(9[6&Y\OSD#^4XD3/9AT--.PK7(KC3;6Z,YFC+>?%Y,GSL,I
MSQP>.I_.A-H&DQ+K3+6\(,RN<1M'Q(PRK8R#@\]!0FT#29)#9003"9%;S/+$
M6XN3\HZ#D^YHN%DC+NM'GN+N[E622%Y2/+FAN738`H&2@X8@YZYR..*I2LB7
M&[-"/3;:*29D#@2DLR>8VW)ZD#.`3[5-V59(:=(L3&L;0Y18#;A2[$>6<9'7
MV%%V'*AZZ="L*1[YSM.0S3,6Z$=<^A/\^M%PL%O8Q6TRM&H6.*%88D'\"C_(
M_P"^:+@E8MTAA0`4`%`!0!'/;PW,+0SQ)+$PPR.H(/X4;"M<RAX?6V_Y!E_=
M6('2-7\R/_OE\X_#%5S=R>6VPX1>((>%NK"Y'J\+QG]&(_2CW0]Y"^;XA_Y]
M--/_`&\R#_V2CW1^\)GQ$_1--A]]TDG]%H]T/>$.EZE<<7>M2!3U2TB6(?F=
MS?D11=+9"Y6]V6K'2+'3F9[:`"5_O2L2SM]6.2:3;92BEL7J0PH`K7NGV>HP
M>3>6T<\?HZYQ]/2FFUL)I/<YJ'P):Z;K-OJ.ESF(1M\\$OSJRG@@'J./7/-7
M[1M69G[-)W1U/V>#_GC'_P!\BL[FMC-UG5-+T*U$]Z@"L<*$BW%CZ>GYU44Y
M;$2:CN<6/'G]I:O;VMM;0V-HSCS)I$#OM')XQ@<<=ZU]G9&7M+NR.XM=1T6]
M8);7-G*_]Q67=^76LFI(V3B]B]]G@_YXQ_\`?(J;E6#[/!_SQC_[Y%%PL'V>
M#_GC'_WR*+A8/L\'_/&/_OD47"P?9X/^>,?_`'R*+A8/L\'_`#QC_P"^11<+
M!]G@_P">,?\`WR*+A8D````&`*`%H`S[_1[:^E6?,D%V@PEQ"VUP/3/<>QR*
M:DT2XIE8-KUD,-';ZE&/XE/DR?B#E3^8I^ZQ>\APU]8^+K3-0MR.I^SF0#\4
MW4<O9AS=T'_"2Z5WFE4^C6T@/Y%:.5CYT'_"1V#<0I=SGTBLY3^NW%'*PYT)
M_:NH3\6>BS_[]RZQ+^7+?I19+=BYGT0TZ5?ZA_R%KX"'O;6F44^S-]X_ABBZ
M6P<K>YK000VL"001+%$@PJ(,`"IO<I*P3P17,+PSQK)$XPR.,@CZ4;#W,M?#
MX@&VRU._M8ATC20.JCT&\,15<W=$<MMF/AT"V6X2XNIKB^FC.4:Y?<$/J%`"
M@^^*.9]!\JZFK4E!0`4`%`!0`4`%`!0`4`%`&-KQ\]M/TX<FYN59A_L)\[?^
M@@?C51TNR)=$;-26%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`->-)$*
M2(KH1@JPR#0!SLO@K3$U*#4=/#6-S"X<>7RC>H*^XXXQ5\[M9F?LU>Z-J[TV
MROT*W=I#./\`IH@:I3:V+:3W,U],O=*!ET>9I8AR;*=]RD?[#'E3^8^E.Z>Y
M-G'8TM/OX-2M%N("0I)#*PPR,.JD=B*35M"D[HM4AA0`4`%`!0`4`%`!0`4`
M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`&+8'^T==NM1ZP6P-
MK`>Q.<R,/Q`7_@)JGHK$+5W-JI+"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@#%*C3?$Z%?E@U)"&`Z><@R#^*Y_P"^:K>/H1M+U-JI+"@`
MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`R-
M7O9FD32]/;%[.,LX_P"6$?=S[]@.Y^E4EU9,GT1H6=I#86<5K;KMBB4*HI-W
MU&E961/2&%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`%#6+
M!M0T\QQ.([F-A+`Y_AD7D?AV/L33B[,F2NA=+U%=2M=Y0Q3QG9-">L;CJ#_0
M]Q0U8(NY>I%!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`-9E12SL%4#)).`*`,:369=18V^AHLW.&NW'[F/Z?WS[#CU-5RVW(YK_
M``E[3=-CTZ%@':6>0[IIG^](WJ?Z#M2;N4E8NTAA0`4`%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`&9?:1YUR+VRG-I?@8\P+E9!_==?XA
M^H[&J3MHR7'JB%=5O[3Y-1TJ8X_Y;68\U#_P'[P_(T63V8N9K=$B>(]-=U0/
M.KL0`K6TH.?Q6CE8^=&K4E'+>)?&<?A]_)%A/-,?NLRE(S]&[_A6D8<QG.IR
M]#'\+>+;[5+^ZNM0\]XHU"QP6EL[JI/<[03VXR?6JG!)61$)MN[.K_X2&W_Y
M\M2_\`9?_B:SY37F0?\`"0V__/EJ7_@#+_\`$T<H<R#_`(2&W_Y\M2_\`9?_
M`(FCE#F0?\)#;_\`/EJ7_@#+_P#$T<H<R#_A(;?_`)\M2_\``&7_`.)HY0YD
M'_"0V_\`SY:E_P"`,O\`\31RAS(/^$AM_P#GRU+_`,`9?_B:.4.9!_PD-O\`
M\^6I?^`,O_Q-'*',@_X2&W_Y\M2_\`9?_B:.4.9!_P`)#;_\^6I?^`,O_P`3
M1RAS(=#KD$TR1+:7ZEV"@O9R*H^I(P!1RV#F-">9;>!Y65V5!DA%+,?H!R:D
MK8X#5?B<L3/%IVGL74XWW'RX/^Z.?U%;*EW,)5K;&]H_B:T.E0/J6HQF[<;I
M`$*A,_PXQVJ)1=]$7&:MJR]_PD^B#_F(Q`^ASD_A2Y9%<\>X?\)-HW:^4GT"
ML3_*CE8<\0_X233FXB^U3'TCM)6_]EHY6+G0?VW-)Q;:+J$A/0NBQ#_QYA_*
MCE\PYNR$\WQ!<\);V=BI[R.TS#\!@?K1[J#WF`\/I<,'U6[FU!@<B.3"Q`_[
M@X/XYHYK;!R]S65510J*%4#``&`*DL=0`4`%`!0`4`%`!0`4`%`!0`4`%`!0
M`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%
M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`$<T,5Q$T4\22QMP4=00?P-&P
M6N96G^'=/T?4FNM/C:#SE*/$K?(>^<'H?IZFJ<FU9D**B[HV:DL*`"@`H`*`
M"@`H`*`"@`H`*`"@#'UGPSI6MHQN[8>;CB:/Y7'X]_QS51DX[$2@I;C_``TS
M-X>M`S%C&#&">I"L5&?P`HEN.'PFK4E!0`4`%`!0`4`%`!0`4`%`!0`4`%`!
20`4`%`!0`4`%`!0`4`%`'__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g685450g55t09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g685450g55t09.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0A04&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````R0```EX````&`&<`-0`U
M`'0`,``Y`````0`````````````````````````!``````````````)>````
MR0`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````!;,````!````<````"4`
M``%0```PD```!9<`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``E`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U5),YS6M+G&&M$D^00S>T-W.:YK=-2(Y_K)*2I(/VNG]X:\>YO_DD
MCETB9<!MG=);I',^Y)22S^;=\#^1`]/`<R`*@"-"W;W_`'4XRVZ`E@<=-I<)
MGF$PR*G;2-AW?1@C7X?>BA&<7!VF'`]P-S?+2?[*$,>@GW-:V=);8#&CA/T6
M^*M[M0#6!)@$\3_FI.J>7;MK1I&A@\[N=J5JIJC'QR]H+6AH&TN]1O&OO+=O
MN>BLQ<%A!W-=``AQ:Z8C][\Y3KTF&E\$M),G4'6):%(N($FL`#D_ZA)3$MQ`
MYIK%8?N&W;$_RHV_R-RLJJ<NMK2]NP[>8<WC2=43[343`,GP!;_Y))29)";>
MUPW,:7-/!$$?E3FV`26.`&I,()?_T/4;VN?18QNKG-<`/,A1^T5Q!99\/3=_
MY%.RQ]C&O:T;7@.$G6#KKHHNR2UQ:6.D::!Q!TG0M844+>K1_HG?]M._\@AV
M'>\N#K&@\-]&8CXU[E*S)<6@M#VB?<YK'$@;7/\`HNJ/[O[JB++"8#[>8^@!
M_P!50U)3)CZQ.\/LGQJ(_(Q3]6CCTW?]MN_\BAL?8]P:++6N(F'-#?Q]':IE
ME[=38^)`TV=S'^B"2E.O9:&;`Z-S7;G-<T0-?I/#5851^(UM<N>YXK;I+:R8
M:/-BF*\B/YQP\I9_Z224NRT5[F.:^=SCHQSA!)</<T.\4_VEG[MG_;;_`/R*
M";7AQ:;+9;S#01\06T%J=F18QYW;WL<-)8[0@[7`[*F_2]1FW_KB5*M8GW$L
M=8SP`I.G_@:3B"9:7L[:4G_R"F<N&EWIO<!/T6NG0;OH[`Y3%Y+]@;K$CZ4$
M>3]FU)2S;ZVM#=K]/^#</^^I/O:YCFAMDD$#V.[_`-E3+W@C<T03!(,Q/R"(
M@E__T?3<<W_9ZMK&$;&P2X@\>&PJ.0Y_M]1G?V['V<QW]*M?+Z2*W6GZ<K<Z
M1M8_C\Y]W_HRM,':'V/Y$2^Z9_DS6OF1)%6K]0T.MV>QFG_"/?/`_P!+7N4W
MFZ!N:T-ELD.)/([;&KY;203J_4]W\R_^J?R*.[(_<9_GG_TFOEI))1?J*]UO
MI_I&#;(^@]\S/M_FZ]RK!WM,LM\Y??/'YL5_]0OF9)$(-OTWN'J"&/W>WA]T
M<>W?^CV_1^EN_P"N*WNR/W&?YY_])KY922*A;]2.-QC>UH;N&H<2>?#8U&7R
MJDFI#__9`#A"24T$(0``````50````$!````#P!!`&0`;P!B`&4`(`!0`&@`
M;P!T`&\`<P!H`&\`<````!,`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O
M`'``(``V`"X`,`````$`.$))300&```````'``@``0`!`0#_[@`.061O8F4`
M9$`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#`0$!`0$!`0$!`0$"`@$"
M`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P/_P``1"`#)`EX#`1$``A$!`Q$!_]T`!`!,_\0`S0`!``$$`P$!`0``
M``````````@$!08'`@,*`0D+`0$``@,!`0$``````````````@4!`P0&!P@0
M```&`@$!`PD$!@8(!04!``$"`P0%!@`'"!$2$Q@4%1965Y?7F-@A4M25,2(C
M.%AX)':V%[<)43*U-I8W=[A!<3,E-4*RL[1U*!$``0,"`P,)!0,)!@4%`0$!
M`0`"`Q$$(1(%,1.305%AD2)3TU05<3+28Q2!DC6AL4)R(S-TE%528K)SLS3P
MP8+#!M'A0Z,DHH-$_]H`#`,!``(1`Q$`/P#W\81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(HR\I;M=ZW4J+2]:2B=<OV\=I5O3
ME=N*K-&2]!T9F)L=KM=Q;1KD!:2,M`T6FRBL<BN((&D>X[T#)@8AK#3H89)9
MI;AN:&&,O+=F:A`:VO("YPKT559JD\\<,$-L_+<3RB,.VY:@N<ZG*0UKJ5PK
M2JQF.X%<4$VR8VC44#M&P'(096\[>.[V9>[`\`H=_(S5HMJ\D_6<.UA,J9)$
M46J9SF!)%,G0H;':UJ5?V=TZ-G(UG8:.@!M!_P`^<K4W0=)`&]LVRR<KI.VX
M])<ZI_,.8!5W@/X9?PPZ4_X!@?PF8]9U;^H3?>*EZ#HW],@^X$\!_#+^&'2G
M_`,#^$QZSJW]0F^\4]!T;^F0?<">`_AE_##I3_@&!_"8]9U;^H3?>*>@Z-_3
M(/N!8K>N(?!'7%*MNP+;QNTI'5>DUN:M=A?!KV"5.VAX".<2DBJD@1IWCA<K
M5L;NTR]3J'Z%*`B(!FR'5-9GFB@BOY3(]P:.T=I-`M4^D:%;0S7$VFP")C2X
MG(-@%2H\VW2G&+6]$IFW=B\'-`0VM;'*4IE:PC(^'D[=JV.V!*1<'7YVQ,3U
M)I"3S2/E9UH2<(R>D\U%%0[8\FFGVS=T5WJ$\TUK!K$YN&AV6I(:\M!)`[51
M4`Y:C'ERJNELM,MH(;RXT.W;;.+0Z@!<P/(`)&6AH2,U#V<:9E\JVL^%3_=U
MNT+>.&6C]>VTKB5-IF6D8>#D*KN^/@&B"EB3@I<*E'GA+36'C@@2,,HDZ=IM
M#E=H"X0$PE27&K-LXKV'59GQ8;P`D&,G949C4'D=@*X&A2*VT5U]-83Z-!'-
MCNR0"V4#;0Y11S>5N)IB*A5E=TCQ0NUGIFNZQPPX]$O<QIVO[HO2CN)8O:AK
MN`MST8^J1`2K>ELI.TV2Q.FCXR+86D61-JP6744+U037Q)>:E#'+/)JT^Y$I
MC;CVG%N)-,U`!AC4XD"FVDH['29Y8;>+1K??F$2.P!:P.-&BN4%Q.-!1N`))
MV5NJW'?C&A=ZYJ%QPFX\(;5LB-RL235-G$/:C'ZQIAJPQ>;(<RI:<VF5`?3U
MRCX]K$"Q266>"N071$$#.AB+[4##)=#5Y_IFY1RYB]U>Q3-38TDNKLIA4T4C
MIVF">.S.B6_U3LQY"T,;E&>N6N)<`&TVUQH*K4VSJMQ&U)$;P86?@OH5SL?2
M<3K6V>CS5O$L:SL'7^SK6%-A[A6;&O0W<HQ4C9M!TWDF#B+4!HZ0[I-TY3.1
MP;IMY-3N76;H]8F^GF+Q7&K7,&8M(S4Q%"#7$&M!L7)=1:1:,OFRZ%;FY@#'
M4P#7L>[*'-.6HH:@@MP(I4[5M'>&D>(6A9_5;RW\+="?W/W>SM*7>-L@PB6[
M?4]@FTS(55U9(%2C*-E:?.SHI1YI=629(LEUTQ7(0IBB//9WFJ7K+D1:M-]4
MQN9K,>V!MH<WO`8Y:&HV+JOK'2+"2U,VBV_T;W9724'[,GW:C+[I.&;,`"<5
MTWS0/&VI:=OV[XW@QQQEJA2*/L?8C9G*'0K\U9ZG3816?K\@P;DU9,%C'-NC
MHUVL#9T!3-$%6AC'.HJX0:H;V_ENH+-VL3B5[VMPQ`+C0@]L5RDC$;<>2A*?
M3]-AL[B^;H5L86,>^AP+FM%01V#3,`<#L%.4D#'+;I_CE2Z9JB[RW`[C0O'[
M=OVA*#!-(^4;*K1KG=DZ6%6D9)=QJ)MVBU;R]DH**:0@\!10`53$@`;9%=7\
MLMS"W6;C-$R1QJ-N[%:#M\M#[%JFL].AAM)WZ#;99I(F"AV;PTJ?V?Z-1ARX
MXA9C4^.O&':@[#D]4\,N.4E5Z#=[3KQA*VR*9P1]@V>DK$C+2,%YLIDZA#5J
M.LI'$:C)*F=F=N&:QBMB(`DLMJEOM1MMPVYU6<2/8'4::Y0[$5JX5)%#3"@(
MQK@-T6G:7=?4.M-&MC%&]S`7`#.YN#J4::-#J@'&I!PI0FAU9I3AWM/8EUHK
M'B+QQ@Y'6EA9UJ_U2695\-D0/EVOX"W)6DM63K8).ZNI89PL*V7(OW+WL'>)
MKE[L6ILW-WJEM!%,=4G+9&U:X5R&CBVE:[:#,>;93E6+6RT>ZN)H&Z1;-=$X
M![2!G%6!V;+3W:G*#7';7D5@W-JWB5JS:;C6D?PHXU37<Z%NF\DIRRR$/24W
MB=+LU>K;BG-&9=:V9-28EE+"11HH+DI#BF8ABEZ@;-EI<ZG<VPN':M<#]LV.
M@!=[P)S>^,!3'!:[VUTFUNC;-T6V=_\`G=+5Q#?=<!E]QV)KABJ1]3.$,%:Z
M_'V[A1J*FT]_Q-L/*^S3MCK$0TM=+@ZP[J;66I4M14JFN56QLS6LA5.S*%$J
MS=1($S'$H&R)M7?&]T6KROE%R(0`3E<3FHX.S;.SS<JBZ'1(Y8VS:+"R$VAG
M<2T9FAN6K2W+M[7]KDI17BVZ4XQ:WHE,V[L7@YH"&UK8Y2E,K6$9'P\G;M6Q
MVP)2+@Z_.V)B>I-(2>:1\K.M"3A&3TGFHHJ';'DTT^V:$5WJ$\TUK!K$YN&A
MV6I(:\M!)`[514`Y:C'ERJ<MEIEM!#>7&AV[;9Q:'4`+F!Y`!(RT-"1FH>SC
M3,JF:T#Q^AMVTC21N"7%US*7JA[`O\=.'F"LVC./HDS4XH["18IZ9D%$W\B%
MN1/^Q6722%$X=LX"4PX9>WS[2:[]9N,K'M:13E<":C]H,!E67Z?I[+V"R]"M
M2Z2-[P:[`TM%"-V<3F'*59ZEJ+C'9-J;*U2ZX1\5(:7U;<]35"85?62);OYX
M=C4NIWJ7?U:#5U64)%S582PN!*S%X47RC$2@LD53MDG+=:A';6]R-7N2R1CW
M#`T&5SF@$Y\*D#&F%=A4(;33)+JYM#HEHU\3XVFI%3G:UQ+1DQR@G"N--H67
MU/CKQAVH.PY/5/#+CE)5>@W>TZ\82MLBF<$?8-GI*Q(RTC!>;*9.H0U:CK*1
MQ&HR2IG9G;AFL8K8B`)++:I;[4;;<-N=5G$CV!U&FN4.Q%:N%210TPH",:X#
M=%IVEW7U#K31K8Q1O<P%P`SN;@ZE&FC0ZH!QJ0<*4)M>M].</+K?MW:^L7#;
MCE0)?3KK7\>!9A:MN5YZ1OFMJ[L4K9RW]"V*<,G")V$K%PHBK(E.LB8Y.I1#
M)7%UJL,-I/'JL[V2AQPK@&O+?[1K6E>11MK/1Y[B]MY-&MHWPE@QIB7,#_[(
MI2M#2N*J]2Z3X@;2XM0W)$O"O1,&XF]>3-_:T@T9#R2*:,6VD7248O:0I;$Y
M5'1(_H94L88$Q/\`84_3J.+F\U2VU%]AZM,0'AN:I&VF-,W3SK-I9:1=:6S4
MO18&ET9?EH#LKAFRCF_LK48Q_"Z!@N.U^V)P8TE4-2[RUG3KU8]DLFD)/Q6F
MI383.)<4V(O+-6BPBH5F6=RQ&*D^51)JR>B0KA)-)0BV=6;5GOOH8-8F=<PR
M.:&8@R!M<Q;VCB*5R[2-F."Y,NBQQZ=<7&AP,M)XFN+Q0B,O`RAW9'9-:9]@
M.T`&JVU=-+<.Z:\5AC\,M"35AL>Y:OIG5$3$1T0MZ:25BI,1L!U8K"[4I)"T
MZOUJKO73Q^JW),]ENQ-W?>*K(HFY8;O591G&JS!C8C(\DGL@.+:#M=HDT`KE
MQ/,"5US66CPN+/1K=TCIFQQ@`=HEH?4]GLAK22:9L!AB0%MNO\)..XV!2(MG
M#GCDC#'ACR+2U5N#CGJ7G1)XV06K\A!2E8CW3,_D[GO6[M-RX(X*DH!TT#`4
M#\K]7OLF:+59\]:4)Y.<$$_:*8<Y77'HFG;S)+H]MDRUS``X\Q!:/L-37'`+
M8'@/X9?PPZ4_X!@?PF:?6=6_J$WWBNCT'1OZ9!]P)X#^&7\,.E/^`8'\)CUG
M5OZA-]XIZ#HW],@^X$\!_#+^&'2G_`,#^$QZSJW]0F^\4]!T;^F0?<">`_AE
M_##I3_@&!_"8]9U;^H3?>*>@Z-_3(/N!8O:^#NIX:*>3W&^(:<<MO1319W3;
MEK,SJN0RDRW(=9C'7VGL%BU>\5*1<@5%^U?LUU#-C&[E1)0"'+LCUBY>X,OW
M&>U)[37XFG*6N.+7#D(.W;5:I=#M&,=)IK!;7@'9<S`5Y`YH[+FGE!!PV4*W
MWH'9RVYM+:SVB[C"0DE=*C%2\S#(G%5O$SXH^33\:T6%147#-C--UTD5.T;O
M$BE-U'KG%>VXM+NXMPZK6.(!YQR'[11=^GW1O;*VNBW*Y[`2.8\H]@-:+;^<
MJ[$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$7__T/?QA$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBB;R:_P!^N&'\V37_`+=.
M1>6>G_N=6_AO^[$JG4_W^B_Q?_9F4LLK%;)A$PB818+L_7L#MG7-ZUA:/*?1
MW8%3GZ?,G9*%1>HQ]@C',8X<L5CD4(D]:D<]XB8Q3%*H4HB`@'3-UO.^VGAN
M(_?8X.'M!JM%U;QW=M/:RUW<C"TTVT(IATJ/LEHW9.P-1531&UYZI2]5AG5#
M1N=W@U9A.Q[,@-=3D1.L8YS4WT9YOIKZX.*^S),.4I>3`J(NBM4TC.$E&G<V
M\MX+J6\MF.$A#LK32C"X$5S5JX-J<HRCDKL-:]UC<W%G%87<C#$TMS.%:O#"
M"!E(HTNH,QS.Y:4J*7+8_&UMN>@7*G7MVE79M;84CL35U^I$E(^E.M[4B)%:
MI;HAZJTAUVD]"KDZ+I)*B@[0.=(Q@*<>D8+\VD\4L(S,R!KVN`H]OZ33MP/Y
M%*YTT7MO-#.<K]X7L>TG,QWZ+@<,1R\A&"LU7X_7S75VUUM"IV"N3EGC]!TC
M1.UZQ/*R4'7[LE1S*2%?N\)8(R+F7L)/PLM)2)`27C':+U@][H1;'3(J$I+V
M&>&>WE8X1F9TC"*$MS8%I!(J"`-A%"*XUHH1:?/;SV]U%(UTHMVQ2--0'9<0
MX$`D$$G:T@@TPI57.:TWM"3VA0]_MIVG,=E5!E>*7(TY(\SZ%6/4MS<5Y^2F
M.K5YN\^(3L#8*NUED9CS4=-5P=9`S$$C)&1BRZMVV\UD6/-NXM<'89@]M1FI
M6E""1ES;*&M:UD^SNG74&H"1@N6!S2W'*8W4.7-2M06AP=EVU&6E*:_W=Q1M
M6Z(+=LT]F:O%;,VW5=6Z[AP%>5?5>A4'6-Z6OZ<:G(DB6,K9Y2QV22?.G3@[
M-B1,BK9N0G1J==UOM-2CM'V;`QQMXG/<=@+G/;EK2I`````J>4\M!SWVE2WL
M=Z]SVBYF8Q@VEK&,=GI6@+B222:#D')4["Y`ZEVGR!T;N/4LBO0JFIL2L1]:
M@#-I6=L+6$5!XN\EYV4D5JQ!.)`ZX%:D;LTVB14NX,<7`BIT)HLKFWLKRUN6
MA[MVXDX`5Y@!4TY:FOV+IU"TNM0L;RT<8V;QH:,2:8XDG**\E!3DVK9^ZZ+8
M-KZ*VIK%JK#Q$_LO6-UH'EKAV]<0\.YN=9DZX>3[U.-(]?H1H27?@EW*)ENQ
MV.TGU[8<]I,RVO+:X()9'(UW2<I!IMPK1=-[!)=V-U:@M$DL3F5QH,S2*[*F
ME:[,5JO8^B+A==5\?Z0TDJTTF-/[*T+?YARY=2@1LNGI:;B)E>-C5$HE5TD>
MQ#$]V115(`:]YVA*KV>R;H@O(H;F]F+7%LL<C1LJ-X"*G'DK]O0N6YL)I[73
MX`YH?#+$\[:'=D&@PY:?9TJJU]J79NDEMI0NN'5'L]+OFP+AL^J-+C)SU=D-
M<6"_OU)JT0`(0D#8&MOJ8V9RO),R%5AW*`.%&IE%"BFNDGN;>[%L^</;,QC6
M'*`0X-%`<2,KJ4!]X&E>@YM[2ZLC=,MBQT,DCGMS$@L+S5PP!S-S5(]TBI'2
M+,KQPEK!NW4NZ;8E1V]\U5(V<'FTJBG(0UQV93YRJV6OQ]`ME>2C$(EM!Q;N
M?;O.\5D)0P+191;)M0>+`G(7[66ES:1E^YD`[#J%K'!P)<TUK4T(V#;C6@4#
MIKY+VTO90S?Q%U7MJ'/:6N`8X4I05!VN]W"E33NVGH*S73>[3;#2-UE98)+0
M-UTFM5-AIR;U@JYN=NK%G-8WD>VA'S>281A*UY,I'@LV4>I.3@#IMTZF6U['
M#9FV+I&OW[9,S:5[+2*5KA6M:XTIL*S=6$LU^+L-B='].Z/*^I':<UU2*&H%
M*4J*UVA:T;<(7+AQ5:W;KNXNM$C>&-PXE6:8E';Y"^3OI?,5.6<75L*K>48L
MCL/18$FS91TN9(%B&%4_<=E;H.K@"22*'),;MLP`IE&4.&7DVUQ-![,<.4:(
M28HYI\\`LG0.)KF.8M.;E`IEP%3[<,=ER6C=D[`U%5-$;7GJE+U6&=4-&YW>
M#5F$['LR`UU.1$ZQCG-3?1GF^FOK@XK[,DPY2EY,"HBZ*U32,X24:<[;RW@N
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MK@0*4=F<7<^&VFP\^"YV6%Q'>:A=-$1WSV%I-:LRL#*^[B32NT<V*O\`K[4N
MS=)+;2A=<.J/9Z7?-@7#9]4:7&3GJ[(:XL%_?J35H@`0A(&P-;?4QLSE>29D
M*K#N4`<*-3**%%-=*$]S;W8MGSA[9F,:PY0"'!HH#B1E=2@/O`TKT'9;VEU9
M&Z9;%CH9)'/;F)!87FKA@#F;FJ1[I%2.D6>A<:E(?:&_=E;$AM:;'D-M2&O)
M2'4E(5!1U'NJ+K"LZ\=I//.%>D$HUM8W==&1$K452M/*.Y`JW=]Z>4U_GM[*
MW@?)&V(.!H=N9Y=R$5I6F.VE<-BA!II9=7]S<,BD=,6$5&S*QK.4&E:5PV5I
MCM5VTUH:S:OXCP7'=[+04K8H'6<W0$YYJI(-X5ZM(M9-HWDSD58G?-$RED`,
M=($U1`2]`,;KUR-W>1W&IOO@UP8Z0.IA7"F&WH4[.PEM=(CTYSVF1L197&AK
M7'97E35V@Y.MZ]U]JG8+.F6ZEUGC=5-#V=N"\DY+9S5Z*9P3]V>*>P[=N6'G
M(YEVA2,OWR!U!*!E`*!Q7%ZV2>>Y@+VS.N#(-F%348UV@]:6M@Z.WM[2X#'P
MMMFQ.V]J@`.!&P@<^"U-"<)IFG4*#J]6VG(.YW4W(-GNK1=AN*+ZPJP]:C:=
M'TECJ6YK"^;RLK625%1]!^4(.2N",?)5RAWB/<9TOU=LL[Y)+8!DL&[D#<*D
MN+L[<*`YJ.I2E:CEJN1FB/AMV1171,D5QO(BZIHT-#1&[&I;EJVH-:4/)121
MG$^2$CW#JOJ:=J2B#NL)*Q,BZMUZ:/X\UDCG-T>*3"4-0W3*02JS==K%($:J
M)&=KBJX4`O8*EP,^@;4/WKL#B,K:&ARX5=A6A=CLV=-D_P!2=0Q[EF+<#F=4
M5&;&C:'+4-%-IJ3S;SSC7<F$3")A$PBB;P7_`'3=*_U<D/[23>6>L?B=W^L/
MS!5.A?A-E^J?SE2RRL5LF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB__]'W
M\81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(HF\
MFO\`?KAA_-DU_P"W3D7EGI_[G5OX;_NQ*IU/]_HO\7_V9E++*Q6R81,(F$3"
M)A$PB81,(F$6G+#MHT?KG8-^KM8=6I:JRMIK-5KS6039N[S;JW,J4I.!2<F:
M.@@1DMD-5X<JRJ2Y4R)@Z$IDS`3.IEMFG@@?(&AP!<:>ZTC-7IHRCN3F7')=
MY;:XN(XB\L+FM%?><#EIT5?5M<>=8C-\@6IXO1-DI,:PL=8W?$V">BI)W)+,
M3H1K'4%CVE!&3(W9/B&\Z!"D;KF,/5L4XB":AOL+M98G->1S.+9(2`13E+PP
M\VRM>E:7Z@,MA)`T.BG!(-:8",O'(=M*'FZ5F&K=QU786L:S?G-@JD<X=TVF
M6*Y1[>QQR[>ER=LKL9.!$3*ZC@JD8=,9$"I`Z!)10G0>GVYJN;62"XDA#'$!
M[@TT/:#214<^SD6ZUO(KBUBN#(P$L:7"H[)<`:'FV\JRF8V;KBOHG7G+]3(A
M).+)-F/(V>%9_P#LZL7+S:4H4J[TACQZT-`/W9%2@)#MF2ZA1$B*@EUMM[AY
MHR!Y-:8`[:@4]M2![2.=;7W-M&*ON&`4KBX;*$UV[*`GV`GD7?%;#H4Z>O)0
M]UJLDO;63V2J[5G/Q:[RPL(T3EDG<,S(Z%U(H1ATS%<F2(8&YBB53LB`@&'0
M3,SE\3@&FAP.!.RO-7DYUEEQ;R;L,F82\$MH1B!MISTY>94^R=@P.K*3/7RR
M%?+1<$BT#R&*01<R\Q)RD@TAH&`AFSAPS;.)JPSLBV8LTU5D4CN7!`.H0HB8
M,V\#[F9D,=,SN?8`!4D]``)/0%BYN([6"2>2N1O(-I)-`!TDD`=)5%'V._I.
MXH;52*_#0SU%^I*2L1?%)PU:%K&FD$%)IM(U&LH"S6,@J@HLV<.`16[O]4R9
MS*)Y='"0[=S.+QL!;2N-,*./Y0%%LEP"S>P-:PUJ0ZN7"N-6MPY,"<:<F(K5
M=GZU0A6ED7V'1D:Z_9N)%C/JVV`3A7D>T<E9.G[25/(`Q<,VSPY45%2*"0BH
M@41`P],P+>X+S&('YP:4RFM>:E%(W5L&"0W#-V14',*$;*UK2E5?%;1649:)
M@%K%!)3L^T<R$%"JR\>G+33!FF"SQ[$QIG`/)%HT1,!U%$2'(F4>IA`,ANY"
MUSPPY&FA-#0'I/(IF6(/9&9&[QPJ!45('*!RK5ZFYHC^^PNJF[RLN&#'5]NO
MUDF$;"U5?UM]6+148,T5-1Y`[F);'96-1P95PJ4_[$0[!2E$QNCZ1_TGU)#L
MQD:T"FVH<:@\NRF"YC>L^M^D#FEHB<\FN(+7-%".3`UQYEF!]B5]1WKTT6_C
M)ZO[*>2<56[)"2S.3CGLLSKDM;6:315F*[5_'/Z_6914722X@FHU3)V#@L)D
M]6X?2?,TM?&`2"*&E0WKJ1AT]"V_41DV^1P='*2&D&H)H7<FT$-=C7DZ<,]S
M2NA,(F$3")A$PB81,(F$3"*)O!?]TW2O]7)#^TDWEGK'XG=_K#\P53H7X39?
MJG\Y4LLK%;)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(O_2]_&$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"*)O)K_`'ZX8?S9
M-?\`MTY%Y9Z?^YU;^&_[L2J=3_?Z+_%_]F92RRL5LF$3")A$PB81,(F$3")A
M%&.O:WMKB-K5.DTQ:U:I[,VC.SCMO:+15K'*LI2QVJ7UVI#OJX@EYT:^9+<W
M<R*A'S/LRC3N@*'=JI!823Q!TDK<9'1L`P!`H`'5!V8M(&!P->95D=M,6Q0N
MPB9*\GM.:2"7%E"-N#@3B.T*<X6MZWQNV)`M:-7"2-1]$=:;/WI8:8BI8K-)
MRK/7VT*E?HBKU=RXD*X*J[RI25\41*8ZZA2Q;1$@***`(CT27\#S-)E=O9(X
MP[``9F.:2<#^D&]9*YH]-N(Q!'F9N8I92W%Q(8]KPUN(VM+J;?=`Q)6(.>(5
MT&!TQ,LR:];WW3VO=0T5[7&]@L<;2MIL:`IW$DQM]ICJ>E/1S-@U66=5]4D2
M^-'2"ACG2.0YBYM&J19[MA+]Q+(]U:`N87;"T%U#78[M"H6DZ1-N[)XW8N(8
MXVD5(:\,VAS@VH`VL[)H>19_+<6SRKS<PMX'6L#'["XSU72E/18HO'IZ38(A
M3?:TI(H`Z@$5`B'9-QMV_?(K)N'"<<<YT4P5*BGH;J.46E7R.<RX,CN3,#NZ
M#;M[!/,*[>5=#]+SNO:1Q-;);-C;3'*1O:G9L_:`8&IILQH+>31&W'=IU=/N
M(73E?8T&\Z[N+F(K4_*B=Z,%KBZ:_LY'4PKJ=C)S$B@-K%U&*"=BS41`R"C5
M!43O%I?66HCN6!\KB]CFU('*YKAAGH!V:':>6I&`C]!=F6UD+(6MC>QU&DXT
M8YCL=V"3VJMV"F!`/:.SIRCW3D!H.=IVRR1VO[E*S+IU#2U:;R3YE$2E!V*6
MR:INZ4-9$8V2$!>5>)E5XUT)#&ZF1,<H&ZEYV316-ZR6WJ^(#$&F(<VCVU%1
MRN%1[5TR03:A820W-(YB[`MJ0"Q]8W4-#^BUQ!]BK+?#;\N%(6@',)I)I+G:
M('?&>3=HLE?GI%B]CU6Y$XR3HB!:XV7,DH\3.X+/E:.$445$'J0J'&,3[**8
M/#YBRO,`0,>4.QYL,M14U!4IF7\T!C+(`^F.+B"01R%N'/CFH:"CA5:8J?&*
M]1=F;S4V37SY&/?\LG39QYVD'TD])R*GX6RQ@.B>@$.R8GBW+-TT?E0**2B*
MW>I%_6,W#LEU&%T98S.*B'D%/V0(/Z1VX$=1YUQ1:9.R4/?NR`9^4DG?$.'Z
M``IB#3GJ.94L9QLVZP/I1N9UK0C74S[3SQ62C)*08S4RM2],V?5%F?O'#K7<
MH^?RC16PB[A^V]29';$\G6;(*BH[5.O[4_5FDE90_`@$#-('@>\*#"CL*UQ!
M.P8;IMXWZ(5BI$8\02"<L;HW$]@DG&K<:4P(!Q--$<>M\,V6NTWS?23R1UMI
M^,U*W>+S5GD6MG-$;0U):T[LO&RNO'3>O6%U`Z_=.FY%AFT8^P+-U3^7H%4`
MV7WUD3/0S!LDI?L`I5CQEJ'8BK@#[M6U'9*PS3[\-M\P@+HX1'M<<U'QNS4+
M,#1A(]X!]#VA5;'USI^YU"'UW29]*)<D@N1&\]RNI6$?/7[+T4NEJVU>*^T=
MNEJW66K&T(6#:C!HJT2;G;KMF+I=$Q0_9HZ)[J*5T\S"16"..A%.TT,:>4U%
M&$UK4$@'IZ;:SFA9;P2`'+<2R5!)&5SI'#D;1U7@4I0@$CF$O<JU;IA$PB81
M,(F$3")A$PB811-X+_NFZ5_JY(?VDF\L]8_$[O\`6'Y@JG0OPFR_5/YRI996
M*V3")A$PB81,(F$3")A$PB81,(F$3")A$PB81?_3]_&$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"*'O,"2;U-OQTVA,CY-3-4<
MEZ=9[],'$"MJW5K+1-EZG+9))0P@5O#P]BV1'JO5C?JMV@**F$"D$0M-+:93
M?V[/WLMNX-'.0YCZ#I(::<YP5/K#A$-.NGX0Q7+7//,US7QU/0"\5/(*E2_2
M53633614(JBJ0BJ2J1RJ)JIJ%`Q%$SE$2G(<H@("`B`@.5>S`[5<`@BHV+GA
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$6(7Z]U36%*L^PKQ,-("IU"&>SL[*O54T46S%DD*ABD[PY`6=N5.RBW1*(J+
MKJ$3(`G.4!VP0R7$T<$+"Z5QH!_Q^7F"TW$\5K#+<3O#8F-))/,/^,.<X+3'
M#FM3U1XOZ3@[1&.(2?3H\?)24,\*)'T0M/JN)\L7()B`"E(QZ,F5%P3I^HL0
MQ?\`PSKU61DNHW;XW59G(!YZ85'0:8+CT>*2'2[)DK<LF0$CE%<:'I%<>E26
MRO5DF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB__]3W\81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(J&4BXR;C7\--1S&7B)5
MFYCI2*E&C=_&R4>\1.W>,7[%VFJU>,W;=0Q%$E"F(H0PE,`@(AF6N<QS7L<0
MX&H(P(/.%%S6O:YCV@L(H0<00>0CF446G"_7,`B6-H.PN0NL:P@`!'TFA;WV
M%&TZ%+U,8Z-?@I&6ET(!@8QNI6C,46:7Z$DB!]F69U:=YS3P022<KG1M+C[2
M`*^TX]*JAHMM&,MO<7$47(ULKPT>P$F@Z!0<P55X28S^('EE\P%NS'J;O(VW
M#"SZ2W^H7?%<GA)C/X@>67S`6['J;O(VW#">DM_J%WQ7)X28S^('EE\P%NQZ
MF[R-MPPGI+?ZA=\5R>$F,_B!Y9?,!;L>IN\C;<,)Z2W^H7?%<GA)C/X@>67S
M`6['J;O(VW#">DM_J%WQ7)X28S^('EE\P%NQZF[R-MPPGI+?ZA=\5R>$F,_B
M!Y9?,!;L>IN\C;<,)Z2W^H7?%<GA)C/X@>67S`6['J;O(VW#">DM_J%WQ7)X
M28S^('EE\P%NQZF[R-MPPGI+?ZA=\5R>$F,_B!Y9?,!;L>IN\C;<,)Z2W^H7
M?%<GA)C/X@>67S`6['J;O(VW#">DM_J%WQ7)X28S^('EE\P%NQZF[R-MPPGI
M+?ZA=\5RT(AHN04Y02>J3<A>4_HBUT+!["21#>UK!^%C?["L-;<*&>]>V9H,
M9&I`"73H!P$W7[<[3>-].;<_0VV]WQ;^[%*90?SE<`L7>J.M/4+K<BW#_P!Z
MZM2\C;[`M]^$F,_B!Y9?,!;LXO4W>1MN&%W^DM_J%WQ7)X28S^('EE\P%NQZ
MF[R-MPPGI+?ZA=\5R>$F,_B!Y9?,!;L>IN\C;<,)Z2W^H7?%<GA)C/X@>67S
M`6['J;O(VW#">DM_J%WQ7)X28S^('EE\P%NQZF[R-MPPGI+?ZA=\5R>$F,_B
M!Y9?,!;L>IN\C;<,)Z2W^H7?%<GA)C/X@>67S`6['J;O(VW#">DM_J%WQ7)X
M28S^('EE\P%NQZF[R-MPPGI+?ZA=\5R>$F,_B!Y9?,!;L>IN\C;<,)Z2W^H7
M?%<GA)C/X@>67S`6['J;O(VW#">DM_J%WQ7)X28S^('EE\P%NQZF[R-MPPGI
M+?ZA=\5R>$F,_B!Y9?,!;L>IN\C;<,)Z2W^H7?%<GA)C/X@>67S`6['J;O(V
MW#">DM_J%WQ7)X28S^('EE\P%NQZF[R-MPPGI+?ZA=\5R>$F,_B!Y9?,!;L>
MIN\C;<,)Z2W^H7?%<GA)C/X@>67S`6['J;O(VW#">DM_J%WQ7*IB^'NJBSL+
M8;O,[5W*]K+]&6K+'<^T[CL*M0$PW[8MYEC3I62+459EN)^J3MRQ7<(&`!2.
M00`0P[5+G(^.%D<0<*'=L:TD<Q<!FIT`T66Z/:;QDD[Y9G--6B1[GM!YPTG+
M7I()'(I4Y6JU3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(O_5]_&$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PBB:U_?IF_P"4VK?XP7#+,_@[/XD_X&JI'XZ_^$;_
M`*CE++*Q6RC6TE;`PY,;)C22T].QC;0-#M$55G4CV8IK,O+QM%BX3B6**";-
MFXDF\(U14<&24<J`F0%%#E(0I>\M8[3X'96M=OW`FF-,K#C[*G#8JT/D;J=R
MW.YS1;M<&UPKF>,!LQH,=JBV[V9L*`I6I;!#SLM(2N[N+L+>=BRYI=\LV@;;
M([!XZUM:\PL>Z>.F=97-7]UV)RB#<$6Q&\"U1`!19)E2LA;P/FN6/8`V&X+6
MB@Q:&RG*3RXQM&.-7$[2JLW-Q'#:2,D)?/:ASS4X.+X1F`_1PD><,*-`V-PW
MPRA[M.63<6NZI..25ZC[;U)/M6\W8IHZ#VO2-6J5DO6L%IX$YN::1;LR?G(R
M!P6*N66,S4*5@L!"\1="R.UGD8-X^)XP`V@N#7TP%>3_`*:^\%W-9/))>6\3
MSNV31G$G$%K2YE<33]*F-<U#V2NO5=Z850(&+V/L%S.RM<AJ11HV0%65D&+M
M38MX=T:NV^8?J%.L\0V%L*"&MUUZ_P"^7>(Q)GA5$RR;@,7,+I<[K>"C7%SB
M,![K<Q:/U6G,X#`9J?HA+6=L6[9<W!<]K6M!Q([;LH<3RYWC(PG$Y<WZ14Q,
MJU<)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$7_UO?QA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(HFM?WZ9O\`E-JW^,%PRS/X
M.S^)/^!JJ1^.O_A&_P"HY2RRL5LL61I=;;V]Y?$F*Q;7(0K.NO)49.5/W\''
M.WS]A&&8G?&C2M6;V3<+)E!$.PHNH8/M.81V&60Q"$N_9`UI0;3@37;R!:A#
M&)G3AO[4M`K4[!4@4K3:3UJQLM2:WCV%CBV]0B31=LB7->GHQV1:0C7=<=K2
MKA>M(L'ZSEI'5DR\X\.$<V(BR(9RH)4@$PY,W-PYT;C*<S34'8:X8U&TX#$X
MX;5!MI;-;(P0C*\4(VBF/9H=C<3@,,3@K]$4ZO047*1,4S<-D)M9PYF78RDL
MXG)9ZY8-HM62DK(Z?+6%]*A&LD&Y':KHSE)%ND0ARE23`L'2O>YKG'$;,!08
MUH!L`K4TI3$\ZFR&.-KF,%`[;B:DTI4FM2:`"M:T`YE:U]8T%Q(QTJI58HKR
M+8U:,9]RD=LU+'T:5<3M)9N(]NHE'OF]-FW:KR)*NDH$:Z5.JW[LYC&&0N)P
MUS=X:$D_:X4=CM[0P=SC`J)M;<N:_="H#0/8TU:*;#E.+:[#B*+.\TK>F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81?
M_]?W\81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+\S>*?'F
M+VGQKT=L>Y[EY6R%LNVLJE9;$^;\L.04>B[EY6);NGJZ3%EL%%HU(HNH(@FF
M0I"_H``#/0:E?.MK^\@BM+81,D<!^QC.`/ZJ\SI6G-NM-L;F:\NS*^)KB=_*
M,2,<`]2`\'=%]K/++YO.1?Q&SB]5F\M;<"+X58>CP>;N_P"8F^-/!W1?:SRR
M^;SD7\1L>JS>6MN!%\*>CP>;N_YB;XT\'=%]K/++YO.1?Q&QZK-Y:VX$7PIZ
M/!YN[_F)OC3P=T7VL\LOF\Y%_$;'JLWEK;@1?"GH\'F[O^8F^-/!W1?:SRR^
M;SD7\1L>JS>6MN!%\*>CP>;N_P"8F^-/!W1?:SRR^;SD7\1L>JS>6MN!%\*>
MCP>;N_YB;XT\'=%]K/++YO.1?Q&QZK-Y:VX$7PIZ/!YN[_F)OC3P=T7VL\LO
MF\Y%_$;'JLWEK;@1?"GH\'F[O^8F^-/!W1?:SRR^;SD7\1L>JS>6MN!%\*>C
MP>;N_P"8F^-/!W1?:SRR^;SD7\1L>JS>6MN!%\*>CP>;N_YB;XT\'=%]K/++
MYO.1?Q&QZK-Y:VX$7PIZ/!YN[_F)OC3P=T7VL\LOF\Y%_$;'JLWEK;@1?"GH
M\'F[O^8F^-/!W1?:SRR^;SD7\1L>JS>6MN!%\*>CP>;N_P"8F^-/!W1?:SRR
M^;SD7\1L>JS>6MN!%\*>CP>;N_YB;XT\'=%]K/++YO.1?Q&QZK-Y:VX$7PIZ
M/!YN[_F)OC3P=T7VL\LOF\Y%_$;'JLWEK;@1?"GH\'F[O^8F^-/!W1?:SRR^
M;SD7\1L>JS>6MN!%\*>CP>;N_P"8F^-6@.#NJ"SI[06_\G`LRL2E`*6(.56_
MPG5()!XM(H0IY<-@><#Q*,@X47(V%3N2K*&.!>T81&7K%SDW>XM]W6M-S'2N
MRM,M*TY5#T.TWF]^HNM[2E=_+6FVE<]:5QHKOX.Z+[6>67S><B_B-D?59O+6
MW`B^%3]'@\W=_P`Q-\:>#NB^UGEE\WG(OXC8]5F\M;<"+X4]'@\W=_S$WQIX
M.Z+[6>67S><B_B-CU6;RUMP(OA3T>#S=W_,3?&G@[HOM9Y9?-YR+^(V/59O+
M6W`B^%/1X/-W?\Q-\:>#NB^UGEE\WG(OXC8]5F\M;<"+X4]'@\W=_P`Q-\:>
M#NB^UGEE\WG(OXC8]5F\M;<"+X4]'@\W=_S$WQIX.Z+[6>67S><B_B-CU6;R
MUMP(OA3T>#S=W_,3?&G@[HOM9Y9?-YR+^(V/59O+6W`B^%/1X/-W?\Q-\:>#
MNB^UGEE\WG(OXC8]5F\M;<"+X4]'@\W=_P`Q-\:>#NB^UGEE\WG(OXC8]5F\
MM;<"+X4]'@\W=_S$WQIX.Z+[6>67S><B_B-CU6;RUMP(OA3T>#S=W_,3?&G@
M[HOM9Y9?-YR+^(V/59O+6W`B^%/1X/-W?\Q-\:>#NB^UGEE\WG(OXC8]5F\M
M;<"+X4]'@\W=_P`Q-\:>#NB^UGEE\WG(OXC8]5F\M;<"+X4]'@\W=_S$WQIX
M.Z+[6>67S><B_B-CU6;RUMP(OA3T>#S=W_,3?&G@[HOM9Y9?-YR+^(V/59O+
M6W`B^%/1X/-W?\Q-\:>#NB^UGEE\WG(OXC8]5F\M;<"+X4]'@\W=_P`Q-\:U
M!LW3K;2MQXWV"F[5Y%NE[!R+I=.G(RX\C=SWFN2]<EJY='KZ-DJW;+I+0KU%
M9S%(&_:(&$!)]GZ1SJM[HW<5^R6V@`;`YP+8HVD$%M""UH/*N.YLQ93:;)#=
M7)+KEK2'32.!!#B00YQ!V#D7Z(Y1+T281,(F$3")A$PB81,(F$3")A$PB81,
M(F$3"+__T/?QA$PB81,(F$4,4]P;XW59K.VXV1FKJ_K*D6*:IDCN';T?:[4V
MO-PK;QQ%V>,UM1*?/TUP_K59F6IV+B==S**#EZFLFT;K$0,L:V^ELK2.,Z@Z
M1UP]H<&,+1E:<07N<'8D8AH;@*5(K14WUE_>RRC36Q-M6.+3)('.S.&#@QK2
MVK6G`N+J$U`!I57SS%SI]JG$WW!;@^I3(9]'\M<\1GA*>[UWS5IPI/&3S%SI
M]JG$WW!;@^I3&?1_+7/$9X2;O7?-6G"D\9/,7.GVJ<3?<%N#ZE,9]'\M<\1G
MA)N]=\U:<*3QD\Q<Z?:IQ-]P6X/J4QGT?RUSQ&>$F[UWS5IPI/&5,WCN;KLS
M@C7;W$1R=HN9LZ*WT3MQ8S9R0`$[=P5/DL845R@8!$ANA@Z_HS)=I`I6UNL?
MF,\)8#=;-:7EF:?*D\95/F+G3[5.)ON"W!]2F8SZ/Y:YXC/"6=WKOFK3A2>,
MGF+G3[5.)ON"W!]2F,^C^6N>(SPDW>N^:M.%)XRMJ27-)>4=P:&Z>':TU'MF
MSQ_$):0VNI*,6;T5"LW3N/)R9%VV;.S(G!(YR%*H)1[(CT')'TD-#S:760[#
MO&4Z]TH@:T7%@O;/.!4C=25%>C?*Y>8N=/M4XF^X+<'U*9'/H_EKGB,\)2W>
MN^:M.%)XRXDA><R@"8FUN)9R@8Y!$F@]OF`#IG,FH01#DH(=I-0HE,'Z0$!`
M?MQGT?RUUQ&>$F37/-VG"D\9<O,7.GVJ<3?<%N#ZE,9]'\M<\1GA)N]=\U:<
M*3QD\Q<Z?:IQ-]P6X/J4QGT?RUSQ&>$F[UWS5IPI/&7$D+SF4`3$VMQ+.4#'
M((DT'M\P`=,YDU""(<E!#M)J%$I@_2`@(#]N,^C^6NN(SPDR:YYNTX4GC+EY
MBYT^U3B;[@MP?4IC/H_EKGB,\)-WKOFK3A2>,GF+G3[5.)ON"W!]2F,^C^6N
M>(SPDW>N^:M.%)XRML<ES2ES2)(G=/#N4/#R2T-+$CM(;7>FBY=LBW<.(J1*
MVY,JBQDD$':1SH*]E4I%2")0`P",G>DLRYK2Z%145D9B.<?LMG2HM&M/S9+V
MS-#0TBD-#S']M@>A8;J;3',K36LZ%JBL[@XQ/J]K^L1%1@WD_HK:CF:=Q\*R
M(T:JR3B/Y"Q;%P^.@CVE#(MD2"/40(4/LS;<W>E7=Q-<R6MP'O<7&DC*5/-6
M(_G6FTLM9LK:"TBO+4QQM#16)]:`<M)0*_8%L3S%SI]JG$WW!;@^I3-&?1_+
M7/$9X2Z-WKOFK3A2>,GF+G3[5.)ON"W!]2F,^C^6N>(SPDW>N^:M.%)XRH4&
MG-=T\?QS;<G#]Q(1?DOG-@AHS;*SR.\N2%=EY>U3Y,&7:>5H%$Z7>%+WA`ZE
MZAF2=(`:XVMUE.P[QF-.;]DH@:V7.:+RS+AM&ZDJ*[*_ME7>8N=/M4XF^X+<
M'U*9C/H_EKGB,\)2W>N^:M.%)XRH46G-=P^>QC?<?#]>2C4V:TC'HZ,VRJ^8
M(R`+BP5>M"<ES.&J;X&JHHF4*4%03-V>O9'IDG2``XVMUE.P[QF--O\`\2B!
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M<A94[(JHAV15!LX%/KVN[/T[(@_1JXV]T!_F,/Y-T/SA8+-=`PN;0G_*D'Y=
MZ:=1]BS/2&Z9K8,E=]>;&IY-=[FU<M#$NE6:2OGZNR\+8T7BE7V!0Y\S1@M,
M4NTFBW9$0700>L7359JY3*HF!E-5Y:,@;#/!+O+22N4TH01M:X8T<*CE((((
MVK?8WK[AT]O<P[N]BIF;6H(/NO:<*M=0[0"""",%(3.%6"81,(F$3")A$PBB
M;>-R;4M6S)_3/&^`I+Z?H*$,XVQL[9QYQ:@:_>6)B66K]/C:W6G,9.WZ\2,*
M<C]PV2D(QI&,UFYUW(J.4T@LX;2VCMV7=^]X8^N1C*9G4P+B34-:#@#0DFM!
MA55,]Y=2W,EEIL;#)'3>/?7(PD5#0&T+W$8D5:&@BIQHGF+G3[5.)ON"W!]2
MF,^C^6N>(SPDW>N^:M.%)XR>8N=/M4XF^X+<'U*8SZ/Y:YXC/"3=Z[YJTX4G
MC)YBYT^U3B;[@MP?4IC/H_EKGB,\)-WKOFK3A2>,GF+G3[5.)ON"W!]2F,^C
M^6N>(SPDW>N^:M.%)XR>8N=/M4XF^X+<'U*8SZ/Y:YXC/"3=Z[YJTX4GC)YB
MYT^U3B;[@MP?4IC/H_EKGB,\)-WKOFK3A2>,GF+G3[5.)ON"W!]2F,^C^6N>
M(SPDW>N^:M.%)XR>8N=/M4XF^X+<'U*8SZ/Y:YXC/"3=Z[YJTX4GC)YBYT^U
M3B;[@MP?4IC/H_EKGB,\)-WKOFK3A2>,GF+G3[5.)ON"W!]2F,^C^6N>(SPD
MW>N^:M.%)XRMH)<TAEA@`W3P[&="/&6&%#2&U_.P18."-!DAC?$SY8$>#I0J
M??=CN^\,!>O4>F2KI.7/])=9*TKO&4KS5W6U1IK6?=_6V>\I6FZDK3GIOMG2
MKEYBYT^U3B;[@MP?4ID<^C^6N>(SPE+=Z[YJTX4GC)YBYT^U3B;[@MP?4IC/
MH_EKGB,\)-WKOFK3A2>,M>7_`$OS,V,O0'$WM_C&U/KG8<+LN$"*T3M1`KJ=
M@HZ:C&C25!WR%?"O$J(3JPJ)HB@L)RD$JI0`P&WP7>E0"<,M;@[R,L-9&;"0
M</V6W#_V7/<66LW)MR^\M1NY`\4B?M`(Q_:G#'H]JS&-2YI3`/1B-T\.Y4(V
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M<C+R.21UB'97M[.\8X@EHK[I:XC!U.?LUP.MM[J`D?8RQ1-U`MS1N[1B>T$!
MQI[P<T'%E>:CJ5(__]'W\81,(F$3")A%$O@J0B?$W2X$(4@'@)18X$*!>VLX
MM$ZNNJ;H`=I1==0QSF'[3',(CU$1RSUC\2N_UA^8*IT+\)LOU3_B*EIE8K9,
M(F$43>;T]9:UQNNLS71F$V;66H1;XZKHOBS[#4SB_5EOMA]$J1ITY!NNWUZK
M(BJN@8BS9MWJR9B'3*<MGH[(Y+^%KZ5H[+787Y3D!KA[U-NTX*IUN26+39WQ
MYLH+,U*U$>=N\(IC[E<1B!4K`]T5F`A]A<.K%H>/KT/:Y3:L?#`K16<>TBK'
MQV6H]GD[^C+D@2MX^5H,0V-&O6)U3&:-IA1AY.)5W"0*;K21[X-5CO'.,8C)
M[5:B7,`VE<0XX@\I;6N`6B]BC9<:/)8-:)3*!V:4,.5Q?6F!8,".0.RTQ(6E
MU>;&WJI68?9=NC:+.U>RZ4Y6[`:56M5:R1<G79KCMLRK5./<2-@7MEC-.0$K
M#VGOI`$HYHJV(T,JGV^HICUC2;661UO$YXD;-"VI(((E87&@RBA!&&)K6BXC
MK=Y%$RYF;&Z)T$[\K6D$&%[6BIS&H(=C@*4JI%/]T7<M[U5KFN[!U;;F^X93
M94C%;+AX!1Y#UF"J.MZ[;H&K.(=CL!=O.VB??2[F20<%>-DU*XR.'<"L47H\
M+;2'<W,\D$C3$&`L)Q)<XM)KEP```.![1VTP5BZ]GW]I;1W$3Q,7D/`P:&L#
M@V@?BXDD@U'8&RO:47]<[@W%LBP[)W=1:E6&.Z)K_+[TC<H"I2\?+R]3L%DB
M]K\GU6;6/;,9Z$F5H.\)QQ3Q*HO@43;O6YU#*`4P&L)[6UMX[>TFE<;07TC2
MX$!P!9#MP(JVO:PV@JKMKR\N9+F^@A:+UVGQN#2"6DB2?90@T=3LX["%NGQ!
M[.N-EXFS=7M5&J6NM_VF\2#%O.TB1=R4O1H;6BDW7&CQTXO485.1L<H@Y>,E
MVG=!W*[`3)K%2<(NN3Z&WBCU-DD3W3P-:,'"@<7T/Z)P`H#7^]LJ".WU"ZFE
MTE\4L;+>X>XBK34M#*C](8DU((YV[:$'%M/\DGTQ$T77[!SI_1DS/TS<6UB2
M#NM+-->R2U8W_8:O,Q,+#*6N`*FL=JBXE9Q0)`71E9`KE,$R]Z(;;JP#733N
M$LS&O8RE>T*Q@@DT/0&X4PIS+59ZDY[(+=IA@>YDDE<O8.64M(`S#I<[&N->
M=2%X_;JMNQ;CMFC[!A%ZO;J$YB9-"#)"%""?4NSV"]Q]-N-/O#*=F(V[5>R1
M=3[L%#(L'K:59/R+($(*2*/#>VD4$5M-`_-$^HK7$.`:7-<V@+2"[I!!;0\I
ML-/O9KB:[@N&99HR#2F!:XN#7-<"0YI#>@AP=4;`/SEJ<1'UR^3=[""@D&D/
M_FJ7&M)/*<=*$VX^<6H&%=:5V.<D9F3G:"1U.$D+!#@=,5HAHX<`("W^V]D<
MZ2%D.=U3IK3VL685-3S.PHUW]H@<J\[$QL<[Y]VV@U5S>SA(<U!0<[,:O;_9
M!/(I7Z^WG<'<]4M=5RNZXH;_`&1OWFC6I>W1U6=^CQ9+1MPL;))^->+9(U>5
MO&QG;8TN_56?F$[=E("4H#V%4:V>SB#))Y'R/;'!`0TG&DC1A6AHUONC#:6_
M;:V]],9(;>...-TEQ<M+@W"L3B*TJ*N?[QQV!WM&J*YS9V\XC;+M"RI4R,KM
M>X65'?Y=8$K\B#J:LTO9]R5Y],PEI"S*R9*<X)KMK,@J9@_,6`<E`J9%RG<K
M=+](M0Z.WCSF1UVZ//48`!AH12F;M%NT=H<V`Y8];O"V6ZE#!&VR;+DH<7%T
M@)#LU<O8#MA[!V5Q,@'?(&[QD]1=;3FPM&MIK:LCM<U%VK6U7UCI23&DTND6
MBM5^PQ;F9AFS6[SAKBL\%!*240<P4699$Q%G91:\0L87,FN&039(PS,PX.[3
MG`D&A[(RTK3!QH<!CWG4)VR06S[B`/E,F5XJ6T:UKF@BH[1S5I6A:VHQ.&EM
M<;&O]$VOL)_7YJAR]+V5S^AM=W!@A69$SN64M_$W4$VG;JE:&]R681C!)]#H
MJIM%6#\SA)4PB[^T!SJN(()K:!KV/$T=D7--1AEF>,KAEJ<#MJ*<RXK:YN(+
MNX=&^,PRZ@&.&4XYH(SF:[-0"HV4->=37GEU)CD33ZK+(D6KL=IS8%G8Q[HJ
M2[&8GW]FIM5D'JK5;M@JXK=<?JM"CV>SW%@6(;M=L.E2P9+&61O[PRM%>8`.
M('VG'VM"NY#GU&&)X_9B%[@.0DN:TG[`:>QY7Y1\,GD;K.N<)+R_95>&1L/%
MW>*`R56DCU]1XE5R1ET?V+?R246\<2U(@$*^9O'R2(*FBI:1$ID5A=I]UZ35
M0ZX?J\+2XEMQ'@X5VU:!'C@XUJ0?>:-HICY31BVVCT2=S6M#K67%II[M'$RX
M8M%*`CW7'8:X268\P=MR1KFUB%:$[$-J<.JU3)V5HMDCFA:GR?GXNNOY):L'
MOK.P2+>)*\+(1AWJD*\<MER@X;(]I,^<#M+M6[HNSC]G.7`.![4()`KEH*[#
M3,`=A*LFZQ=NWP88S^UMPTEI'9G(!.7-4TVMKE)!Q`6+2-WW%I78/*B[5I_K
MRVV>O[!X>QVPZDE2I:,6V?)7NF46ARX4KR6ZN7-0EIF4G#N(E%PG,"=TB1NH
MHJ43FS8V&UNX=.AD;(V-S)RUV8'(&N<X9NSV@`.U3+AC@M3I[RRN-5GB=&^5
MLEN'MRD9RYK6G+VNR235M<V.!)69V'G!9:[;=COFB55N6O:YH+?6SX-:#A)]
MFV/8=+[:K&O`01LK^2+*V*ND;V549MZ2"9,D%XU8\>X=MR'5S5'H\;XK=I+F
M3NGC8:D;)&%VP"@.'9&8FA&8`X+?)KDL<MRX!C[=MO*\4!VQR-9[Q-2.UVCE
M`!!RDC%6)KLRSZLWQR$F8N2IUQDME;#X,47TR:P@QM3@(G9R-CAO2B49L+*Z
M-,E3:."H1IO."/E"KQ@F<Z@%,=:1MX[FSL6.:]C8X[AV6M7$LH:"HPZ<,*.^
MS6+F6UO]0>US'NEDMFYJ4:`^HS$!V/,,16K1[<QD>6>V:X55S9*NS7IE.WQL
MW4-XV34*NO.E&-JLSKUC3[H>C&MY9M"DKN+7(0MID8Y215AYV.)W;;NU^Y)J
M;IEM)01R'>OA8]K7&F)#LS<V6F;LAS`:9FG;A5;G:M=QU,D0W+)WQN>UM<&E
M@:[+FKE[1:\BN5PV4-%*?5*KAMLGD964_P!K7(_8%:FXPG:(9M%R=PUM4Y:U
M0*"!3F!`J\N49M8IBE,HYG55!Z@<,KKFAM["3],L(/2&O<`>KL^QH5K:$BYU
M&+_XQ(TCH+F-+AU]H]+BH%\:;E>*G5J'K36!Z-67&WN3?.&,>V"PU*1LB<*>
MD7'94]"K-86'M-.(\`5(]%$P*N>A$$P*4.GV!=:A%#))-<7&=PBM[<T#@*YF
ML!Q(=S\RH=-FGBB@MK7(TS75R"2TFF5SR,`YO-3;L6XM+<M++N)IJV(DK#KO
M5MMF^/\`H/>\R>R1KIW&7E'8EEL,'>H6FM'5HA%8UC`(ULJ:2PN7BZ<A-,P.
M!TFRI'G)=Z9':FY<V.22(3R1BAQ;E`+2[`UK7F&#3SX=EEJTEX+5CI(XIG6\
M4IJ,'9W$.#>T*`4YR:N'(#6=E5M]5O4,C8Z79(.V0#AU),4)JNRC*8BUGD/(
MNHB5:IOF"R[8[B.E&2S=<@&[2:R1B&`#%$,IY(I87F.:,M?0&A%#B*C;SC%7
ML4T4[!)#(U\=2*@@BH-#B.8BA619K6Q,(F$42EDDTN=D<LF4"*O^)4RD].7[
M#.DXC<4">,*M]\&)IMV*77_5\H4Z?ZPY9@DZ.X<@N1^5AK^8=2J2*:ZTC:;0
MU^R04ZJGK4M<K%;)A$PB81,(F$3"*)?%8A"RO*PY2%*=;EIL,ZQP*`&5.G2]
M:MR'4,`=3F(W0(F`CU$"$*7]``&6>I>[IO\`#-_Q/53I7OZK_%O_`,+%+3*Q
M6R81,(F$3")A$PB81:,Y*Z7BN0>C=D:DE"-R+6NM/T:_)+IE.:`M[-(7U2L3
M<P@"B+B$L+=NX`Q#$.)2&*!@`PYV:?=NL;RWNF[&N%1SM_2'VBH7#J5DS4+&
MYM';7M-#S.VM/V&A4.=9;Q>7#7^M]]SD9"5#8TVRK/&*&:SM6D9292V6S8SD
MIN".H,!%A'DDS/KY7"1X-7,C'QK5O673IP[332%,]K<68BFN+)CBZW!,QH0!
MDJ`PN)K2C36H!)+P`,536M\9K>VOWM:RY<&PBK23G`)D#`*5JX4H2``PDF@H
MM5P_)RP%<5'D[8XN`5M?@-L,W,H-4W#*LMY4V]Z;`GEWJ*$A,.V=;CE5O.+M
M)-XN9-H50$UQ^Q3.AVGLI+IT;G;KZT`<]-VXTV#$[!@,>1<K-3DK#J<C6[WZ
M`D\C:[UHJ<3@-IQ.%<>5;_N^]]_PDA&4V(M6@WLK-:[Y+;!C;G7HBR7J,)'Z
M<1UG(5*-E(M&VU5NQGI>,V6F$@":[A`IFB;A$.[=>3H<4-G9/:Z5T<X:'Q-+
M20TU?G#B#E.`+,-FVAV5-A/?Z@QS862VY>Z.9X<`7"D>0M!&9M"0_'$C"HVT
M&4ZSY,7BU;.U)6[A6RUVM;?UI4[13)J$A3V"KS=G?:J3V/<Z?*V1"P#)46XP
M95?*H]G(1YVC^#2.J5P9RJF5+7<:?#';W,D4F:2*1P<":$#/D:X"E'-.PD&H
M=A2@*VVVISRW5I'-'EBFB:YI`JTN,>=S2:U:X;0"*%N-:D4T;OS2Y=V<P]PT
M&&+7(.T63A3J<8>\R#109>ARQ=Y[613O]:4CT4Y-2VUY)BW,R%-TQ,)T4BF<
MID*`#V65W])I=K._,8VW;ZM&QPW;.R:X93C7`^Q<-_9?6ZQ>6[,K9764='':
MT[V3MMICF%!3$<F*K-97Z\ZLVI8&K*7JKG7>Q^?>T=8VZ.EZ\Z1LZ;A;C\OL
M!&X-[@VL;2$:%;/J"4'#4T,)5BNE3=\3H7LXN((;FV82QV_CLF/:0</WN7+E
MI78[`YN38LVMQ/:W4@:]AMY+]['`CM?NL^;-6FUF(R\IQ72IS8V<M'[3EX(V
MO9V/C-3\:]F4*3]%K.R@5@W/LZ<UK/BQ!_9HVS6NJ,RQ:;Z*?O6-=>/1$QC,
MTVRJ!Q>DVX-NU^<.,LK'"HK^S8'BM`0UV-"`7`<]05CUNZ+;I\>[<T10O:<K
M@/VCRPTJX.<T4JTD,)_L@$+(=P\DN1&IG.T8LTKJ*==Z98<2)&9?#KJVL$;J
M7D1M^UZPG6[-B7:C@U4\QMHE%XV.*TEVE"F3.`E/VBPM;"QN1;NRRM$IF`[3
M3EW3&O'Z&-:T.Q;+S4M1M#=-SPN,(MR3D<,V^D<PX9^S2@(Q*JY?E1L^!I.S
MHB7G]=#M"J;0WI1JJ[BJ18S^D\;JVAQ-_;R36D.KDK',4(MA-%"8?2-E9LFK
M9`IB=XNX(F&&:;;OFMW-9)].Z.-QJX8%[BVF;+7$CL@,))Z`I/U6ZC@NF/DC
M^J9+*UM&GM!C0^N7-04![1+P`!RDJJYBV=39/^67L:]S#&.3D+AQ_K%T=,VR
M9E6,?+3D?7IE=./!T=PLF1B[=F*D8QS*E`H=3";J.1TJ/Z?_`,@@A8XY6SEO
M20"1BLZQ*;G_`,9N9WM&9]NUW0"0#A[%N7DYL^PZY@M:Q.L;A2J;+R6XM*U&
M>/.P"=@CH:CWBR.XA`ZL4WL-93CXV1&$70*;OTC*-T5R-U$%"@NERZ?;LG?<
M.N(GO:(I'"AH2YHKMH:D5K[:5KL/;J=U);,MF6LS&/,T;345`:XTV5;0&A&W
M8#2AQ$>;GLB0VQMGC?-*25<08Z^YX[`U$-60A#DLS5_3-);RC%+`^F7$RNX:
MLK,#`TDBS(T!):-?QR@*F,D*KGNBMVVUM?MRNJ^R:^M<.U)&:`4VBM*UVAV&
M.%=-<NN[O37YFY8[]\>6G:JV.45)KL=2M*;"W'"I_1JIV^JWROQ]LI-D@[=6
M)8'(Q=AK<HRF8:0!D\<1SSR.2CUG#1P+20:*H*@4XBFLD<ANABB`44L4L+W1
M31EL@V@BA'+L/0O1Q313QME@D:^(["""#3#:.G!9%FM;$PB81,(F$3")A$PB
MB7O@A2\@N#S@H=E<VW]L,#*E$2G,Q<\8MSO7#0Y@$!.V6>1;94Q!ZE%1!,W3
MJ0HA9V7^QU@<FZ8?_MC_`/4]:J;_`/$-#/+OI!]FYD/_`"'4O__2]_&$3")A
M$PB811.X,?NFZ5_JV^_M'-99:Q^)7?ZW_(*IT/\`";+]4_G*ECE:K9,(F$7P
M0`P"4P`8I@$#%$`$!`0Z"`@/V"`AA%C$#2*75E':M8J%7KBL@7L/U(&`B8A1
MZ3MG5[#L\>T;F<E[Q4QNAQ,':,(_I$<V/FEDIO)7.ILJ2?SK5'!#%4Q0M:3M
MH`*]2-Z/2V9VZC2H5=JHS;/V;0[>`B4#M6<J)S2C1N9)H4R#:2,J87"9>A5A
M,/;`>HX,TQK65QKTGDV=2""$4I"T4!&P<NWKY53(:[U^VKZ=2;4:G-ZJBY5>
M(UE"LPJ5?2>+J+*KNTX9-D6.3<K*N%#'4!,#&,<PB/41ZY,\Y>93,_><]37K
MVK`M[<1B(0,W5:Y<HIU4HDY3&4BREP@G1J19)6'2@D[O6(FLC:HN/0.4[9%@
MXGH*<C54VG0>Y2<M7#=,1Z@GU`!`R4M+<XSQ@URDFA/30@]1!22%KFOW9R2%
MM,S0W,!T5!'6"%5!2JCY!6(Q:MPSQE2A8GJ24C'MI,U<7C(\\2P=Q"\BFZ<,
M7[:,5.@5P0X+]T<Q1,(&-UQOI<TCA(07US4-*U-36G)7D6=S#EB:8VEK*9:B
MM*"@I78:85VJF6U[07"<(DXH]/72K4F::KB:U9A54X"9,J5<TM"$.R,6*DS+
ME`XKH`FJ)P`>UUS(GG&<B9_:%#B<1S'G'M6#;VYR`P,HTU'9&!YQA@>D*Z0]
M9K=>6E'$!7H.#7FW@R,TM#Q+",6EY`0$HOI11DW0._>"`B'>JB<_0?TY%\DC
MPT/>2`*"I)H.CF4V11QEQCC:TN-30`5/.:;50QE%I$)*K3L-3JK$3;GRCRB8
MC*]$,)5?RL_>N^^D&K-)VKY4J':4[1Q[9OM'J.9=-,]H8^5Q9S$DCJ46P0,>
M9&0L#SR@`'K7):D4MS&+PKBH5=Q#.9!:6<Q*T!$JQCB4<"87$DNP.T,U5D%Q
M.;MK&(*ANH]1'K@32AP>)79J4K4UIS>Q#!"6EAA;D)K2@I7GIS]*JS5>LFE$
MYLU=@C3*,(I6DI<T1'C*)5Q98CE:`3?BW\K)"*N$BJ&:@<$#'*!A+U`!S&\D
MRY,YR5K2II7GIS]*SNHLP?NVY\N6M!6G-7FZ-BL1M:ZT7KS.FFH%%6J<,](\
M854U5@%*]%2)%QD4W3.#%@,:Q>E<N17*<B15`.IVP'J;J,_J+@/,N^?O2,34
MU(V;:U/,H?36QC$/T\>Z::AN44!V[*4!Y5=3TRGJ.3/#U2M'=FERV`SH\%%F
M<FGB)"B2;,N+451ERHB)`<]>^`H].UTR.]EI3>NI2FT[.;V="EN8:UW3:UKL
M&WG]O3M5/+TZN6*<@;,^:IN96N-+-"M')1343<0EH0:-+-7)%(Y%4GD-).X=
MBNNW,`=74<W,(_LQ*;+99(V/C![+B#]HV$=(J0#S$K#X8Y)(Y7"KVAP^QWO`
M]!H"1S@+LAJ-2:XF^1KU/JT$C)H^3R24-7XF+3D$.R<O</B,FB!7:/94,'94
M`Q>AA^S[1S#IIGT+Y7$C94DT66001APCA8T';0`5]M%;&6K-8QK=%I':YH;!
MJV0CFS=LRJ%?:MV[:(=/7T2W110CDTTD(M](N%FY"@!4%5U#D`ICF$9&YN'$
MET[R<?TCR[>7EH*^Q1;:VK0`VVC`%-C1R5(Y.0DTYJE7L]1J:D^G:E*Q7CVA
M(HD2LAX6--/ID,W(T,1.8%L,B0IFJ94A`%.@IE`OZ`Z9'>RY-WO';OFJ:=6Q
M3W,6\WNZ;O>>@KU[5;6FN->1[M=^PH=,9/W2\\Y<O6E7@VSMPYM)6I+.X7<H
ML2+++V,C%$'YS&$SP$2`J)^P7IDW$[@&NF>6BG*>39U<G-R*(MK=I+FP,#C7
M'*/TO>Y.6@KS\JXP^M=<UV-=PU?H%*@H=^V*S?14/58*,C7K,ASJ$:.V+)@@
MU<-B'4,8$SE$H"81Z?:.9?<3R.#WS/<X<I))_.L,MK:-I9';L:PBA`:`#]@"
MJU:+2%F\&S6IU55:5AR1Y6FJM>B%&]>>).$GB3J#0,S%*)<INVZ:I3MP3,"A
M"F`>T`#D1-,"\B5U7;<3C[>?[5(P0$,!A91IJW`8>SF^Q54'6(BO#/*1Z`^4
M6:>?62>=N#`LYDY1\BU8E5=*B4HJD8P\<T8-BB'[)DS12^T"`.8?(Z3)F.#6
M@#H'_N22>DDK+(F1[S*,7.)/23A^0``=``5"VH%#9@B5I2:BU!NJ]<-P;5N&
M0!!>21\GD5D029%!)5^@'86,7H*I/L,(A]F2,\YK69Q^T\FQ1%O`VE(&#;R#
MEV\G+RK[Z`43OJXX]"JEW]..LK45_1N&[ZK*.`,5PI7%/(NW"'7`Y@.+84A,
M`CUZ]<;^:D@WSJ.][$X^WG^U/IX*QG<,JSW<!V?9AA]BO,-!PM=8$BJ_#Q<%
M&)KNW*<=#1[2,8)N9!VN_?N",V2*#<J[U\Y466.!>THLH8YA$QA$8/>^1V9[
MRYW.34X8!;&,9&W)&P-;S`4&.)V<YQ5TR*DF$3"*)SK]^B#_`)3K5_C!3<LA
M^#O_`(EO^!RJ3^.L_A'?ZC5+'*U6R81,(F$3")A$PBB;Q7_^3Y4?S9;&_LCK
MK+/4O=T[^&9^=RJ=*][5?XM_^%BEEE8K9,(F$3")A$PB81,(F$6-2M,I\[')
MQ$W5*U,1*,N-@2C)6"BY".2GC/UY4TVFR=M5FQ)<91TJY%R!06\H4,IVNV81
M'8V65CLS)7!U*5!(-*4I[*84YEJ?##(T,?$US*UH0"*UK6G/7&NVJZV5&I,:
M)ACJ?5F`G:R+$XLJ_$M1.REW2[^69F%!HGVFLH^=*K.$Q_4754,<X&,81$9I
MG>]*XXCE/)LZN1&P0-]V%@P(P`V'$]9Q/.J-G0==,6<=$Q]+I3./B8^1@XF,
M9UR";LXR*D.V:6B(YDBS(@SCWW?&%RW2*5-7M#VRCU',F:<ESG2O+B02:G$C
M83T\Q41;VS0UC86!H!`%!@#M`%,`>4*O8TNG1DFVFHVIUF/F6<:$,TEF,#%M
M)-K$`"0!%-GZ#5-TA&@"!/V!3@E^H7]7[`S!EE<TL=*XL)K2II7GISJ3886N
M#VQ-#P*5`%:<U>;H5:6N5XDVI920,,6QJMRM%9\L6Q+-JM2$!,K925!`'QVY
M2%`H$%02@`=.F8WC\F[SG=\U<.I2W<>?>[MN\YZ"O7M5&%,IY72;XM4K17J,
MJI.I.P@HL'24XJ0$U9E-P#7O22JA"@4S@!!80#H)LSO9:4WKJ4IM.SF]G0H[
MF&H=NFYJUV#;S^WI5F9:IU=&H`UCM;4%@U!L9F#9E3JZU0!H>1\\':@BA')I
M@V/+_P!*$G3LBY_:].W^MDS<W+C5UP\G]8\U.?FP]B@VTM6BC;:,"E,&CGKS
M<^/MQ5V?4BER:SEQ)5"KR"[U)BB\7?0$2[6=HQ9BGC$G*B[10ZZ4<<@"@4XB
M"(@`DZ=,@)I6T#97`#I/+MZU-T$+B2Z%I)I6H')LZN14B^N->.E4%G-#ICA9
MK-GLK95>KP:JK>QJH&;*3Z"BC$QD9M1L84S.BB"XD$2B;I]F9$\X!`F?0BFT
M[.;V="P;:W)!,#*AV;W1MY]FWIVJXFI]2/7V]2/5ZZ>JLV[=HTK)H2,-7VK5
MIV?)&S>&%L,:@W:]@.[(5,"DZ!T`,QO9<YEWCMX>6IKU[5+<P[L0[INZ'Z-!
M3JV*SH:UUH2+=1+6@44L-(.XY^]C4*K`%BWSZ&=E>1+UTS38`T<NXI\F"K=0
MY3'05*!B"4P=<D;BXS!QG?G`.-37';R\O*H"VMLI8+>/(2"1E%"1B#2G(=G,
MJH^O:"I85;<I1Z>I:UW3!\M9SUJ%-85GL4U78Q;Q6:,R&24=1K)TJBW4%43H
MI*&(00*80'&_GR;K?/W5#A4TQQ.&S'E6?I[<R&8P,WM0<V45J,!C2N`V*^0L
M'"UN,;0M=AXN!AV7?>1Q,+'M(N,:>4.%7;CR9@Q10:H=^Z7.J?LD#M*',8>H
MB(Y![WR.+Y'ESSRDU/6MC&,C:&1L#6#D`H.H*Z9%23")A$PB81,(F$3"*)N^
MO^?G!W_K7M'_`+6-[99V7^RUC_)9_K1JIO\`_?Z'_GO_`-"5?__3]_&$3")A
M$PB811.X,?NFZ5_JV^_M'-99:Q^)7?ZW_(*IT/\`";+]4_G*ECE:K9,(F$3"
M)A$PB81,(F$3")A%J78LDZ);=+UU-PJVC[)L)^>8[`@FG(H5>@7*UQD1WP=E
M5-8UBB&3\"D,`JHQRI#@9(RA1ZH&C=7<E.TU@IT5<T$]1(^T<JY+EQWUE'6C
M72&O3E8YP'6`?L/(OSEUC;9/5\__`'C214HNG#RAYR:T*>,M2<>2V232^;2F
MZ)";(;3#.,@JWK^C0NN'B+&3*O)'AB]R/991OEPC>W$3;AFX;C+]-;OQ;6@R
ML#BVE27.+Q44&;':ZB\Y:S.M9/J780_57+,'4S',\M#ZT`8T,-'5.7#W6YE)
M9+DMLF1*^@8:ET=>W)<CD="LW4G-7&&K*B$WH"+WQ!6=1N]J!+()6K6?0CET
MA;I%=]P9T@<B:Z9$Z_T^W;E>^5^Z^GWF`:3A(8R/>IR5VX;#L5F-3N79HV0L
MWWU.ZQ+@W&(2AV+:\H!PQI48'##ZULRXZFLFZYI.I5:8I\QRO<URV)I656%F
MH>3L.F]5+M9^.5D(E*"=0;.;2[,D9VJT%)DNH_.J0K91%3;);Q7,=HS>N$HM
MJC"H(#WX&AK6FRE<:-IC5:8KF:TDO7B%AA-W1W:H03''B*BE`=M:8$NKA0[(
MJ_)J7FI5]4I.'K,?9)+<E<U13IEH[L3BI.@M6E#[R;3+X9>'@)-X6.KK!\T;
M`EW"$Z]2:@DLS*\_H^B33VL:)6O<8Q$7N&&;"3=TP)&)()VEHK4&F/3%J;WO
M="YC1(9A&TXY>U'O:FH!P`(&P.-*$5PU_P`>]DV"NTJ\4N*AX!Q.U*U<R]G2
MBCQ1["5V56;<QM\Q+*M0"Q2/#QC1=U#NQ=.U`=C$HG:=INX\HZDWWUO')-#*
MY[@QS8&#E(_81FIY]HH,,V.(HN?3[F2.">%C&E['W#SM`/\`^B4!HYMAJ<<H
MI@:J_P`IR&<7VL;(BU(]WKM^KIFR[5UBG8XF:C99ZA68&`LD/<(BPD,M4;$:
M!FY9$):(360DJ^Z:)IO4%DW8&2UML1#);N#A(W>ACZ$$8D@M(]X5`[+MC@30
MBBF_43<17+2TQNW+GLJ""<H!#@?=-"1F;4%A`#@0<)MQSI1['L7JS59BL[9M
M72K)P!BKLU'"!%3M5P,1,P+-S'$A@$I1[0#]@?HRH<*.<`:@%7;27-:XBA(V
M*LS"DF$3")A$PB81,(F$3")A$PBB<Z_?H@_Y3K5_C!3<LA^#O_B6_P"!RJ3^
M.L_A'?ZC5+'*U6R81,(F$3")A$PBB;Q7_P#D^5'\V6QO[(ZZRSU+W=._AF?G
M<JG2O>U7^+?_`(6*665BMDPB81,(F$3")A$PB81:EV=).T9S2]>2<*MV-QVT
MA&RXMQ!-PJTJ^N]B[/CVY%_]9!):Q4!B"X%Z]\V[Q$?U5#"'3;M!9=O(Q;%4
M?:YK#^1QITXKDNG$/LHP>R^:A_Z6/>/RL%>BHY5'.Y7.P07)#7.T",K$76DA
M9Y?C'.2H/HQ2F*GLR[`:U/A%>D)YEM:6.]H(U5,N:-20.W?@`*'$$Q'OBB8^
MPGMJM^H#1,!CFPVBM*4W9STK6H5=--)'J5M=97?3%QA)J,O:IE-*US"49*TI
M0[5IVDI69KMNKK:_C:LXM26P/\Q?S2C9W#Z,A%%!W3071FSQW#Q\@_;HOG!`
M(8Z:1^Z%3OA(J*?<J=4IC-M()W.W62UK2A/[MW.0,/\`VPVKC@$HNXC;M9O=
MY=TS5`_>,Y@3C_[X[#N*A<M;=LRI6"^UK4XL(*J5A-_9&5BM$,S5C)UWH.$W
M:R:%>MG;B<=MUG=F8128$@>[<LE32R3D4RE9J<LVF16\K(9+FKW.PH#B-X8_
M9R$^]@>S3E79;ZM-<PR3Q6E(V-J07#`[H2#';^D&^[B.V#3!=D-R`W4>Q1I[
M)6M/Q56'C\\WA)"6\SD<"3)TN@$6@_L4]6F45!(1H%$KY=4JB":!U%P$PIE1
M,=96F1PCDE,F_P!V.R#[:`&IKR=72C-0O=XW>10B+Z?>GM$8<E26@"G*=E,>
MA;MTOMM[L-"[,[,SB(.<J&SYW7;9-FK+,TK&$;6J]<&S]A%V:/B9MLX+"V(I
M5D3)J=?)CKD-W)R@7CN[40&(QDN8Z,.Y,*DMH2"1M'Y:;5W65VZX$XE`;(R4
MLPKC1H=4!P!V'$=%=BP)-9M=^4^PZ%L9%M(0-4U1K2RZLIDPDFZKTV6=F[TS
MV#>/-;HBC"<G8B2CHN,$RA5#Q#<4S)E2\XG.MN(,.FP30&CW2O#W#:*!N5M>
M0$$G^\>?+ASU$^JW%O<@&-D3',:=AJ79W4V$@AK?[HI2F;'ID]KM=66^BZWI
M,?`350D]DLZC+AZ4RLS/P+G8,U>G1O)D&4?)QE4A*M98=:/8QT@Y0!=L@LT9
M)MTXXH*Y;;&XBFN)G.$HCS#``'*&](+B0:D@8$@FN;##KL6LT%M`UKH3+E/:
M)(SEW,"&AK@0`2*@$-H&XXO7>4UT<EKLC9Z;0H:*L]:Y`2#8`OSUHUAIC1&R
MHZCN!G+--UJ.8(UR=92?E!G)6OE#0S8>RBX%8J26U^G0C>-CE>7-=&/=&(D8
M78`$XBE*5H:[13'5'JDQW;I88VL<V4^^<#$\-Q<6@4(-:TJ*;#6@R>D<AIZZ
M.XRC.(FOPE^F+_MRF-WKUK8PKJD7JE&->O9DE=ET(&P'E91I8&"81*SAN=(H
MNG(+JIMNZ5U36+(@Z8.<8`QCN2M7UPJ*B@H>U0\@H*U&V#49)BV`L:VX=)(V
MIK2D="30T-34=FHY34@4.E>/V[)BCZEXFTEI!UE]&3<)J>GSY$)>15G(P+Q#
M6#S9*I,HZ(<QM?C6+^``C=.4605F">4^3E2\D$RW9?6C)KG4YB]P<"]PP%#E
M(J,34FAQI[N%:UPXM/O7P6FDP!C2US8VG$U&8&AH!0`$89B,V-*4QF3JQ\\%
M[M>N.#++,Z?MB:CHAZL8YS.V%IKE3V<LF10_4IF\-+WYU&I%(/9229%3^P2"
M`5-R!2VD&UT0)]H)9^4-!^U7-JXYKN,[&2D`]#@U_P"0O(^RBVUG,NM,(F$3
M")A$PB81,(F$43=]?\_.#O\`UKVC_P!K&]LL[+_9:Q_DL_UHU4W_`/O]#_SW
M_P"A*O_4]_&$3")A$PB811.X,?NFZ5_JV^_M'-99:Q^)7?ZW_(*IT/\`";+]
M4_G*ECE:K9,(F$3")A$PB81,(F$3")A%8)RN1\^M7W3OO$WM7GV]CA7B`D!9
MG()L)&&=]CO2*)BG)0$R]8K=2]KN'9^P)3]DY9LD<P/`V.;0^S`_D(!]H6N2
M-LAC)]YKJCVT(_*"1["L1::5TXP3FD6&IM:L$K(E84+"1E1:NT+.HVTK@MJ2
MF/)XM/SD2RE=*A(`MV_+.\-WO;[0]=IN[IV0FYD);2G:.&7W:8X4Y.;D6H65
MFT/#;2(!U:T:W'-[U<,<W+S\J[66G-31SPTBRUI1$9$TK&SQI'T5A%)`T]#P
MOHY%SAGJK([H9IA`=6:3OM^4%;"*8'[(B`C=7+AE-P_+0BE3L)J1["<:;*HV
MSM&G,VVCS5!KE%:@4!K3:!A7;17/^[?7XNYYZ:F5DZ]I<NWUE`\,P.WGY"0A
M0K4C)S#,Z)FDC*2-;*6.<.E2&<.&!2MU#F1*!`C]1/1C=ZZC=F)P`-0!S`'$
M#8#CM4OIK>LCMRVKS5V`Q)&4D\Y(P)VD8;%CI]$Z74C9"(5U705HV6]'C2C1
M:JPZQ)%:I%2+5W;TRK0ZCF0KX()BT<G$5T#$*8AP$H"$_K+O,UPN7YA6F)PS
M;?L/*-BU_061:YAM8\II7LC'+[M>D<AVA75IJ75T>Q)&1^O*7'QR9[*<K%A6
MHADT$+G(!+7!$[=LT224:VJ3(5Q)(F`4GRI"F6*<2EZ1-U<N.9T[R[#$D_HB
MC>H8#FY%,6EJUN5MNP-[6`:![QJ[[QQ//RKA+:HH$LE/E&KPC%Q:6CR+L;]A
M%1S=_,0<R\CW-H@G;OR4RP1MN2CDT9($Q(HX*!3B8%DTU"&W,[<G[0D--0"3
M0$5H?:VN'-[%A]I;O$G[)H+Q0D`5(-,P]CJ8\_MH5L7-"Z4PB81,(F$3")A$
MPB81,(F$3"*)SK]^B#_E.M7^,%-RR'X._P#B6_X'*I/XZS^$=_J-4L<K5;)A
M$PB81,(F$3"*)O%?_P"3Y4?S9;&_LCKK+/4O=T[^&9^=RJ=*][5?XM_^%BEE
ME8K9,(F$3")A$PB81,(F$5@GZY'V(L1Y;WB;B"GXJQQ3QN)"NF<A&+&`_<J'
M(H!$Y*-7<,7/0`,=F[6(`AVNH39(Z/-38YI!]A_]#0CI`6N2-LF3-M:X$>T?
M^HJ#T$JQK:MUDYKWHBXUU1'%4&<"SC6%JC7U:]Z2%EO/X6'S*>/-&^?`G?Z:
M#ONO*/*_VW;[S];)BYN`_>B=^]I2N8UI2E*UK2F%-E,%`VMJ8]R;:/=9LV7*
M*5K6M*4K7&NVN*Z1U/K'OV;I/7U.:NH^0L<HS<L:[%1[A%]<NZ"Y+@NQ:MU3
M^F)4"!+E,(DE"D*#H%0*`!GZFXH1OWT(`VD^[[OW?T>;DHL?26M6D6[`02<`
M!B[WMG]K]+^URU78YU9K1Y-R=D>:_IKN>FH-"M3$JYK<0N\E:^U07:-X:255
M:'%['(LW2B!4E.T4$#BGT[`]G,"YN`QL8G>&`U`J<#SCI0VMLY[I#;L,CFY2
M:"I',><<GLP5++:>U/.I,F\SK6BR;:-K,M2X]L\JL*NV95&=0*UF*RU;'9"@
MA!2+8O=JM2E!$Q!$.ST,/7+;JY8267#P2X..)]X;#[1SK#[.TD#0^VC(#2T=
MD8-.UNS8>;8K*ZT+J=>=@+$VI%:BI:OW)"_HOXJOP;22>VQI7U*PTEGLOYN/
M+@X2AU.Z.=%=%5P0H)K'.B95)28O;D,?&9G%KF9:$FF6M:4K3;T8<F*@;"T,
MD<@@:'M?GJ`*EU,M2:5V<QQY<*@YO9J-3[F,:>TUJ'G7$*NLYA'L@Q15DH1R
MX(1)RXA9/LED(A=TBF":IVRJ1E4NI#B)!$!TQS2Q9MW(6@[:;#[1L/VK?+!#
M-EWL37%NPD8CV':/L6-'TGIX[A-V.KJ`#A%:&<(J)U*#2[EQ7I%U+0CA$J;$
MA$G$9(OEU4CE`#E,L?[>AC`.SZNZI3ZE],?TCRBAZPM7T5G6OTL=</T1R&HY
M.0DKO=Z;U&^CTHIWJ_7JT:@UL3)LR-3:\"#1K;G17]J09$)'E!F2R/R%7?=U
MV/*ER@HIVC@!L"[N@[,+F3-A^D?T<!R\@P',%DV=HYH8;6/+0BF4?I8NIARG
M$\YVJG<:2TZZ1%NYU=05T369M<^[5J<(<H6QHQ"+1L9.TR$23`Q@F;'<%Z**
MMU54SB8BJI3A=W0-1<OKER^\?=VT]E<:<_L6#969%#:QTS9O='O4I79MIA7F
MJ.4JG;:'THR(P29:FUVT2BR5].-1:U"";I,2U1XX?UP6B23$B;<\,[=JG0,4
M`,053AUZ&,`Y-[=NS$W,A)K7M'EV]?*L"PLFY0VTC`%*=D89<1R<G(LZKU=8
M5IF[:,.V<9":G+`_<K`EY0[D[!*NI9ZJJ=--/MD25==R@!NT9)LDFGVA`@#F
MF21TA!=R``>P"G_'2M\<;8@0WE<2?:34_P#H.B@5^R"V)A$PB81,(F$3")A$
MPBB;OK_GYP=_ZU[1_P"UC>V6=E_LM8_R6?ZT:J;_`/W^A_Y[_P#0E7__U??Q
MA$PB81,(F$4,N#MAC&NH0TL^<$8[+T'/6/7NQ:HZ.1*6C'+>QS#ROV!-H806
M7K%TKSAO(Q;T@"@Y06$I3B=-0I;75XW&Z^K`K;S-#FNY#@*CVM-01M!5-H<C
M19_1.-+FW<6/;RC$T/ZKA0M.PCV%3-RJ5RF$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB810QH4\QVGS%V'=:>NC+4G3^G
MV.EI:TLU".8>6V99;BE>+%6X60;F59R*M&@X>.))BF?^C/9'R<X`JDH4MM,P
MVVE012BDTLN\`Y0P-R@D<F8DTYP*\JIK>1MUK%Q/":P0PB,NY"]SLQ`/+E`&
M;F)IM!4SLJ5<IA$PB81,(F$3"*&/'VP1U.W=R=TK9%T8J[S6UG>\Z@Q=+)I>
MF>M+S4Z?'DL%<(J)%9`E<LT`^C),A`,+1PDF8W0BZ0FMKYCI;33[N,5A$6[<
M?[+VN=@>:H((YQ["J;3Y&PWVIV4AI.Z7>M']ICFM%1ST<"UW,?:%,[*E7*81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M%#'9$ZPOW+CCK0ZLZ;RLAHQUL#;^UE6G:<-Z<PM.K;7JNAP$R[2ZM&%BN4A?
M5WK-DH;RH["+57%,$C)G/;6[#!IE]-(*-FRL9_>H\/<1SAH:`3LJ0%37,C;C
M5].@B-70%\DG]T.8YC0>8N+R0-M&D[*+_];W\81,(F$3")A%I#9O'#2VWYB/
MLEZI2;FV130T?'W2N3MGH5Y:QIU2+C%IW>@S59MGFOOB`<&PO!0`XB($`3"(
M]EO?W=JUT<,U(B:EI`<VO/E<"VO32JX;G3;*\>V2>"LH%`X%S74YLS"UU.BM
M%KSP3:#^YNOYJ>4_QFS?ZO>_)X,/AKG]$L/G\>?Q$\$V@_N;K^:GE/\`&;'J
M][\G@P^&GHEA\_CS^(G@FT']S=?S4\I_C-CU>]^3P8?#3T2P^?QY_$3P3:#^
MYNOYJ>4_QFQZO>_)X,/AIZ)8?/X\_B)X)M!_<W7\U/*?XS8]7O?D\&'PT]$L
M/G\>?Q$\$V@_N;K^:GE/\9L>KWOR>##X:>B6'S^//XB>";0?W-U_-3RG^,V/
M5[WY/!A\-/1+#Y_'G\1/!-H/[FZ_FIY3_&;'J][\G@P^&GHEA\_CS^(G@FT'
M]S=?S4\I_C-CU>]^3P8?#3T2P^?QY_$3P3:#^YNOYJ>4_P`9L>KWOR>##X:>
MB6'S^//XB>";0?W-U_-3RG^,V/5[WY/!A\-/1+#Y_'G\1/!-H/[FZ_FIY3_&
M;'J][\G@P^&GHEA\_CS^(G@FT']S=?S4\I_C-CU>]^3P8?#3T2P^?QY_$3P3
M:#^YNOYJ>4_QFQZO>_)X,/AIZ)8?/X\_B)X)M!_<W7\U/*?XS8]7O?D\&'PT
M]$L/G\>?Q$\$V@_N;K^:GE/\9L>KWOR>##X:>B6'S^//XB>";0?W-U_-3RG^
M,V/5[WY/!A\-/1+#Y_'G\1/!-H/[FZ_FIY3_`!FQZO>_)X,/AIZ)8?/X\_B)
MX)M!_<W7\U/*?XS8]7O?D\&'PT]$L/G\>?Q$\$V@_N;K^:GE/\9L>KWOR>##
MX:>B6'S^//XB>";0?W-U_-3RG^,V/5[WY/!A\-/1+#Y_'G\1/!-H/[FZ_FIY
M3_&;'J][\G@P^&GHEA\_CS^(G@FT']S=?S4\I_C-CU>]^3P8?#3T2P^?QY_$
M3P3:#^YNOYJ>4_QFQZO>_)X,/AIZ)8?/X\_B)X)M!_<W7\U/*?XS8]7O?D\&
M'PT]$L/G\>?Q$\$V@_N;K^:GE/\`&;'J][\G@P^&GHEA\_CS^(H\\D^+^K*!
M5->252D=UQ+V=Y#<<J-*K>)SDL_\JJU\W12ZE:XONY/;;Q%#SK7Y9PW[],I'
M*'>=M%1-0I3AW6&HW,\D[96PD-@E</V40Q;&YS3@SD(!YN=5^I:7:V\5NZ%T
MX<ZXA:?VTQ[+I&M<,9#M!(KM')BI#>";0?W-U_-3RG^,V</J][\G@P^&K#T2
MP^?QY_$7P>$^@BAU,7=0!U`.H\JN4P!U,(%*'V[F_28P@`?Z1QZO>_*X,/AI
MZ)8?.X\_B+H6X3<<US`P?LMIR9'**RAXB:Y,\E)E@_:H'1(X!W"RVWGC&19I
MG<)@H55%1(!.4#!]H9D:O?CM-,8Z1%$*?:&8+!T33CV7-E->0S3$'[#)0A20
MIE2IFOZ_&T:AP$!4ZU7&B;>,K%<8LHN-B6JZBRI>ZCF1$DT/*U^]4,<2]I94
M3G,)CB8<KY999WNFF>YTCCB3B3]JLH88;>-L$$;61-&#0``/L'_!60E>,SIG
M6(Z;&1274;**E72,FFY27%LJW.<#"4BZ;D!3,01[0'_5$.OV9"AV4Q6S,*5J
M**IS"RF$3")A$PB81:LVEI+56Z6,8PV=2HJT^8W2CZOR2IGD98JX]6(5-9Y6
MK3"NHVR5QTNF0I5%&3M`ZA2@!A$`#.FVN[FT<YUO*6U&(V@^T&H/V@KENK*U
MO6M;=0!^4U!Q!!_NN%'#["%J#P3:#^YNOYJ>4_QFSJ]7O?D\&'PUQ^B6'S^/
M/XB>";0?W-U_-3RG^,V/5[WY/!A\-/1+#Y_'G\1/!-H/[FZ_FIY3_&;'J][\
MG@P^&GHEA\_CS^(G@FT']S=?S4\I_C-CU>]^3P8?#3T2P^?QY_$3P3:#^YNO
MYJ>4_P`9L>KWOR>##X:>B6'S^//XB>";0?W-U_-3RG^,V/5[WY/!A\-/1+#Y
M_'G\1/!-H/[FZ_FIY3_&;'J][\G@P^&GHEA\_CS^(G@FT']S=?S4\I_C-CU>
M]^3P8?#3T2P^?QY_$3P3:#^YNOYJ>4_QFQZO>_)X,/AIZ)8?/X\_B)X)M!_<
MW7\U/*?XS8]7O?D\&'PT]$L/G\>?Q$\$V@_N;K^:GE/\9L>KWOR>##X:>B6'
MS^//XB>";0?W-U_-3RG^,V/5[WY/!A\-/1+#Y_'G\1/!-H/[FZ_FIY3_`!FQ
MZO>_)X,/AIZ)8?/X\_B)X)M!_<W7\U/*?XS8]7O?D\&'PT]$L/G\>?Q$\$V@
M_N;K^:GE/\9L>KWOR>##X:>B6'S^//XB>";0?W-U_-3RG^,V/5[WY/!A\-/1
M+#Y_'G\1/!-H/[FZ_FIY3_&;'J][\G@P^&GHEA\_CS^(G@FT']S=?S4\I_C-
MCU>]^3P8?#3T2P^?QY_$3P3:#^YNOYJ>4_QFQZO>_)X,/AIZ)8?/X\_B)X)M
M!_<W7\U/*?XS8]7O?D\&'PT]$L/G\>?Q$\$V@_N;K^:GE/\`&;'J][\G@P^&
MGHEA\_CS^(G@FT']S=?S4\I_C-CU>]^3P8?#3T2P^?QY_$3P3:#^YNOYJ>4_
MQFQZO>_)X,/AIZ)8?/X\_B)X)M!_<W7\U/*?XS8]7O?D\&'PT]$L/G\>?Q$\
M$V@_N;K^:GE/\9L>KWOR>##X:>B6'S^//XB>";0?W-U_-3RG^,V/5[WY/!A\
M-/1+#Y_'G\1/!-H/[FZ_FIY3_&;'J][\G@P^&GHEA\_CS^(G@FT']S=?S4\I
M_C-CU>]^3P8?#3T2P^?QY_$3P3:#^YNOYJ>4_P`9L>KWOR>##X:>B6'S^//X
MBXGX1Z`4(=-1+="B:A3$.0_*CE*8AR&`2F(<IMRB4Q3%'H(#]@ACU>]'+%P8
M?#3T33S@1-QY_$6?,>,NAHS64UIV-UG`,-=V-\WE;!!,QD&SB<F6<DPF&D]+
MV!%Z2RR-B:RD6V73D%GAWI%&Z8@J'8+TT'4+UUPRZ=<.,[10'#`4(H!L`H3A
M2F.Q;VZ98-MGV;;9HMW&I`KB:@U)KF)J`:UK@,5__]?W\81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(HF\Q/]
MQ=3?S9<0_P#N+USEGI7[ZY_AI_\`2<JG6/W%I_%V_P#K,4LLK%;*,V_V+<UU
MXO20]^+I+D&P8D_I;KR8K=?5.VUU?Z#WWD(KF4;D_:BGWH%#L@;LB(#861.Z
MU%O)N#_C8JS4&C?Z6[E^H`_^N3DV+4%L7E%[7L"0.9JMLJ%YG<=X.A]HG>2K
M'6LC"Z4&VQT*<2B^+!N-8S5Z?."E/Y+Y4I)F^P2*D+U1!HB@;C].;24NYB\&
M3*3TYQ&!RTRKCE+S+<.P^I;>PAO.&$1Y@.6F0RD\E<W2K=0VTI.R^DSG>G:[
M`M\[RUK^W)>)4%O/(P3*;L$;/&(^3(*J1:?L-G6&,<90Q@8H`@BA^R$N2F+6
M-NZ#]@T0E@.RM`1A_>;G)YS4G%1@#Y'V7:I</=.)"-M`2#C_`'7A@',*`8*]
M5RM1>IK;!5!Q)K6]O)6G7]6;QD3$I5FNRVS=?:07EJM$+,G<M)L(\E?H>MUK
M"^=.%S@I)'A$6XE.T,0T))'7,3Y0W(0UQJ34ACI*$[`35S\H`Y,Y.U;(XFVD
ML<)=G!>QM`,H+V15:*5(%&LSDD^]D`V*8U&M\3L*DT^_0)'R<'>*M7[?#)RC
M0\?)IQ-EB6DU'$D6"@F49/BLWI`61,(BDIU*/VAE5-$Z":6%],['%IIB*@T-
M#S*X@F9<00W$=<CV!PK@:.%14<AQ64YK6U,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81?__0]_&$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3"*)O,3_<74W\V7$/\`[B]<Y9Z5^^N?X:?_`$G*IUC]Q:?Q=O\`ZS%+
M+*Q6RM$G7H":68N)F#B)9>+<`[C%I.-9/UHYT`"4'+%1TBJ=HX`#"`'3$IN@
M_IR37O8'!CR`=M#2OM4'1QO+2]@)&RH!I[%S4@X5671L"L/%J3S9H+!O-J1[
M0\N@Q,=50S)&2,B+Q)H)USF%,IP)U.8>GVCC.\-+,QR5K2N'4LY&%XD+!O`*
M5IC3FKM1K!PK&1D9AE#Q;.7F/)_.THUCVC>1E/)4BH-?.+Y)$CE[Y,B0")]Z
M8W8*``'0`P7O+6M+B6C8*X#V(&,:YSVL`>=IIB?:>5<'-?@'K,\<\A(AW'JO
M%9%1BYC62[-207<J/%GQVJJ)T#O%GBQU3*B7MF4,)A'M"(X#W@Y@\AU*5KR+
M!CC<,KF`MK6E!MYU=2$(F0B:9"IIIE*0A"%`I"$*`%*0A2@!2E*4.@`'V`&1
M4]BY81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81?__1]_&$3")A$PB81,(F$3")A$PB81,(F$3"
M*`ETU+1]S<T[O!;&93<W#5KB[I:6A(QC=+K6&3*3FMK\@F<J_P#)ZG88--PZ
M>M8AJF<ZH*#V$"@'0`RZBNIK3287P$![KF0$Y6G`,CH,0><J@FM(+W6IX[EK
MG,;:QD`.<T`F26I[)&V@ZELGP/<:/4BQ^]S<GQ`S1ZQJ'?-^XSX5T^AZ9W#N
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M>^G*F[8NT2*HJ``'24(!BB!@`<R-9U%M2V<#"GN,Y=OZ*P=!TMU`ZW)%:^_)
MM&P^_P`BJ_`]QH]2+'[W-R?$#,>L:AWS?N,^%9]#TSN'<23XT\#W&CU(L?O<
MW)\0,>L:AWS?N,^%/0],[AW$D^-/`]QH]2+'[W-R?$#'K&H=\W[C/A3T/3.X
M=Q)/C3P/<:/4BQ^]S<GQ`QZQJ'?-^XSX4]#TSN'<23XT\#W&CU(L?O<W)\0,
M>L:AWS?N,^%/0],[AW$D^-/`]QH]2+'[W-R?$#'K&H=\W[C/A3T/3.X=Q)/C
M3P/<:/4BQ^]S<GQ`QZQJ'?-^XSX4]#TSN'<23XT\#W&CU(L?O<W)\0,>L:AW
MS?N,^%/0],[AW$D^-/`]QH]2+'[W-R?$#'K&H=\W[C/A3T/3.X=Q)/C3P/<:
M/4BQ^]S<GQ`QZQJ'?-^XSX4]#TSN'<23XT\#W&CU(L?O<W)\0,>L:AWS?N,^
M%/0],[AW$D^-/`]QH]2+'[W-R?$#'K&H=\W[C/A3T/3.X=Q)/C3P/<:/4BQ^
M]S<GQ`QZQJ'?-^XSX4]#TSN'<23XT\#W&CU(L?O<W)\0,>L:AWS?N,^%/0],
M[AW$D^-/`]QH]2+'[W-R?$#'K&H=\W[C/A3T/3.X=Q)/C3P/<:/4BQ^]S<GQ
M`QZQJ'?-^XSX4]#TSN'<23XT\#W&CU(L?O<W)\0,>L:AWS?N,^%/0],[AW$D
M^-/`]QH]2+'[W-R?$#'K&H=\W[C/A3T/3.X=Q)/C3@Z*OACU^DJZ>O/(Y;9L
M<@O(OGDF\\CC-L7F/8(K/Y!=R]<^3,FR:13*J'/V"``B/3&L4]1G(`%0PX"F
MUC2<`FAU],MP230O&))-!(X#$X[%++*Q6R81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A%_]+V?2?(;8EWM]GIG&K4T5LEO1IIU5[KM/8%
M[4UQJB(MT>)`E*E`OHJJWNW7F>A#F[J1\ABTX]BO^R.[,N4Z`6;;&"&*.74+
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MG,F/2&X.GN@?\IGBK`EUMPJVVLR/\V3P54^?>=/LKXF^_P!W!]->8R:/YFYX
M;/%6=YKOE;3BR>"GGWG3[*^)OO\`=P?37C)H_F;GAL\5-YKOE;3BR>"K:TNW
M-*0>24<PH'#M[(0RB",PP:<B]KN7D4LZ2%=LE)-4>.!UV*CE`.VF54I!.3[0
MZADC#I+0USIKH-.P[IF/L_:XJ(GUISG-;;V9<W:-])4>W]C@KEY]YT^ROB;[
M_=P?37D<FC^9N>&SQ5+>:[Y6TXLG@KB2P\YE"$43U=Q+434*4Y#DW_M\Q#D,
M`&*<AB\;!*8IBCU`0^P0QDT<?_\`1=<-GBIO-<.(M;3BR>"N7GWG3[*^)OO]
MW!]->,FC^9N>&SQ4WFN^5M.+)X*U6QIO.%ENVS[G"A\4E'5EU91-8'@!WCMT
MJ#1"CVW8MK2F"2'AS%19:14V$=$R(I%*F5J4P',)Q`O09='-I':;ZYHV1SZ[
MMGZ36MI3>\F7\JY6PZXV]EO=Q:5=$UE-[)^BY[JUW/+GI3H6TB6#G,H4#IZN
MXEG(/7H8F_\`;YBCT$0'H8.-@@/00SGR:/YBYX;/%75O-<\K:<63P5R\^\Z?
M97Q-]_NX/IKQDT?S-SPV>*F\UWRMIQ9/!3S[SI]E?$WW^[@^FO&31_,W/#9X
MJ;S7?*VG%D\%6V*NW-*=;&>PE`X=S#,CERS.[BN1>UY!L5XR6.V>-3+M.."R
M17+1PF9-4@CVDSE$I@`0Z9)T.DL-'S70/3$P?]U19/K4@S,M[,MK3":0[-O_
M`,*N/G_G/U`O]UO$SM"`B!?[_MP=1`H@!A`/#7U$`$P=?_/(Y-'\S<\-GBJ6
M\UWRMIQ9/!7WS[SI]E?$WW^[@^FO&31_,W/#9XJ;S7?*VG%D\%="]GYP-03,
MYUGQ&;E671;(BOR#VZB"KEP<$T&Z8J<;2@===00*0@=3&$>@`(YD1Z.:TN+K
MA,\58,NN"E;:T'_^LG@KN"?YSB(@&K>)@B4>A@#?VX!$H]`-T'__`#7]@]DP
M#_Y#F,FC^9N>&SQ5G>:[Y6TXLG@K[Y]YT^ROB;[_`'<'TUXR:/YFYX;/%3>:
M[Y6TXLG@IY]YT^ROB;[_`'<'TUXR:/YFYX;/%3>:[Y6TXLG@IY]YT^ROB;[_
M`'<'TUXR:/YFYX;/%3>:[Y6TXLG@IY]YT^ROB;[_`'<'TUXR:/YFYX;/%3>:
M[Y6TXLG@IY]YT^ROB;[_`'<'TUXR:/YFYX;/%3>:[Y6TXLG@IY]YT^ROB;[_
M`'<'TUXR:/YFYX;/%3>:[Y6TXLG@IY]YT^ROB;[_`'<'TUXR:/YFYX;/%3>:
M[Y6TXLG@KI7M7.6.1.]5TIQDGTFP`HI#0'(?9+.:D"`(`9O&N9_CLPA4G0@/
M4HN5DDAZ=!,'7K@1Z.XT%W<-Z3$R@]M):]2P9=<:,QLK5P'()GU/LK"!UE;,
MTGNZ(W+&6-(U=L%!OE"G`J^R=:6])HE9Z78#LD))H591@X=QLU7YR-<D=Q4L
MR5592+4W:3,!R*II\]W9NM'1_M&OA>*L>W8X;/:"#@6G$'[%U65\R\;(-VZ.
M>-V5['>\TTKR8$$8M<,"/M"W9G(NU,(F$3")A%HK=>]([4):I!QU5L&R=G[&
MD7L1K?5]2-'I3MG=QK=)U,2CV2EG3.'K-/K39PDK*R[U4C9DFJ0.BBJB21^R
MTLW76\>Z1L=O&*O>ZM!78*#$N/(T8GV8KAO;YMGNF-B=)=2$AC&TJZFTDF@:
MT?I..`]M`L`)9N<KLH.4M-\7(I)?JHG&RO(7:+J29$,(B5N]<Q?&]:.6<IE^
MPQD3&3$?T#TS?N]'&!N[@GG$3*?EEJN?>ZX<19VH',97U'MI#3J7+S[SI]E?
M$WW^[@^FO&31_,W/#9XJ;S7?*VG%D\%//O.GV5\3??[N#Z:\9-'\S<\-GBIO
M-=\K:<63P4\^\Z?97Q-]_NX/IKQDT?S-SPV>*F\UWRMIQ9/!3S[SI]E?$WW^
M[@^FO&31_,W/#9XJ;S7?*VG%D\%//O.GV5\3??[N#Z:\9-'\S<\-GBIO-=\K
M:<63P53)VKFZJY79):VXB*/&I4CN6B?(3;AW+8BX"9$ZZ!>-PJHE6*`B43``
M&`/LS.[TB@/U%U0_*9XJQO=;)+1;6=1\V3P54^?>=/LKXF^_W<'TUYC)H_F;
MGAL\59WFN^5M.+)X*>?>=/LKXF^_W<'TUXR:/YFYX;/%3>:[Y6TXLG@JVJ7;
MFDC*MH)6@<.TIMXT7D&<.IR+VN25=L&JB:3IZVCS<<`=KM&RJI2J*%()"&,`
M"("(9+<Z26EXFNL@-*[IE*^W>J)GUH/$9M[/.16F^DK3GIN5<O/O.GV5\3??
M[N#Z:\CDT?S-SPV>*I;S7?*VG%D\%<2V#G,?M=C5W$LW9,)#=G?^WS=DY?\`
M6*;IQL'H8.OVA^G&31_,7/#9XJ;S7/*VG%D\%<O/O.GV5\3??[N#Z:\9-'\S
M<\-GBIO-=\K:<63P5JO2U-YPZ;UQ"Z\;4/BE/(P\C:Y`LHOO';K!5<;3;YZV
MJ)&:I\<W1$P9J3@H`(''ME3`W0!-V0Z;N71[N=\YFN6D@"F[8=C0WO>A<ME#
MKEG;,MQ!:.`+C7>R#WG%W<\E:+:1;#SF,)REU=Q+,9,P$4`N_P#;XBF<2$4`
MAP#C9U*84U"FZ#]O0P#^@<YLFC^8NN&SQ5U;S7/*VG%D\%<O/O.GV5\3??[N
M#Z:\9-'\S<\-GBIO-=\K:<63P4\^\Z?97Q-]_NX/IKQDT?S-SPV>*F\UWRMI
MQ9/!5M;W;FD\DI*&:4#AVZF(9-@M,13?D7M=>2BD94BZD8K),4N.!G3%.13:
MJF0,J4H+`F82=>R/21ATD-:\S708:T.Z90TVT.]QIRJ(GUHN<P6]F7MI4;Z2
MHKLJ-SA7D5Q&?YSE#J;5O$P`Z@'4=_;@`.IA`I0^WC7^DQA``_TCD<FC^9N>
M&SQ5+>:[Y6TXLG@K[Y]YT^ROB;[_`'<'TUXR:/YFYX;/%3>:[Y6TXLG@IY]Y
MT^ROB;[_`'<'TUXR:/YFYX;/%3>:[Y6TXLG@IY]YT^ROB;[_`'<'TUXR:/YF
MYX;/%3>:[Y6TXLG@KX$_SG,'4NK>)@AU$.H;^W`(=2B)3!]G&O\`24P"`_Z!
MQDT?S-SPV>*F\UWRMIQ9/!7WS[SI]E?$WW^[@^FO&31_,W/#9XJ;S7?*VG%D
M\%//O.GV5\3??[N#Z:\9-'\S<\-GBIO-=\K:<63P4\^\Z?97Q-]_NX/IKQDT
M?S-SPV>*F\UWRMIQ9/!3S[SI]E?$WW^[@^FO&31_,W/#9XJ;S7?*VG%D\%//
MO.GV5\3??[N#Z:\9-'\S<\-GBIO-=\K:<63P4\^\Z?97Q-]_NX/IKQDT?S-S
MPV>*F\UWRMIQ9/!3S[SI]E?$WW^[@^FO&31_,W/#9XJ;S7?*VG%D\%<:_P`A
MKW6+U5=<<CM4LM72-^DE(#7VPJ9=#;$U);K2FDJX2J*\\^K5,L=-M4NU2,I&
M-)2,21DA3.DW<'<%[G#[&&2&2XL+DR-8*N:YN5[1_:I5P<T<I!PY13%(]1GB
MGBMM1M!$Z0T8]KL\;G?V:EK2UQ_1#FX[`:X*6F5BMDPB81,(F$3")A%__]/V
M?\"VZ27#CCLZ*7^DS>LX.T2S@WVJR%@MA5;)8I5R?]*CN5FY5PX5,/VF45$<
MM-:).JWPY!(0.@-P`^P`!5&@@#1]./*Z(./27=HG[225+G*M6Z81,(F$3"*'
M/-.>=P%)U.K(BHEJV3Y"ZKA-[NQ$Z<8SU/)NI5%T:SN2G23;TQ[=@@VDUWQ@
M:*Q;A=%R!FZBI#6NDL#YKD-_W(@>8^?.*;/[V7,6\M0",:*GUJ0QP6A=_M3<
M,$O-NS7WO[I=E#N3*2#@2M?[S07UCR%T_<M-Q,3%RB6J=_RNWX>(9@R@9[7%
M.H(2>OG]S90XM$531&T1CV<.X4$%R(/Y!-N(D[\";[,BXL;J*[<2W>QAA.T.
M<ZC@VO.RI<.AM>1<]\#:ZA9S6;`';J4R`8`L:RK"X#F?0-.VA<!RK"6?,C95
M/CGLSLQ77[V(E],\-]K1TW#U>=K4/KM#DGLN:UE:W5Q![=+&M.UZC>:PF._2
M7C3K$`S8W=]L%T]ITJWE<UEN'AXEG802"7;I@>W+V10NKEY>?H6@:S<PM<^Y
M,988;>0$-+0S?/+'9JN-0VF:M1S8;5G%_P"1>T*>]V+686U:HL3O6G'/9'(,
MEV5@GHP%O/5KE+Q\70S,HV]"6,7KU>CFZ5BD$5U!*\E6BR+9NG_1E=,%C;RB
M"1\4C1).V++7%M6@EV+<:DG*.8$$G:-]QJ-U"ZXB9+$XQ6SY<U#1V5Q`;0.P
MH`,YKM<"`-AUPGM?8=/6YH[PIM6CV=@A/##L>WTNV1$E+/6=,+IJFRNRXI-"
M(FX!RE;:U4%'JK8XF73,[9`D9`X*=2[_`*:"7TFSED)8=ZQKFD#M;QP8<0>R
M74KT&M5S"[N(3K5]#$!(W</<UP)(;NVEXP([36UIMQ%*+:LKN;<1]QZV@1L^
MN8>HW+CQO';!*Y+4B266G305]URSU]'+.UKXS>-+`-+N"'E2:/>H`X!^`MU0
M4;&8\[;2U^EN'[N0RLGC94.&%6NS'W=F9N'+[N(QKUOO;SZRVCWL8A?;RR4+
M3C1[`P>]6N5PKR5S8&HRX_H/D0^N4#JNBP#C4VGGT/QSXH;8"FO(-2*KUJA]
MLQCT)^JZX8#8XST=K<"2+2BHQPCYS.RDW2)7"*R:947<[VQ$3[F9XEE!GF9F
MK4@L.!=@:DUJ1A4`T(VC78:BZ:.U@C,,+A;029:4#A(#5K!44`IE:>U1Q%0=
MAWEQ;W+9-R52VI;#AW%?V#4+$T@;G4W-=3BXZ'6DZG7YU$L!,-+#:H2\T^8\
MY+.XB6;.P\JBEVX+I%6*=17CU&TCM)8C`_-`YM6NK4FCB,10%KA2CFD8&M,-
MG=I=Y)>13"X9EN&.HYM*`5:#@:N#FFM6N!Q:145V_G#Q4BFU35X;VU*'@69K
M)N;F7KV*5H_98WF4>2-\W6Y2<;*B"(-_3#4]4:5X5%"D<HFB7_FI4.H&[.7V
MI.,HU6+.XY8H''-BT4;'[A_1>:\W:&8+S>E,$1T:8,:,TUPP9<'&KI/?'Z4;
M:<_9.0K?U"Y,WDVM:0PJ-:U1J_O>+6XN1)E1KC].AJR]&O+6-]$("$:66$5C
MH9N61.\G78N5ERE>H'("1CF./%-I\/U$SI9)9/\`]+(MHS4<VN8FAJ<*-%*8
M%6%OJ<_TT#88HHO_`,LDVPY:M=3*!F%!C5QK7$;%PC.8.T61-P7:VNZ978.'
M8<3&L+KVR0#J)D]8.N0K36!9RU7FR)6<Z[JNZY>;!=#+)C'I^4&9I%3<,P`X
M*':7;GZ6&(/<\F:K@:A^ZST#13:[*,N.%3@4;K%TWZR>8L:P""C"*%F]R5<X
MYMC,YS88T&+>7<9=_7A*X0VHK'L#1]2N:U$O6QDM@H^<+!KVSQ53V=Z-,81H
MA(3U2,RGHVH%(XL[9-\H=D\<=6Q^X3,?.7Z*$Q/NHX)G19VMRX!P)96N`=@7
M8,-,0,<2NSU"<3,M)+B!DV[<_/B6.#7Y0,2VA#<7BN!.&`6HN.-]OM-V/"TE
ML\JCG6^U>5O/^$<POHU(M;/"2M.VOL>VQ\JWLQ;,K&.V:PQJK86GFI#L)K`;
MO3&(&=5_##+`^8AWU$=M;&M10AS&M(I2O+6M?L7'IL]Q#<L@!8;:6[NA3*<P
M+9'N!S9J4PI3*-NU;DWJD_M[_EO6G+!24+6N'35"GPX(%>G7=[,+N[TA=MFI
M"J&76FW^M89LFD8HG*K%=HG_`*F<EF1$W3)`:9KKM']3=TZL[C]J[;X.F=J\
M1;7+9]D;??WM>LL:/^GI5KU>A6IO4W^7(I&I0,FW:-ZE-,?)BQS@J#=CQ4V:
MU>R+),O:$H,;`]:$643#JD[43[8@?LY*X,C+G7LV8$Y@=O+,S#[0#]BA:B)]
MI_XYE#2!E(V<D#ZD>PD?;1:[Y3VQ:2)!\G=0N=4<C-7ZXU1=VNV=3R,RP?HS
MFJ+78$`GKQJRQLS/(A*\1[W6+^/407[PCQ)HLV3`'1")GZ--B#<^G70E@N))
M6Y'@$4>T8->-N4YP>BH.Q<^JS%V[U.S,5S:QQ.WD9(-8W'%S#LS`L(H=M"-J
MEI07CE#?>\81L1<D!)TS1VRS$7`"J-+E:TMD4FP1ZJ`G.JT<HU?55?641,!`
M`SCM]GJ<QC5DX!LK-Y]\/D9_TC(X'K>[J5M;DB_OF#]V61/_`.IV=I'W6,ZU
M!O3MUM&N9/8<!KMO38AYN#_,RWCJV0E)VMOIA&&:AK6P7YK*-HN'L%5,^.@M
M11;=RHY(7L.S'*8HDZ&M[J&.=L#YR\B+3XW@`TKVPVE2#3WJ[.14=G/+;.N(
M[<,!FU.5A)!-.P7UH"VONTV\JV7K/EA<[Y'ZXJ5AM6L];WV<U??;_)7&QP;T
M*79GFMMNO=;2K"$AWEPB#L4!C(562DD?.BKEJD^1%(P)I*''1<:;%"Z>5D4D
MD`D:T-![0SL#P2<IKB:#"AH:[5TVVK33MMH9)8HYW1.>7$'*[)(6$`%PI@*G
MM5%1385/BM6^JW)O)NZE9(.RM86>F*M,+P4HRE$HNRUYX>/G(&1.R66!E+Q+
MQ,4W#=3LJI&Z=HH`(=:62*2(M$L9:2T$5%*@X@CH/(5?Q313!QAD:X-<6FA!
MHX8$&FPCE"R+-:V)A$PB81,(HCQJ"+/G9<%&I`;FF^*5"<2X(B*9))S";9V`
MUB73U,H@FX=1[64<))*F`5"I*"3KV0``LW$G1HJ\ERZG15C:]=`JAH`UV:F&
M:T97II(^E?94J7&5BMTPB81,(F$418ULF^YY75TZZK*5CB/JY&#`_9,5@%XW
M'N$UG,AU*)DSRG]W\2"@E$.T#0G7KT#I9N--&B`_2NGUZ<K&4ZLSNM5#0':]
M,3M;:,IT9I),W7D;U*765BMTPB81,(F$6F^1,A?XG0FYY/52#EQLF/U?>7E&
M19(^4R!K0WK<BK##&M>R?RJ4(]*0S5(2F!5P!"B`@/0>NQ;`Z]M&W)__`#F1
MN;FI45KT<ZX]1=<,L+UUJ";D1.RTVYJ&E.FNSI4*-I1%%?<1='[!X^-HY+9`
M3VBW>BK+"$3-;Y>X3]OJK>U1,U+(F/,S![#`EEPN:3Y905FZ+]:2$1064);6
MSIAJEY!?$[C+)O`?=#0TT(&P4.7)3H#=H5)=,@=I%C<:>!]3FBW3A[Q<7-S`
MG::C-O*G8'%VPK*F')W;Q=F5U&2;4Q_0Y+?W)32+BJP%3G2W-9OIK65YOT!/
ML;$YN3QBZE)=QK\S91B$6F0?+Q[*HBF41UG3[7Z>0M+Q,(8I*EPR_M'M:13+
ML&:M:\FQ;6ZG>?4QAP88#<3190TYOV;'/!!S$5.2E,O+MP57`<I+;9:MQ[M<
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M7%;4K[Z#2*19!P5&/4$'1C*E4+'T^SBN;V`L?((XGO%'`5&89#@TXEA#N48[
M,%+U.^EM+"X:^.(R3,8ZK2:'*=X,7C`/!;M!H#CBK_7.0[J,G5*(FVUOJZ7V
M3R8Y(:]:WE&N*-:RI+ZRBSN8Z2G&*\XS2E-@7I9LDH=1=ZF5P1JNFF!E.ZZ0
M?8AS-]621L=O$[+7&CSB`:8-;T#"HZ5LCU$MD,`$<3Y+F9F:G9JP8$BN+W=)
MQH1MHMJZHWK<[#O"9U3>D(TB*],?7'75EJ<`+S7FSZQ!$UY'SEIJET:VZP"Q
MD(BQ6U1.2A'Z)5FS=_&B@X7*55PZYKFSB99MN82:YPUP<>TPG,0"W*,"&X.&
MTAU0-@ZK2^FDOGVDX%,A<QS1V'M&0%S79C0@NQ:1@"VA.),`>0$)'M=L<_KH
M>&KWDM"F.'ESD):/52@ML,RQ\*SDW+?4-E!DY+%WZS@R,Q:$-T&277!H(_MN
MH7=B]QMM$BSNJ\3M`.+,33MCE:-IYMO(J#4&-%WK\V1M(S;N)&$@H*_LW4P>
MZE!SDTY5+61WW8JOLK:<'"TRC1,K-<L]%:0=7,L`Y9N2Q6P=(4>[-K3L`H3"
M2T_9XYI)(UF,#RA!`'1V1>[,7M(J5C;*.2WMGOE>6MMI),M>5LCFT;A@#3.<
M":5]JMG7\D5S=,9"P/==Q19J<CXFNS/QQ<*Y&X@5RX<AQ:O<G=T2^W:!6)>1
MID37F,SS#K]C294UXM_>TIQTO&N*W"/J0JZO!7,)*6!G;W#,&P*/DVLTR=`8
MCM/N2(;'Z=:-MIY&M>7D0$=KW-ZUQ.;LX@90:X5:1LQKJCU.]?=V\3W,$8-P
M#1I_:;ES`"WM8$AQ%,:.!VX4OE:Y<6MQ1-57RSV32Q:UOJRZ3A*O-5:5E)-Q
MJP^TZO=)V5:;'CGRK-H0&\S4TH*&=F<-^^EWBA';<GD@IKPDTR,37,,<<V\A
M;(2"`,^0M`RGV.S.%#V1@<<-D6KRF"TGED@W4[HPTM).3.UQ.<'I;E::CM$U
M&%#JBR;'V?K3;G(?9U;M^L+1*0&N>"S2^.FE.DUH*]M)G;^]J++H5E=EL%4:
M>_:MY%8#++'F@*X0`G=D`H@'2R"WN+6QMY(I&M=)<9>T*MHR-PKV>UL_NX%<
MDES=6UWJ-U'-$YS8[7-V31U9)6G+1_9./+FQ"GMM)^[4V3Q[K"G:3K\Y?+-*
M2OZQ>XDY.H:[M$[6(-RF8?VI4Y9,)E("AVBN81(_4`*8!I;9H^GOI/TPP`=`
M<X`GJ[/L<5?73C]3I\7_`,;I'$]):QQ:.OM>UH4(-9Q,"3BW_F!588^%1?.>
M0',R`3@U6\>W44F+19)D-<10LE2IE!Y-^?8OS0F)0,KY4V[@![:?6XN'/]1T
M23,:;B`UQV`#,?LH<WL-526S(_2__((LK<QN+@4PVN)R"G35N7VBBV-SRGZA
M8].%J]9?4RRVB@<C.+<7,54TFQ.:LRLSM>A/86*L;=FWE'U;;34*_((&,U.8
M[-4PD34`!(//HS)8[K>2->V-\$Q!H<0&.J1LK0].U=.O20R6>ZB<QTL=S`"V
MH[),C"`=I%0>;9SJ^\8MRZU"FWZU[51K.HM\5FWPU+Y,I6YY"0;J*O;M:/KU
M/192ZYFK=36-@;JM"5`R:AVJK-0I>]<//*W"L-0M+C>P1VQ=+9.:719:FK<2
MZH_MC'/RUY`*`3TR\MMS<2W8;#?M>&S9J"CL`VA_L'#=\E.4FI.]M<+.F6Y^
M0E=0$3P'EFM+HWZ'(9!C9+34W$-8XMND4YO)`,TI<=)*I@4@'<2:BX@)UCG/
MQS@&TL9#[]'M^P.J#_\`T1[!3D7?;$MO=0C'[NK'>PN;0C_^0?:XGE4$=!7.
MWTAZ^U_K4E*KRVY/\P;G#27\W.U5]/HP*-3:[:OL([90L-9:>#TJ#BDIM114
M=$*""G0@E[/0;F]BBF`GN,[A%8V[@`ZE<V1IQ(=_:KLVJAL)IH'.M[;(TS:A
M<M)+2:9=X\4`<VONTV[%M74O+*V[.::PK4S9=;ZSN\YHJO;FF9RPQ#QQ6+88
MNR9BC6N*K4>[MD(K&M8IE6CN')1?.5VRDTQ,!A315!QS7.F16YN)&1R20MF,
M8`.+>P'-).4UJ308"N4\XIUVFK370M8GRQQ3N@$A)'9=VRUP:,PI0-J<21F;
MR`UGE6+?5+M'+R]/LD':8MK*RT$YD:_*,I=DA,P+]>+F8M5RQ6713?1DBV.B
MLD(@=,Y1`0RFDBEA<&RQN:X@&A%,#B#CR$*^BFBG:7PR->P$BH((J#0C#E!V
MK(\UK8F$3")A%$CG0W1-Q=V5)F('EU75I-S@W(")%F%AJ%_JUB@W[98@E6;K
M-I&.3$3)F(IV!,4#!UZY9Z.3ZC;MY'9FGI#FD$=151KH'I=R[])N5PZ"U[2#
MUA2WRL5NF$3")A$PB81,(O_4]HW`_P#<RXP_]%*#_L%IEGK/XMJ'^<[\ZJ=!
M_!M,_P`AGYE++*Q6R81,(F$3"+H<MFSULX9O&Z#MH[05;.FKE)-=LY;+IF27
M;N$%2G26062.)3D,`E,41`0Z9D$@@@T(6"`X%KA4%8[$T:DP#!_%05/JT+%R
MJ8)2<;$U^)CF$BD"1D03?LV;1%N\3!$YB=%"F#LB(?H')NFF>YKGRN+AL)))
M'L6MD$$;7,CA8UIV@``'VH%&I)4W:):?5BHR$02OOT@K\2";V!2+V$X1VF#3
MLN8A,OV%;'`R(!^@N-]-4'>NJ#48G;S^WI3<04(W+*$4.`Q'-[.C8N!:%121
ML'#$I=3)#UCN_1N*+7(<L;7NZ.FHEYC8@S!K$]V=(AB^3E3Z"4!#]`9G?39G
MOWKLSMIJ:GV\_P!J?3P96,W+,C=@H*#V"F'V*T6NCP%C9S$"V?%JDA;O(U[,
M\KC.N(6&TUV.>,T9N'D5Y*(DG"L7,Q2YHQRZ2*F^9H/!,T<MG/<K$E',^,L>
M1F:W96M`3L(H1B#B!L-,014*$L$<@?&'9'/IF(I5P!%0:@X$=DG:`<"#0K)I
M&KUF8>QLE+UV"E9&&;2K.'?R,1'OGL4SG6J;&;:QKIRW578MIADB1%T1(Q"N
M$B@10#%``S6V21@<ULC@TTJ`3C397GIR<RV.BB>YKGQM+F@@$@$BN!IS5&WG
M5"%#HP/*](!3*H#^I(J-ZH^"NQ`/*R@LF=)5&O.?(^^A454E#%,5L9,#%,("
M'01S.^FH]N]=E=M%3C[>?[5C<05C=N69F>Z:#L^SF^Q5L'5:Q6&"\56ZY`UZ
M+=.%G;F-@X>/B6#ETY331<.5V;!NW;K.%T42$.<Q1,8I``1$`#,/DDD<'22.
M<X<I))_*LLBBB:61QM:T\@``_(J.%HM(K:SMQ7:=58!=^@9L^7A:]$1:SUL8
MW;,W=J,6:!W"!CAU$AQ$HC]O3,OFFD`#Y7.`YR2L,@@C),<+&D[:`"O4OJU&
MI+B.81"]/JR\3%.!=Q<6M7XE2.C70G%47+!D=H9LS<"H(F$Z92F[0]>O7`FF
M#BX2NS'::FI0P0%K6&%F0;!04'L"[W-/J3UU./7E7KKM[9XI&"LKMS"1B[JP
MP;<CI-O#3CA5L=66BD$WJQ2-W`J(E!8X`4`.;J$LH#`)'`--1B<#SCF/2%DP
MPN+W.B:7.%'8#$<QYQB<"J)77U"7:UEBO2*@LRI:[=S3F:M:AE&M3<LP3!HX
MK+<[(4H%=J").[.U!(Q.R'00Z!F1/,#(1,ZK_>Q/:]O/]JB;>W(B:8&96>[V
M1V?U<,/L50C3Z9'K-Y!"KUABO&NI&4:O482*;+,'LF!32TBW<D;$.U=2`)@+
MA8IBG5`H=L1Z9C>RN!:9'$$`;3C38/LY%D0PM(<(F@@DUH,"=I^WE7$E9@'=
MJ9;":@!ID:LXK)7[-<@M96`?2+";9@[[H#$D`CG;8YV*@F$$"O7/8_\`7,.-
MX\1&`^YFK3F(!'V5Y?8.9-U&96W`]_)EKS@D'[:<G-4\Z^PM'I=:?/92N5"K
MP$G)=[YQD86`B8I\_P"_6*X7\M=L6B#AUWS@@*'[PQNT<`,/VAUP^::1H;)*
MYS1L!)('6C((8G.='"UKCM(`!/MHJ(FM=<I)PJ*=`I2:5:,L>NI$JL$1.`.X
M?><W!X4A6`%BC+R7](.*`)B9?]H/4WVY+ZB<EY,[ZNVXG'DQQQPP4?IK8!@%
MNRC=G9&&-<,,,<<.57:(K43"2=GF&*)BR-OEFDS..5#`H==TP@8BN,TTQ[("
MBT;1D(B!$@_5!0RA_P#64.(P=(Y[8V$]E@H/M)/YRILB8QTKVCM/-3]@`'Y!
M_P`55&A0Z.U5*NVIE4;K%E3SI5D*[$(JEG%"&34F2J)LRG"5.F<2BXZ]\)1$
M!-T',F:8X&5U*4VG9S>SH6!!`#40L!K78-O/[>E=*FN]?K)0:"U%IRJ%8DAF
M:TBI684Z5>EQ5*L,K!IF9"2)DA6(!^_;@FKV@`>UU#,[^<9R)GU<*'$XCF/.
M/:L&WMR&`P,HTU'9&!YQA@>D*^Q4'"P2;M&#AXN&1D))],OTHJ/:1R;V7E%Q
M<R<J[(T11*YDI%R85%US@958X]HYA'[<@Y[WT+WDD"@J:X#8/8.9;&,9&"&,
M#022:"E2=I]IY2KID5),(F$3")A%$UK^_3-_RFU;_&"X99G\'9_$G_`U5(_'
M7_PC?]1REEE8K9,(F$3")A%$V"_?IVI_*;H+_&#DIEF_\'MOXF3_``1*IC_'
M;K^$B_U)E++*Q6R81,(F$3")A%B\?2*7$S+JQ150J\98'QG!WL['P$2SF7AW
M9BF=G=2;9HF]<&=&(`J"<XB<0#KUZ9L=-*Y@C=*XL'(2:=2U-@A8\R,A:)#M
M(`!Z]JYI4RGH.FSU"J5I%ZSD7DNT=I046FZ:RT@0J;^4;."-050D7R9"E67*
M(*J@``8P@&#+*00974(IM.P;![$$,((<(FY@:[!M.T^T\ZI6NOJ$Q83$4RI%
M09Q=BD/.U@C6M:AF["=E.\15\Y3#-)D1O)R'>MDS=\N4ZG:3*/7J4.F3/,YS
M7&9Q<T4!J:@<PY@L"WMVM>QL#`UQJ1E%"><X8GI*[7E.A%&:2<0QC:Y*QD$^
M@:O8(F#@32E/;/&8M$S5TDA&/H]JFSZ$.1L=%1H<4RE42.3J4<"5]>T2YI()
M!)H[VT-?MV]*RZ%F4!C0UX:0T@"K?94$?92G.%3,J#6$:S#564C&EI80KEE*
M$7M+"+EW;ZQLWHRPVU^!V"3(]H=3ISR"CM)%(P/5#*D`@B'3+IY#(^1KLKCA
MA48;,HZ*84YL%AMO$(F1/:'M:0>T`:D&N8X4S5QK3;BNN8HVN'T4M#6"GTAY
M"2DTC(KQ,Q7X%Q%2-B75`&[]9B]:':.YI98W0BIB&7,8?L'KF637`=G9*\/`
MI4$U`YJ\WY%A\%LYA9)"PL+JT(%">>AY?RJ],JO68Z8D+#'UV"83\L@@VE9Q
ME$1[68DVS;IY,WD)-!N1Z]0;]D.P10YBDZ?8`9`R2.:UCI'%@V"IH/8%-L43
M7ND;&T2':0!4^T[2J$:-1RS@VHU/JA;(5879K(-?B`G`7!+N1<C,"T\O!8$/
MU.WWG:['V=>F9WTV3=[UV[YJFG5L6-Q!GWNY9O.>@KU[5W$KE/DFLFLG`UI^
MRM@-7TPJ2+BW36RE*FF9D\DS@@=&9`J($%)145.A>G9'ITQO)6EHSN!;LQ.'
M/3F3=PN#CNVEK\3@.US5YUS)3ZDFI75DZO72+5`'05-4D)&%4JX/FHL7H5TY
M6P&A`>,C"BKY,*7>)#V#=2_9F-[+VQO'4=[V)QY<>?[5G<PUC.Z;5GNX#LUP
M-.;#F5H6H>M4(J2K"],HR,)<Y5X[F*\M78!.*MDX[04?R#F2B3LP:3LJZ;1Q
MUECJIJK'(@)S"($$0F)K@N;()7YV#`U-6C8*'D&/Y5`P6P8Z(PLR/.(H*..T
MU'*<*_8JT]"HJJ2B"E+J:B"S2*8*HGKD.=)5C`]V$&R43,S$AVD,"1?)$Q`2
M-^R'=@7H&8WTP-1*ZM2=IY=O7R\ZE]/`10PLI0#8-@V#9R<G,NZPU&$LQZVM
M)MS>55"R,+77'K8X(.HF89-'T6HJU4[)@(E(P,N]C7)>G[5B]73ZE[?:#$<K
MX]X&G![2T](P/Y"`1T@))"R7=EPQ8X.!YB*C\H)!Z"0J9:HT)U:0L"]8J#BZ
MHH-'(3:T+#*VE)LW[UJQ<!)';&EB((=#II'[8%+T,4HA]H9D2S"/()';GFJ:
M=.&Q8,-N9=X8F&?GH,W1CM78]H=&D5I)S(4RJ/W$R^8RDNN]KL0Z6E9.,:$C
MXV1DE5V9SOGT>P3*@@LJ)E$D2@0H@4`#`FF:&ALK@`*#$X`XD#VG%9=!`XN+
MH6$N()J!B1@"><@8!?9&B4B85<+R]-JLHN\0CFSM:1KT0^5=-H=XVD8ENX4<
MLU3KH1<@R17;D,(E061(<@%,4H@;-,R@;*X`5V$\N!ZP<4=!`\DOA82:;0#L
M-1U$`CF*JX6M1,`ZL;^/1,5];)TUBGWBIP.N_DPBHJ!;**"!2%*FQ@H-FS1*
M`!V46Q.O:/VC&B^1SQ&''!K:#H%2?RDD_:LLB9&9'-':>ZIZ30#\@`'L"HFU
M"HK(R)V=+J;0[9ZYDFYVU<AT#-Y%ZCY.\D$3),R"D]=M_P!154O110GZIA$/
MLR1FF-:RN.%-IV+`MX&TRPL%#78-IY=FU=9M>T$P5X#4>GF"HO!D:H!JU"B%
M8D#&$QGU>ZLO_97AC"(BJV[HXB/Z<;^;M_MG=H4.)Q',>?[5CZ>W_9_L&=@U
M;V1V3SC#`^Q7R(@X6OM5&,#$1<(R6>OY)9I$1[2-:JR,J[6D)204;LTD4CO9
M)^X4775$!466.8YQ$PB(P<][S5[B30#$UP&`'V#8MC&,C!;&P-;4G`4Q.).'
M*3B5=,BI)A$PB811.YS_`+INZOZML?[1PN66C_B5I^M_R*J=<_";W]4?G"EC
ME:K9,(F$3")A$PB81?_5]HW`_P#<RXP_]%*#_L%IEGK/XMJ'^<[\ZJ=!_!M,
M_P`AGYE++*Q6R81,(F$3")A$PB_.CDTN6?U=O!],%2<JQ?*KBE3&C9ZF0QXB
MLM-I\;Q&*4(J8Q/)9D+M+O3")""LRFS)'[Q$P":]T\9+FS:W`&VF=[3DEQ^S
M*T>UO.O.ZF=Y:WSGXD74#<>1N>'#[<SCTAU-BNVP;ZZX_;CLX:[B@<Z\/K"D
MC<ZF@N9I1J+M*^;MH6LM;3X)")8NHM92N6J:DYULU.S3<,($CI4J9S^4GC!`
M+VUCW[J3[QV5WZ3F-C<]XYW4(:&DUH74',I7%P=/O)?IV5M]TW,W]%KW2-8P
M\S:ASG.`I4-J>==TY=+?`[UI%CMC2AP=V7TIL2IG.22D'\#TD^0FFZU7E4VT
M:@]FY:?6:2B:B->;JG5<RROD";P@*>5EPR&)]G-'$7NBWS7;`#A$\G;@!A[Q
MV#M4Y%E\TT=]!)*(VS[A[=I(QEC:-E23C[@VN[(.-57!R?V(GKO6UP6JU:4D
M-B'V]KF,:IM)QNW=[WI,[8(77%=!)[(HKPU?V@>GR9.CL_?1CSR=N9985NV7
M'IT&_N(MX[+'D<=G[MP!<=F)9F&S:*F@HI>J7'T]M,8FYI-XP;?WK20P8G`/
MRNV^Z:"IJJMSRAL\UJQ+9--2IC="5J`OH5A98JTN)PUWK-#DKEL"K%K$`]7=
M2J4')H)0KU8KMH2OO6\B+LRYV9&[G`TZ-ER;>4OP=B013*7!K75.RH[0P.8%
MM*5J,G5)7VHN80RA94!P=7,UI<]N4'&A[)-1D(=6M*'KG>4%\BT-A6U*L4\M
M&UQIC5VV)9FY?3)K"Z-LZOW)PBQ\ZE*A#1<16YJOH*OGRR!P+%]^IW93E#H9
MIT#MQ$9'[Z25[!@*=@MY-I)!P'/1)-4G:+B81,W$<+)#B:]L.PKL`!`J:>[5
M2<HEJGGB8PNPE*;$W51Y*'C8:`G47#F6@&*$4Y\[^95G;QY'K-@F$B.$2.'J
M:93HJBJ4'!4B5\T;!VX,YAH*DC8<<*\NS#`<HIA56<$LA[%QD$]30`[0*8TY
M-N.)Y#7&BC-16T:RV3_F%H2*+!LB>U4V8[EV1LFEZ.2'&37/>R!TU0`A(E[9
M8^7,8Y@!)1XFZ,/4_>#EA,7&WT,M)KE</M$KL/;0M^RBK(`UMS_Y"'``9VG[
M#"S'V%P=]M>E6"B;IV/48ZOU-:N4YE7:#?.-FEY2/40F@LD@WVU0]>KJRA'!
M7C6-@I2KSEQ(*J)FSTCY))0O:;'Z'-.:T@E<^42/,CV2R`X4&1SL.<@AO.*=
M*UP7MS"V.(QL$<<D,9&-3O&LQY@6EVRAKT+%&O*+8%:82D^TK&N8NA4K6FX+
MS/5N*C92-5>RM9WQ;M<)OT93S@9C7XKMPY)*17406*DFX>+'[792[&PZ=!(Y
MK#)(9WR,:"2#@8VNV4J3C0#H`6H:I<1-=((HQ;LBD<0`14ME<RM:T`PS$TY7
M'F6SME;-OLK5=C:ELC/7\%;W6D]P71\Y,=Y/14I3H:.A(I%JVKZ4PT.TE7@6
MLWE_63>I1R)6BIB+ED2)M^>WMX6R07,9>Z+?,:.0AQ).VFS##`5Q&&7'IN;J
MX?%<VD@C;,8)''E!:`!LKM[6/:-!0XYJ"ZV>KVZUZ"X]HT5S1WUG@6%`M#;7
MFR%U6U*VW'L-9R<9+4.;<MV4JZ9F(RFAF&+@C)\5K*1+995!1!-7I&.2*.]O
M3,'B-Q<,S?>82\$.&SFRD5%0X@&M%.6*:6PT\0%AE:&.R/\`=D`806G`\AS`
MT-'-!(I58+KGD-;9.2L?F*M4?76L:?I;4-L0I5M*_8S%<M5]V1O;6TO!)3M<
M7EHJ0BXNRZN*6/2CV+@LJV,@1B!3.2=-T]C$UK,\CY+ATSVYFTH0UL;P:&A!
M(?C4BAK78M%MJ$SG2;N)D=JR&-V5U00Y[Y6$5%00',PH#F%,NU54+R/VY,S]
M%9A&T\K%O(\H$+ZBUK=H3EK,RX]76"K:"E1A'TP+^L2=GB)4RR;)XJ_.@]$B
M9U#D*8I\/L+5C)CF?FI#EQ%!O6D]HTH0"-HI@LLU*[?)`W*S*#/GP=5PB<!V
M035I<#6AK0JY*\F-F1^N:[LV;JE1;4ZQ5V(V&>RUD\E?_1;7\I65)PTW9:A7
MI4EG6J;!T9%%Q8XP)`6Z:@K*1!4R',6(T^W=</MV2NWK7%M#1M7`TH'$4S'D
M::5V9E(ZG<MMH[E\3!"YH?F;5^5A;6KF@YLHV%[:TVEE%(;64@JM:MTQ2"I7
M$#&;`B7L$=`W5JR+:-;46SS,8D7M*`"B\[*N9=0W4O;-+]>P'V'4X;AH$=HX
MCMEAKTT>X`]0#?\`I5C:N)EO6`UC$@(Z,S&N(ZR7?]2W%G*NQ,(F$3")A$PB
M811-:_OTS?\`*;5O\8+AEF?P=G\2?\#54C\=?_"-_P!1REEE8K9,(F$3")A%
M$V"_?IVI_*;H+_&#DIEF_P#![;^)D_P1*IC_`!VZ_A(O]292RRL5LF$3")A$
MPB81,(F$6KMW3TG5]/[-L$*[/'2T31[*[CI9,A3^8W9(IR5&?4(<2IBW@3F\
ML5[1B$[M`W:,4.I@Z+1C9+JW8\5:7BHY\=GV[%RWTCHK.ZD8:/#'4/-AM^S;
M]BAY9->1LYS"N]/;:ZH=LK"/%SCBSDFUND7#%6N0:^X-YP$S/5HY*]..'-H9
MU&+*""PNX]<5&#4OE/ZI13M8YW,TN&4SO;)]3+3*-IR1D`XC#,<<#M."IY+=
MK]8GA%O&^+Z6&N8TH-Y*"6X'M!HPQ!P&*R9YRBOS!TE,^9->2E2=;>W1J>.:
MMYEU$.9#^[W2.Q-UU>VK7>:D4:Q#1<RSUVK'O4UVHMVX/2/`>%31.B?6-.@<
M"S/()1%&\X5IFD;&6Y0*DC-48U-*4QJMIU2X:0_)&83-)&,:5R1/D:[,3E`.
M2AJ*"M:T%%07:ZW>ZH:BFK77(V/K;7?VAY:F39HN7K;R84FJE(R\\*D+8UW$
MA%H0CF2.R!R<4P7_`&@=DH%.&9BAAA-RR*0F0PR!PJ#2C@!B,#6E:<BC///.
M+-\L8$8N(BTT(K5I)P.(I6E>552?*:_J-K(HTA:!,BQMW$1M"R$>I;6L`\K'
M*+9<=KA7R&2D&J;BT!5W3DSIE.-V[1C,-3D5(T1[/84QZ="#&"]XJV>H[-:P
ML+M@V5V%IJ6G"I61JEP1(0R-U'V]",U"V=X9@3[V7:'``.&-`KB7>MKN"=PU
M%*%I#"[-V?(=D]GUHF7/5IR"U,^I\.<(RINK$1^62G(_8;8[E(9=V2/!JJ<W
M?$62*&/HXHC%=-SF&L6%14%^8XNI2@+33LBM>2A4OKI9A-:.R"<"8$T.4B,M
M&#:UJ0\5[1I0[:A99KRV2]6XN\:DJ\ZK;.?L^L=6UR%5L;:;F"><#:F&=3\U
MU&M@E.W60*G!&,JP;.F)D6!7+TZY4FBA3ZIXFR:CJ!>'%C9'DTH,,],7'!HQ
MVD'&@I4K=;ROBTO31&6B1T3`*U..[K@T8N.&P$85=6@6J#\N-DR&O6>QHFJT
M>/CDN)^EN44C%2*T]*/71-B*3"E@HK)TV<1*#$S-G#J>1RBA'`%4$O>,SE,(
MDZ?3+=LY@=(\N^IDA!%![M*.Y:[<1A[5R>KW+K<7+(F!OTD<Y!J3VZU:-E-F
M#L>D+(++>G6R=M<8)]JI`MJ_7.8.\-;)0XLG*MP;3.ON/'*ZH2K^4DC21&K!
MC,/(%5VW8E9"=6.<,'0N.BG=A".$6]MJ+#4O=:QOK^C1TL+@`*8TK0FNT.%%
MLEG-S=Z7(,HC;>2LI3M59#.TDFN`-*@4V%IKC183S%H,4PN(3K@%8^$Y"ZXL
M&BI.4CVY%7T!NFMMY+8W'.WQK?J!'$P[G(Z4A@(8!-(/G,4T,(DZ$'=I4SG1
M9!B^"02`'EC-&RM/10AW0`XK1K%NQLV\.#+B,Q$C:)!5\+ATU#F])+`N6H+0
M5[5*??*]%TRO7\RMDUU-$GHB2=N(CD1<%K#>.0$&RIM7[$_=UZM.TEBP9,VS
MID9E"IOE1=BW9*$-BZCI)+"]SW08.%"!6)M&Q',<&U#B22#5U!2I2SES10SQ
MM8VXQ8:@X3.JZ4!K<792T``$4;F-:-5DB.04BXN-'W4RJT:VLN]>+G#<K6+<
M/.U"5^:W)L/8BC-*3E51C%7C"+>3PMFP'.V,]=G10`R)E^T6;K%HBFM#(=W#
M<SX\I$;6[!CB:5.V@J<:*#-0<9H+UL0$L]K;X<@,CWTJ<,!6@V5-!A52+8[=
MM;V]US6&U:Q7X*,NS>1J1G<6WD[;5+79RP%IE)FJM[A%/E&M.LZ4+#E<J04T
MQ3!9F=8S62=*I"B/";6,0R7%M(XN91V-&N`J`'93[PJ:9FG;2K0#56+;N5T\
M=K=1-:U]6X5<USJ.);F![+J"N5PQ%:.)%%M_2$S+6'3NL)J==*2$Q(T6LN)"
M55.)SS;D8EJ4\_VA,?\`5G^SY84.TH`%7``.?_6'EO&M9=7#&"C0\T'-CL^S
M9]B[+%[Y+.U?(:O,;:GGPV_;M^U;2SF74F$3")A$PB81,(F$43N<_P"Z;NK^
MK;'^T<+EEH_XE:?K?\BJG7/PF]_5'YPI8Y6JV3")A$PB81,(F$7_UO:-P/\`
MW,N,/_12@_[!:99ZS^+:A_G._.JG0?P;3/\`(9^92RRL5LF$3")A$PB81,(L
M%D]:TB<4L06&MP]DCK5(0TS-05CBXV=@G,]!,6\6QG_-DHT=(EE@C(]DW%3[
M2E(Q0$A2'`YC[FW$S-WDD+7-!`()!H36E1R5)/VE:'6T#]YO(VN:\@D$`BH%
M`:'EH`/L"N84FF!7)"GA4:P%1EFKQC*58("*"N23*01%N_9R$)Y)YL>-7S<1
M36342,14@]DP"'V9'?2[QLN]=O0<#4U%-E#M4MQ#NW0[ENY(H6T%"#MJ-AJK
M0MJG5SEE&1SC6U!<1\*R91D.P6IU=591,;&RS.?CH^,:GCC(,&3"=CV[U!)(
MI$TG:":Q0!0A3!,7-R"YPN'YB:DYCB2*$G':02/9@H&TM2UK3;1Y6@`#**``
MU`&&`!`(Z1572,HE(A&"<7#4VJQ$8C.JVA*.C*]$,&"5F7=G?KV)-FU9I-R3
MJSY0RQW8%!P94PG$_:$1R+IIGNS/E<79:5))-.;V=&Q3;!`QH8R%@;FS4``&
M;;7VUQKM72^U[0)1LQ9R='I\BTC)68G8UJ^K,*[;1\Y859)>?F6*#ADHDTE9
MQ:9>'>.$P*LY,[6%0QA5/VC9YVEQ;,\$@`T)Q`I0'H%!0<E`L.M[=P:'0,(!
M)%6C`FM2,-IJ:GEJ:[5PBM<:\@6KEE!T.F0S-["(UIXTBJO!QS5W7&R*C=O`
M.4&;%%)>$0;K'(1J<!0(0PE`H`(AAUQ.\@OF>2#7$DX\_MZ49;6\8+60,:TM
MRFC0,.;9LZ-BLK+3NMHJ3H4E"4^N5\FL6\TWHD97H""@HRM$L#%:,E2Q2,7&
MM5V35VP=*IJ-$E2,E3'!51$ZR2*B4S=7#FS-?*YV\IF)))-,16IY^7;R5H2H
M-L[9CH',A:W=5R@``-J*&E!AAR;.6E0",CE:)2)R7;V&;IM5F)]HV*S:3DK7
MHB0EVK,BJBY&C>2=LUGJ+8BRIC@F4X%`QA'IU$<UMFF8TL9*X,/("0.I;'P0
M2/$CX6&0"E2`3U[5R<4>ENW#QV[J%7=.Y"6BY]^Z<0$2LX?3L(0J4+-/%E&A
ME',M$)D`K5R<3+-R@`)F*`8$TP``E<``0,3L.T>P\HY4,$)))A:22"<!B1L/
MM'(>16O^ZS6/?,7']W%#\HBVD_'QB_HA7^^CF%K,8]H9,5?-W;:-+(<XB_33
M$I'@B(K`?KDOJ;BCA]0^A()[1Q(V5QY.3FY%'Z6UJT_31U`('9&`=[P&'+R\
M_*J%?3&GG,+7JVYU/K5Q7:BF^2JD`O1*NK"UA*30.UDDZ]%J11F,*G(-5#)K
M@V32!5,PE/U`1#)"[N@^207,F\=3,<QJ:;*FN-.2JB;*S+(XS:1;ME<HRMHV
MNV@I05Y:+(I"D4N6B8F!E:A5Y*"@5&RT'"R$!$O(F%69,G$:S5B8YPT49QRC
M2.=JH)&1(04T53D+T*80'6V:5KG/;*X/=M()J>7$\N.*V.@A>QD;X6F-NP$`
M@4%,!R88>Q6N5U9K&>536G-<4.961KR=125E:A7Y%5*II*]^E6$U'D<L<E>3
M7'ME9`(-@/\`:!.N2;<W#!1D[P,V;!Q':Y]NWIVJ+[6UD(+[:-QRY<6@]G^S
MLV=&Q<4-4ZN:NV#]KK:@MGT7/N+7&/4*=747<=:7;8C)U96#A..*LTGW+-,J
M2CQ,2N#I%`HG$H=,R;FY(<TW#\I;0]HXCF..SHV+`M+4%KA;1AP=F!RC!VS,
M,-O3M70VU!J5E'!$,]7:Z:1(2DE.!%MJ36D(X)J9Z^=Y@&2481L$I*]1\I<=
MGO5__K,;!NKDNS&XD+J`5S&M!L&W8.0(+.T:W(+6,,J33*VE3M-*;3RGE650
MT!'P1IE5F"IW5@FW<_+O'!B'=/9!RBV9(BLHFFD!DHV'CVK!L`AVB,VB)!$P
ME$PZWO<_(#L:*#V?^Y))Z25M9&V/.1M<ZIZ3L_(``.@!7O(*:81,(F$3")A$
MPBB:U_?IF_Y3:M_C!<,LS^#L_B3_`(&JI'XZ_P#A&_ZCE++*Q6R81,(F$3"*
M)L%^_3M3^4W07^,')3+-_P"#VW\3)_@B53'^.W7\)%_J3*665BMDPB81,(F$
M3")A$PBMLS$1M@B)6!F6B;^'FXU]$2K!83@B]C9)JJR?-%13,10$W+58Q#=D
M0'H;[!#),>YCVO8:/!!!Z1L47L;(Q\;Q5C@01S@X%86_U'K.<6(^M-#IMQFS
M1#.#?62UU.M3=@EX]DB**:,K).HD5'1#]HQC)]"H@8YNR0H#TS:VZN&"D<SV
M,K4`.(`/0*K0ZTMGG-+`Q[Z`$N:TD@<YHNJSZCHEEK4[74X&+KBDRA8SMK#6
M8B%C+)7)^SP#^MO[G6I(8U<(NXI1LBH5-^!#+?;V3]H@B4<QW,T<C),Y=2F!
M)((!!#2*XMJ-B2VD$L4D>[#<U<6@`@N!!<#3!U#M6OM=<8=5T"7>6!M2==)2
MCF/KD6@UJNN:Y2ZTT2J3J7=0DPG7(XCMNK;B#,J$4DCJ"8B9")M4VJ8JD5WS
MZC<SL$9FDR@DXN+CVJ5%3^CALZZX+GM],M;=[I!!'F(`[+`UO9K0T'Z6/O=5
M,:[%8Z<U%%@D$9JO7$<"+2!8(@QH]8:`DQJK_P`ZUADD#>+3!-I7)3^DL$PZ
M$9K_`+1("'^W-#KNZ=[US(<2<7':10\O*,#SC:NAMG:-IEM8Q@!@UNQIJT;.
M0XCF.Q5,IJG5TYW036MJ#,=Q-O+*AYTIU=D.YL<@AY*_GTO*XY;NYM\V'NUG
M0=%U4_U3&$/LR+;FX97)</&%,'$8#8-NSH67VEJ^F>VC/:S8M!Q.T[-IY]JN
M;BAT9W#0===4RJ.:_6%F+BM03BNQ"T-7EXQJLQC5X.,49F91*T>R<J(H&;D3
M,DDH8A1`IA`<":8/?()79W;34U-=M3RUZ5,P0%C(S"PQMIE%!04P%!L%!LHK
M8SU3JZ/C3PS#6U!8PZL.G75(IG3JZVC5*^D_5E$H([%&.(U/#I2:YW)6HE[@
MJYS*`7MB(Y(W-RYV=UP\NK6N8UK2E=NVF%>90%I:M;D;;1AF6E,HI2M:4ILK
MC395<B:LU@G8QN*>N*&2W#(-)8;42H5XMC&481CF$8R0S@1P28R#*&>+-$EN
M][Q-JJ=(H@F8Q1Q]3<;O=?4/W5*4S&E":D4K2E<?;BL_2VN\WWTT>^K7-E%:
M@4!K2M0#2O-@LND(N,EDVZ,I',9))H^8RC5*0:-WB;:3BW23Z,D6Y'":A47T
M<]0(L@L4`415(4Y!`P`.:FN<VI:X@D$8<QP(^WE6US6O`#V@@$'''$8@^T'8
MK+(4>ERS5!C*5"KR3)K.KVAJSD(")>-6UF=*/5G-B0;N&BB*,ZX6DG)E'90!
MP<SA01.(G-UFV:9I+FRN!RTP)V<WLP&&S!0=!"\!KX6EH=FQ`/:QQ]N)QVXE
M6$-/:C+".:T75NN0KCV#+6'D`%(K(0CNMD?*RA*\YB@C/(5X,DFN=P#0Z8MP
M7.93L=L1')_576<2?4R;P&M<QK796M=M,*[5K^CM,AB^ECW9;E(RMI2M:4I2
ME<:;*JX&UQ2$S@ZC*O7X&80AQ@XNQ04#"Q]@@F!(QQ#LTX23)'F6CPC8YT=)
MN0O5)),PD`G8$2CC?S;'2.<RM2"2036N(KC4[5+Z:#:V)K7TH"``0*4P-,*#
M8LFB8J.@HN-A(AFA'Q,/'LXJ+8-B]ALQCH]NFT9,VY/M["#9LB4A`_\``I0S
M6YSGN<]QJXFI/25M8QL;&L8*,```Y@-BN&14DPB81,(F$3")A$PBB=SG_=-W
M5_5MC_:.%RRT?\2M/UO^153KGX3>_JC\X4L<K5;)A$PB81,(F$3"+__7]@_$
M;8E6U91X3BELR>C*5MK1S,U*:PMI?,H0VP:%%O7C6A[(H:[U5LWM<#/UI%OY
M69IVEHZ237;.4TCE(*ESJ<$ES,_4K=A?;3'-4`G*XCM-=_9(-:5VBA%50Z1<
M16L#-*N9`R[@&6CB!G8"<KVU]X%M*TV.J"`IF^F50]:JW^>1GXK*K=2]T[J*
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MGD9^*QNI>Z=U%-]#WK>L)Z95#UJK?YY&?BL;J7NG=13?0]ZWK"HY#8=`B63F
M3E;Q3XR.9(F</)"0LT*R9-$"?:==RZ<O4T$$2!^DQS``?Z<RV"=Q#6PO+CR`
M%1=<6[&ESYV!HVDN`'YU%C1EB2WAR#V?R%J9%%=01VNZIH_7EJ.V<(-MFR<%
M:;1;KS<:V=R5$7U(C7TRSC(]^D0S>1<H/#HJ'2(0PV5Y&;.QM[&7_=&0R.']
M@$!K6GF<:$D;0"*XJKL9!?:A=:A%_LQ&V)CO[9#G.<X<[02&@["0:8*:^5"N
MDPB81,(F$4(-N6QCQ^Y,U_>5Y!2.TYLS5$/I2XWP2">$UG;JA=[!:]?2=W7[
M`^8ZA;";`EF!I0X@T9OD6Y71DTUB*%M[6(WVGOLX<;J.4R-;RO:YH#@WG<W*
M#3:16FQ4EW*W3]3COI\+.6(1N=R,<UQ<PNYFNSN&;8#2M*U4LF=^HL@U0?,+
MK4GS)TF59L\9V.'<M7")PZD50<(O#I+)F#]!BB(#E:8)FDAT+@1T%6HN('`.
M;,PM/2/_`%53Z95#UJK?YY&?BLQNI>Z=U%2WT/>MZPGIE4/6JM_GD9^*QNI>
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MJM_GD9^*QNI>Z=U%-]#WK>L*%W*38]6W`S8\3M7S<;=]C[.GZFG<V]8?(33/
M5^JX.W04Y?KA?7L8HNWKJ;F!CE8Z,;.%4'4A)/42H%$"J&+;:=!):EVI7#"R
M"-KLM<,[RTAK6UVXFI(J``:JEU2YBO`W2;5X?<RN;FRFN1@<"]SR-F`HT&A)
M(HIZY2J^3")A$PB81,(F$7__T/1E_GF_\@Z1_6PG_P![7/7_`/A_^]F_57A_
M_.?]A!^NO*EGTA?*TPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$6R-/_\`-"B_UDCO_P`P9HNO]O-^J5T6?^Z@_6"_H#TW
M_="J_P!6X/\`V8USXG+^]E_6/YU^@(?W,7ZH_,LDS6MB81,(F$3"+"=E_P#+
MF_\`]2;5_L)_FZW_`'\/ZX_.%HN?]M<?J._,5_/NOG^^=H__`+<A_P#L'S[;
M#^ZC_5"_/\_[Z7]8K$\V+4F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB]<7^2A^[-/_UL;_[(0SYE_P"6_B#/U?\`FOK?
;_A7X9)^O_P`E^R.>57L4PB81,(F$3")A%__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g685450g61u08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g685450g61u08.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``@&!@<&!0@'!P<*"0@*#18.#0P,#1L3%!`6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`"\`X`,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/>+R\M["TDNKF58H8U+,S'%)M)78)7."AU3Q)XYD9=-)TC2
ME.&GZN_T/K],?6N=2G5VT1K91W+D?PPTMSNO;^^NI/5I`!_+/ZT_81ZL7M'T
M!_ACIT1WZ?J5]:2=BK@C/Y`_K1[!+9A[1]2FVM^(/!-S';:UG4]-=AMO!G<@
MZ<GU[X/YTN>=)VEJAV4MCO[>XANH$GMY4EB<95T.01]:Z$T]C+8EI@%`!0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`>>^(8G\8>-(-"BD(L
M-/'F73+T+'M]>@]LMZ5S37M)\O1&D?=C<]`CC2&)8HD5(T`5548``["NG8S'
M4`%`$5S;17=K+;3J'BE0HZGN",&DU=6#8X3PIYGA3Q1<^%[AR]O<?O[25N,\
M=/R!_%?>N>G^[ER,TE[RN>@5TF84`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!
M0`4`%`!0`4`%`!0!P'PN9KJWUC4)/];<7.6/O@G_`-F-<U#6[-*FED=_729A
M0`4`%`'GGQ`_T?Q1X7NT.'\_'X!T/]37-6TE%FD-F=QJ=T]CI-Y=QA2\$+R*
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MC03%$+:*`2A\'>3A??'?TI*;]IRAR^[<Z2M23D]?\2:IX<U6![FTBGT:4X,T
M:,'AY_B.2#Z]!FL9SE!Z[%J*:#7_`!B;2XM+#0X8]1O[K!7:VY$4]"<?YQS1
M.I9I1U8*/5G1%;_[!M$MN+W`^?RV\O/?Y=V?UK76Q.ARFM>(]>T;6M+TUCI\
MIOW"!Q"XV98+TW\]:QE.49)=RU%-7.HLDU-7;[=/:R)CY1#$R'/OEC6JYNI#
MMT,/7?$MYI?BS2-*ABA:"\($C.I+#+8XP<?I6<YN,U%%**:;-G6M7MM"TJ:_
MNCA(QPO=V[*/K6DI**NR4KNQE:/>^)-8LDO72QTZ*4;HXY(GE<CL3AEQ41<Y
M*^PVDM#8T\:DJR#4GM7;/R&W1E&/<$GFK7-U$[=#F]2\5WL7BMM%C^R:?$J;
MOM5Z#A^!]T9`/7U[&LI5&I\NQ2BK7-.&37'DC-MJ6E7L.X>8?*9&4>V'8&K7
M-T:%H<_\.HQI>H:[HLAQ+;SAE!X++R,_3@?F*RH^ZW$J>MF=]729A0`4`%`'
MGOC56U'QOX;TV(;FC?S6`[*6!)_)#7-5UG%&D=(MG9ZW$\^@ZC#$A>1[:154
M#))*G`K>7PM$+<Y/0/"J:GX!ATS5K62WG1W*,RX>,EB01_GFL84[T^61;E:5
MT9VD:7XCC\?:8VK0/-%8QO"+L*2KIL?:2?7YL5,8S51<W0;:Y=#KO%OAT>)=
M%-F)?*FC?S8FQD;@",'V.:VJ0YXV(B^5F99>)]7L(5M=7\,Z@TT:A1)91>:C
MX[]>/SJ%4DM)1&XI[,WM'U.XU-)7FTNYL50@)]HP"X^@Z5I&3ETL2U8YK4M)
MU+0?%TGB/2K,WT-RFRY@4@.O3)7U^Z#64HRA/GCJ6FFK,MW/BZ[FMFBL?#.L
M-<N"JB>V\M%/NV:IU&UI%B4>[)?`WAJX\-:3)'=R*UQ.X=E3D)Q@#/>BE3<%
MJ$Y79D7@U#2OB1=:LFD7EW:O;K&#!'GG"_X5#O&IS6&K.-CH],\07&H7JV[Z
M'J%HI!/FSQA5&/QK6,VW:Q+5NIJWD*SV4\+('62-E*D=<CI5O5$HXOX9Z/=:
M787SWMD]M<22``R)ABH'\LYK"A%Q3NC2;OL=W709G#^+],OKSQAX;N+:UEEA
M@F4RNBDA!YBGD]N!7/4BW.+1I%I)G<5T&9P_B?3+ZZ\=Z!=P6LLEO"5\R15R
MJ?/GD]JYYQ;FFC2+2BS=\5>'U\2:(]D9?*D5A)$V,@,`0,^W)K2I#GC8F+Y7
M<Q]/\2:QI5M'9:OX;OWDA0(LME'YJN`,9X/'YU$9RBK20W%/9G0:/JEQJBS/
M-I=S8HA&S[0`&?UX[8_K6D9.72Q+5C%UC6G%U-9ZCX1O+RS5ODDCB6<,/7'\
M/YY^E1*6MG'0I+LSD;W0GU;5+23PUX?O])9&S)/<`Q*.>H!)Z>Q_"L7#F:Y%
M8M.RU9T'C2QOM*UBT\5Z9&9&MQLN8U'WD]3[8R#Z<&M*J<6IQ)BTURLZS2-9
MLM;L$N[&8.A'S+GYD/HP[&MHR4E=$--%^J$%`&7KNNV6@:=)=74J!@I\N//S
M2-V`%1.:@KL:39SG@;3+RZNKSQ-JT12\O#MB1AC9'QT!Y'0`>P]ZSI1;;G+<
MN;MHCK[Z[BT^PN;V;/E6\32OM&3A1DX_*MS,RM*\5Z?JU^ME$LT5RT7G*D@4
MY7.,Y4D#Z$YH`U[RZCL;*XNY<^5!&TC;1DX`R<?E0`ZWF2YMHIX\[)$#KGT(
MS0!GWVNPV5^+".UNKNZ\KS3';H#L0D@$DD`9(/?L:`'Z1K=EK=O-+9N^8)3#
M-'(A1XW'52#WH`AUWQ!%H$`GN+*[F@RH,D*J0I9@H!RP/)(_.@#0M+AKJV65
M[:6V)S^[FQN'UP2/UH`S-4\36NE:BE@]O/-.T0EQ&4``)('WF'<'I0!LJ=R`
ME2I(S@]10!E7>O0V]])906MU>W,2J\J6R`^6#G&XD@9..G6@#41B\:L5*$@'
M:W4>QH`SKW7K#3M6M--NI?*FNHWDC9B`F%QG))Z\T`.TG6[/6UO&LG+K:7#6
MSL<8+*`3@CJ/F'-`&C0`4`9^F:Q:ZM)?);;\V-RUM+N&/G4`G'MS0!'KVOV7
MAVRBN[X2F*6985\I-QW-TX_"@">SU:RU"X>*SG2<)$DOF1L&0JQ8#!'7[AH`
MCU;6K+18H6NW;S)Y!%#%&I9Y7/15`_\`U4`36%Z][&[/97-H5.-LX4$^XP30
M!;H`0@$$$9'I0!Q%[X#FL;]M2\,7YL+CJ8&YC;V]A[$$?2N=T;.\'8T4^C,N
M]^(/B#0YA;ZOH]L)?]B3&?R)J76G'22&H)[#K'QUXD\0.T&CZ3:A^A9Y,[??
MDC^M"JSGI%`X);FKIG@)GU!-4\0Z@^HWJD$)_P`LU(_F`>W`]JN-'6\W<3GI
M9':UN9D5S;Q7=K-;3H'AF0QNI_B4C!'Y4`4+?P]IEK?17J0.]S"I2*2:9Y3&
MIZA=Q.W\*`-"X@BNK:6WF3?%*A1U/<$8(H`6*)((4BC7;&BA5'H!TH`HW^AV
M&I7"7,Z2K<(NQ98)Y(7VYSC<A!(SVH`ETW2K'1[8V]A;)!&SEV"\EF/5B3R3
M[F@"2^L;;4K1K6[B$L+,K%22.58,.GH0#0!8H`H76CV=Y=BZD$RSA!'OAN)(
MB5!)P=K#/)-`%U$$<:HI)"@`;F)/XD\F@#/O-"L+ZZ^U2I*EQM"&2"XDA9E'
M0$HPR.3U]:`-".-8HTC7.U`%&22<#W/6@"O)IUI+J,%_)"#=6Z,D<F3E0V,C
M]!0`6>G6FGFY-K"(C<S&>7!)W.0`6Y^@H`M4`%`%6RTVTT]KEK6`1-<S&>8@
MGYW.,GGZ"@`OM-L]22%;R`2K!*L\8)(VNOW3QZ4`,M-)L+"[N[NTM8X9[PAI
MV08WD9P2.F>3^=`"ZCI5CJUNL%];),BL'3/!1AT92.5/N.:`'6.G0:=&R0-.
GP8Y)GN))C^;DF@!NH:79ZJD"7L/FK;S+/&-Q7:Z_=/!YQZ=*`/_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g685450g72m57.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g685450g72m57.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0D*4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````.P```1@````&`&<`-P`R
M`&T`-0`W`````0`````````````````````````!``````````````$8````
M.P`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````!FT````!````<````!@`
M``%0```?@```!E$`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``8`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#N+;LWK6??AXE[\/IN$_TLK)JCU;[8#G8V+;[OL]>-]#*O_GO5_04^
MCZ7JJ7_,[ZO@[Q18+9GUQ??ZL_O>OZWJ_P#34_JE)^K^*7?SA-INGGU3;:<C
M=_*]?U%L)H`(!(N]=4DD:!P\>_.Z/U"CI^=>[,P,TEF'EVP+:K6C<W#R[-&Y
M'VAN_P"RY'\[O9Z-OJV>G8MQ8OUPD=#>6?SHR,4U$<[_`+3C[-G\I0ZOF]8J
MZUCX_32VQHQK<FS$>`!=Z=E%3JF7GW4W>G>]U'^"]7^>_1_I$KJQY?BJK=U)
M<[A]<ZAD]*ZSGXE;LNW&NL&#COK-;X;319]GLJAEV^O(?=O9_/?X-7.EY>/>
M^HCK'VRUS)=C_H628EWZNVH9=.S_`$5EOJ5?X9+B&GBJG627.U=3LMLS1U#J
M7[+MHR+*Z<8BE@])A_5[_P!;KMMR/M#/TOJ4O]+_``'\Y4H_MOJ8Z/T7-S`,
M*[+R:V9K7,V`,<VXNW-OW/HW^G6_W?02XPKA+TB2H9C\C-PS;T7,J%];I8[V
MVTO+?I8^1MW/96_]^A[+JOYS])_,V5>A9F?U?&=U2RS[-BY;(PL9@:7UM'M=
MD7VO:[?DOLW;:_Z/75Z?\[8C>M*IV4EB]*MSKNJ]2HNS+;*L"ZNNIA;4-S7T
M57N]5S*6.=^DM=_-^FH,ZIU,#ZP.I8<N[`LC"Q]H$_J]-[:O8&OLW7/=_P`(
MEQ?R\E4[J2R.E9=%[J7?M?[7<]DNQ@*6`N+9?^K>E]LI]/\`T-EWJU?X99F5
MUC*Q<R]V1G"^IEQ%5'3WT.M#)#6X]F!?39D67M_PWI9-C_\`"55T_P`T@9BK
M5PE__]#M[/M?0<W(R&4ORND9EAOM92"^S&M=`NL9CL#K<C'RK/T]OH_I*+O6
MM]/])[#_`/.OZO>GZGVUA_X,!QM^'V;;]HW?]:7S8DF>K]&J_K+M.OX/T;2W
M+ZYGT9E]+\7I6$_U<:FYNVS(MC;7DW4/_28U.*[<[&JL_2VV_K'Z/TJEH95W
M5*\JEN-C5W8KBT76.LV/;N=M>YC-I:_TF?I?Y:^8DDZ/X]4%^I=U_P!I+-@^
MS[)%D^[?/T-G[NS\Y5F7]5.:VMV,P8I=8'6[]6M:&^@]K?\`"NN=].O;5Z/^
MDL_PGS&DBA^HV.R_MEK7M8,4,8:GCZ9>39ZK'-_=K:RKW?X3UO\`@DV-9FNN
MO&34RNIKHQW-=N+F?OV:#8[^0OEU))3]1XUF6]UGVBL5@.<*PT[@6ASA6_?N
M^E97L>YGI,]+^;_2_P`X@MOZL<_TW8M0PM[AZ_J^_8*ZWUO]#9^?D.NJ_G?\
M&OF)))3]5*B;NK?LQ]K<:H=1AVS'-GZ.=Q;7NN#?H^GML?[%\QI)*?IUV1U3
M]GNN;B,^W`D#&-HVD!^S>+]GYU/Z>MNRO_16>BK&^QM/J&LV6@?0:&M<=>V^
MS9_X*OEI))3_`/_9`#A"24T$(0``````50````$!````#P!!`&0`;P!B`&4`
M(`!0`&@`;P!T`&\`<P!H`&\`<````!,`00!D`&\`8@!E`"``4`!H`&\`=`!O
M`',`:`!O`'``(``V`"X`,`````$`.$))300&```````'``@``0`!`0#_[@`.
M061O8F4`9$`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#`0$!`0$!`0$!
M`0$"`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P/_P``1"``[`1@#`1$``A$!`Q$!_]T`!``C_\0`L@`!``(#
M`0`#`0````````````D*!@<(!0(#!`$!`0`"`P$!`0`````````````%!@$"
M!P0#"!````8"`00!`P0`!`4%`````0(#!`4&!P@`$1(3"14A%!<Q(A8803(C
M"E%A0B0G,T,E)AD1``$"!`0"!0@%"08'``````$``A$#!`4A,1(&05%A<8$B
M$Y&AL3)"<A0'P5*"(Q7PT6*2HC-#)#3A\;+"@R728W.S1#46_]H`#`,!``(1
M`Q$`/P"_QPBB0WS]LN+-2Y%]BG'<03,NPYO"S_A[!PJ6L4Q^_3(+`MTDV`*O
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MOF=U/!`91-#?>_L'H6.O_4)O?K81:P:=;GRDJHPZNDJ<YD[/B<\JD@`E;17Q
MA)^Y4&Q*IIE3*4LJ+)F82]P^/M*7GR=L7<EIC-L.X"XCV8NEQZ(:GL=]J`ZE
MN+[;:ON5]O`CQP=#IR#AV1*RW!7M\S=@3(K?`/LNQ9*TF;242:)Y7CZX,2]0
M1\@,DIJR5J**O7[96W;I)8WS=9.#8"DZ)-'`=RA?O;=]7&V58MF[J)TN9EX@
M;`\HN:.ZYIQ[\O#DTYKYU-BIZF4:JT3@YOU8Q[`3B#T.\H5AVN6.`M\!#6JJ
MS,;8JU8HUG,P4[#/$)"*EXJ00(Y8R$>^;'4;NFCINH4Y#D,)3%'G4I4V5/E2
MYTF8'R7@%K@8@@X@@C,%59['2W.8]I#P8$',%>USZ+5.$3A$X1.$3A$X1.$3
MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1?_T+17MHWRDM1\
M41%"Q8\$-@,R@\CJ>JU03?.J966YTV<Q<RM#)N"J2ZKIRFRATE$Q*JZ,JL'?
M]H=,]'WON5]CHI=-1._W2HB&\2QN1?#G'!O,Q/LP4Y9+:*Z>Z;.'\K+SZ3P'
M5Q/1UK$_63ZR837J$CL_9^C@N>TES`]D<.+(<TR;%AIDRCU9DR6>J.!?9!?"
MX%27EU!.NFN<[9L<"`NN[^.T-H2[7+9<[FSQ+S,[W>Q\..,!'-Y]IV<<!A$N
MWO%X=5.-+2G31-PPPU0_R\AVGHF:Y?E`)PB<(N;=H=4<,[=XW?8XS!6D9)`4
MUUJW:&1$&UNI$PHF!4INK3)DE%F+DAR$%9`P':/$R^-PDJF(EY$WFR6^^TCJ
M2ODQ'LN'K,/-IX=(R.1!"]='6U%#.$V0^',<".1'Y$<%`SHYF7+7K4VW>>OS
M96;-(X>O<LB?$%O>**I0D+(V5\Z+5;-7EWBHA'T[(#XJC&48]QTHV?*)P.GV
M/E''-=N5]=M&^.VO=YD:":[[IQR!<3I<V.3'G!PR:_'#O$V6XT\B[T(NE(V$
M]H[PXF&8/2W,'BWLA9XYV!4].$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A$X1.$3A$X1.$3A$X1.$3A$X1?_]&8/7:+_OO[D<Q9AMR9)O&>KKR22I;!
MV7[R(!3'\V>DXR2:IJ?N;D?60LC;DP'J!7R1^H=#=H<?M3/_`*;?M?7SQJHZ
M,G0,QW#HE^5VJ;UA7"J=^&6&1(9A.G#'GWA%WF@WJ5G7G8%3TX1.$3A$X10A
M^]/71ADG5QEG6)8@6]:_3\?(&DFP`F]<T"VR<?`V"/,9,@+.`C9M>.D4C&-T
M:I-W)B`'E.(\[^8]J;5V9MR8W^9I7`QXZ'$-<.PZ7=`!YJQ;;JS*K#3./W<T
M?M#$>:(Z<%W]H1G1SL?J%@O+4H[%]8YJFHPUO=*'[G#FY4U\\IUI?N2"8RB2
MDM-02SPI3?44G!#!U*8!&S[:N1NUBMM<]T9KI<'>^PEKCVD$]147<Z84E=4R
M&CN!T1U'$>0&"Z^Y.KPIPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G
M")PB<(G")PB<(G"+SI&8B8<B:DM*1T6FL82(J2+ULR(J<H=QB)F<JI%.8I?J
M(!U$`YH^8R6`9CPT=)@LAKG>J"5^MNX;NT$G31=%TV73*J@X;JD6062.'4BB
M2R9C)J)F`>H"`B`AS8$.`<TQ!6""#`C%?__2FZ_V[S-NXIVU=J7=(N9^:NN.
M&<GW`07P-V,7<9%LZ<'!03^%\]G778'C(7O2/T$WU`G*/E8T&GO4XNC-=,E@
M\\`XQ[22K9NDD3*)@'=#7>D?F5C[G5U4TX1.$3A$X1<K;T1[.3TLVU;/D"N4
M$];\U2!$SB8`*\B<=6*5CEP$ABCW-9!DDJ7_``$Q`Z@(=0Y"[C:U^W[X'"(^
M$FGM#'$>0A>VVDBX4)!_C,\[@%P+Z&W[IYHNJW<*=Z45FG(+!B7M`/"U4C:G
M*'3Z@`";J]DEC]1^O[NGZ`'*S\M7.=MP@G!M0\#J@T^DE2>Y0!<@1QEM])7-
M7^X<FYF&IFKGQ$O*17W-GRG]Q\:_=L?/X8JD>+S?:JI>7Q>4W;W=>WN'I^H\
MB?FE,F2Z>S>',<V+YF1(X,Y+U[6:UTRLU-!P;Z2OIU(W%RCZ_LLQVD^[\R[D
ML4RR;)Y@'8*4!Z6,;5B9$IX$DK)2!E55*&Z\Q43'5556J[X#M5SF8E*HTQ8[
M]6;8KF;>W%,)HG0,F>8P#3ZL2?8.6)C+/=/=Q;FNH)-TD&X6YL)X]=@YC/[7
M^(8C'/S_`&4R4RR]M_KO=1=DD4H6>?ZV,SQT?(NTHYT1/9:P&<NE"-W(-':4
MHREB)&ZE$#II``B8H@`:;M?,;OC:SF33X;C($`3`_P`P[L,05FT!IL=U#F#4
M!,_[8]$%9*55202477431113.JLLJ<J:22291.HHHH<0(1,A`$1$1```.H\Z
MR2`"2<%4L\!FJR.(,KYO]QNS>2ZPKEZ_8*U`Q6R3DCTC%TR>MVJXQLE)KQ58
M9V2723`[V2LR3!R_=B[3>,8TC<&Z#853_=<Y#0UMQWY>*R2:^;36*2(Z)9TN
M>"8-#CQ+H%QC$-A`"/>5PGR*>PT<E_@-F5[SFX1`XF`Z,A"!.9/!20K^F#U]
M*1I&Z&*+0RGR"58+LURYE,;3]^505@E.KJVN:\$AYQ`_<$>!>\`$"_KUMAV!
MM<L@*)XF_7$V9JCSQ=IC]E1/X_=(Q\=NGEI;#JRCYUWUA+#E5P)C:NXMIDA;
M92`K:*J;:1O%KF+E8WBKA4R[A=[+S+A8Y046.(E;MR-V:`#VHHID_;RS6Z@D
MVRDE4=.Y[I3.+W%[CUD^@0`X`*,J)[ZF<^=,#0X\@`/(/[U`KMYL?F[;+V+U
MOUTXJRI8\+8J9RY8+(-EHCT8VUVMS#T5WDJ\B::;+-G[=I&0D>O%M6!52ME7
MB9U71'!3$2)S2^W:XWO=<G:M%6OIZ(.@]S#!SB&&8_'.``+0V,"8ET<`++0T
ME/0VI]UG21,GPBT.R$3I;ATG&/+*"[R:>F'U\EB_M9O$]GMLXHD)7ESL67<J
M'LTBY,0"FD'H0]NAZ\=X(AW#VQY$A'_HZ?3EE;L#:^C3,H7OF<7NFS-1Z3!P
M;'[*C#?[IJBV>&MY!K8><$^=1<;!7S,GIQVFQG'8\RMD/)>J>38\)YUBK)LX
MXM98J/82B,3=(2!?NR$+&2\0@NV>QKYD5JH;RI-WI'2:9S.*;=*FOV%>:-M+
M6S9UEG#49<PZH`&#PTG(C`M<(<`[4`8S-+*I[]13C-DL96L,-31".$03T'$$
M'K$.%I;G95356A]#,[-S&9-T2R\Q*RA4!I)D"R,@[?%1,I:LB`H*0.5E03$X
M$#KTZ=>@<Y'\M9LR9<-P!\QS@-&9)]IZMVY6M;(M^EH&?H:K+W.N*HJ-KV(>
MNRF;O5&/F8R21H>?*&R4)CG(Q4UQ17;)+K2*5.MA6ABNUJXYDE3*MW*0'=1+
MI4SA`JA3N&SFI;IVK3[BD,F,?X5SE#[N9Y]#H8Z8X@C%IQ$<09:U769;GEI;
MJIG'O-^D=/F.7(B/;7'VU6/6BJY+U^]A-?MT?G'`L.JE6Y<C,9"<RPBT%JUA
MJW).R&.S<V5XD[079V#R&CI:+$SM=8%4S+/*O:=[S;1)K+7NF5,%QIF]TPB9
ML(`-)R+C$$/]5S>\3$1=*55D95ODU5K<TTTTXC@WF>KFW,'#J_%J=KWGOV4Y
MA0W;W$=3=8P4U7*;"F#(^2E8R$LL(T=&7C2JLBJ-55*$DJ`*.GBQ"N;,YZB/
M8P*0A];):[GNVO&X;\YS+:#]U)!(#@#AAAW.9.,P_HX'-;54UHD&W4`!J?;?
MA$'_`(NCV>M3BY^UPQ7LO1XS'>5HV;>U>(L3"TQ[6MVJQTMRC+QD9+P[,QG]
M6DHIXLS383;@HMCG,@)A*<2=Z9#%Z+<[317>G92UK'&2UX<-+G,,0"!BT@P@
M3AEY`J[2U<ZCF&;((#R(8@'"(/&/)5E/<CJ?B33^N8%D\$#?:PZO,WD!C91D
M<EWBRD>MX)A4W$8"9)^<D`:&;J2:_44NSO`_[NO0O3D._;)0V*3;7VTS6.F.
M>'1F/=&`;#UB89G)6^P5L^O?4BITN#0V'=`SC'(*;:']2VET+)Q<LVJN1UW<
M2_92+<K[-65';59PP<).4@=M%+5]NY0442#R)F+V'*(E$.@].=#E[(V_+>QX
MDSB6D'&;,(PYC4J\Z]W!S7-+V0(^HW\RD&N9SI4^UJ)G,FHG6ITZ:A#"0Y#D
MBW1BG(8H@8IBF#J`A]0'EGJ"13SR,]#O05%R_P!XSK"KM_[=0YSTS:GO.8W6
MU8J./<83=3GBKUWG^HC^X_:'4?U'ISEGRJ_I[U[\OT/5JW5^\HO==Z0N\O;'
MO99=*<,5A'&S=@;+F8)2<@J=+2B2#QE4XFO,F#BT6TD6X(JC,2D:>;8(,VZQ
M!:@N[!98%")?;KV7>VY)VWK?)%(!\=/<6L)Q#0T#4Z'$B+0`<(F)C"!C+);6
M7"H>9Q/@2P"0.).0CP&!CQP[1IS7CU8T;,^-:3EW>J^97V8RGD*O1%VD82TY
M/N<;2Z:6R124E'P,(TK<U%2GW<(S?@BLJF](R$Y.QNW31*'?X+5LRFN%)3UV
MY*F?65LU@>0Z8\,9J$0T!I!B`8'&'(`9^BJO,RGG3)%ME,DR6DB(:(F!S,01
MCU1YE=78E]7VIF"<J0&5\00N1J%(5Y19PWJD/EO(*U+D'RB9$DWDY&RD[(2L
MT"!2!_VSAZ=BM^BR"I0`H35#LZR6VME5M!+FRGM]D37Z">9!))ZB8'B"O#/O
M%=4R72)[F.!XEK8]D!`>2/(K=6Y[#8B3UHRDPU5=M66<'$.U+4EUG31B^\!9
M1BI8$*^]D>D8SL[NO$=)1RK@R:2;HY#>1,P%4+(W]MU?:*UME<!<2T:<0#F-
M6DG`.+8AI/'B,UY[>:45<DUHC3QQ^B/1'-5@]=7?KPKB,A`^T:@;'!M%\W+!
M;K+F-SF5U%&CG$DZ)%+1C:E3C.Y'*A'F`7)W[-Z91T*BS=8Y#D(EQVU.VM*#
MY6\J6K_&=1U.FF;"$3"&@A^6>H'&)!X"XU8NKX.LTV5\'`0#-';F(>0CI"E.
MU;UO]4EHRS4K_J%G^S5RS04PE,H8MI.?;C5CVPS,QUDV<]3KJJAE":@TC$+Y
MT47*:*Z903<>1(YR'N=FM.RIU=(JK%<WLG-='PV3GMU0X.:_[PCF`0#D8@P,
M+6U=[9(F2JZE!81#46`PZB.Z#^07_].9GT[2)-=]W-U-/)TWQZ[B6D'M22>=
M$!?_`(FMD_&MPC2F!(5C3]-N*4DF`$_>S9BH`%`H]>1[#>+5N'<-AF8$N);'
MCX3G##WF/#NH15NOP^+MUOKVXB&/V@/01#K*LO\`.N*HIPB<(G")PBC=]M.8
M6.'=#LWN%7@-Y?),0AAZN-_(9(\D^R"<\;-LTS%,41%&D)2SHQ?J!TVQBB`@
M(\J>]Z]M!MJXDNA,G-\)O27X$?J:CV*6LD@S[E3B'=8=1^SEYX!>)Z=\8/L8
MZ!X<"5;BUE,@*6;)[E`4BD$&-NG79ZPX[P`IEP?TYE'.`,8.H`MVAU*4HC\]
MAT;J/;-!K$'S=4SL<3I\K0T]JVOTX3KG/TGNL@WR#'SQ7)OO6P%FO.M2UR;8
M:Q==LFN*U8LD+SZ%+@'T\M$(RD;3TXY9^DP25.W2>'8K%(8P=!%,0Y"?,>V7
M"Y2+4*"CF3BQ\S5H:3"(;",.<"O=MNIIZ9]6:B<U@(;")A&$5)%L+J#B_<C7
M6!Q=EF$=1,HVK$0]J5G*S03N.-;8,(T1^^8^0W0>U0@(R4>=3[=ZD04SB4Y$
ME4K9=+%1WZU2J*NEEKPP%KH=Z6Z`Q'H<W(C#D1$TM=.H*ITZ0Z+8F(X.$?R@
M>"K=U33/?ZF;G:C4_*>.[YDJ@:T9OQ'$5C+T+#RL[4&V((K*L!;TCIV?H9-"
MLUUHJZ<)(.P([BTU%&AQ!)!!)'D\BP;GI[_8Y%;2S9U+1U,H-F@$M$H3&N];
MZK1$P.+<6Y``6Q]PMDRWUTR3-:R;.EN):2`=1:1ES.&6!SXE7$>=W5#5<BNZ
MA;;^K_8Z]Y@U0QD39?6W(R9F=AQ=&31(W(D%!E?*2L5')M5TUG;Z5JCMPJA'
M/V2$K]TS44*Y;(J*`<G*95BOFSKM4U]DH_B[3-P=+!@\",0.9+3@UP#HB,0"
M8BUOKJ&\4DN16SO!JV9.([I.1[#Q!A`Y$KO%E[+;*^9(H)^NOV+IV=9+M"/<
MZ^%95LKT.HF1/;7]E:%29]I1Z.#LB=1Z!V?4.61N[IKF@#:MU\;EX$&Q]XN&
M'3!1IM#`3_NM)H]_'R0^E=SX-R)=\HX^86[(6&K9@FQNWCU!2AW*9K$Y*ILD
M#D%C+$>5B2?)IM7Z*G3PO$F3U%9-0ID/&"2RUCMU545E*V?54#Z::2>X\M)A
MP,6DX'D0"#'"$"8VIE2Y,TRY50V8SZP!`ZL?HB.E0Z;JZ([!TG<>K^Q#3Z*8
M9#N$7+0<S?\`#[Z3;1$M*KQE?3I<TM67KY5LQ>1-KI!3M'S4%2/FZYSK-BN1
M6\2%$W!MNZ4]^D[IL+!-GM<"^43`F#=!TDX$.9@1F#B(Q@)ZWW*EF4#[57DL
MED$-=F!C$1Z0<0<N<./4\1[+9X8@5+5Z]/8K#V9LDB5_"P&N;ZV0YWIC"1=&
M%LX3,*E*,VQ@Z_<*MFGD)T$A##^WDRS=TS1]]M:ZMG#,-D%PCT.B(CI@%XG6
MANKN72D+.9F0/:(&'G4>N5-7=J?:QLYC_(N7L-V'5S5S&C)O%,(?)"R33)UC
MA3RWRUD31JQ1+*Q]HMJB2+8RCE%K'QK)(AB*/%TS$<5:MLUZWK>*6KKJ!]'9
MI(@!,PF.$8N[N8<[`8@-:`,7$0,K)K**RT<V5(J!.K7XQ;ZH,(#'*`\I/(96
M3>=:5255OUR);*Z-9-V+GKWI)M/>([*#J':PBE$QZ9?[?^/V"UO5'#D\P[BT
M%6KU"<(*1T3GZ]H]0Z"`\XQM07?;E9=9M3MZMF,G$0T,^JYQXD9QP@KI=OA+
MC)I&RKC):61C%W,#E'DIHL;;P7[(%\JM+?:*[AT%G9)=M&.KI=J-7XFIUENN
M)A6F+!(&LHF;1K,A1,H)"G5,`=J9#G$I#=`I-Q5554R:=VVZ^4U[H%[V-#6]
M+CJR']T2J_.MTJ5*?,%RD.(&0))/0,%(%RSJ+5<+W1:O9HS=L-K?9L5X4M^2
M(B.JJD+<9JK5-Q.-&B*-U2>MXVPNVS=4I&J;-ZNH1-P/C`BJ@A]!/SE&_P"S
M7"XW2TSJ*WS)TL,@\M;$#OQ@X\H$Y]*MFWZRGIZ6K9.J&L<71`)APX*QLU:M
M6+5LR9-D&;)F@BU:-&J*;=JU:MTRHMVS9NB4B2"""1`*0A0`I2@````'.K-:
M&@-:`&@0`'!50DDDDXK[^96%`?[UL"9JSK5-<6F&\77?)KFN6')3B>0I=?D)
M]6(0DHVFIQZL@1@BL+9-XHS5!,3=`,*9NGZ#SFGS'MEPN4BTMH*.9.+'S-6A
MI="(;",.<"K-MNIIZ9]6:B<U@(;")A'-3X<Z6JRL?MC5P]JME9-$C+NG=?F6
MK9`@=3K.'$<Y212(`B`"910X`'_,>?*>TND3FM$7%I'F6S"`]A.40H+_`$4X
M$S5@JJ;'-,R8NN^,G-CL.-7$"A=*_(0"LNA&QMR3D%8\C]%$7*;-1XD"@EZ@
M45"]?U#G.?EQ;+A;9%V;7T<R27OEZ=;2V,`Z,(\HA63<E33U+Z0T\YKP`Z,#
M&&2[5]ENB"6].&8JNP4ZRJ^4\=RKZQXWF9<7/P#I>29ILYNKV(6B#MTTB)])
MJV,+M!%5=JX:(G`BB?E24L&[MMC<E`R5+F!E;*<72R?5Q$"UT(D!T!B`2"!F
M(@QUHN7X;4.>YNJ2\0<!GT$=(Y<8KE_`.X6YFMM*K&%=K=$=CL@O\?0[2IQ&
M5=;ZLWRZA:H2!9)1L"YEXN*?DBTI$[!H3SO/E4SN!'O.T15[R##6R^W^TT\F
MWWK;=7-=*:&B9(;XNH-$&Q`,(P&)U8_5!7MJJ"@JYCZBBN4IH<8ELPZ8$YPC
MCV0[5UKC;=W)>5\@U2LUS0S;JITV6E$&%HO^9JO5<2$I[-P;Q&FAK\_9G#BP
M1S`_51R1JY!YX"B*"#A42(GG*3<576U4B3*VU7,IW&#GS6ME:1STN=W@.,#&
M&0)@#X9MNDR)3WON<ATP#!K"71Z(@8>CG!=(;%9.R;B3&SJWXEP18MB+@C*1
MS-+']<M-?I[@(YPH<TE-O)B=*\6%K'-DA`B#%C(.UW*B1/$1$5G*$M=:RLH:
M1T^AMKZJ?$#0US6X<228X#D`XDPP`B1Y*23)GSA+GU(E2X>L03V0'TD#T&.Z
M6]D,=,1:4-GCUI;NHNEA,F2#/KS&Y(K;A8`2^\)'R5C?U="133,9(.]-J(&Z
MAU`H@`#5G[L9,8)=RVC<=1X>`)C>F!<6QX<%*MM):[537>GASUZ3YH^E1>Y:
MTNRMO)L?2;AK3I19]"Z!7W#92SY%R+"IXBEGC]M-)/&UN:8PC!8FCK%$)-#"
MT2AT5C.W1P5=/$R"15.G5VWZW<=VIY]HV\^V4K?6F/'A$F,0X2Q"#A##0,3B
MYPP(F)%PD6ZDF2ZNX-J9IR:TZAEEJY'C'(9!?__4FV]MF'LC:R[&XI]FF#&G
MD7@I:NPN6&J*)P02EXUI_'X63G#-?]=2M7VG'-7)!0>P&XHMR`<3NR`3D^^*
M"KL]VHMWVUN+7-$SK`T@F'LO9]V[E`<7*V6.?*K*2?:*DX$$MZLS#I:>\.WD
MIQM:-CL;;58?J^8\82:;N%GVP)2L2JLB>9J-D;)I?,U.Q-TQ[FDO$KJ``]0`
MCA`Z;A(3H+)'-T6T7:DO5!)KZ-\9;AB.+7<6NY$><0(P(*KE923:*>^GG#O#
MCP(X$=!_LS6_.2:\R<(G"+ZU54D$E%UU$T444SJK+*G*FDDDF43J***'$"$3
M(0!$1$0``#J/,$@`DG!,\!FJK6T60I?V\[T8[UAPL_>+ZWX:?OI*WWB/\@1[
M]F@Z9-\@Y&()T2)G0!$J,%6@4!0JSI<5RG*B]/XN,7FJ?OK<=)9[>XFTTY)<
M\9$1&N9Z&2^9,<G&%THY3;%;9M94`?%S!@/\+?I=Y."M)P$%$5>"A:S7V"$5
M`UV)CH*$BVH&*UC8B(9HQ\:P;%,8QBH,V3<B9`$1$"E#Z\[+*ELDRY<F4T-E
M,:``.``@!V!4USG/<Y[C%Q,2>DK$<A9>Q/B-K&OLK9/QWC%E,N%VD0\R%=:U
M2VLJZ:ID6<MHUQ9).-2?.&Z2A3'(D)C$*8!$``0YNM5ZU/O]#R$Q6E*#=JC>
M(QLJF@XD:?9(:S,4%E42.$D5G<*]>MTE56ZA3E*8P"8A@,'T'KPBR[A%CE8N
M%2NT>O+TRTURW1363DH5S)UB;C)^/;S,,Z.QEXE=[%.G;9*3BGJ1D7*!C`J@
MJ42'*4P"'"+(^$6E%]E-<VML&ANL_84;7DKT8TU,7RI14;8$B`&$6`UU2=+,
M`]`"B/B\/?T`?IPLP/);KX6%K'(>;<,8A4B4<L9<QCC!6>(\4@TLAWZJTI29
M3CC-BR"D22R2T8:1(P,]1!840."0JD[NG<7J1?''F;\+9=6E&V*,O8OR>X@T
MFJ\TACR_U2ZK0Z+XZZ;%:42K<M)'CTGAVJI4C*@0%!3,!>O:/0BV0[=M6#5R
M^?.6[)DR;K.WCQVLFV:M&K9,RSARY<+&(B@W01()SG.(%*4!$1``X1:.K&U&
ML-VGXRJTS8[`UNM$VX^TAJW6,OX^GY^6=`F=86T9#Q5A=R+]QXDC&[$DSF[2
MB/3H`\)!;YX18+?,HXSQ7&H3.3\B47'$0Y5%!M*WRW0%0C7"Q3(D,B@^L,A'
M-552G<)@)2F$0$Y0_P"H.I%^ND9"H.38,MGQO>*AD&M'=+,B6&D66%M<&9XV
M*D=PT++0+U^P,Z0(L03I@IWE`Y1$`ZAPBR_A%B$3D&@SU>EK;!W>H354@5IQ
MM.6:)LL+(UZ&<5DZZ=D0EIIF]6C8Y:O*-5"OBK*D,T,F8%0()1Z$7O0\Q$6&
M(BY^`E(Z<@9R.8S$)-P[YM)Q$Q$2;9)[&RD7),E5V<A'2#-<BR"Z)SI*I'*8
MIA*(#PB]'A$X18Y9+A4J:A&.KA::Y5&LU.1=8AG-DFXR"0EK+.+"VA:]&+2C
MIJF_G)AP`IM6B0G<.#_M3(8?IPBR/A%B=AOM%J,I6(.UW2IUB:N\F>%I<18;
M'#PLI;IE,$C'B:Q'R3QL[GY,A5R"*#0BJH`<O[?J'"+]P6FL&LZE)+8X$US2
M@4;2K40EX\;.G6'$@O$H6-2`!Q\J2!7E6RC4CP4@;F<)F3`XG*(`1>]PBTO9
M=D-=Z79CTJXYZPO4[BF=%,]2LN4J/!68BC@1*W3/`RDZUE"G7,`@0!2ZF$/I
MUX2!Y+<Q3%.4IR&*<AR@8IBB!BF*8.I3%,'4#%,`]0$/UX1?+A%__]6^M;JC
M6+]6)ZEW2!B[/4[/%NX6P5^::)/HN6BWR1D73-XU6*8BB2A#?\C%,`&*(&`!
M#Y3Y$FIDS:>HE!\AX(<TB((/`K=CWRGMF2W$/!B",P56+RCJKN!ZE<HSN>]-
M74YE76V841<W2AR"#RR+QD.T[EC1^1J[%$:.7\?$`JL+"S1Q$W#!$QRN12(9
M077'ZRRWW9%9,N=@+IUI=Z[#%T`.$QH@2!CIF-Q:(QACJM\FMH+Y);35X#*L
M9.RQ_1)Y\6G/AT2':X^[/3[,L>P8Y(F7^OUX420(]BKVDL]IZSTX@57X:_13
M56-!@F(@/DE48DX`(]"&`HFY:;3\PK#7M:VKF&EJ>(?BV/0\"$/>#5%U>WJ^
MG),IHFR^;<^UI^B*D7BMG-;9V/5EH78/",M%H($=.)&.RM1'K)NV5!0R:[AR
MWGE$4$C@B?H8X@'[#?\``>EK9>+3,:7R[I3N8!F)C"/+J44ZCJVG2ZEF`^Z[
M\RYTS%[0=&<*L'KB=V`IEPE6A52I5C%3]+)DX]>(B<IHXIJFI(0D6\`Z9BC\
MB]9)$,'0YRB(`,57[QVY;VN,RYRYCQ[,L^(2>7=B`?>("]4BSW*H(#:5S6\W
M=T>?$]@*A4R9MUNK[;YU_@?4S'<UB37UPY^-R!<9%\L@#Z+.=,RR>2+TR;A'
MQ$>X8JD.-9B!=O7I!.50[U`1*GSVLOFX-\3'6VR4CI%K)@]Y.8_YCQ@!#^&V
M).,=0RL,FAM]C:*FNFA]5[(Z?T1Q]XP`Z"IV-(-)<8:0XI3HU)($U;YX&$AD
MO(KQJ1"8N\^T16*B/C`ZPQE<AQ=K)QD>4YR-4U#G.95PLNNKTG;NWJ/;M$*:
MG[T]T#,F$8O</0T1.EO#',DDUNXW&=<9_B3,)8]5O`#\YXGZ(+L_D^H]1;>P
M_1_)FV63-/,C8[L-8C":U73)UFL,'.7.?QW+65K>ZI$5UDA6;K!XZRD$`^CG
M$<9551>(<E.F($*`"83%+(,(K&-"-!\P:L;)[,YMMMNHW\-V!AJ<16AL)^<R
M[?$[;4A!LSL4MFRQ8]Q)(F@V\4N[13@DH0[0JSOS)*-_&*2V%DF("EPYE:KA
M#UX:IW'3S"-NQA>+%6;/+V'/&9LK-I"J&E#1R$-DJW+V&*CEQEX^-<_)L&RH
M$<=J9DO('[#F#Z\+),2NK<N4'\K8IR=B[^1SE._)./;I0?Y=6''VEEJO\QK<
ME7?Y'7G74OVTY!_(_=-%.H=CA(@_X<+`4-E?]?\`LY4M''V@S/#6@UGKA\3V
M7$3+8F7MN082R'3G&$E'M,G2F!$M;;*P=Y%8B]*^,J3(1`/+D!V"Q.T$C86T
M1&,2I8=8L-OM>->,+8*DKS+9+?8DQO4Z`XO<VW%E(V8U9B6T661.Q,]DCQ[4
M2-P(W;F<N3MVQ$TS+*F**ALK!Q,5X^VV#"[':U9]PRR0K"5JR?@_+F-*;/VI
M@#R.K%CR#1)FL1,TLNDQ?R+)I'RCUNX7.U3,N!4`,0ICE*'"`P(7]U+P?_73
M6O`6&I!*LKVO%^#L0XRN-@J['[6/L]AQW0H2JR<R@NLR823UD]DF#A=N=TF1
M?L6ZG*4QC!PA,25L_*=4>7S&.1J/'.6S.0N=#M]48.WOE!FU>6*OR$0U<NQ0
M367^V07>%,IV$,?L`>@"/TX6%%?H/HQG_4"#PS5;.A1KRWQ[4V%)G)\FS%U?
M09&92IMWMEJ.)9#4R.(RDVK4I@9LEK64A0,8AG8`;N#"V)BIC.96JBMR?I9E
M]AO58]W<;L\'Y\4MF'(/$R6(=E)ZV4U#%(0+I)=:5PQD:NX[S0C6(ZW=55IA
M@>KF46=J*J%=`5PHF7"VCA!=_P"'V%WCJB9O?L?XLQG-FF)%T2K8?M<O<ZBB
MU>^%V=X:=FL:8E=NIAW)+N#.!"&1*IT*IW"90Q296JVGPB@\P]ZFLA4;5O8K
M#,_LID>+MV8;)LG.047C?)-@A,.-D<QFFS5QM9:\[J@2IP($DF2:*V`P+$`_
MB$PCU'$%L78C!2EZLXIF<$:QZY8/L4C&3%@PU@?$.*9V7A1=##2DSCO'U>J$
MG(Q(OF[1Z,8^>PYU4/,DDKXC%[R%-U`,K!Q)*WQPL)PBX2WZU2M^VU*P'5J=
M9*W67.*-M<$;`3CJS?*"A(5C%<Q)R$U#118MB^4//2"+XH-06\3<3%'R*D#Z
M\+(,%W;PL*,C?KU[L-Z,K:A2MS/4Y'#V$9W-KG*U0G7,\RG[-$Y/QRVJ,$O1
MY"$:F&*LU7GFJ4DV>F=,UF+ENBX;J>9,O0L@PBL0U/T.V)P3N=;L]9:V/;;"
MX]CM7XS6'$,W;X]VVST2F0^6'64H)++TPT8)5J[S\`,Z^C5+`DH@\F$DF[AR
MV(N98PX6201DI2K/"GLE:L-=3E9."4GX.6A23D*N#69ACRC!PQ+*Q+DQ3@WD
MXXR_F0.("!%2%'H/3F5JHD]2M.ME]-\/5S7V"P]I#G&$J\O/R),ZV>]9(Q5D
M>Y.I2P/K(C:<@X__`*^YO1G;NJ]=E(N[+<TR%*DF*12E3(D&%L2"8Q*F(YE:
MK360?["?D;#'XJ_#7XD^9M/]AOR#_-_R-_'O@B?PK\,?QS_ZS\S_`";N^4^<
M_P!#['IX/]7KPLX+_]:_QPB<(JA7LE_'/Y(NW\K_`/RU^;^;??%?C;^U/YMZ
M="=_Y'_"_P#X^_E/3_U?F?W?IV_7G#-V_"?%U'C_`(-XFHP\/XGQ?]3PNYJY
MZU>;3XOA2]'QNF&.KP]'V=?>AU*!N0\'WSO[;[/[?SJ>'X_Y#['Q]P]OVGRW
M_P`EX.G^7S_ZO3_-]><U=#4Z$(1X1AV1Q\N*LHR$<_RY+M#5G\7_`#+'^2_T
MC^<\K;XO^TW]P/AON_$GW???B3_QUXO\_D^8_P"R[NO;_P"WR?LWP?B-\;\.
M\3A\1\5"/3X7<_6P\R\%;XVDZ/B-/'P_"C^UWO)BKQFL'3\&8^[?P/V_"-^W
M^L_?^$NG87I_!/)_J?$]/\O=^[_C]>?HNS_^MI?Z;U?_`!_W/V.A<ZK/ZF;^
M]S_B>O\`:Z5OWDFO*G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G
3")PB<(G")PB<(G")PB<(G"+_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g685450g89q14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g685450g89q14.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0H<4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@`````````````!A````F$````&`&<`.``Y
M`'$`,0`T`````0`````````````````````````!``````````````)A```!
MA``````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````!W\````!````<````$<`
M``%0``!=,```!V,`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!'`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U5))))2SA+2`8D1*S["<38RW*LAC"X0T.EK"P%UA]_P"][W^Q7WV5
MLC>X-W:"2!*SLI^-=<_]-LAOI?HCN<[=[G^LQH>[TV^W9]!_\ZB$%LUXN0Q[
M2<I[VCEI`UU_\C[5:5)E]NUA$L@-W,%+R-/YS:[3Z?YB0R+VD2;'@1,4.$\3
MW2I3=25?[8W_`$5W_;92&8T\U6CXUN_N0I-MA)`^V5=Q8/\`K;__`"*3<W$<
M0/5:UQT#7>TGX-?M<E2K3I*++*WSL<'1H8(,?<I)*4D@6Y%E;X+&[28:7/#9
M\>5)F32YH)>T.,:;@=3K"2G_T/3BW,?R]E0G\T;G1_6?M;_X&F^R,<9ML?;_
M`"7.AO\`F5[&N_MJPJQQ':ZLDR#+3K.[PL;^\BAFS%Q:Y<VMH/=Q$G3Q>[W(
M!8_+%=A8*ZZWBR@$N#B0';7O:PL]NUW\TY6#4YU#JGN$N:6RT%L`Z-[O6;6+
M#<2\[;&%CBPO-98UH].RNJHGT7MMV?SO_"?\%6D%%N4LK?8ZN]FV\>YT.)#@
M?SV:_1_D_P"#1V8]3';FMAPG62>>>4*IPOR!=7K2QA:U_P"\7%I]G[S&[?IJ
MRD5!2222"5)B`>4Z22D3\7&L,OJ82.'0)']5WTFJ`PJFC]$Y]4?NO,?YC]]?
M_05A)*U4U_1RFGVW"P>%K`3_`)U7I?\`4)M^6T@/H;8.[JW#_J+=G_GQ64DK
M4__1]522224U#F/D@"LD&/IN\_\`@OY*5]+LJA]>0UOI/:X;ZWN%@!'M-9VM
MV/V_G[T7[*S]^S6?SW=_FB^2*&O58S+;MLKTVML`)#I:_=LG8?I>WW_X/_C%
M,X>,[FL&1$]X^/S4!OJR36RMK,=["]UP+1%DCV^EMW.]5CM_J[OS%,5WZS=,
MQ'M&B2DJ=#8RQI]]F\1$0!KXZ(B"5))))*4DDABZLDAI+MNA+02)_K!)21)0
M98Q\[3JTPX'0CXM*FDI__]+U5)#O:'U$'[I(GR);*J-M`_.`!$-_26=A.C=G
MYK$:5;?0S;#RW8_3O&G!.GW(--3+)<'O@&-'N,Z3^=M_>4;K[:996-Y:#LK)
MA[]-WMLL]KOW-J5(M@]C;GAXI=6XNT<6$&00-Y<RQG]96V/#7"DR#'M+C.Z/
MI:RYW^<@TY%C[=L2`2"TQN`B6VNCZ#7?1])[/44/M3<EKS4YFZE[J_4#B=EC
M?8\>ZO;[=Z2FU99Z8!B0=.0-?S1K^\[VJ-AM=4'":W<D""?#\[VH'Z8U5UVO
M#WLVE]FK2XMAT[/3VLWN"EZ]AH<<BNMDO+-'%[`S\RRTN93])OTJ_P"QZGYZ
M2F+;+Y.KS,.C:S02(_PGYVUR(QM[G$^I`&D;1!_.W"#Y[56)(#7/QPPAT.>Y
MC=C6D']+](.:WV[7_N(U62UI;4VH5R?H`@&/](Q@]SJ_Y7_4)*29&]N/!.XR
M`X\:3[MW[C-OTW_N(&19+O2)97LB`+C68]OM,,5Y!](5_0>YC3#0P00/S1MW
MAVW^RD%(6O>74^UFA+0\6%SC'M>W^;'J?1_2*XALJ:P[I+G\%[M3_P"8_P!E
M$02__]/U5)?*J22GZJ3.VQ[HCSX7RLDDI^J6[8]L1Y(.7]B]-OVWT_3]1FSU
M=L>IN'H;=_\`A?5V>E_PB^7$DE/U&T^D98"ZAPEI;[MI_=:T?F*7VAOJ/K++
M/9'NVG:=PGV._.V_GKY:21TZHUZ/U$+\61#=>T-[_<I6Y+:ZGVEEC@P26M8Y
MSC/[C`-SU\MI):*U\'ZF%P)@->3_`%2/^D[:U1AS[&OMA@:3Z;"=2Z#[O\S=
M[%\MI)*\WZJ27RJD@E__V0`X0DE-!"$``````%4````!`0````\`00!D`&\`
M8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````3`$$`9`!O`&(`90`@`%``:`!O
M`'0`;P!S`&@`;P!P`"``-@`N`#`````!`#A"24T$!@``````!P`(``$``0$`
M_^X`#D%D;V)E`&1``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!
M`0$!`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#_\``$0@!A`)A`P$1``(1`0,1`?_=``0`3?_$`-L`
M`0`"`@(#`0`````````````'"`4&!`D"`PH!`0$``P$!`0$`````````````
M`P0%`@$&!Q````8"`0,"`P0%"@(&!PD``0(#!`4&``<($1(3(10B%18Q%Q@)
M,B.7UUA!4234)956UE>80C-Q-);F=VEA4D15M2<XU2:V-V<HJ!DI$0`!!`$"
M`@4'!@H'!`<(`04!`!$"`P0A$C$%05%A(A-Q@9&A,A05L4)28I(C<H*BLM(S
M4Y-5!O#!T7,D-%1#8Y1%X<*#HT0E-?'BL\/3919F)N-D=*1&_]H`#`,!``(1
M`Q$`/P#[^,(F$3")A$PB81,(F$3")A$PB81,(F$3"+@R:<FK'NTX9VQ82AT3
M%8O)..<2\>W7].U1W&M92$</$0#[2$=H"/\`ZX9U':)#>"8]A8^EC\A7,MQB
M1`@3Z"0X]#A_2%UCZ7Y3<HMNZ'V[N^,C-&N'FH+QLNK.=<#6KW#*7!GK%FVD
M)%>,OJFP)Q&`DYINL<K5%>#=H$6*4%5@(83D^@R^7<NQ<W%PY2N:V$#N>)V[
M]`\=H<#I[P\B^9PN:<TR\#+SHQHW4SG'9MD-VS4M/>6)Z'B1UE7ET!N6"Y":
M9UYN>ML7D5$7^OHS"45('35>13Q-=Q'RL6LND4B3H8V69+H`L4I2K%3`X%*!
MN@8^;B3P<N_$LD#*$F<=/2#YPMSE^97S#"Q\VN)$+(NQZ.@CS$$=JF'*JN)A
M$PB811WJI3:RM(BS[K:T)GL874T$RAK-S/NZ:5F6;D"U\T:M9DD9DS@]>!J+
MORE`ONQ4[.A.T`GR?=A=+W0S-#!M[;N`=VTXNW8J^*<LT1]]%8R7+['V\2S;
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M/$K``,J]-XC)G!(ZN@%M5VF[,W?3]5_EY3NZN+C2.3I]<TPQ7U"A&M".6E?;
MNP95N*7=L'!WGD>4YV\,K((NC*G!RS6(Y$QP4Z_.8^';D\\AB<Q)\65IWOT]
M)U^MT-T$,OJ<G.IQ?Y>LS>5@>#&D>&W1P`TZX](/2"_2LCKS2FX(F^:@O\+<
M:G&5:*C)-'9:C&\;&OK[>,#.5E-"&D[`:U-FT>K8XN;0:R+.5`1<I)"JV(8&
MJRB)^;\O%E3E4SJD;"1L[L8BL@Z@-JQ#@QX<#Q#KO'PLR%^'D0N@*@#O:4YF
MT&.A.[1P6(EQXC@64=\08O\`%CQSEMR[3E[.39.U[AM+P/H^=E(BQ:%0K]VL
M%0JU4UHZ9NT5J0XK4=!-WJAVY45W[I<QWON`-T&?FDOAF?'$QHQ]WJC#B`18
M\1(RG])R2-=`!HRK<HC\6Y=/,RIR]YMG/4$@U-(QC&#>SM`!T8DGO.J\.K=M
M[>?Y;&O.2DE+3\EM[14Z]OLNZKTU,5:-W#2M/;(E8>ZL9UO`2$:TDX2WT&!6
M=N2>,Z:SUL/B*0JG0+PJQ</G]^!&(&+<-H<`F$IP!BS@L8R+#L.JSS=F9W\M
MX_,I3D<RB1F6)B+(US(D"Q#B4`2>LC17\U6WJ>[;W=MYUV4GW-$E*55-<4%Y
M%VNT1L1,-SPKFPVZ^0;2-EVT:WD5PMS.`3?IIED6;NO.035*!@$<7)-N'33A
MV1B+A,SDX!(U:,2X=NZ9-P(D-%OXHJS;[\ZN<C081A!I2`.CRD&+/WA!^(,#
MJNOV%M-Y7_)HM%S'8VQ$KS$16ZY!*]I72?+=G:\5R$O\8B$E:C/3S3XCB-(#
M=;O6$QT?AZAT#IMSKI'\UUU>!7X)-?=VC;K5$Z#@-=5\_"V\_P`FVW>\V>.!
M8=VX[M+9C63N=-%/V\=,L]6<1.3^TH78^YI2[W'1+2RR$M.[2M+@L59:97GL
MK%354:,'D<A5%#/711.V8@DQ*B@DBD@FB42&I8>6<GFG+L:=%0IA<P`@-1(L
M1+B_E.NI+NK^=A#%Y1S3*ADW&^=&XDSEI*()!BS;=>@::``,OW?TA.1U:_+A
MML=:[O'3-CY$<<J790C[S;V,/9JW8*!;IR98V6M-9M&MV%9_)Q#=0[EXT7==
MI!("@)G.4S"C"5G/JI50,(T6R#QBX(E$`@LX8$Z`LG,)3C5_+ET;9B<LBF,F
ME("0,)$B478N0-2">U:/R0MTYJ?;&V+7R&J^RI7C_:GE.;:IY':@M4PJYXQN
MV\##PCYA9:;!S4?)UDB=W%:2<3"";KYJ5XDT<$<)]C)M-@50R<;&KP;*QFQ$
MM]4P/O=2=)$$'NZ");:Q(;B8>973Q,O+MYA5:>7S,?#NKD?N=`")1!!CWM3(
M/N<`N.Z.VU%9%RBDX;JIKMUTTUD%T5"JHK(JE`Z2J2I!,11-0A@$I@$0$!ZA
MGS!!!((U7U@((!!T7LPO4PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB__]'[^,(F$3")A$PB81,(F$3")A$PB81,(F$3"+@R;->0CW;)M)OH
M9=RB9).4C"QYY!D8W3]>T+*L)2.%8`]`\K=4OK]G7H.=1(C($Q!'47;U$'UK
MF0,HF(D8D](9QZ01ZE`W'_C11>-D18:[KN9NKBNV>P2MMEH6US;2Q-U;3.`R
M)+3J3US%)3*3I^FP3*HD#KVIA$Q_%Y#"?+F=S"[F$X67PAXD8B(,0V@X#BVC
M]3]JH<OY91RV%E>/.?ARD9$2+]XLY=GU;K;L6,UUQ)T]J^%V53*LQFPU?M52
MS*V?4$K*A*ZS:FMXG+/)5FO.FIE:O'O6ZRJ(LV3A%EXE>GB$Q$C)]7\SRLF>
M/;81[Q4S3`:?=X.>D]I#]O%<X_*</%ADTU1E[K;NW5DO#O<=H^:#P8%NS@O?
MI_BY1-+DB64#:=JV6!JW5.B52^[$F[56*`U!NHS09UB)=&12%-@Q5%!FH_%\
MX8HB8C=1(IS@;S*YC=E[C.NN,Y>T8Q`,O*>TZEF!Z77N'RNC"V1KMME7'V8S
MF91AT=T=@T#N0.!"YI.--$CAO[6HR]SH-<VK+2<_L:H4R;;1M?LT[/$30L<T
MW%Y&2,U3)2R-">-\O77L.HN817$0<]%P\^(72\`VQA.RL`1E(.0!P'$"0'0)
M"3<.&BZ^&T1]X%,YUUVDF<8EA(GB>!,2>DP,7X\=5+T)2:C6Z?'Z_@:[$Q-)
MBX).LQ]78LTD(9I`)M/8%BDF9"@F#06@B0Q1Z]P"(B(B(CE6=UMELKYV$W$N
M2>+\75N%%-=,<>NL"@1VB(X-P9EK&M=2533^JJSI_6_OZO5JA`A`U]PV,P>2
MS,HF677E5%I2/?1[V7>/W"KI=1=LHFJX5,8R8@/3),C*MRLFS*R&E9*3GBWD
MT+LVG'@HL;$JP\6K#QGC5"+#@2.W4$$OJ7'%0ZTX<ZR9<?I/C$WGK\744LM,
M>\AC2\(I)F86&<E+1/Q!)X];-*D8RUEEU7JAP4]TFIT3263;]R)K9YKD'.CS
M$PA[T&U8LX``+.V@#=76'U5,<GQ8\OERP66>Z%W#AV),B'9V,B_7U%M%,\AJ
MVOV#6,YJ2Y.I2[5&QUF3ITPG8!BT'SNN2D:>(6CA<5V*@4DS(,5!*DX*F#HA
M^BGD%0`,%2.3.&1#*J`A;&0D&=G!=]2?1P5V6+79BSQ+B9TRB8EV=B&;0#HZ
M>/:J^(\&-1&KFL:Y+VC<EF)IVU5ZUZ[EK!M*P/)FL+52,E8F`B8EP@+1M&1+
M%K*_%[5%!VX%JU!9=0C9(A;IYQE>)D60KJCXL3&0$`Q<@DGK.G2X#EAJL\<C
MQ/#Q:YVW2\&8E`F9>.T$`#J`?H8E@Y+!2!<>,5&O/U?%SMAOZU$V),1L[L#6
M061%>EVZ1C20J0>^-(Q;ZV1,=(I0#8K]C%2L>Q?@!Q<(J"JJ)X:N874^%*$(
M>-6"(S;O1!?J.TD.6)!(Z#H%8NY91?XT;++/`L(,X/W9$-Q<&0!8.(R`/2"Y
M5BR$(F0B:9"IIIE*0A"%`I"$*`%*0A2@!2E*4.@`'H`906CP7EA$PB81,(F$
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M\)XI*%DDE%&4Y6YEN(`9I.UF;:N&#Y$0ZHNVRA/Y,\RL>S$R+<>WVXENPCH(
M["&(["NL3*KS<:G*J]B8=ND'@0>V)<$=84CY75E5DU]M&V;6WKL9M57+-+1F
MGVKK6\K("P*H[OF\3O8]]94HB25+WMZ_JF*0+&N12Z%=S$BX3$1]CFA?CUXV
M'0;`??+3O`?V:]0''7,ZCJB!])9F/E6Y>=DBHCW&D;"6]JUP9,>JL:'KD2/F
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M*A'C,V28EP!&<(B$'V"4M9;2P(`7PF)=S'.MS9\ENG779:9<("N+@`$F5=DC
M9-M\H081W#<1(E2K;-8?F/:[@INS[(Y$["VU$IQSTSV0XZHZEK-KJ:16``C-
MI:@L>AO%L-C%+$,JZ:15DBY9VEZ-DQ6#XJU61R&^<*\?!A5)^%N\QEKPWBSN
MOT$Q,1TZ*U;B_P`QX]<[<GF-ET&+FGPXRCIQ\,U=\#I$9QD>@.K5_ES;)UYL
M'BKK]E046+!QKYNI1KQ&,W#IR8;S']C^>LZKB021D7Q-BK206)-RX**ZY93J
MJ(K`J`9W/L>^CF5YN)(GWHGZIT`TT[K;6'5IHRU?Y<R<?(Y5CQQP`:^[(#Z0
MU,M=3O?>YU.[75U>G,9;J81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB__U/OXPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M*%]FWS;%2DXYIK[1$KMB/=,3.7\LPV%1*<G&/`<*)%CCL[7(-';LYD"%5\B1
M13`#`7KW`(!;QZ<:V,C?F"J3Z#;*3]NBI9-^75*(Q\`VQ(U(G&+=G>*HCRQV
MMNRUT2NZTV'HJ7TOKC:5T84R\7%]LNFV=&:BC1$U.,=4E+27SJ1@3[HG85K6
M#2*YDFJ*4F=+N\RR)3;/+,;$KNGD49@MOKANC'9(,7`,^]H?#!,VXZ=0*PN;
M9>;;17C9&":<:V8C*1G&3AB17W2X\0@0<Z=YN)"M=PAK%>JO$KCZWK9D5VT]
MJZI7B4D4D2H&FK/?XEM<[7-+)`FD=):3L4XY5\9@`R!3`EZ`0`#-YO9.SF><
M;.,;)1`ZA$[0/,`%J\DJKJY3R\5\)51D3URF-TCYR3Y."M1F:M5=']57DN.7
M-_=!M$5>2V`MLG>,_6+;HJKO*_$.K#7CZ!UGNZ1V+$2MAE:[2H!SJW95Y>LE
M32+MN5PWM8,R'\Q&Q`^OL$<_D^)[Y8("ND&-A<L?$G6(D`&1WPB#H"Q@_!U\
M149<NYWF^X5&PVWF,JHL''A0L,P21$;)R(U(<6-Q9=C<9O'>3R2CV;[A=N2(
M9.GK1L\EG.R^,CEM&-5UTTG$BX;1^[W3]P@R2,*AR()*+'*40(4QA`!P98>&
M(R(YM42!PV6Z]FM;+Z..=G2E$2Y+<(D\=].G;I:^G8K2YG+43")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(O_]7[^,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81:#M+6M6W#KRW:RNC51W6KE#N(B1!NK[=
M\T,<2+L96+=`4QF4S"R*"+QDX*`F0=()J!ZE#)\;(LQ;ZLBDM9`N/ZP>PC0C
MI"KY6-5F8]V-<'JG%CU]A'40=0>@A=-_&;DC;.#<9<..'(EPUNU6U%<I*NQ,
M]79>`)LFLQ$P'U57Y)QKR8E8F:N^LK=#RQ7\6]@@D'\,X.XBG342-VZP_4\P
MP*N<2JS\$&%EL`2"#L)&A&X`B,XD,1)A(-('4A?'<LYE;R.-W+>8D3JIF0""
M-\0>\#L)!E"0+Q,7,2\"-`59>=_,\U!8V*\1H]N>P7)R@J#65V\LGHS657`$
MSB:<MUBV&K!3$C&QQ2BJ9C!LI&0=]OB("0G\I,^'\O959$LP[:NJ'WDSV1$7
M`)ZY$`<=>"T[/YGP[(F&"-UQZ;/NH1[9&;$@=402>&G%>O\`+?T:]AX&Z\GK
MT^=6/8O(*5DIB(L,K'A&2*FNWLNK+MYL(H4BC!'V=,B,U[0ASE;PQ(=H81,Q
M[A]Y]F"4Z>74@1HH`!`+C<`S/T[!W7Z9;STKS^7,&4*[^:7R,LC()()#'82[
MMT;SWFZ([!\U=G>?/+Z=,(OSJ'42]0[@`!$O4.H`81`HB'V@`B4>G_1A$`0,
M`&*(&*8`$I@$!`0$.H"`AZ"`AA%^X1:%K;8,=LVM.;-%QLK$(-+ELFCN8^:+
M'ED$9?5^QK5K.?.;Y6_DV)VKB<J+A5L8BYQ.V.F8P%,)B%FR*)8]@KE($F$)
M.'9IQ$QQ`Z)!^U5\;(CDU&V,2`)SBQ9WA.4#P)'&);7@M]R%6$PB81?@"`B(
M`(")1Z&`!`1*/0#=!_F'M,`_]`X1?N$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A%__];[^,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB815HV[R<I^
MLXS9S*-82MMV+00H$/&T&.9.2OK7>-O*/F&K*O%.O&=)4;#+,CD<K$`X,6Z:
MBR@=I!`=#%Y=;D2QS(B-$]Q,CPC&&LR?(.'6=%F9?,Z<:.5&,3/)KV`0`UE*
MQQ"(\I&IZ`Y6/TEQFK-.IJCG:T)4-E[@N\R^OFV;Q,UV/F/F]YL!&WS!E!GF
M6[QS'U"LLFK>*AVA1(1&.9)=2`H901ZR^866VMC3G7BP`C"()#1'!VXR.ID>
MLE<X7+*J:7RX0MS)R,K)$`O(\0'X1B&C$=``4KO-(:8D&;I@]U+K5PS?-EV;
MM`]'K78NV<I&171/VQ@&[5$CB4>@@/0<K#,RXD2&58X^L?[5;E@X4@8RQ*F(
M^C'^Q4NIFY'/$BI;/T5>T)*WOM%1M?L.DC.)%1.6V/H*Y7*,I='8C+.D'93S
M^KK#,HUB24.0"^%)@Y/VE=]P:MN*.9VX^921$7$BS32-D8F4M.J8&\?C#H6+
M3F'E%.5@W@SE0`:]=9U2D(Q#]<"=A_%/2NR',%?2*BG-.UV*+J=UA:@ZVLVN
MJ>B-I7/7@T9]=(".-?*FS1>UX[)_08=]+V^W-Y,&YP@'RY(9Q&`X,\342,82
M[/*:ZY6TSM%7@^-",MPB3MEQTD6C%G[P[P+,L+G5MD:KX4FT7>!.4-ID!NCJ
M&,`3*3MW"=IB[AEBKY#)3N\]ZR#-]ME-W;.(FNY/625?M6XH&$?V)-7DPPLX
MM(J!EXZNM)F-BW]<.5!TBFLR?/$%T2)O7)E%.J9[,/"B14T<J0FX@2!]T1J0
M2Q(EPX@$'0+B^`LSLZ0E:\\.!@TK`"?OA+0$!P##0Z@D$-(J(;_8W,%QBBH+
M6LGOT;7^%BW7FB*LK%NEN?[SJO5H=]'I,)@K*:N-HLD9/`B!*N[<I5TL>FZ(
MX0\0*%):IK$^8RGD1H\+WF,9:5^P27TTB`1\\#<[,54R+#7RR%>-+(\7W64H
ML;/;C$$,6,I$'YA.QG<,K+2E]93VYIRG7QQMNN1SI#65ET4^I3?9T1!W*).T
M)+V0'CJG,RLG<VTL:*C6:BYWHFWAO;*"@FDLX5-GQI,,2%M(JE+OBS=L)B>`
M;=T-K$QXR?70!:4LB-F;.F\W1B=DJC'>!(<3[.COI*,N$6+`$E1/J]A,U>=T
MW/1DW=F/U7S,YIPUY@SV*Q&IBVL[#;.65YJDO(5!9V:KQK65M3>I.XR9!LDX
M=?.&Z:3A1&0334LY!C9#+A*$#MQ*#$L-V\1IB0)<2PW@Q=AM.CQ53%C.JS#L
MC.8WYN2)!SMV&5\HDQ]D/+PS&3.=P8M(+7=6QERE`T"ZM5WW9[BS;CY94R_-
MWFS-FLVSG7$?:MR.]7.)1(L\B6O@DS@ZV$++H"S>+MG2*:3A1)V4JDF3*J/O
MHKII:-5,H]R'M$0WMIKQENB7#@N'"CQ8W2]P-M][RNOC/OS]@2LV/KIPAMD&
M)!`!8KUURQ;$<0.HZAL'9&UJK3G]8W56H[8;)M<GUIE;K5ML+P-"8VV<C#FG
M_J.4U>DW>0IY(52SJ@.#J>Z<&2[DZZ!/*MHHKE:)5DQ[H`B8/(Q!T83<2;V=
M.`2NS(->)3D9-L*3&R(F-QD91L:`D1JY@QB_M:\2RVBX$NK9WNB<:W;;"\M3
M-V<:C4'MN%QC&"T&^::=1V2)Z?&2#*M3D"^%W/FEF+IDYC6:I'71%`S<?''5
MX)&)`TU;9TV[N[$EQOV=XAP1W6(()TU+J6[QP<V8OMWPOIV=Z0#'P]_=!$2#
MW]P((&N@;2:=(Q3./WYRN.[>7TTPYV?!2E?:3%DV1(4X]%F]%:$6/)0D5+2;
MF@%%2^L)ELW7;I`]0*U<-$3$:HBB2IF2,L+EK"&WPR"PB);A99H2!N]DQ)?0
MN"=2ZNX,(QS^:N;-YM!#F9CM-56H!.SVQ(`C4,0-`RMKF8M9,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA%K@6VO&MAZ,$D3ZK3KY+4:'%!T"OT^I(FB2R8.!0!F=$9$HI=H*"H!@_1Z>
MN2>%9X7C;?NMS/VL[>A1^+7XO@;OO=NYNQV?TK8\C4B81,(F$3")A$PB81,(
MO__7^_C")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$76U06.Z]W;CWER!
MT3LNC:QUO8%*CIJN25PU5([5-M%KH]_>4I/8$`=ALO73>%K1KA>9:,9*$._+
M)HQX.0\1!)Y-^XXF'BX>%F8\[,B.ZPB,Q#9X@BT2\).=L8D\&=M5\WCQS<[,
MSN88&3"K&EMK!E`SW^$9/,-.#1W2E$<=S/HNQ6)1DF\7&MYE\VE)="/9HRLF
MS8&BF<C))-TR/GS2+.]DCQK9VZ*91-N+EP*)3`05#].X<*1B92,`T7T#NP\N
MC^5@OHH"0C$3D#-@Y`9STEG+>1SY5I.O-EP^QU]@H1+*19'USL:=UI+_`#`K
M<I7<Q`Q\-).'L>+==<3QR[><2[!4\:G<4P"4.@",M^/.@4&1!\2L3#=1)&O;
MHH,?)ADG($(D>'88%^L`%QV:JMV_>'#3<#*YR\;MC;D1<Y-+YI4F$C>G\MK2
M&LD3)Q%GKC-[0WC=>,=TT+76HYP]C?\`EKE0`?0Y2&+H87-3BFJ,L:HU#21$
M6F000>]QW;20#T+.S^3#,C=..7<+CK$&1,`01(/'AMW1!(Z64U<?-P%W9K.+
MMCV(5J]QC'LC3MFTISU]W1]FU5?Y9<ZLOW'4,H@QE$Q49K"8?=1ZR"X>BH93
MSL7W3(E4);JB!*$OI0.L3Z./47'0KO+\SWW&C;*&VX$QG'Z,XZ2CYCPZP0>E
M3;E174PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%5;:=@V\[W-&ZWUYL2KT)A*Z
M-NUX3?6"BI6T&=CJMVH\4B^<&4L<$88M9C9_$LGU`$TBJ&`14.DHAI8T,48D
MLB^B4Y"Z,=);=#&1;@==/Z:OE95F8<V.-CY$:XFB4G,=VL91#\1HTOZ%FAR$
MVO-/;76MQ61&LT>PS'"2LVZ81GE)=:K0$Q.7>.=.2^)BDK8)./2>/1]FT(5-
M\]ZI(=4EE!$EJ>-`568M>Z<!F&(9G($3UZ`]9X#4ZA4X9<Y6U9E@C"PX49%W
MV@F0ZM2-=!Q.@T)6SL]P;H<5?=[.);_6=EUKR%@M?Q:,9%U>O7Z:UW)ZOU+M
MBR)5V#FYTU-?[*@(B]R:4>W>*H$508)^Y;'=E505C.+B"S#,CLKLH,BY)B)"
M<X!R!NV$Q#D/J="S$2C,S35G1@-]M60(!A$3,#"NPL"=IF!*3`MH-0[@QW9.
M1^UYEG;7FM[O7$H2O<.%.0\'*V#5T@TL$K:H2PW!@[A[/#/[,T)$-WQ:L1L_
M;)-TE6RIE_`H4?$<D]>!C0-0R*9;Y97A$"88`B)<$#5G<%]='Z56LYEES%QQ
MKX[(X?C`F!<R!D&D#+1]K$-IJW0I;3W)L*L6W8,9;+11E(-/46FMH5N7E8&6
MC&]9E-A7:WTR<K2D;!+RLK:6H!#,5(5L10)%]).#,S+%*JDHE6.+1951*JN>
M_P`6<"`07$8QD"Y8#B=QX`!VT+W!F9%5V1&VV'A^#7,$@C:9RE$Q8.9<!M'$
MDL^H(DWC]>K;<FFU8ZXOD)5]KS<%@H<?*%B6,*^?0S:MU"S,AFF$7(R48G+,
MCVA1JH*!D@,1`@J(IK>0N5LVFJHXTJ@T9U"1#NQ>0T)`+:/_`%LK/+[[KAEQ
MND\J[C$%@"0T9!P"0XW-IU<`75@<I+03")A$PB81?__0^_C")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(JA\I;=8YLU.XSZSDW$7LC?)Y%G-6..4'WVL-*
MPXMB[0V/W)E.9G*GCWJ<-`F4%(JLW))'(<0;J@&IRZJN'B\PR(OCTLP/S[#[
M$/(_>E]4'K61S2ZR?@\LQI-DWNY'&%8]N?E8[8_6(ZBK'UZ"IVKZ9`U:";15
M2I5.AHROPC$5DF49$Q$8V281[0J[E0I0!-%(I>XYQ.<WJ81,(B-"<[<BV=DR
M973))ZR3J5HUUTXM-=58$*81``X``:!1G9.4_&:G^0+1R%TG!*IAU%K);1I3
M9\;X$E>U%@>:!ZN?Q+$-VD3,;M,`].@Y8KY;S"W]7@W2\D)?*RK6<UY93^MY
MA1$]LXOZ'=4KXW\Q./$/(<C%`NTK8D[+R7O=D@#T+76SME$EH)_6*0W:23$V
MO:99RK-USQJY@Z?%XDQ4$`3Z&'6S^59TXX'W(CMQX@[I0@Q!EIWI#K6+RWG'
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MGQ@U/64_"4ZCZ]<G5DDH_J`J*KO&=/TG:B+-6B0?K1(Z*;NZ]H&*`&&C[ORH
M'7F-LOP:N/VK(_(K_O/.)#N\KJCVRNX?9KE\JCR7W5R0B_(-BV!P"UX*1P.N
M27VM?+-[5-4PE:-U%'T?K7O.Z*<AP6,5(`'X`2/U`X6(XF!+]71FS\D(C^N:
MKSS>90_69'+Z_+9*7RB'].A1?+\G[(VZIS_YBWY>M2704.W.VJE$<6QY[HP=
M54I!O(\JS.&H,A2$"'!),#F,('*`]H98CRZL^QR+.D/K2V^AJ55GS2P:6?S%
MR^!^K'<?.]_0L"'(MO(=OA_,A:27E0\K7[M^*K&<\C<>WN?K^.(OWF:#Y4_"
MLGX4![O45.XO3OW`QX\A(_"N;S<8J/XB)</YD!_`H!\_"?IX+]#9K.8%-,>9
M?/\`NBA0/[-IK?AB2*7=FZAYGJ#]EPM6CY:.*DD)BB54Y>T>\AA`1ZO=S#_E
M6%#\.]_5X[@I[S&?_.>83ZMF.WG<8S$+]&29NRG,:Y_FTV)$3"+E<-93M,,^
M4Z@JHD1JGJ2AOV!1Z@7N:(M4P^PA@Z#T;2/]ERR)_#$O^O)_.2O=P/\`MN;2
M'X!B_P#W<2/,R_31+=R8A5==_FT6!81[&[,NY).IE*8_05%3R#/>U*8B!2$_
M]J="4/L('<;H+<1POY9$?@"7J\.1]`38#QQ^;2/]X8^OQ8CTE!UZPE3@7\)/
MYCUODP#_`*W?.9"\"#9BGU$&[:2+S:3;*`5=43%1,7N$3G,!O3ICQY1_YG@0
MC]6A]?)[NGN\9_\`*>93E];(;3R^\K]'2K9R8`'\O_DH_=&Z%![>.:T5*I(H
MD`Y_"615Y57&713[S#V))("EWG$1[>IC8][(_P"=XX'U:"/5X,1ZT]R!_P"0
M9)/7+)!]?CR/J7Z.@FZ@@#K\NZYR*0#U%I+\N8Z9CU!Z"!16CI7:#Q@N)!'N
M+WIF[#@!B]#``@]]/1SV(/921ZQ!/<!T_P`NS([<@$>@S(7X7CDFL`J)?EKT
MALD8QP31E.3;!!^4A3F*4SA&,CIEBF90"]P`FZ5`"B'40-U*#W]O^?S\U/\`
M:WR)\.?4?RW`#MN#^H$>M>?X;?\`RWM<_P"Z'_NUGGO_`/\`?I_N?^E/AO\`
M^MU_O_\`W4_#;_Y;VN?]T/\`W:Q[_P#_`'Z?[G_I3X;_`/K=?[__`-U/PV_^
M6]KG_=#_`-VL>_\`_P!^G^Y_Z4^&_P#ZW7^__P#=7@;CFB@)#N/RUJ:Y0[A*
MJ2'Y,QCI^4!(;M.DWEV<`R4*"@%`W<Z((%$1`#"':/OOY/#G\G[:C_4_R)\.
M`X_RU`CLN#^MAZT)H))(H)H?EZWUJB7J";9GS$09M$"=1$$FS1KM9%LV0)UZ
M%33(4A`]```#ICWT]//(/_<?^XGN`'#^7K`/_P#(_P#ZB%TRB@(E3X$<K8PX
M?`LG4.<;"'AUSD,8`<)I,N7M:,Y,<H@'E79I+B4`*8``H`#WLGCSK&/X6.2?
M_@'Y4]R`X<ARQ^#D@#U9$?6'0M';QW<U;\9OS/ZN8AA%Q%5'EZ>1@R./T3+M
MI!3FJJ+PRR92B8X"!>H=`#H&/&,M3S#ETNV5#'T>`G@".@Y9S2/9'(<>GWG5
M>OV231(@EA/S:X!-$R0D<_5KRW*QW14HII':*W.[.YDI3=$S"H@_[BB)CF$`
M%0#N?;Y9+\7:_P"3%O4O-H`]CFT1^%N;\J3^@KS"=!FH</O5_-HKHJ$3'VPZ
M!&Z)N`*94`7(Z_#5?2LCAU[3)@N@)@`HB0?0PMC_`/AN62_[3;_\V/R+WQ-I
M_P`WS:/_`&6[_P"3)O2%^%W6+/Q__OQY,L`.F(#]X/!<T<V,)?'T(R=!Q?I)
M%79.X>\HK.1,7U`H=!,+W1_^38Y_!R'_`/G2_J3WUF_\^R1^'BMZ/N(_*5X#
MR@68@4I?S*=!,%3MU!`FT>,[NO"99($@*@"A]JZ^]G(`900<(*)JK%^T$4^P
MX"^'"7_(+C^!:_\`U):=7RKSXH8__P#2XX/UZ6_Z\->L>I;Q%<H=E2?3Y#RW
M_+1O1Q!HM[9G8K)4'(%<J=H,UDD=R[$<,U5"!U(H=(3>01(*`=HF&&7+L>/M
M\LYA#S"7_4C_`$Z5/#FF3+]7S?EEGG,?_F3_`*="E2'W'RN>F`(BA\0]J`87
M3=).A<H;;#OEG2"97?4S23T;8&R(E:=>Y$KE8P=04,<A/3*\\3EH]N[*K_"I
MB?DL'R*U#,YK+V*,.W\"^0/KJ/H=;9]]/)EB/25X86.0#NZ=:3O/3,Q\)B=Q
M#=+E-:Z_1.`E4#_AZ@)>_J/;%[IR\^SS:(_"KL'YHDIO?>9Q]ODTC^#;6?SC
M!>'XJY5F7K8>*?+2OB'V]FNJA<@$/'WE,0-:[&NR@E.8IB@`E*<HE^,I0,03
M/AL3[',L67XTH_GQBO/BLX_K.59<?Q(R_,G)?@<W-$M.XEI+N'7S@@"91#87
M'7?M1*DGV)J@HH_E=;I1)`%-03]!<=_C(8XAV%$V/A&8?U?A3'U;:Y>H3?U)
M\;P!^M\:L_7IMCZS!O6LY"\TN)$^X%FQY(:90?@8$_ELUL"N5N4\IA.`(A%V
M)_%R`K_JQ$2>/O`O01#H("/$^4\S@'.!;MZQ$D>D`A20YURBP[8\RIW=1F`?
M02"IVKMUIMO2!>IVVLVA$R8K%6KL]%320HAXNJH*1KIR04P]PG\77I\9?YPZ
MT[*;:BUM4HGM!'RJ]7=3<'JMC(=A!^1;-D:E3")A$PB81,(F$3")A$PB81,(
MF$3"*#[7I"#NNX*ML^S(U:P1E8U_:Z0VJEAIC2=/Y[5-5J76G64U(22C>.<-
MR5LK84RL#BJBX4`5`^S+E69.G%LQZS*,I3C)Q)N`(9@->+\>A4;<&%V95E6B
M$HQKE':8O[1B7!)TX-PX'BI'F:-2;&I(JV&G5:>5F(5Q6Y=29K\3**2E==]W
MNH&1.^:+F?0KGN'R-51,@?J/4HY7A==7M$+91`+AB0QZQV]O%69T46;C93"1
M,6+@%QU%^([."PZ.I=5MVDC'M]9Z^083"D,M+LD:97$FDJM7&J;&O*R+8D:5
M%\I`LDBHLC*E,+5(H$2[2@`9V<K))C(Y$]P=N\='XMKT]/6N!B8H$HC&KVEG
M&T:MH'TU8<.KH7--K?79TUD3T*EF1<5Q*GKI&JT&9->I(%`J%66(+$2J5Q$I
M0`C$P"V*`>A,Y]XOT/C3?=NXGVNOR]O%=>[8[$>[P;;M]D>S]'AP[."\7NL]
M<22$BVD=?TE^VF*^UJ4NW>U2"=(2E58J'68UF1278*)OJ^S54,9)DJ!FR9C"
M)2`(CGHR+XF)C?,$2W#4Z'K&O'MXKR6-C2$A+'@08[2\1K$<(G34=G!<^!IU
M0IP2JM1J-<KBDPLV>RY:U!Q$(K,NX^-;1+!:0,Q09$?.FL4P0:(G7,(IMT4T
MP,5,A0#F=MMNWQ;92;@Y)9RY9^TOY5U7333O--,8OJ=H`=@P=F?0`!^C18O6
M%_C-J:]I^QH9A)Q<5=(%A8&$=-%9$EF3602!9)M(DC7LE'E>)%'HH"+A9(#=
M>TY@Z"/611+&OMHG(&4),2.&G4['U+G%R(Y6/3DPB1"<00"SA^MB0_D)6]Y"
MITPB81,(O__1^_C")A$PB81,(F$3")A$PB81,(N(_D&$6T7D)-ZTCF#8H'<O
M7[E%HT;D$Q2`==RX.FBD43F`.IC`'40#/8QE(B,03+L7DI1B#*4@(CI*KO9N
M8O%FI//EDMOS5Z\SW+)_3U>M<;;[,*K?_F(A6JDK-SPK=>H%)[?O.8!`H"("
M`7J^5<QM&Z.%9LZR#$>F3#UK.MYQRJD[9Y]6_J$A*7V8N?4M8)S&J4T`GUWI
MWDWM!N(%%O(5O0]SJT,]\B/D3]E/[<0UI!.2'-\'D!SXRCT,8P)F*<9?A5L/
MU^5CUGJ-D2?1#>?4HOC%,_\`+X>5:.L52B#Y#9L'K]2#N/E--]1J_$$*\W5(
M)D'VX]]4"J@B0Y.Y-P\CM91VYW9`3^TZ0F(H'Z(B4>O;Y[KRZ'ZSFFX]4*Y'
MUS-:>^<TG^JY1M'79;"/J@+%#5NY`;DK_E)?^3?Y?6A2=Q@51=3-FV?.-P#N
M5(BQ3GM@Z4(^=]B2A>WV`BH"8F*0HFZ)VZL+$FW@<OSKO,(#U1L^54[N89E;
M^\<SY?C^>4SYGG6_H46$W0RM92)'Y[;_`-BIN.TR<=Q6XFH/$WX'3^`&<_%Z
M2W&J@4Q54U"B$F0%"=_:(B9/QV?=#7K\%HK[;KN'F-D/D53WV-NGQ[(L'511
MQ\A%=GYRPR6M*=9K&XMY>/\`^93N*W2L&RKCF?N^U#:23?UYB]>2K.$EE7FY
M])NDXID^E72R+4S$R(.0$1(4%0.IT<BVNL5>_<OJJ$G:,/$UX./N[-6`U?AY
M%P,:FVPW?#^977&(#RGX;@%V/WE>@).C<?*MH8\:7+]TDXCORV./?NS`?MF>
M1.^&M]=-C'`"G%VU;ZWW2N^`_E5]`>?#VI'ZB8`(G'+F`B")<_O;JJKV_P#7
MK^12QY:9$&/\MX[]=UN__J6/Z>I3;6=/<GX(4PJ=7X'Z8(00\9JAJ6^W1RQ#
MH50#LUVDWIQN9=%RH<Y#&0`G5,!$GZP03J697+IOXMF;;^%.,7]4U>JP^:5M
MX56!3^#7*3>NOY%%/'/5G(N?DN1O;RI6IPM.2MY8SPT#26OF_P`YG4JW1%7T
MZQ#8KC9WR9%XV.BDFS'W1$?&<PJ'%0/'9S\G`A'`_P#+=[X\6W62T#R8';L?
MRZ*IR[%YC9+F/_FNQLF0.RN&I:+D;][=&FK*RX<6K$_`#V?EIRLL"R@)BZ*S
MN6O:*T.H`^54&J&N-85%PR;G<CW%*58QRD`$Q.9/J4<_XC7']7RS&B/P92_.
MG):?PNR7ZWFV7(_A0C^9"+>GL0.%>FWH`-IG=]WM4`3*)[GR=Y#2R)B$'R"D
M>-2V6SAU&ZBXBH*1FPI%/^B4H```^+90_5PIA^#54/7L?UI\%PY?K;,BP_6N
MN/JW@>I>:?!3B'Y"+/\`05!L*R9A4*O<6+N[./*<X*++&7MSR;6.NZ4*`KG,
M83KB`>03=`Q\9YIPCFSB/J]W\UO^A!R+E'&6!7(_6&[\XGS]:D2&XS<;ZX8A
MJ]Q]TC`F3.HJF:&U10XLR:BR?A64(+&!0$AU41[#"'J8OH/ID$^89]GMYUTO
M+.1_K5B'+.6U_J^7T1\E<1\@4HP]7K->`I8"NP4&4B`MB!#Q$?&`1L)RJ"W*
M#)N@!4!4(4PD#X>H`/3J&5IV66>W9(^4DJU"JJO]77&/D`'R+.YPI$PBX,H_
M+%1DC)G:OGQ8YB[?F91;11_)O"LVZC@6L<Q1`5GKYP"?8BD3XE%!`H>HYU&.
MZ48N`Y;70><]2YE+9&4F)8.PU/F'25[6;D'K-J\*BY;E=MD'(-WB!VSQ`%TB
MJ@BZ;*=%&[E(#]IR&]2&`0'U#/"&)#\%[$[@"Q#CI7)SQ>IA$PB81,(F$3")
MA$PB81,(F$3")A$PBT:6UAK6?#MG=>4::*)%DQ++5*`D0\;@`!PGT>1ZP=BX
M!\8?8;^7KDT<C(A[%\QY)$?UJ">+C6?K,>N7EB#_`%**YKA[Q.L('&8XSZ&>
M*J`F4[H=345!_P!J)@,F0L@V@T7Q"%Z=.T%``0]!]!$,LPYIS.'L<PN`_#DW
MH=E5GR?E-GM\LH)_NXOZ6=:M^!?BRB`!$ZP/5NT$P3^A[ULBA"@"!NYK[8:7
M<($6HL!_ZL*?:+8/1+L#)/C',C[61N_"C"7YT3Y^M1?`N5#V,79^#*</S9#A
MT=70OT>'E-8@):MM_E-3D2@H#=I%<E]MSK!GW#WI^VC[[9+BQ*"*W4X`9,Q5
M!,(*@H4>W'Q2T_K,7&F>VJ`/IB(I\'IC^JS,J`[+K"/1,R']-5XFXY;9B>@T
M_FCR%CP[NXS2X0>A-A,3%(J55)`%)C3C2=*@/50J@^_\QRF*`*$[`Q[_`(TO
MUO*:#^";(_)-O4GP[+A^IYUD#\(53'KK?UOVK"S>D^4;U$$G6^](;):I?`G$
M[@XKMY=%9/R]Q17?4[;513(H02IJF\;,I%%T2"`)EZESN&7RX%QA75GKA<WY
MT)?+P4<\+FD@QSZ+!U64/ZXV1^3BH#L'$B_2/:YL'$?\N78;A,"K*NX.*N&F
M;&JJD5,2ECYAKKC8;I%8H^0$A.\(4AS$/W`*?Q78<SHCI7S//K':8V#SC='Y
M%0LY1D2ULY1RZP]@E6?,=D_E6MK:,M5<*=6/X=;WHZR(*]7?&?GO.HH($`CH
M#"PK]MV'J:&7;@/:9-,8T%#IE23%/L`R(2>^53]KFM,Q_O<8>LQC,^OK\JC.
M#;7K'D]\#_N<H^H2G6/5U!NA>?SZ\50#*-+K^:-K$R8J=R%PTUK+D=!MTNKE
M3HY4K%%V_.+(D$B13*IRO4$`]#E.=14OFRFSC3RZS\&R=1]<H#U)XE]7"_FE
M7X5<+A^3&P_E</2B/*VRUM=-+\<>B5A$P)#&\F>+6S]&R7QJ=I`4G%[GKIHW
M<F*U.`":([2B8Y^PQ1(4@\MKL#_![O+5="P>C;+\Y!S6VLM\<H\EU$ZCZ=T/
MS5-E4Y,;[F_&6MUWB!OU-<I3(.-(\K_:2BI?$4W5.O6774A'*F<N'")$P":[
M0*/<8W4Y2!4MY?A0_63RJ/[RG3TB0/Y*NU<SSY_JZ\/('^ZOU]$H$?E*2?Q-
M;`@P,2_\0.2-?5(903/*@TUAMJ&40*<J::J!]?[(E+*<RH]Q@3/%)J%(`"8`
M$>T*_P`/HG^HYICR_"WP/Y40/6K/Q/(A_F.3Y,3]798/R)F7Y*!SEXW,1(G<
M;7:M6.O0%VNX-4;6U2#,PF$O:YD+W2X*&#ITZB8CDY``!ZCZ&Z/@^?+]57&P
M?4G"?JC(GU)\<Y;'2ZV=1_WE=E?KE$#UJ::7N_3&QP0'7VV]9W@7/_()4KU6
M+$JJ;O\`&)"I1,H[5\A5?@,40[BG^$0`?3*EN'ET/X^+9#\*)'RA7:<["R6]
MWRZIO]&43\A4H975I,(F$3")A$PB81,(F$76QR:+L%Q<>5IZQ:MM1A*GPXJU
MXU:VI-PO$0Q3WO%3NZEFK.%C*_(H,)J>D2Q]81>PQDG!'R#ML5=N<'28GW^7
M^`*N6^)74=V48SW1B?NR*^)(<`/-I:,06.B^;YG[P;N:^%;<-F'&4-LI`>*#
M9P`+$EH/'5P0XU7(V--7ZB7G<+:F6O9DAK-S'\3[?-RH2%SO[ZJ1ELONUH3=
M,K0C.GLG+ILF%2AZM(2\?"G(2+C7AW3=!!1<#G\HA1=3BFZNL9`-T0&C'<8Q
M@:Q+@-9&8B9<2&)++W)GD47Y@IMM.,11(EY3,1*=@L,-26$1`R$?9!<`.L])
M1LHYNO&:!C=I;<M>N[#8MW+W"<):+U42.ZX]H4A(5=&1GXJ0B)Y2!C[,0A86
M1<O#JG4$"(.3D$I<XC*(IYA.6-5&^,:]H:,M=P!8$$.1[0`\H7<HS-_+*XY5
MT\>4K=QW2CH8$Q<@@L)>R2?(5BM%'O+";XLR4C<=IS#RPU3<E4V6TN%FM\XQ
MD&U;<MU*%*V*%FW:L)!VE`D85-&1(U:2,JFX5%95QW&-G>9X,H<RC&JL",JY
M0VB((?V@"-2->#D!@P"YP?'C/E<I76R,H61GNE(@M[!(.@EIH6!DY<E:KH^`
MM45K_0DI3[3L:(!/1E]@]U5*6FK=\A@"P]:,UK#I"NV)91AK;8T3>O`DS(Q0
MCG<BP,].H1P1J"B/>9.N5^;&VNL_?1-<@(N7.NHUG$QXNX!;@^L6#7;#'P)T
MVV#[B0LB3)@T>[H=(3$F9@"1N=VTW^OF5A-/Z-2M5HWK-R^XHBO&NYAOFRD3
M,+J&GXUM+P[ZVUIK,W[7#A68AUU6L5#"Q4=V-4Y3=HF.F,,^_E9AKKI$:B=O
M=AK'>6(B6C+0ZF3M%3UO##P1;;?*=P&[O3TEX8<&47G#4%HQ9Y^A:=1'EUV'
M5M"J7JV;:8.97@HM);`!M<-A:X?CN:))KM%5],#!259D8Z[`]<SINH"DLZ32
M4-T421());A319F^#540,QH]V,AX9W:!P08^SY/*5#0;\BK`-]MP)P7GWIP/
MB#9J6,2)/N\NO$!<V%M&P[1(:SA-C[$V;K\)SCMHZ?J,Q6(2?.YLNUC?41-P
M1LH,2W-&KW:+>EAA<0\LT<-P;*B9-OT*^`ODZZ*XY$Z**YM?8)`D:0TV$/KM
M/>[T2"_3P74+<BV6-#)R+:]V/48F(/>LU\0%M-P.UXR!#='M+LES`7TB_]+[
M^,(F$3")A$PB818:>L5?JT:M,V>=AJY$-_\`K$K/2;*(C4/A.?\`7/I!=NU2
M^!,P_$8/0!'^3.X5SLD(5P,I=0#GU+BRRNJ)G;9&,!TD@#TE5FDN<'&A)TYC
M*KL!?;4VV4%N,%HRIW#=DBHZ`0Z-.[6,%:(]LN;^3SKHE'I]O7-"/*.8,)64
M>%#KLE&L?ED%9DN><L!,:LCQICHJC*P_D"0])7'#D)NJT#_\M.'^TW#4P&!.
M;W);M>:9AE%.@B01C?G5ZV&BW-]@F4KY#E'K\`AT$SW'$K_S'-*WZH1E8?2T
M8_E+SXAFV_Y;D]K==DH5CT/*?Y"AN];TW963+([6Y)<&^,B9%3$<1B<C/[<O
M")@.<2L&);5:=/-%I,R9!`P!".^TP")4SE*/=;IP\2QCC8&9D=K"$?+W1/3\
M8*G?G9M3C+YE@XO8YLEY!NE7K^*5$OUM&7<H*#R#_,$Y'*`4Q56W'[3[W3E%
M4(9,P`BVN5>UKK=L!ENX3)JA;E#^@=J@=HCEGP94Z>XX-'][/?+[)G/\Q5/'
MC?K\0YAD_P!U6:X_:$(?_$7/C^/Q9QZV>P_Y=<7/NB]Q&=HYI\B8^\OB%7'J
M63?Q`/>3D@"X=0.='JBHD'4B?:`%`?)9VP&,N>F(ZJ*C'S`_=!=1Y?OD)0_E
MT2/1+)N$CY2'N/FT5AJWJ7EHT9FC(.V\4N/,,=,O6.T_HZQ7.0(=-7HFB26L
M5QH=?%(K;H`'-`F$H@(`00,`DHV9/+"=TZLF^?7.P1'H$9'\I:%>)S81VPNQ
M,>'5749'TF41^2MJ'C)?)X15V%R[Y(V$YN\AX^G2&N-00A4#&34(FB&N=?0U
MI343.40!4TN=02#VB(^HFB^(4PTHY7CQ[9"4S^5(C\E2_#+[-<CF^3+LB85C
M\B`E^4@<&.,SWJ:VT>;V<X44%=RZV_LK9VV#O%Q5(N*SEML&X6&/,;SD`_0J
M)2`<1,`=QC"+XQS`?JKA6/J0A#\V(*?`N62_742M/^\G.S\^1'J4U5#26F=?
M>$:%J365*%L)3(&J=#JU=.B8BA52'3/$130Y3E5*!^X!Z]P=?M]<J6YF7>_C
M95D_PI$_*5=IPL+';P,2J#?1C$?(%)^5U:3")A%4SFXEN1MQRO5NT#;)6I[4
MUJW)L:OJ1K>/?HS[2KI.'%CK,I#RS5]&S;.4K*SP46JJ*@'?I-S%#O(7-/E!
MQ3GTU9M0EC6=TNX9^!!&H8MKU.LGG8S!RZ^[`M,,JKOAF+[>,2"X(,7TZV72
M-^6SR2Y5\IN2KJK+VIK4]7H7"=Y%[I3I,&A#FLTP9K6X6(KKF:>*2,DSB)J?
MBF/ECFJZ)7;('I5`52#M3^NY_@<MY=R\6"K=D;157N+L-22V@<`G4C0MTKXG
M^6^9<UYIS(U&T0Q=YNLVAMQT`#ZEB0-`0XW.XX?39GY\OTQ5VY;2\I7^-6Z)
M^%GIJL2T%1)>:CY^O2#J*F(QS$E3?IN&;YD(.D1ZM^TX$]3IF,3[#9>Y9&,^
M88D)P$HRF`00X+Z+.YM.5?+<VR%DHSC62""Q#:Z$*L-OM-]H<E;I6C[5LMNT
M#-6G2Z]EV#8G4C?4]=*V5[?FVQS5J>@'M?EBT1%)K4U)44)%-*N(2+I9LJ@4
M%2-=&JNFZ-4;L:,<T1L:(:.YMNUP7&[VVT[S`$'IS+K<BB5TZ,J4^7RG7NF7
MGLW&>_:00=OZO<Q[@)((U;?DTY.2NVDZHMNFX6FA66F\@)*=GZW.3-.CY=LV
MG:6\H@M+,TE75E480$?*/V\1*DF5G$DS:"J=V[Z*JG@>,:<RT8D(W1G6`"!(
MC26[1F<D`R&U@2S!3]Z5^%4<V<Z)0M)()B#K$Q[S[F`)$9;G(#N=2HBJ6RME
M6.(U-6;YMN3UK]2<;Z-)5.[/X&=?3MHW*C.6R'OS!$8FQUR,G]B0L<A6G36`
MDF$PG)J/'(BP5*59,]JW'QZY9-E.*+-N1(2B"`!6P,>()$2=X,@8LP[PT52K
M)R;(8E5^6:MV-$QD0296/(3&A`,P-A$");G/=.JS%QDI^L%_,(?0&P]A1NPX
MBQLY6@Q!)Y^Z38UR6T3Q_D&,M5Z](-GD4!'=V0EXMJY01%4/"Y;HG!5(YB<U
M1A9\$C.B!H,6D6XD66!B1K[.TD'L)T*[NE95_P#D$J\BP9`D#`.=`:JB#$'3
MVMT00.@@:A9/DC:WFLZ?:J_5=H;3?V:+UU/[CH\FZLKPON9!&Z2$FZ"-F8:-
M<NME(0;)T5`U;605AXVO(^X?"`&06)Q@5#(MKG9CUBLS$)!NC:!J">XY^>^X
MRT'2%US*TXU-M=65:;16;(G=T[B="!WV&FQMHAK+H*S]L>J-MU\FI5O?KK&R
MRG'&C6'6L:SLTHWA7`FA=RM7<S7(0`-#ORQ$JDS4!4J:A$)!RGW]5'!"GXK#
MXG+XFF!A[Q(3+!^,-">(</YAV*2V39O,Y#(F)^[1,!N+<+-0.!8MY"1TE9^O
MVN;E%!;['N5OJM=_#/JN>IE@BG\DP6D[N^0N)=GRR+MFF;ZIO4`NS@Q"(<@[
M[07((-5?=+!G$ZX1UQZHRL]XF)`L6B-NP=D3WN\&X<0P4E=LY%LFZ<*_=H&)
M!(>1W;S]:0[O=+\>!<J$[#9-U.:5N*Q6^W7BN[-IG'7CI?(^LUJ?=Q4+";J=
MP5F6V%%1T-$>%K8&BLY%M4'<6Z!ZT4*Z#N1[E$3%MPKQ!=BUU50ECSOMB20Y
M-;C:23PT)8ACIQXJC99FFC,LNNG'*ACTR$8E@+&EO``XZ@`Q+C7AP7:,DJFL
MFFLBH15%4A%4E4CE43534*!B*)G*(E.0Y1`0$!$!`<^=X:'BOJ000XX+SPB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$7@JDFLFHBLF15%4A
MTE4E2%43534*)3IJ$,`E.0Y1$!`0$!`<<-1Q0@$,>"A.V<9N.=[%8]ST-IVS
MK.#&44=S6MJ>_?\`E.90YEB2#B'.]27,94XB<BA3]3F]?4>MRKF&?2WA9ML1
MV3D!Z'5&WEG+KW\;`ID>V$2?2SJ,?P,\>H\.^DQFQ=5.R%[&[K4N[-Q:[(T+
MX/;`5O$UJ\LJ^!01].TS,Y>@F#IT.?NL?&,Z7ZZ5=@^O7"7K,7]:K?`^7Q_4
M1LJ/^[LLAZHR`]2]GX:ME00&-0.8G(B%$3'$K"[I:FVS$`4QRF!,3W/6JUK$
MI"E`H"$N!^@?I=3'$_GQ#'G^OY50>V.^!_)FWY*?#<FO_+\XR(]DO#L'Y4-W
MY2A2X\1MMSQC?4L/P:WZF<J7](VMQ?=4RT$,502G!.U5>XV]LD8C7J!5$HI(
MPB?IT*4H^2Y5S/&A^KGF4?@7;AZ#&/RJE=RC+L_6PP<@?[RC;+[492_-45CQ
MUV;30,$5Q>O5/<HH@D:7X@\]+S"M'*0NC+`DVH6UU-75(B:9"]3D635[Q[1#
MJ/0J5GW_`![?:YC"8ZK\:)_*AODJOP[)I]CE=D#UX^5(?D6;(_T]`-A;>I'D
M%3;7.S6,<B9RHNGOSB-3.1-;CE3]$4`=6OC[`*S1HTBW0">2:'N#MZJ%,8QC
M^>!BW?\`AL.R7^[NE43^+:6?\5/>,RC_`,7GU1_WN/&Z(_&J#M^,MHK?-'8*
MLA\IC]T<$-L23=1-L:M3-ZV#Q6V$^5,4`*DG5;ZRVJH22,8?UB0E3*40$?A$
M03".SE-`CNEB9M4>L1C=$>>.S12U\ZR#+9'-P+9#YIE.B9_%F)ZJQ;#DYLQB
MU;/;GQ)W&$6\.H#6RZCL>J=VUI9%$YB*NB%KEWBKF=N`E^'MA#'./4H%[@$H
M49<OQR2*N9U;AT3$ZSZXF/Y2T8\SR8@2NY3=M/36:[!ZI"7Y*Y[;G)QJ251:
M7&[RVHY)4Q$U(W>-!V!IA5JLIT[45WVR:Q6X8YO4.IDG2B8?9W=0'IR>3\P(
M)JI%L>NN4;/S"3ZET.><M!`NO-,NJV$Z_7.('K5B:G?J+?6?S&C72I72/[2G
M]]4['#V-GV&Z=IO<P[QXCVFZ^@]W0<HVT74G;=3*$NJ0(^5:-611D#=1="<>
MN)!^0K;<B4J81,(F$3")A$PB81,(F$3")A%__]/[^,(F$6HW*_T3744>=V!=
M*I1H0@*":7M]BB*W&@"10.K_`$Z8=LVPBF40$0[NH=0R6JBZ^6RBJ4Y]402?
M4H;LBC&AXF1="$.N1`'I+*N!>:FK+%W)Z=K&W>02P&%/W.GM96"3JOE'IXR&
MV7:TZAJT/-]I1";'X0$WV!UR_P#"<FO_`#5E5`^O,`_8CNG^2L[XUBV?Y.J[
M(/\`NX$Q^W+;#\I8"S[:Y5GB5YMQ0^/W&:KH=`6M'(;;0VZ4;`<.[N7JNNDX
MBG(F;I%,)@&YF`QN@!U+U,'=>+RW<("Z_(LZJH;1Z9/+_NU';E\UV&9HQ\:K
MZ5MFX_9@T?\`O%69[M6&N[E9C(\T.07()\50X#3^#.G_`)+4Q60,(NR_>%1Z
MS>9!HU`1*F`KWIN!>H&`WZ1@T!C3I`E'E-%`^ED3>7V9&(_[LK,EE0O)C+G6
M1D2^CC5M'[<8R/IM"R-?T4O+O$Y>E?E\UUQ+*$$6.R><VYV5ZM*9E>Q=245A
MDE^1UK1<K+E-U;B\BCE,/IXR>F<SS!$;;N=RV_0QZ]H\C_=#U%=5X)F1.C^7
MX[^B>38)2\K??2\SQ5G([4/*R99-V-@Y$T/4D(D4R"-6XZZ1A6:D>S$YC"BU
MMFVY?8;0RARFZ"HC`,NPPF,4`,)>S/EE<M@288,[9]=MAU_%@(_G%:<</FLX
MB-G,:Z8?1IJ&GXUAGZH!<@>%&K9P2GVE<MZ;N4(8Q_#M#=5Z<0`G.;JJ8U&I
MTG3=?"58``IR?*?&8H``EZ`'3SXODP_RU5-/X%<7^U(2E^4O?@N+/_-77WGZ
M]DF^S$QA^2IFH&A-'ZI!/[M-0:THBJ8%#W=4I-=A)!02AT*HXD6$<B_=+=!_
M344.<?Y\J7YN9D_YC*LF/K2)'H)97<?`P<3_`"V'56?JQ`/I`=2UE96TPB81
M,(F$3")A$PB81>)R$4(=-0A5$U"F(<AR@8AR&`2F(<I@$IBF*/00'T$,)Q5)
M.&?"^I<1%-XJ5X63@^T]IRMEB#MFQ45('7;7O&DTHY^T!5"NGD7X]X=I3^X#
MX0[>HZ_->;6\T]SWO]W6`>V7SI>=AZ%B<FY+3RCWXUL?%M)'9#YL?,Y]*N[F
M0MM:3LBAQ&T*-9]?3[J39PEMBG$-*K0ZK1O)>P=@!7!&J[UE(-T3J$^'N%(P
M@`^G0?7)J+I8]U=\`#.)</P_J4&31#*HMQ["1"88MQ;S@K<D4S)(I)'64<G3
M333.X6!$JRYB%`IEE2MTD&X**B'<8"$(3J/PE`.@9"=2=%,-``[KV87J81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PBUJRTRGW1H$?<:I6K8P`#@#*RP47.M`!0.U0`;2C5TCT.7T
M'X?4,DKMMJ.ZJV49=A(^116TTW#;=5&<>J0!^55TD.#O%APZ<R$'J6+UU)N2
ME`TGIZ9M&F'Q%"#U3<)JZKG*@7SE-ZB)BF`X>AP,7J`WH\XYB`(SR39'JF!9
M^>)+.ER/E1)E#$%<CTUF59_(,5C7'%BXQ""R>O>6/(JO)K%*@I$7R4H^\JVL
MSZG%1LZ0VS2[%:E_*!@**@3)%!+U`1$>@AT.952(\?EE$NV(E6?R)`?DKD\J
MN@",?FV3$=4C&T?]Y$R_*5>+;PGV([>#(O*!PAW%($7.NG8G^I+CQJV0)#>4
M?"KL+5<_?%E%B`)0(JFQ;@4PG/VAW`4+U7-Z`-HOS*H]0G&V'V9B/RE9UW),
M@G<<?!NEUFN5,_MP,OD"T\]#WMKDB9HS7O-O6#)FX`K(VCN36O.5]09'+W%2
M[Z?R6,%N7A^B?>*+:.*`@8>\`.(%--XV'?[5^'83^TJE3+[57=?RE1>!GXWL
MX^=5$</"NA?$?BW=YO(%["\L]H:_/[2Q\A:`@N"J::L1R]XL[GXS22'>J=)N
M7[T(14^MW8.3"`"JWB54Q^$Y!`I@`WGPS&OUKP9MUT75VC[![_IDGQ;*Q]+.
M85OU9%%E)^V.YZ(JPU0Y;[-F&Q'Y^/\`&;5@DD2G=VSBEOS5.\(DQ!*0$W[>
M'L;_`%19SLW!S=0*DU<J)E]`\@]O?1MY9CQ.WWXUS^C=7.L^1P)CUA:-/-\F
M8W?#Q;7]*BVNT>5B:Y>HK="<XN/T:*:.Q9:ZZ1?G,F0[/>6L-A:M;)F5,5-/
MMLMGKC2F.RF4-V][:36)UZ#UZ&*(P_!\Z3FB,+H_[N<9^H'=Z0IOCG+XL,B<
MZ)?[V$X?E2&WT2*L94-@T+8+$)2A7>H7>-$H'"1J%EAK*Q$@CT`X.X9Z];B4
M1]`'NZ91MHNH.VZF4)=4@1\JT:<C'R([L>^$X]<9"0]1*V_(E,F$3")A$PB8
M1,(O_]3[-5][[]O/N4M-\9IR$BR*'1+L'DI8VNH:^F0@&.I(M*'$M+EM20:I
MD+_RWT;!B<3?\PH`80U!AX5+'+Y@#+Z-0WGR;CM@/,9+'.?GWN,/EDHQ^G<?
M#'EVC=,^<158+3M,9N66K.SN;T_;;2!04=Z-X!ZV<NYMN[%,O;%R5F@&FY-G
MQZ8$!3^D*R=:*;O`YO%VDS1KQMD19C\HC&O]IDST\H!\.!\C3\ZR[<K?,U97
M.Y3M_98L-?(9#Q)CR[H>9<ZEZ=F'$L6QZDX)U6N32RA%D-R\V=D_6FQC!U-[
MF00AFCS=NPDG*RW<8K=U,P8FZ^H)E-\/EN5$1\/)YS*4/H8\-L/(_P!W'SB,
MEU3AS,_$Q.10C/\`:9,]T_*WWD_,91\RLC]PO("[ID';7*VTQ#0X"=>I<<J;
M7]/PB9C=`!H%JL)ME;+5:HI]2E.WEH]0WZ0]!`.E#WW"I_RW+8D_2MD9G[(V
M0],2M+W#F%_^;YK,#Z-,16/M'?/T2"SU;X6\9Z]*)6%[J^-O]L2^/ZRW!)SN
MY;8+@1`YW:4[M"4M;UBY44#N$6HH%`1Z%`H>F1V<VYA./AC(,*OHP`KCZ("+
M^=25\EY97(62Q19;]*PFR7IF9$>9E9YLV;,VZ+1FW0:-6R9$6[9LDF@W013*
M!4TD44BE323(4.@%*```?9F>22227*TP!$``,`O?GB]3")A$PB81,(F$3")A
M$PB8105N'D+1--K0T#(HSUSV1:R+&I.HM?1@679-O*@)RN'<=!$7;(QL"R%,
MPNI:179130"CY7!1Z`-S%P;LH3G$QACQ]J<BT(^4])ZHAR>@*CF<PHPS"N0E
M/)G[-<!NG+R#H`Z9$B(Z2J6;,W+M9S*M:_N#<S7CS*3S,'4'QIXO0)-\<IYM
M@ND)P3F[1].61A67"HG3*"\5`$8HF$XEF#%+Y`UL?$QA$SQ<0WQB=;;CX=(/
M8'!/XTG^HL7)S,LS%>9FC'E(:4T#Q;R.V3$1\L8-]=:<WT'(7L@.T^$5RV(#
MPX`G;.<?*R8=R+]/U40D7U$BGN]"Q[5!T0O6/,QC#@GU`$B=>@S'-C3I\7A6
MWS<>D,.P2/AOY7*A&!*_7X).Q_G9-Y<]IB#:WD:/D614X:3#4H.%.`7Y?SXJ
M)TE`;5K;%]K\Z8Y5""DK&S2W&9N2.<-E.BOD`Y3`4@@4>X0SGXK`Z?&LT>6$
M2/./%U77P:8U^`<O/X-DP?,?!T6#=UQ;4QR/WVO.:G$%)J`K_5NF=E*\IM%1
MX-BJ`F^LNOY!ULQ>.B$2D`5__NA')>(!$RR0B)Q[%@R7C&_$RB>BR'@V'L$A
ML<]7?/D49K.)WI8^;A@?.KGX]0[90.]AU_=CRA3O1^3&T:M6&EWMBM,Y2Z'4
M[BJ;_P"-;%TM:ZLW0`5'+S9ND&[V?>G3CD#@>06KSQRZ9>,_EBDP`1"E=R_'
MLL--0GC9O[.TZ'\"S3CT;@`>B2OT<SRJJA?:896!^UI'>C^'4Y.G28$D=,`K
MR4F[U#9%5A;O0K'$6VI6)F1_"V"">HOXV0;&,8AC)+HF,!5D%B&362/VJH+$
M,FH4IRF*&/=3;CV3INK,;8EB#H0MRB^G)JA?18)TR#@@N#_3U+:<C4J81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A%X*I)K)J(K)D515(=)5)4A5$U4U"B4Z:A#`)3
MD.41`0$!`0''#4<4(!#'@J]V_B5QFO;P)2R:,UHO.%$3)V6+JT=6K8B82"GW
MM[;6DHBRMCE(80*9-T42]?3IEZKF?,*1MKS+-G423'[)<>I9UW*>67G=9@U;
M_I"($OM1:7K6AFXA)P"1T]5\A^2FM$2`<K2%7V27;]11243%(S%6N;ZB-G@>
M,,0P]44G"'4WKW=1-UF^*;_\S@X]AZ]FR7IK,-?,H/A`K'^%YCDU#JW^)'R-
M:)Z=CA5VN/![8;N1&66KO#_<CT"G.$]/:DM'&[:JAA$"^)7;&D+#,'.H9,G4
M%B0R/C4-U(F4`'NOU<XH$=HLRJH]0F+8?8L`_.6==R/(,MYKP[I=9KE3/]Y4
M3Z=H6H&K7)+6:H*,Z]S7UJS;@5)%36NX-7<V-=H)HF,0&PUG>;5ON?Y<9```
MGLT"*IE$"E`!#O3E\3`R.-F)8?KPGCR]-?W;^50^%S+&+BO-J'U+(9,/LV_>
M-Y`N?%\U-G55^WB)W:W'*R.RG(D-=Y"4K='!'8BZYR"H:,.ZO\1L&DOY4ICE
M(0S9%!!7H(@`#Z!S+E./;$SAC7Q'75*O(CY>Z8R;RN5U#G655(0LR\:1ZK8V
M8L_)WQ.)/D8*S4/R[G$&#>1O7&S=$?$N`!1.X:D)4^1U#7;=4P,Y;2.H9^;N
M0D3!3N,"T`@8$P[P`2B`CGSY7`DQISZC(?-GNJEZ)@1_*6G#F]@B)7\MN$#\
MZO;='TUDR_("D"H<P.,EWD"PL-NBEL+$8$A"IW)ZOKNY?KA[4RC3=@-JQ:"G
M$WH)1:=Q1$`$`ZAD%O*^84QWSQ)FOZ4>]'[47'K5BGG'++Y;(9L!9]&1V2^S
M/;+U*R!#D4(11,Y5$U"E.0Y#`8AR&`#%.0Q1$IBF*/4!#T$,H+2XKRPB81?_
MU?MJOW%C5>V+A(6K:A[KL2.=%C@8ZWLMZLI]1PIF#)NS.JSUK&/XRKR:\D9#
MS.3RJ$B8ZQS"42$Z$+?HYEDXU4:\;97(.\Q$;R_UR"0W0S+-R.58N7=*W*WV
M1+-"4I>&&'T`1$OQ.X%395J?4J-$-Z]2JO7:?`-``K2#JT)&5^(:E``*`-XV
M);-&2(`4`#X2!Z!E2RVVZ1G=9*<STDDGTE7JJ::("NBJ,*QT1``]`T6Q9&I$
MPB81,(F$3")A$PB81,(F$3")A$PBK5R!W18*0K6-7ZEB8VV\@-I^_0H-?E5'
M):[68:-\!;'M/8:[(IW4=0Z<FZ3$Y2]KB4?*(L6WZU83IZ&%B0N%F1DR,<*M
MMQ'$D\(1ZY2]`#R.@6;S#-LH-6+B0$^86OL!X1`XSFW",?3(M$:G2GFM*3:;
M39+E1=#WB1=2)I56#Y9<[IEI%25_NMUBBMDI;5&DFCHKN+ACUU%?VY5T43P-
M33("#9-U)E54+J9%U===5V92!%GIQPXC&)X3LZ2_'Z4^):++'QJ+;;+J,"\F
M3M?E%C.4AQKKZ`W!QW:^`>3E7]U'HW6.CX9Q$Z\K2$:XE%".[+9GZ[B;NMTE
M0+T5F[I<)51W8+/++G$3"JZ74`G=VIE(F!2!B969D9DQ*^QP.`&D8CJC$:`>
M0+?Q,'%P8&&/4Q/M2.LI'KE(ZR/E/D4MY65M,(F$55-E<7XN1L;S;&CILNC-
M['[5G-QKL>4]4V'X3G5"$W+16ZS*(O\`$O!.)/>*`G-,>H*-':8E[3:6/S&4
M:QC9D/&P_HDZQ[:Y<8GL]D](65D\KC*PY>#/P,_Z0'=GV61T$QV^T.@A5"KL
MQ>:1=+G?]749.E[TJ)4I[EKPWBGYSU3<M?>&%$.0''PZB:#5W9I,C,YFSU!!
M,TPHD:*E2)R:22BFI9"FZJJG(NWX<M*;R-:S^RM[!TCYOM1[I617.^BZ[(Q:
M-F=#6_'![M@_:U?6/00.][$VD`3V;:]V!4=J4FL[$HDPWGZC;HIO,0DHW`Y`
M6:K]2G1<MUBIN6,BQ<D.W=-5BD7:N4E$52$4(8H?/7T6XUUE%T-ML2Q'].CI
M!X$:A?38^13E459%$]U,PX/].!'`@Z@Z'5;ED2F3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PBX,G%QDTQ<1DQ',9:-=D%)U'R;1N_8N4S>@IN&CI-5!8
M@A]H&*(9U&4H$2A(B0Z1HN91C.)C.(,3T'4*LDQPGXQR,BM.0VKH_6]B6^(;
M+IF9LFE9X%O00<FD=5S%14<+@8.HBL"H&'KW`;J/70AS?F$8B$\DV5]5@%@]
M$Q)9D^2<LE(SABBNSKK)K/I@8^M1[;N'=QE8XT3$<B;';X'KWA3>3>L]9<DZ
MEU`XF\?FG(2I7T43D^`WDGE3B`]1$1`O2>KFM49;I8,8S^E5.=4O491_)5>[
MD]TX[(<QE.OZ-T(71]8C/\M5Q/Q1W5K4YW50U#6&(]7)PDN&W)+9O'-Z)C*^
M7H.DMEFLVEGA%C"!BI.I11(#A\7H4@C?^)8F1I;E2/9?5"W_`+R#6>@+.^%9
MN-K3AQ';CW3I/[N>ZOTR62@-][DU7-1'WF[+W54:8R?L$I]IREXEEL0'AP<(
MC)I1F_\`B[+(:X92J,>FM[9S+,U$U3]#+`(_";F>%BY,)>[X],K2"W@W-KT/
M7<-[/Q$3Y%U7GYF+.'O.3?"D$/X]#Z=+6T'8"W`R'E5O?QR</?XE-._]N(7^
MLYE_!^:?Z"W[)6O\<Y/_`!*G[07_UOOXPB81,(F$3")A%X**IHD%150B1`$I
M1.H<I"`8Y@(0!,80#J<Y@`/YQ'ICCP0D#BO/")A$PB\$U4UDRJHJ$52.'<11
M,Y3IG+_.4Y1$I@_Z,<.*`@ZC@O/")A$PB818R:F8NN0TM89MZC'0L%&/YF7D
M''=X&$7%M57K]ZOV%.?PM6B!SFZ`(]"CT#.H0E9.,(!YR(`'63P7,YQKA.R<
MFA$$D]0&I*ZFHR0V!>6<3.Q;R2K/(/\`,`E'*L/+'`AI[COPMIZ1WS9Q$=H?
MV-/EJ$PV5*(>#R7*TD4.(F:%[?I91HI,H2`E@X0U'1;?+37K&X'_`+.':ODX
MRR+Q"R),>8<P.AZ:<:.NG4=I'5]Y/L7:30:)5-84NM:^H\.V@:E48EK"P44U
M`?&U9-"=H&44,(JN7;E43*KKJ"95=<YU%#&.8PC\[?=;D6V7W3W6R+D_T]74
MOJ,>BK%IJQZ("-4`P'9_3B>DZK;\B4RC'<>TH;2^N;!L>=8R$HQA%(-DC%10
M(#)2TQ9[%$U.O1++W*J*/N92?G&R!>XWH*GH`CT`;&+C3R[X40(!+ZG@``9$
M^8`E5<S*AA8UF39$F,6##B3(B(`\I("D[*ZM)A$PBJMR>U;99V+@=S:C:I$W
M[I)1W8Z,!0,F%]KABD5NFF9XR8E,[@-AQ3<440,/5E+)M'29B&3-W:7+LFN$
MIXF4?\%=I+ZI^;8.V)],7"RN:8MMD:\W$'^/HUC]<?.K/9,<.J3$<%"VA;Q6
MJGMVMKT58Q-`<V:S)[FU<Q71!H-,W;&QC2;V93"LTS'2BS7BMG4G#L^OZB8B
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M+**Z5D:K94P$K1$D`Z`GH#]#\'Z%4^:W\VNVA9[:S*GTV^T8E?T[*MX6R$53
M;O+):UJI8)AI)1[EI.MBC1VUBC'3<IB@N:6(JU4%JHT]PII0PC5FPQC;.%VZ
M8<=4=P#'3VF(/U6.KLLJ>>+\"S+C3"RC;66/7+:2XU]EXD=.YP69UGK;O79D
M1(<AG4/2Z*K4^/<7./Y9U)6V?^HK(=MIJ(VC!%CHMK4RQK$KQ_*?+W8*O3BW
M1+[A,5C?J!XJP\>4<$3MGXMY`#1##[PP+G<YT#C3LTXJ2[.R82Y@84U^%C@D
MO(N?NQ,,-K#4L==..O!9>P[VMT3);`C877_U>_K6B:;N.MPL([>'FYUY:).U
MPZ]6!D1FY5>+M%ZN99$6A%'+LJP()-S+`3R<PPZI1HE._:)72@2>`8`OZ^G0
M<79=69]T)9$88^^4:(V`!W)D9#:S?5<-J>`#\9,T[L9CM.C-K=%3M>LK=61F
M8XLG7V<W"('7B9!=DLSEZS8R&L-/L$>LD*#^,>&57:.$S`)C`(97RJ#C7&J4
M)1+`L6/$=!&D@>((T(5K#R8Y5`NA9&0<AP".!;6)UB1P,3J"JYZWW1=IUEIR
MDZ[UIJZEAL#4>ZKW&M/G$LA5ZA(:GV1KRFF@&D'!U6-]_%21MC)+>X349',<
MJA_"3L!->_D8E,)95M^19/9;7$Z!Y"<)2=R2Q&WAKY>K-QLV^R.'1CXU4/$I
MLD-3MB:YPBS"(<'?QTZ=.@V9TY?_`+V-1:KVG\L^2?>5KBCW_P"3>Z]]\I^L
MJQ%V+Y9[WP-O>>P^8^+R^-/R=G=VEZ]`SLJCW;*R<;<_AV2B_!]I(?SLM/#R
M/>\3%RMNWQ:XS;BVZ(+/V.I'R!64PB815$YM*+2VE6FKVQU$E]\[.U9H]=1(
MYB&)7+[=8EOL`P^-5%8Q?NW93`"!#=0^T0$H"`Z?*&CEG(/"FN=GGC$[?R]J
MR.=O/"&*.-]L*O-.0W_D"2XFEF3>W\E^3&R/;H?+-<_0'&6AE1312;1<95ZM
M&;.OR<:BB/:BG(VC8;-HOT*!1&#1)]J0E+UEDU<OY?COWK-ULNTDF$7\@B2/
MPCUKS"B+N9\SR6[M>RF/8(Q$YMY93`/X(ZEL;SD*_P!>;46UYO6LM*#7+?/_
M`"_2NVV,@M(:[N1G0`+*D6R3=-FAZ#M`W0PH,WG]`ER%-[%RHJ0Z!8Q@QOQA
M?AV&=D(O9!FE'ZT1\Z'61K'I#:J0\PECY1Q\ZH5USDU=@+PEU1D?F3Z@=)?-
M).BL%:;=4Z/#.;%=;/7J?7V?3WD[:9J-K\,TZE,</<RDLY:,D.I2&'XCAZ`/
M\V4JZK;IBNFN4YGH`)/H"T+;JJ(&R^V,*QTR(`])T76YOGE'I[:\_P`=:W6Y
MJP/-3%Y&ZZL>PMS+T:X,=)-$:BUL5IHE?4V3*PC*IR;BS[3B(!!%9LNX8)]_
M559/TZ;V%R[*QH9UED(C)\"0C7NB;.\PD=@.X-`RX@'J"^;S^:8>79RZNN<C
MB>\P,[-LA7W7E$;R!$[IB`!!(ZRNT3/G5]0F$3")A%U`7IH&L*)R4AV#<R1>
M'/*G7W*+7":1"E;L-<["=0&Q[W"LTU3G5:1:K2TWZ+,*1DB%05$I.TI#!GU%
M)]XNY?*1_P`UC2IEVRB\8GRZ5E?(7CW6CF4(C_)Y4+X=D)M.0'9WK8^1=O\`
MGRZ^O3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB_]#[
M^,(F$3")A$PBQ%@G8RKP,U99M=5M#5Z*D)N6<H,GTDLWC8MHJ^?+I1\8V>2+
MTZ+9`Q@20256/TZ$*8P@`]0A*R<*X!YR(`Z-3VG1<661JKG;,M"().A.@U.@
MU/F4;PVM]3V75C2K0U;;IZRMQUKLC",5Y>%;NUKA/K;#<OS`S>,I!J,A8)8[
MTR'>0B:A^P"%(4"!8ED9->2;)V?XB/=?0^R-K=6@#*M#&Q+,450K_P`-/O,'
M'M'>_0=279;`75U%`]\,I!BZ+L]N9K?D)"4F9)I9FYH!I5C)OV3^1<LR@:NL
M4F8BD1,10)V_RCUX]XN^Y[[>'[+`!M7Z!UZJ3W6C[]X/XOMN2=VFW4$]0;R+
M487COJBO@L,;$6/W3BH05$6E)'8^RIJ</5ZO*.9JM,1GYJWR$V#FORCM59D\
M!P#UJ8X^-8H>F23SLF;;I1;<9,(0`<AB6$0-1Q#,>I10Y=B5OMA)]@BYG,G;
M$N`YD3H=07<=!4BU>F5RFQ3J'KK)=DS?24I,2"J\G*R<G(RTTY4=2<G(S<J^
M?33^0<K*?\Y9P=0A"D(42D(0I8++;+9"=A<@`#0``#@`!H!YE8JIKI@85Q8$
MDG4DDGB2222?.M4@-+:WJ[NN/X&"=QKNHUZW52MKI66U'-$U^^2T/.VV.;`O
M-JE[9F8K[%R=0P&5(LT2,F8@D+TEGEY%@L$Y@B4HR.@U,01$\.@$CSE15X6-
M4:Y5UD&$91'>EH)$&0X])`/F"V^GU&O4&J5RCU*/^4U:HPD;7*Y$@[?/B14'
M#M$F$5&H.9)R\>J-F#)`B20**G$B9"E`>@`&16VSOLLNMD]DB23UDZDZ=:FI
MIKQZJZ*8M5"(`&I8#0#770+9,C4B81,(JE\H>GU7P]%?N]@7EI7??_I^+J;2
M^\20_G*3U,7ZE.Q[.O4`6[!'T#J&GR[]7S1O:]V+?O*W]3K)YI^MY._L^]A_
MW=K?E,OSB6!2I<D2J=_OPY:[M&0%45#*]RCV%5BN\Z@CU(%<49`D!1[2H]A0
MZ=.@.9\<#J]UK;UOZW3E/#F7TO>['](;U-YE-^WVU#<ZLV%]Z$%%6;7C.GS\
MM<8.;9-Y",?P$+&N)A^1RU=$.B84D6(J)FZ`9-4A3E$IB@(4\4W#)H]WF8WF
M8$2-""2P5W,%!Q<CWJL2QQ`F0(<$`.?D72=PWX=5/ES1Z#MO<R%H?T&KQ+*O
MPK25NEYG+5LNW0Z(,KK)+W*RV.9L%*U?39PBU9B(BM.8PLD$0J[=JJ$5(D/U
MW->:V\KNNQ<0Q%\BY:,0(1/LC:`!*<AWY2F"VX`#1U\5R;D]7-Z,?+S!(X\0
M`'E(RG(:2.Z1)C")[D8P,7VDDEV78M<?R].-5AJTE7JQ6YO6+U]&KQJ<]1K7
M9&Z@H*I`G[6?KTQ*2U1N\,H!0*LPFF#]HL03`)`$PFS"JYYS"%D9V6"P`NTH
MCU$`2B>V)!7T5W\O<MLJE757*J1#/&1]8),9#LD"%4'CEOS<_$R3L_'CD"TL
MNY:]2M@1NK=<SU)9+6+93>2L-9>7'6L&:N/GQ9&QT2^4V*>*Q#TKIPX@'T4_
MC'QQ:-VSHNIGX6)S.->=@F-4YP,Y"6D&!VS+\!*,B-P8"0E&0U)"R.79^;RF
M5O+N8"5U<+!"!B'FYCN@&)<QE$':7)@8RC+0`J]L'?>66P9B-<1&E*5I"BED
M&2TA(;GN`6_9$G"^\(9XA'Z\U8[<5J!D'$<0P)JO+4L9NLH43M5`*8@XTZ>6
M40D)9<[KFT%<=L`>V4]2'ZH:]:W:\CFV1.)AA0HH<.;);ID=D(=T%NN9;J5L
MLS%K)A%U:<AS,@>?FFF6,U!L'!O6Z2QE12!`)P:;RL%NFH)OU?S44U6'8`_K
MNTS?IZ"GGT>"[?RXSO[Y/T;J?5Q]:^6YCMW?S2[-[C#T[;_7P]78NRVJE7+6
M*X5T"Q718&'*Y*X`X+E7"/;@L"X*?K`6!3KW=WQ=W7KZY\_8WB6-PW'Y5]+4
M_A5OQVCY%GLX4B81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(O_T?OXPB81,(F$3"*-]Q__`)0[4_\`#>\?_AB4RQB?YK&_O(_*%6S/\GE?
MW<OS2JLU^T;*@WVD:+&V&<1KFW]%:\3I#N/A*PY1HENHAJP[V.9=^_KKPJHV
M76DV9['$DCKH%<PSM-/JHX;)%T;*\>8S+I0'B572W.3WHR?;P/1,,6;20ZBL
MNNW)A+!HC9+P[J(;6$>[*.W?J0?:@7#N'B1Q("Q%[WUM2BVG=2!5)"S`PI>W
M['I<E:;4^T4216UE6:^,Y7+="Q,:SVO`["I\^Y\ZR"CIQ%S#9T*;8Z;A5L@C
MU3A8UU>(=(O.`L?<)#>2QB2=AC(<"SQ(<Z.3Q?GY5%N:-9-"PU[=LHG9$.)`
M`6"<3J0YC(%@Q(`WO8-]V77)%]`T38D#96\_H&:N<-;[C]*Q<75[PC;*/6]>
MK.IN#@DXAM%;<0M<G[!5XP>-6[J`.H!5D?,CD-%./9$3NHE$QO$3&.XDQVR,
MM"7>&T.Q!:706*GR+\FN4JZ,B,A+',A*6T",MT1#4!FLW29P0#!]0X6.UGN&
MXWVTZ_IKV4O=,)(,=[(VA>V1&N5[:78VL+92Z\?7B$]6H9]K>49P[2>E'J+F
M.;>>2:,4S=P&9R)3=9&+537?:(PFQK;:9;=LXR.YB1,.P#$Z$]L5SC9EV1;C
MTRE9!Q;NW"&[?"41L>(,"`\B"`Y`[)+3XC96YKU<]%4HVRI"E--AT'ETK(6:
ML5J@NU9_[E=I4.G:LVI#$M-:M$8V:7:H60)HS8I5&"J+U,"%*4"FR66/B4U9
MEWNXF:YTL"9:>)"4IP+$'NR&U^.BAADYM]V#3[R8"RO(>48PU\.<8PF-PD.]
M$[FX:K287D-NV&UWKG9;BS?>`_V5^7M=N22]*6K=>28P.S:#%Z,>@O7F]7AH
MRS.H*9^]EX+J/<O'ZRIX],C0R!A.4\T\'$G??CBO9&O.C5N<N82-G%R0XV!B
M`..KJ&',<V&/C9)M\25O+Y7;6#"<!4=-H$F/B%P2>&C*Z6EY:P3*$W(R>V*E
MM2%D$*_)UMS6BP:ZT4SD6;I=0SN5KS.)CG\?+H@@LR`69%DP*H)EE2G("63E
MQA`PC'&E7,."[ZMV%R".G7S#IV<*=DQ.4LN%L"Q&UM'[0P(.C:/QU/1-^4U>
M3"*I?-1LZ8Z2'93!%=P]T1L#6N]S(-T!<*+0&L[E%35\2\9$U5NU777S<HBF
M'DZ#Z#FGRDB67[N3I="=?GG$B/Y6U9/.@8X7O,0\J+(6^:$@9?D;E@-53\/K
MKD;R5J4E+Q<?5-E1="Y2TR4</4$8A>,EJU%:KV0X))KJ)LTT(V<HD2^6$3]I
M0G4C]>BGIWDPG?@<OMC`FRLRID.EP3.&G:)2'XI4>+9#&YCS*F4P*K1&^)?1
MC$0GKPT,8D_A!0KS`Y7Z;OVD=HZKU=:Y/9SVQLXNH[`L.J:M;=A4S7^N9ZQ0
M\1M*RV^^4R$FJK#-8+7[R25.F#M1T*A2E!+H83!;Y7RW+IS,?)R:A6(DRB)F
M,92D`3`1C(@EY-T-VJESCFV'D8.5BXMIME(",S7&4XP@2!.4I1!B&@_2_8I<
M_+^LM9<:$0UK#2<(]E],6VXT:;3A'C1VS>1SFSS%FHERCUFJRI)""V+0IR/F
M6;\GZEY[I02"(D/TK<[KL&:<B<2(VQC(/UL!*)ZC&0,2.AE;_E^VHX`QH2B9
MTSE$MU;C*,AUB<2)`\"Y5X<QUN+I\J4FSW7^:M9Y2NF*_H>HZ&S>/9=,_DC9
MC8NLH>X:W[F0?`1XG$+<C)N/\O:=,DA".2IJ"9,0)]3;$XG\MUQLTNMGPZ1&
M9C/U^%$^207Q],AF_P`U6RKUHIK!)Z#.`E#3R>-(>6)7<'GRR^P3")A%T]7!
M_P#>E0=_3#93R#S5Y;4GC;KA5H*2R$AJ763Z&U_<9Q$Y2F5<P[B!H=ZEA[A,
MF=%8.T.U4`'ZFJ/NU^%`_P#A,65LNR<P91'E>5<5\?=+WK'YA,'_`#N7&F';
M7`B$CY&C;+_VKN%SY9?8)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81?_]+[^,(F$3")A$PB]#ELV>(*M7C=!TV6+V+-W*2:Z"I!$!$B
MJ*I3)J%ZA]@@(9Z"0006*\($@00X6H-::1O<BV@9-08Z/K):[6ZJC'QK.)KR
MCR0%[8Y5NJU;)O';N=(RCT>Q8YDVB;,WA`HN5^Z4VO5X>WO&3DN7.F@\VOE?
M7@%"*6N\7=W1%A%@`-7)Z]6'D;3B5LB,-$-Y-Y--XJ-0F9%!NVD)9%BU2DWS
M9H`@T;O'Y$BNG2#4##XR'.8I.OH`9&9R,1`R.P<!T#S*40@)&8@-YXEM3YUZ
MV\!!,VSYFTA8EJTD_+\R:MXYF@VD/.F9)?WR"2)4G?F2,)3^0#=Q1$!],&<R
M03,N.&O!>"NL"0$``>.G'RKU?35<&);0(P$(,$R*D1G"_*F/REH1`!!$C:.\
M'LT"H@8>T"D`"]?3/?$LW&>\[STOKZ4\*O8*_#CX8Z&#>A>]>#A7*J:[F'BW
M"Z30\>DLO'M%54V"B2R*C)-11$QR-%$7"A!3`>P2G,`AT,/7P3F`PF6=^/2O
M3"!+F`=FX='4OQM!0;-5LNSAHIJNS14;M%FT<T05:H*J+*JH-E$D2G0145<J
M&,4H@43*&$0ZF'J,YD$&9(/:O!7")!$`".Q?L1!PM?:#'P$/%PC`5UG(LHB/
M:1K07+@W>X<"V9(HHBNN?U.?M[C#ZB(XE.<SNG,F7:77L(0K&VN`C'J`;Y%E
M,Y7281<&4C(^;C)&&EV;>1BI=B[C)./=IE6:OH]^W4:O6;E(W4JK=TV5,0Y1
M]#%,(9[&4H2C.):0+@]1"YE&,XRA.+P(8CK!XA=,]HU$63@(K4%HH\'MK<O`
M6QHW;6%.NL1%SX<@^(LZ8\:UB&#.;1<,Y:P,*NS)$=XHJ%:V^ML#J"4CPIC_
M`%=>5MG+*KNE5B9L=LY1)'A7#5RW`$][MA.74OC;<3=7##MHC=F8$MT(R`/B
MXYT8`Z$B/=[+(1?BNV'4]PU]L/6U0M^KEHMQK^>A&[FNI13-&.9LV/0R*L2I
M$HII%B'L2Y34:NF1B$4:.4E$5"E.0P!\UDU7T9%M62#X\3J^NO6_2_$'I&J^
MKQ+L?(QJ;L4CW>4=&#!NIN@C@1T'1=6/(GBZZXH6^1Y5\=K7;-94!HC_`/->
MET%2#77K,;(S0N7EAJ=/MK9[5+S3B24FJY<TUQ[11JX64<03MDJJJV7^CP>8
MCF=4>6YU4;+S[$I/J0.$I1[T9,&$P[C28(`(^6YCRL\INES7EULZL<?K(P;N
M@GC&,GC*+ES668ZUF))!\WM5_-$Y!-?IY*_Q&EM7/VX(R%FMM"AM6;0L,=W@
MFHC]*T'8FWK##'>=O<H*,[4GHI]Q2^$#`40L_EW!.\T&[('`1D9P!\LHP!^S
M,>5>RJ_FCF`\,9`IQ3QE*`A,C\&$["/M5GR*5*IQYVWPT=1FT-?NFV_Z[&46
M!UOL'54!2("@SL%K6JS,Y8HR4T.P8.WRLE-P\O:Y>2E(F:D9*3M"SHPA("]*
MB!ZUF=B\U$L>\&BPS,XS,C(&9`!%A+,"(Q`E$`0;V6=6JN7Y?)C'*QR,BL5B
M$X"(@1"))!J`=R#*4I1D3*;^UN9=@&M-FT;;]-B+]KJPLK+6)E,PMWK,QBK-
M7:(^-]$2S%8J;V&G8IR`H/&+I-)TT7(9-4A3E$,Q,C'NQ;94WP,;!_1QU@]!
M&A'!?08V31F4PR,>P2JET_*".((X$'4'0K?,A4ZJ=R>V596[6"T'J"0%+>V[
M".8F#?,R%=*:LU^!RM;SNV=2\B9&<=4(Y8R<4"IB#(SRK9LD"G18":?+L>LF
M>;E1_P`'3J1].7S:QVR/'JBY/0LGF>3:!7@8<O\`'WZ`_0A\ZP]D1[/7)@'U
M42\?JA6KQMF#EZ"U]MQWX<U65T%H\Y5"K-[CLH[*.@-IWUNZ*FA\U:5*&BR5
MMN^Z*$>2#F94(H;N-EG-MLIQ9QN/^.RI"RSZL-3"/9N)WD=`$%4Y?35?EUSQ
MPW+L.!JJ^M-@)S[=H&P'I)F7787F&OH4PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(O_T_OXPB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$5<^0&E9;8S>MWK6LVQI6^M7.74KJ^YOD'"\.Y(]!$M@U[>FC(Z;N6UU>FC
M8K>01(;RM5B(/4`%=L0IK^%EQH-E.1`SPK-)Q''LE'JE'B.O4'0K.YAA3R17
M?C3$,^HO"1X:\82;C"7`CH+2&H5*]=6JVP5]O%TTA3S5C:IE$9WE=P+M$PQA
MWTG/.A23=[KT)/N5$:ZZE)L"AW/D!)`VI$Q/=J,91/X]:^JJ=--.9;NQN%.2
M`2`/V=@XL.KVH=#Q6+CVW5Y%]V#3MRN-^+(@$G]I4>#GK'=GTF,@I"VUO/7/
M)RNZHU#0)214G+OR'U=![6UU-Q3^M;&H%<U\X<;MML;?:C)H(35<;O&>N2QH
MN3%%F\,[Z-UUTA$1@QL._EUF3E7Q&R%$S"0(,9&7W<3&0T/M.W$-J`K&7G8W
M,Z\3#QY'?/(@+($$3@(?>2$XG4>PS\"^A(78]F"OHTPBUR`IU3JKJQO:S6H*
MON[?.K6>U.8:*91JUBL;AHS8.)V:49HHFD99PT8(IJ.%>Y4X)AW"(Y).VVP5
MBRR4A&+!R[#J'4->"CKIJJ-DJJHQ,Y;I,`'/!SUG3BJS7WE,W>V-_J?C;`-]
M[;D;G!G,!%OC):HU0HL)R%D]P[%:$7BX86OC4.$&Q.[L#P4A33;)@8%0T*>7
M$5QR<^?@XO0_MS[(1XG\(M$=?0LS(YH)62Q.6U^/F#BQ^[K[;)\!^"'F>KI5
M4*=7+3L:P7/7>GM@N[I=K>[+%<P^<;5@@T;1+>-3*F?0_'@J1EXMG,QS1X9L
MB5@HNPJB2JCIRJYFU1[-*VRNB%5^50(4Q#T8_6_^TMZ6/'76?`-`+)IKMR;+
ML?#R#.^9;(R6X-_LJ>@$<-'%>I),RNT*D4FJZWJ%<H5(A6==J52B&4%7X5@0
MQ6T?&L$2HH)%,<QUEUC`7O564,=9=4QE%#&.8QA^=NNLR+;+KIF5LBY)Z25]
M1115C4UT40$:8```=`']/.MIR-2IA$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81?_U/OXPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M*%=PZ"UWNQ"'7M#65A[=55EW=&V72I5Q5=E4-^X)V+.ZM;&`>[;(N.A1<,G!
M7,:\["@Y;+%*`!;Q<V_$,Q60:I>U"0>$AVQ/J(8CH(5+,P,?-$#:#&Z'LSB=
MLXGZLAZP7!Z053#9FB=O^ZCG6V-45'F$PK0D^E-P:ZFF?'KEW4&J0++"*<A'
MR=5K4\LT$WH>(L5=*[4`!-'&-Z#K8^9BM(8V3+%E+VH2'BT2\Q$B/QHR;Z2Q
M<G!S'B<O$AF1C[-D#X61'S@QB?Q9P?Z*C]#:TCK[^SB\K.5NFDRB8Z-;Y:\5
MI#94>R$YR)CX=GPM*@0F6*"RA0,=2VOP`A3#Y0Z'4"<XT;^]\-QK3UTW"'Y!
MD6^P/(H!ERQ^[\5RZ1U7T&8'XXB''_:'RK(J<GYEP`(G_,+TB(''M`E6X<7I
MQ/*G,`E22CD'.X+2FLL942]2`P7,8O4"@41`P<_#H#7X'=Y[XMY^X/E"Z^*3
M.G_Y#1^+CR?S?>2^0K"O"*;>*HT?->=',MM)#XRP<O!)<1^.[M$OP])H7<3H
M]Q8H5'O[E"*_49'`D+^H5$!Z]#_"ZQ.'B$=(/C6^;6QC]ENL*.7^,<2&=F@]
M!'N]/GTJ<?;?J*L+5>,&R+K7V%3VM)4G2>D6B0E:\8>+Y']:@I!FN8IU8G9>
MV$V==L%G9N&YSHOF4%'5YJZ,(^55R3U/2LYCCTSE;C1G=EG_`&MS$CMA#4#L
M,C(CJ"T:N5Y-]<:LN4*,$?[&AX@CJG9H9#H(B(`])*N_5ZM6J37XFIT^`B*O
M6(%FG'PM?@(]K%0\4R2ZB1LPCV22+5LB!C"(@4H=3"(CU$1',>RRRZ<K;9F5
MDBY)+D^4K;JJJHKA536(U1#``,`.P!9[.%(L,_L5?BWB4=)SL-'2"T;)3*+%
M_)LF;Q6(AO;_`#>52;.%TUE(V*]VE[E<"BDAY2=YB]P=>A"<ANC`F+@<.D\!
MY3T+B5E<2(RLB),2Q(X#B?(.D]"U.5W!J6"8M92;VCKJ'C'T`K:V,C*W:M1[
M%Y5D%F[=:RM7;N31;N(!%P\23,\(86Y3JD*)^I@`98XN3,F,,:PR$MK").O5
MPX]G%0SS,2N(E/*K$3'<"91`,?I<>';P65F=A4"N1L9,6&\4^!B)M%%Q#2LS
M9H6+C9=!R+,K=>,?/GJ#5^BN:0;@0R1CE,*Z?01[R]>847V2E"%,Y3'$`$D>
M4='`KN>1CUQC.R^$82X$R`!\A)UXCTKFJW"I-Y8(!>TUQ&=%XVC@A59N,3EA
MD'C(9)HQ"-.Z*\%XZC@%PFEV=YT?C*`E]<\%5ICO%<MC.[%FX._ET71NI$_#
M-L?$=F<.[.S=;:^1<-;8-";V)W4'%WJ"%LCX9Q8G]76LL,E8F5?9^/W<Z[A#
MO2R3:&:^8GD='2*@3O#N,'4,]%%QK%HIEX1+`L6?J?@_8N3D8XL-)OAXHBYC
MN#@=;.[=O!:/7-UZ_P!C&H\AK':.KK)!V"QR\0Z30L3*1EYWY=5)R:&)J*#&
M43-]1M#M&\BX1616,$*FNKXR]2*EFLQ+Z/&CD8UD9QB#P8!R`\M.'$#ZS#L4
M%>;CY/@2Q<JJ4)2(X@DM$EHL>/`E_FN>U;3";6U=9IAK7:YLF@V"P/F3Z390
M4)<:[*S#R-C%TFTE(-8QA(KO7#*/<K$375(04TCG*4P@(@&1SQLFN!LLQYQ@
M"SF)`<\`Y'2I89>+;,5UY-<K""0!($L.)8%V'2N=#[#H%AD$HFOWBGSDHNS+
M(H1L/9H63D%H\W>)7R3-D]7<*,S`F;HJ!1(/:/KZ#G,Z+X1,ITS$79R"`_4N
MH9&/9(0KOA*;.PD"6ZV!X+<,B4R81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M?__5^_C")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%#F^=R--!ZT
MG-IRE#V)L*#K($=6"+UC%P,W9(J$*FLH]L:L7/66L$<PL0"91=F;JK+H)'\P
MI>!-95*UA8AS<B&-&ZN$Y<#,D`GJ<`ZGH?0\'=@:>?F#`QIY4J++*X\1``D#
MI+&4=!TLY'%F<CHVT!^9ULGD/RCTKH6J2$]'ZYFMV;%LLE;K,PA6&P;503DM
M5RHVNIJ/@W,C!PS"L-R$8.EFCA5620:H=3)%!=-Q]AF_R]CX/+LO-LC$WBF(
M$028B6D92!+$OQ#C0D\=&^'Y?_,^3S'FF%@52D,:5\Y&4@!.4.]*,"`X`CP)
M!U`'#5_HLSX5?HB81,(H"V55KRMMO36PZA!1=C952)V?5+"Q?6$M>68(7U"F
MN8R?354C9(KV/CWU,\+M)(IG14W95$DUA3,F-W'LI&+ET6S,3(P(T=]NYQQ&
MIW:=&FK*ADU7G+P\BFL2C`3B02S;]K'@7`,6/3JX!42::TSL"D/>-+^T0,6H
M?4G'';>KK0E$R[&2$]FN=FTA,P81"KXD7[MD,?JR1275."()*OFQ0`Y#N#M[
M67ET7#F$:YG[V^$PX(TB+`7X],QZ#V/3P\+(HERV5M8^YQK(28@]Z4JB&=M&
M@7\H[6UW3^I=[ZAC=802U2HNP:^/&'1FC+C&2UN&&)3+7I^,LD;,2K/K6IUO
M:J'="V(Q^A4DI),S5+R-Q*H)&_>5DX65+(F+9PG[Q99$B+[HS(('$-*+>37C
MUQX>)GX<<6LU5V5^ZU52!DVV58D"?9.Z,G\N@<=6_P`II:WOZQLC7:R;)RUO
M.^&&T8R^D>-TG43`GNE4OBAWZ"Q5),MUIRT"K%P@H).&OMVL:H==``62;PQR
MZHV8]X=X4F!CUG;*.G1MD[RX%S+0Z$V)85TJLG'(!$[Q,3ZANC+7IW1;;%G#
M")<:@8V(UIM_[YZ):Y*LTZ+J-,V+OIR9&!G6#1BK7-E'E).`MD?#)50DRK89
MCW"8V,KR1.*D^LNJV(#,Q5"=2R,7W2ZJ-DS;.NOB#Q@P,279A\UA[+`ZKF&-
MF>^T6RJ@*866\"&:;D2`VNY^>Y]MR--5P-?Z@V="T_B!7YZO1+9WQ]V'*R%E
M7CK$TDB2==1TCNC4K*4BA6:QP@M*S&PX]\5J<>Y)@DN*A@<$2;K>WY6/.WFD
MX3+7U@!PS'Q*YL>/`1(?K;HU'./AY4*>45V5@''L)DQ=QX5E8(X<3,%NI^E@
M<6PU79J!5M335CC&3.(T_?N2NS+NNV<`\\-4V!';A=QQX]M#"K+23ULVO+4S
MM!L3SA[9<$/,<J`+=2R:[[,J%<B96PJA'RQ,'=]![)9^L.VK<1Q;<>K$G9$"
M%-ETY?@S%C,VI/>#@:Z%GT?"<6#V^M3FHZ_<Z`T!]*<<*W7J_=*SM6$O,-%T
MW7Y8Q9B@Y@&5(ICR-BYUU92IM'RKB94.9HFB*PF\RRO?,O"LAE3JOT&028F!
MB3*3OKNDY#:AH\7;@!QRKQJIXE=V.-QQ@!*,Q(",&;01B0#NT+RX,_$GL+S#
M7T*81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81?__6^_C")A$PB81,(F$3")A$
MPB81,(O!-5-4HF24(J4#JI"9,Y3E!1%0Z*R8B41`#I+)F(8/M*8H@/J&.".#
MP7GA$PB81,(F$6,:S4,_._38RT8\4BY/Y+)D:OVK@\=,^!JZ^4ORHJG,TD_;
M/D%/`IVJ^-8ANWH<HCT83CMW1(<.-.(ZQV=JY$X2W",P6+'7@>H]NHT63SE=
M)A%^"`&`2F`#%,`@8H@`@("'00$!]!`0PBZ?)/\`+2C-9<ZM+<H=#,6$50!M
MT^]VAKQ$[=BUJ#V5J%F9IV>G(G,DD-<DI-XFFXC$_C8+J@=L46IC)-/J8_S!
M+(Y-E\NS9$W[1LEQW-(:2[0.!Z1QUX_'R_EJ.-SW"YI@1`Q]Y,X<-I,9#='L
M).L>@\--!W"9\LOL$PB81,(F$3")A$PB81,(L1$U^`@`>!!0D1"A(NE'T@$3
M&LHX'SU4QC*O'GLT4?<NE#&$3*'[CB(CU'.I3G-M\R6#!RZXA776_AP$7+E@
M`Y67SE=IA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%__7^_C")A$PB81,(F$3
M")A$PB81,(J6U'<]E".UC`4O6FNZRKL/>7*C6KYJVF'[&`KTSJ>^[D3=V9LP
MB:JU-87%TD*$\DY$Q_EZJKYX81$3+G62UK<2O=D3MR+)"NFF8T!)$XPT<G3:
M)`#CH.QCBTYMFW%KIQJXFR^^!U(`-<[.\PCKN,#(\-3VN/"J[\VS=K%H2,C*
MW08U"]M-XC?4W<Q/+"C(:5OD3097Z873AA-\OD%'JKUL5R0%3B*:2ATP3.99
M9A8U->;*5DR8&O;H.%D3(/KQ'`MY?(JS\N^S`C&NL"P6[]3QKD(';IP+N'\G
MEYK+DAL&4UK;-SQ.J"N=;L=6[%V/6G\M98*&474IB1GM>A9$\7+VR854N<4W
M=+.#C$,C03EL#4Y'OE\Z7AP*(Y%6)+)^_-D8D`$^UQ(<1'=+-WCN!?1F7L>9
M9$L:W-AB/C"J<XDR`]G4`L9'O!W[HVD-WG<<E]N?=K.W:HH:M+U6C,[CC-H3
ME>ED[E;7L9!Q-,@:G+P?SI@:EQSMY(OE+$J5VD@N1(@(%\:HBH(I^#$Q#5DW
M"ZS948`C;%R9$@L=Q8::/UKJ6;FQNQ*#35ON$R#ND0!$1(<;0Y+ZL>CCJM*B
M>7UICJE3=D;`H,*PI5PXS[/WZ9M4IU[-3\`_U!#U";L=9<C)QT0VET;"PLZI
MF"R*20MU&(D6`_F*<DTN5URMMQZ+R;89$*^\&!$S(`Z$LS:];Z<%!#F]L::<
MG(QXBF>-.WNDD@UB),=0'<2T;@VO%2\&X]@03`%KUK]K`*V2QZXJFNWAYV!.
MPG;)L&3D8]Y$.4X&PV]0D=2VS-)X:3.HV-,HN.Q!FW53$IZONM,Y-3?NVQE*
M6AT$0"^HCK+@VNUM20KGOF17%[\<1,I0C`N&)F2"-#+2/'=IN?2(*@>OS\A3
M[+OU>U5:C7>2D.?FBZVNHHQ7CXJ&<6K0G%"$BKO7HN12L:Z%GA_F*#A,AG1#
M(N3*'(Z-V%*K<G"-M>$*[)PB,*P]9+67$Q)#:%FX<.A4*[)4VYYMJA.1YA4.
M#`;JJ`)`%^\'!X\7UZYU-NVU??!7->DKU6/%6H-I1+(Z5C=/I>(G]>&,YC5Y
MY]$QTE76K6U112KFC2K#+1:2R)W!!.H9!.G[I7[K9?XDMT=AX:$2XLY!T.C^
MR=6ZU>]]M]\KQ_#ALGO`U<@PX.0".\-6]J+A^H1KKSD5M6P4#2*TQ4:]);$W
MA"S]L@V]263<1,76JY&14C++/&%KGJ,1U*)/9YJV19)28&]J*CD5E#(&25L7
MX&-"_+$+9"BD@'=Q))('LB6C`EVXZ-JXK8_,<JS'P3.F)R+XF0V\!$`$Z2,=
M7(#;N#ERS&X=3D)Z6K%?D[37@J5E?Q$>ZGZP65:3I("86;)GD8E.:8%(SED6
M+H3)D<IE(58I0/VEZ]H95L81LG&N>ZL$L69QT%NA^I;%4K)U5RMKV6D!XN['
MI#CBW6M@SA2*+]M;EUWH^ML[9LN8D(:$D)IK76*D55K;<I!Y,O&<A((,FL%2
M8*Q3JYA8Q3A4QRMA3332,)S%#+&-BWYEAJQX@S`?4QB&T'&1`Z1TJME9F/A5
MQMR)$0,F#1E(DL2S1!/`'H68UOL>F[<I,%L37TLI.5"R)/%H>46BIF#6<%82
M+R)>E6B+#'Q,U'K-I%@LD=-PW24`Q!^'IT$>;Z+<6Z=%\6MCQ#@\0_$$@Z'H
M*ZQLBG+IAD8\MU4G8L1P)!T(!&H/$+>,A4Z81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3"+_]#[^,(F$3")A$PB81,(F$3")A$PBBZ,
MTQKB'6K[B.@G3=:K6ZZWN!.-CM"PQ]MV,[GG]WFB@XFE07<6)Y:9%5<BO>EW
MO5A(4O>.6)9=\Q,2F&E&,3H-8Q;:.'0P]`56.%C0-9C6083E(:RTE-S(\>G<
M7\I6D66@Z.UDTUY/S$;,P2%8V&E"TE_%SFQ5U&=OW[=XNN+QLH:%EEU'T!=K
MO86@.T)7S0Y72B:RI"&(0Y9J[LS(-\(2$C*#R!$?9KB2X<<8Q!8Q[S:*"W'P
M<88]DXRB(V-$@S]JV0#%CJ)2(<2[KL2MB8\?M3QD?<H9E7I)"`OJ=F1L-:^L
MKPI5B(W-==S;$JY6%;(I`4I.QN7:RCPL*VCP7475,?J*J@FXEFY,I53E,;X,
MQVQ?N^RY9Y-T;B>A21Y?B1C="-9\.S<\=TMO>]IHNT7U?:`[GK7.E*7K1M;-
M9.))A(C:H!C::_KAX$E<7)XME(0R:EF;>];O56*`NHB-3+YGY^\?"F1$_>4@
M9S&W(-60(R'AR(,](ZL=.WB>CSKJ5.,+<4RB?%B)"&LM`1WM7;@.GJT7KC-$
MZIB6M28-*J!XZC52RT:LQLA-6*7C&-2N";!&R0+F.EI=ZREV,JA&-TS@]3<&
M*FD4I!*4.F>RS,F1MD;.].0D2``=T78N!HSG@R1P,2`JB*N["$HQ!)($9,X8
MD@@L.+J/Y?5''^MP=5T--QED7B=D23=C3XJ4MVU[&\:/M9,%;U"(5V]OK#)3
M.O?HQ&#,]ADV<G&@T61$6)2G`_2:.3FV3LS82CNK'>(C`>WW2\6`EN=I."_2
MJ\\3E]<*L"<9;+"T096$O`;@TB28;6>+2#?-6]-=":N:$E2%A9AP,W>*MLF7
M7DKQ?)9Y(7JEQ=<A:S9G3Z4LSQXI)1D94(Q+J*G8M[%(RI3G+W9"<W(.WOC2
M!@&C$-&1)(T'`F1])93C`Q1O[DCNG&9>4B\H@",G,G<",?0'7Y%Z"U7#6AE<
MHR`DVD_&6VXWF,6)<KN:.C++L,7JMZ=1L"K8SP$>QMSZ16>2+!%J1@[D#^\4
M1,Z`JP)9N3.LU2F#`QC$]V+D1]ERSDQ9@7<#1VT2.!BPMC=&LBP3E(=Z3"4W
MW,'8"1+D,Q.K/JL<7C=I]*MUJJMH"=8Q5*GW5EIBT;L+8\;/T^2>IR#=TA5+
M8PMK:U5N"78RKAJ:*9/4(P6:IFWM_!^KSKW_`"O$LL,XF4XM)XQ(D-/:B8L3
MH"Y#OJ[KGX;ABNJH5R$(2W1:<P8DO[,A+<`Q(V@B+:,RFB.CVD4Q:1K%(46;
M%NDV;)F567.5)(H$**KAPHJX<+&Z=3J*'.HH81,8PF$1&I*1D3(\2KL8B$1&
M(T"H#SLY<[+XQCK!CKC6S2VO;M.>-62L:$J,%.+M7T>T::KJSJ$5%5MLVZG?
M"9BH\(9NBT;KJIH/#D.1';Y-RS'YA[P<C(,1"/`,XX]\O\R+:MJY`<=.#SSF
MV3RWW:./CB1F>,G8L0U<6^?)]'T`!($NC<W?%N2WY"Q,GR[LDY97XOBV!IJ'
M7=OL-$U;KY\=D]9,V3"7IKFMWJZSL6QDUD7$M(27@<J'.+=FU1-XAA',8X4I
M1Y96(Q9M\HB4Y#M$GC$%M(@:=))4IY7/.A"?-K92F[BN$C"$"Q#`QVRD0"09
M&3'H`&BT&^4?9/!W45AM?&MXO>]4T2#G9>4T9LN1>32=.BU%G<Q+777UT0;G
MNSQ&NKN%I&2@91V^+)-"K`S<LG(%!>>F['YQE0JSQLR9D`60#;CP$91]G7@)
M`!BS@CA7OHR>28EEO+9>)B0!)JF2=HXF4)>T6U,HR)W!]IB>,I<(=\WKD-IH
M]UOL#[1^TM$Q#Q%P85^0J]6V77DRMG\5<*G#2SV1D&T<FD_&-<&!PZ:JOF"R
MC=PHF8"DK<WPJ<'*\&F;@Q!,203`\#&1#!]'&@+$.%;Y+G79^(;KXZB9`D`8
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MJD_<-9A.S;NB0'`,7!$^]%G!/%<K;6R5K;%;HKRU]CI2&HW,/@Y%U>0;*U<Z
ME=CIC='&:TR3<'+%FFU>DB)N1>B0[TKA0A$1(L<X)FSS&QQ5+$F*2)SQ<@D:
MZD5V@>D`<&[%[EY)NAFUF\&%>9C")[N@-E,CP&K$GB_:MFLU_P!W:\K^YYUY
M?G5OJ>A]PT6;D[0O6Z@A.SNEGL35;#N"JSS:"J[:(/*ZRKD^[D&TA&LV"SA!
MLBW7-YBN%CQUT8E\\2`I$;;JI`!Y,+'D($.7:9`!!)9R1HP4EN1FX]>;.609
MU471)DT7-9$39$M%G@"2"`'``.KE2BI;]AQUGXT-GMDDB-=JW'9*EFA)"&KB
M+I"O.M:W>^4VN.5$8)JY92%,^5,D%543$4<K)J^<RI#`4*_A42KY@8UAZX08
M@GCOC&1X\).3V:,RM&[(C;RP2L+6SGN!`X;)2B.&ABP':7=U%]'V3??NLH5W
MOV\9!N]W#9CTN+CVU/UK&.XR6@6.W7;E#7\M*QT?68N9G(^L-'[A6T&E6)4H
MAR@U2*X?($3L78]/O-]-&&&JCN)W3+@[/:`))`)(&S:>\"2T2JU&3D>ZX]^1
MG'==+:!M@&(%GL$@1!(B"=^X=T@!Y!8W7]^EMF->"5PGYQM9)U]>MLM)>;;$
MB$1D7D1J';L2#QVW@"(PK>0=MV2:JY&J:3<%3B*29$Q*4.KZ8XYYS5"&V`A!
MAKH\X'IU;J?7K7&/D3R1R*ZR8E8;+'.FK5V!]-'TU;3J783F&OH4PB81,(J*
M\Y=RZLU=`:=;W^V0T6^4WWI>VM:XZ(=W)25>J.R*Z]L=C!NW075C8BDME2RJ
M[Y8S=N0S,J/D,HL1!79Y/B9.3/*-%1,?!LB_0#*!8=IEP;4ZOT.,/GF9BXU>
M&+[0)>/7)N)(C,&4NP1]HDL-&=RQO00Y%"$43.51-0I3D.0P&(<A@`Q3D,41
M*8IBCU`0]!#,9;G%11OBYUC7FEMIW2YN&S>LU^AV9Y*^Z*11-VD:*<MD(M-`
MY3^\=S#M=-H@@!3&<+K$3*4QC``V<*JR_+QJJA]Y*8;T\?-Q)Z%4S[JL?"RK
MKC]U&N3^CAY^`'22RC'AMM2C[,X_ZV;U&P?-Y.A4>CT>ZQSMI(1<Y`6F$J,.
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MVSQA\J8^R=MH]!)JP;N6O@\"Z#%LW331(8HE2(0I2@````\2QQ+>=PZ7Z^*>
M%7M,?#CM/0P;3AZ%[S(PK%LUACI1;-G(&7C&449-HW;/CG:/'KF/:L1`B3DQ
MV+9PL=(A3"*2:AQ#M*80\>9)FY)&K_U^EEZT(@08`'0#KZ6;R.L8R;A/&<N;
M'4FK%S%R\HQB#2)HB86=1B#CQLYMHLW]P,>C+HD!0$#B1=(.@*%`0SHG8PKM
M<$!V<:]7:WH7$1XCFRD`@D!V.G7V/U<5H`3L`.U3:8-1H$(HM$:;42D@*R,V
M-)M+8E!MVYJZ,,5LF\9KM47*+X')E"F(4`3*)2GR?9/W;WOQI;M^QNS:_%_,
MS*OXE?O7N7@1V>'O?3CN;@W$<7=2@6`@B&;')"Q)#LW+MXS.6.9E,U>/W:C]
M\[;&!$!0<O7RIEU5"]#*+&$YA$PB.5M\]>^=>WJX*UX=>G<&A?AUZGTG59;.
M5VF$3")A%6SD-Q3U1R92JH;%1GFCRI.WP-):J2B,)+R->F44T;%2I20.Q?+F
MJ]A]LW4<%;^W>I+-4E6SENH43&OX/,LGE_B^`8D2`TD'`(X2`<:C5G<:D$%9
MV?RO%YCX7C[A*+ZQ+$Q/M1)8]TZ.S$$`@@JJ'(.S;;X#4"IRVG9N.V'J*0O<
M10H[6FUF$Y,.]40S^`L<LS5K^U(V>0GS4J+6KZ<>W8S;.7<(>\0(D^311*@;
M3P:\7G5]L<J!KRA`R,X$#>00-8$-N+N3$Q!8O$DNLK/LR^144RQ+!/#-@@(6
M`GPP1(AI@OM#,!(2(<-(`,MPUAK*9YIZDJ6Q.5<LVL54MT6_DX71=+CIFB:[
MB#'>R<9&V*Q//J*6NEVLZ,>BF[CUEI!I'1KA7SMV?N4T'1(LC(ARG)MHY;';
M;$@&R1$I'0$@:",0^AT)(T)9PI<;%GSG$JR.:S$JI@D51!C`:D"1+F4I-J"X
M$3J`X!5KM&:(U[QXI(437+)^E&*RK^;DY2;?GF+'.RK\Q$_>SLRLFFXDEV4<
MW;L6XG#]2R:HI!Z$`1S<S,OSKO&O(W,```P`'4.C5R>TDK5PL&CE]/@8X.TD
MDDEY$GI)Z6#`=0`"F3*BN)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81?__3^_C")A$PB81,(F$3")A$PB81,(NL?1.NHR9F*K8Z-#6J
M!NNNN6'+>/LUM,A:F%8>:C)O_?[1S33NWZZ%8N$2\=.HY%JS;>Z6C91$7?8D
M9!<Y_H<R^4(65W2C*JS&I(CW2=_AU=[36)XN2SC3I"^9P,:,YU640G&ZO+R!
M*7>$?#\6WNZ]V0X``.TM=&*S^K(FW+W*>GE]=;*I+2[<9G<+9$I*,M:4\?9E
M<F%&*K*XVY)RFK<]C,HZ1$&]C:H-T))%01C%W"*!SIQY,JA5"`OKF89#AB&V
M$?-C\V+C6)=OG`$KO%A<;K+#C6P$\9BXD^\%FE+YTP#I,``_-)`6,C]$0\97
M^&<U.ZOM4T_82T>YW(DJQM-AE6-R=<<G]'^:SL:Z=.7+)L:U04:T7?)ID8)*
ME(NLH1,YUAZEFSE/FT(9$0"#LX`&/B[F!\A)`X]`ZES'`A&ODT[,6<I`CQ-)
M$B7@F+D='>`!/#I);5;`LVV#4%WS^4UM=;KJUWRAVI-7^K1T%(6">>T:RU5T
MVHUC:5!\`KW.E1EK,F9S&-4UUVX^W=(MS%:=H<`T6B,8Y$(9(QH"))`&X2[P
MW?-D8\"6?4$ZJ0C(I,I2QISQ3E3,X@$DQE'NG:?:B)<8AR-"!HN-LBC7QJZG
M'.E*/>*XU:\;6<!6XL@>SF>UOMMG:)RD0\O,NI:,B+)-T0CM&-3<N.QBHX12
M.5$R8I)^X]U!$!EW0D3D.3T>PPD0&)`DSMQ8G7BO,FB\&9PJ)Q`QF`X']9N,
M02X!,79SHX&C,K4:,A(**K\T^KB&PVL;8IM.9%IL&LH49=L\"&BHQTE"45"N
MU`M6CRFC@\Z98MFF\?>=V45_<"X5S<R<Y3@+##=$-W3NZ2=9/)SKUE@PT9AJ
MX,*X5SE6+!&4G[\=O0!I%H[1IKW0Y<ZNYFW*BNIA$PB81,(F$5?.1FT+'INM
MTG8,>G%J4F,VE28C;ZD@U56<1NM;@\6ISRQQS@CUJ5@:JV6>C))VJ8BQ0CFK
M@.W^7+V!CUY=EU$G\8UR,&Z9Q[S'K<`@=I"S^8Y5F'71D1;P!;$6/T0D=KC7
M3;(Q)XZ`JP>45H)A%%*F[]6(7VS:S=7*(96^GU^/M%C8/E_9MXJ&D6<W)%=/
M))P"<>@#.+@%W3D#J%]NV%-0_0IPRS[GDFBO(%1-4Y$`]9##AQXEAUE5/?L4
M9%N,;@+H1$B#T`N>/#@"3U!<%OR%TD\KLO;&.S*K(UZ"7;MI.2C9`)%-!=S7
M(VWII)),B+N7AB5>7;R"O@(IX6AQ54[2D4$OIP<L61JECR%AX`ANDQ^4$>71
M>#F&%*N=L<F!KCQ(+]`ET<>Z0=.`U7.G]Y:@K!&9IK8M6;&D:B%^CFZ$FE(O
M)&D&,F4MLCV,;[QX]KY@5[P=I)G1%,IS]W8F<Q?(8>58^RB6DMIT9I?1+]/8
MO;,[#J;?D0#PWC5WC](`<1V\%FPV;0CR</#H6B,>/IZ.@Y>,^7G5D6BD7:3O
M$JK(.9)BDXC8YG:UXYPE%*.54BR2J"B;853D,4./=[MLI&L@1)!?34<0W$LX
M=N#ZLI/>L?="`M!E(`AM=)/M+C0"3':_%M'6)EMUZHKZ\ZWG[Y7X+Z;@9VT2
M[J:=C$QB-?J[]K$VB6:R\@FWBY-G6)9^@TDC-5EO8.UTD5_&JH0ANHXF3,0,
M*92W2`#:ER'`8:APY#\0"0N)YN)6;!9?&.V)D7T#1+2+G0[20"SL2`=2L<SV
MY1[%8:TE6=I4=S'.G>Q(AY`II!)3%BE*,5HG.F@Y-&::$CFU+6`YI`XLGJ2Y
M'*/:HCU(97HXMU<+#9C3$@(E^``EP<-KNZ-1P/'HY&71994*LJ!B3,-Q),>+
M%]-O3H7<<.G@5GDKH6Y"Z"L[5I\L=G2S;%730D@35"CI%*9S94D7!$57$8Q\
MA`<F3`PM3*IE5`@J)@;JSE^;4WB8TP\]O#YW5Y3T=?0N:N98%S^%EP+0W\?F
M_2\@Z>K1^*5'==%V4OK&9HNR*PO!WN*GI"-K3N+<#:+65I"PLT"L2HK+1Z\(
M%5:21#R1%6#P#B[23$Z!P#R+<2['&1"['EO@0"7T&I&NA=VTU'`\4IS:,DXL
MZ,F.RP$B+=Z6@.FH;:^NAXCAT[BTVMKAZB+I"Y00,AK<I<F\BY>%91DC3X,[
M<DS;8>3>`A'S57BO>(&<2+119FB1RB<R@%62$\1QKP6-1?<(MTB1X1(X@G5@
M==#U%3#+QI!Q=';M,GX`Q'&0/`Q&CD.-1KJ%Z*?M[65_DS0],NL%8Y((!A:D
MFT8Z\PO*W)*>!I.QR@D*C)Q8N1!%19N94B"X@DJ)%!`N+<7(HCNMIE&.XC7K
M'0>H^5>4YF-D2V4WQE+:):=1Z1UCM'`Z%2/D"LIA$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(O_4^_C")A$PB81,(F$3")A$PB81,(M6J%+K=$C'4/5F*T;&O9ZRV=RV
M5DI63\D]<;#)VRSR0*RSU\NFM-62:=O%BE,!!77.8"AUR2VVRZ0G9)Y"('`#
M2($0-&X``>914TUT1,*HM$RE+B3K(F4CJ3Q))/:5M.1J5,(F$3")A$PB81,(
MF$3")A%IVPZ-`[.H5SUS:&_NJ[>JO.U.:1`"B<8V?C7,8[.B)P,";E))R)TC
M_:10I3!T$`'):+IX]U5]9^\A(2'E!=0Y%%>51=C6AZ[(F)\A#*!>,&U59/0<
M"IM2=81=WUA-R&CMGR,T]2CTU]BT&P!0?>*.7[GM4<WY5-C),2@<QG999`$P
M$RA2Y=YCC".;/W:!--@%D`->[(;NCZ.H/5M*H<KRC+`K]ZL`OJD:IDEN_`['
MU^GH1U[@W%6KS-6JJ]N=<WE#;&W;7'%JCNJ[.U=2:LBH]FY=A8(BRTX=C(^)
M6*0K,C'/(.31N;<_NP?)N$#(*$]JH`E/EX7TG&Q:Y;A;79(\`01+;TN"XVG1
MF[5GG&O&7EVQV&JVJ,=2008[^C:0QW#5W#'1:;]T.UX[6VCJ)#+Z_%2CZS<:
MTO;]:2F(^2<-0I,-76+^HV1M47LTC%J3$*FZD(Q,(A9\!&X?,$RMS).)?>L:
M61F73$^_9OB&!'M$M(;F=BP/>;7NZN(?<\N.-@T0-?<JV2+D'V0`8RVDLX<Q
M[KZ=X,QX5'T9L2`;:I-*J4OW=%XI26AI9"/GYQVV<VAW]!>*5CG3FH,%58$/
MHHW<=5%%P'N`Z)#V?%[=F43.3MWM/)%@<#AWM#WCKWO)IQ7-&#D5C$WF#UXA
MJ+$^UW-1W1IW?+KP6%K'''85;EM%RT7,0=:FM;TC4]"N]FK=PLX(7NH4&+<,
MI>GV+7SVL#6+8S<.EEEX:567CY2&4?JF3,8J0I.>[,^BR.9&4#*%DYRB#$=V
M4CI(2=X_6BQ$F'7IQ5RW(KG@SC.,9UPKA*0E+O1@&,3`QVR'$QD2)1<MP8^E
MII#?*_%_8G&"?D-8OF1])7#2VO\`9!+!:CSEH83-3D*;7)^_UHU,0:567BHM
MTFK(F92$Z$HZ(=0OM>\0#TYF$.8T<QA&P'QHV2@P8$$2(B=VH)X.(L.M>#!S
MSRO(Y79*HQ\"5<)O)Y`Q,09QV]T@<6,MQZE/=MI=BF]DZ>OYE*^PB]<HWU6Q
MH+RSX5S!:H!")1-&*#")MUT6(MQ55.N9M\(]`#TZY2JNKACY5'>,K-K:?1+Z
MZ_(ZOW4V3R</([HC7O?4_.#::=':RJWQCU]*[+TEQNLDV6J1;/7NM;,QJK^O
MS3ZPS$DO=*NO4>V<\\%!-X-BVAG!G#R-26?@XD"MC><@,RBOH\POCCY>?7#<
M3.P;@0P&T[M-2Y?0'1@^FNF7RS'GDX7+;)[`*ZI")!))W1VZZ!@VI&KEM=-=
M^K^@]BN:IQTKMO7I\6?4NLK/K6TN*I9I^24>HS.MHW7S::K3J1ID&H5UU8F>
M"DNFCX!."95%>WR&AGFT"S/G4)GQ;!..X`<)F3%I'R:<>Q6*\#)-7+J[C`>#
M5*$MLB7>`@\7B.I]>':MB::3NKJ&T[&SKBG$=:9H%DK<<_A7<PB6SSTI0_NY
M9+KM5X</IJLK1*ZSYRR*I)J$>`V(10Y6WE6C.72)Y4H";6S!(+:`2W=>I?0'
M31^O2085YAAQL,'IK(!#]XF.P='=BSDCO:MU.>7J_3%PI-ATE)RKNM.&>LN-
MHZ4F/E\C*+.7TX#S7;@LO&(N8-HD>*$E&.`@JHDL`N0^$>P>[S(RZKH9<8B3
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MO\.\CNR828]H/$=!Z>I?)))W3E`__,&U/J7DJNI%2SWEQH>QWFGU]I\BH]ML
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MB[LNP)E,2F.4T)K^L-9FYS!3`7H!FS%4O40#KU$,MX^!EY0,J*)&L<9<(CRR
M+1'G*I97,<+#(AD9$18>$1K,^2$7D?,%%2?)+;-LZFU9Q!W3+L@Z=)S;,E2M
M$Q2@FZB3QQ%KFI+8X%,4/7R5Y,2#Z&`!$.MGW#&J_P`SS2D'J@)6'TQ`C^4J
MGQ++M_RO*+C'KL,:AZ)$S_(7,"?YRR@@LWU?Q=IZ!^\Q6TMNC:-SD4NPP)@@
MX"*TC5(_]=T%4%4US]I>T@I]PF,7S9R>.AR,F9[*X1'KLD5UXG/):C%Q8#ML
MG(^JN(]?F09GG1'B*RNN^*UH1+V*'9L=M[7J#XY4S"*K9LN]TY;&:J[L@]"*
M*"@1$P=3`H`_"V<GEH+\F)[80D/SXIOY['4X^+(=0LLB?77(?(N*KR%WC5!\
MFR^'FS4XXH$*M-Z7NE!W0R15$!%4WR,TC0M@N6I.WX3MX-94W\J91'IGHP<.
MW3'YK7NZK(RK];2CZ9+P\PSJM<GD]NWKKE"P>AXS]$?,I`UQR@T;M*:&IUN]
M-8Z^ID`SG6=WC9C76S6A@3.HN537]ZCZ_:UR-/$<JBR#55N!B#T4$.@C!?R[
M,QH>+9233].)$H?:B2/6ZL8W-,'*GX5=X&1]"0,)_8D!+T!E/V4E?3")A$PB
M81,(F$3")A$PB__7^_C")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81>EPNBU07=.52(-VR*B[A94P$3111(91550X]`*1,A1$1'T``ST`D@`
M:KPD`$DZ!5TJSK=MEW0%VC+;0Y7B_9-;5.5J35K`R06-](22<[("^;2)[&44
M7;I-\P74<JL1:K1WC0302<D67/>L&)7B>#*J8YC&R0EJ&`##@WE#.[ZN0P6=
M4<VW-\>-U9Y7*J)CH7)+EW?M!=F(8``N5O.T$MYJ!!_<L]U.S,`R7U(.T(RX
M20*`(,/E`09:G+Q(HB4?=>Y%<3]>J79TZ'ZPX_N??][%IX-L,1UN^X'L9NU3
MY0SCL]RE4.+[Q(]3-M([7?L42^UYT_\`OOB;_P!EMP?YPRT_)_H9/IA^BJC<
M]^GB?9L_23VO.G_WWQ-_[+;@_P`X8?D_T,GTP_11N>_3Q/LV?I*?Z"789*RT
M+M%>F.;B"[SWRU!:SC*LG;"X4%A[1M8GDA*)+E:"4%N]8Y3*`(EZ%$"A1N\#
MQ#[N)^%T;F?MX:+0Q_>/"'O1@;NG8XCV<7*W/(E,F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(M+V'L2DZHI\U?=A
MV..JM3@&Y7$E+R2ABI$%50B#5HU02*HZD).0=*$0:M&Y%7+IPH1)(AU#%*,M
M%%V3;"BBLRMEP`_IH!TDZ`:E0Y&11B4SR,BP0JCQ)_IJ3P`&I.@54FR7(GD\
M'OUY.U<5-$N^P\;&QB+1ER7V''&*82NYB3=IR,?HV$>]2'3:M4G-E,F'ZQQ'
M'$4PTR<'EV@C')S!Q)_51/8-#8>TM#LDLD#F/,^\93Q,$\`-+ICM.HJ!Z@\^
MV/!6$U3H74.DF;EMK.B0E;=R/>:<L0)*RERLZZJH+K/+9=9A5_:[0]67#O,J
M_>.#B8`]0```*.3FY660<BXR`X#A$?@Q#1'F`6AB8&'A1(QJ(Q)XGC*7;*1>
M4CY25+N55<3")A$PBC;9NG=6[FA"U[:=#K-XBTC&59$GHQ!R]B'1@`/F$!+%
M!.6KTHGVAV.V*[=RF(`)3@.6,?*R<2>_&NE"78>/81P(["X5;*P\7-AX>51&
M<>AQJ.T'B#V@@JM#FE\AN-A!E=5SMBY):@9`523TWL*91>[FJT6B;JNIJ7:,
MDHW/=P:-3"*<%9SJ.5P1*FWE"',"9KXMP<_NY,(X^4>$XC[LGZ\![/X4-.N*
MS#3S#EO?Q;)9.&.-<R]D1_NYGVOP9ZGHFK+:HVY0]U5)*Y:_F!DXXKQS$2[!
MXU<Q5AJUCCNPLO5+=7I!-"5K=GAEE`(Z9.DDUDQ$#``D,0QJ&3BW8EIJO@TF
M<'B"#P,2-"#T$+3Q,NC-J%V/-XNQ'`Q(XQD#J)#I!4E975E,(F$3")A$PB81
M,(O_T/OXPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$6NVVH
MU>^UN8IUT@(BTU:P,SL)J`GHYI*Q,DT.8I_$[8/D5VJX)JIE4)W$'L4(4P=#
M%`0DJMLILA;5,QLB7!!8CSJ.ZFK(JG3=6)U2#$$.#YBHG;<9-),]3U_23*DM
MHK7%;-'N&4'69"5I)W$E'MCMAF9-_1WM;>R,M)&4.N]65.(O')Q65`ZG0P63
MS#+.3/+-Q-\GU($M#T#<[`='4-`J@Y9A1Q*\*-`&-%F$28ZCI)B023Q)Z3J5
M3_46I.*^THW:4L]T=MV@L-6V:<@I!:U;`W@0\FT@T%'+MZR;-+PJZ-)-D41%
MS'ID670$Z0%%05``-3*RN98TL:(S*IRLB"&C7H_XO#J/`ZK'Q,3E65'*G+!N
MKC5(@[IVZMTCO<>L<1IQ6J__`.:'_P"HW_\`,G)/_P"0?4_[A1?_`,:_WG_^
MPI,UEN'@GIV0DY37LU>H=Y,,TF$B9]6^4-G0<-D5P<)`#*UPLVR0635#T533
M(J!1,7N[3&`:^1B\YRHQC?"!`+C6H?(0K6+F<BPY2ECSLB2&+B^7JD"%,WXX
M>-'^-['^R/<G[O\`*OP?F'[&/VX?I*Y\<Y9^WE^[L_05DJI:82[5R(M=;<N'
MD%/,TY"+=.HV4AW#AHJ)@354C)IG'RC,3]HB!5D4S]/7IT$,S[*YTV2JL#3B
M6.H/K#A:55L+ZX6UEZY!QH1ZB`?2%L&<*1,(F$3")A$PB81,(F$3")A$PBX<
MA(,8IHJ^D72+-HB*13KK&`I?(NLFW;HD#U,JX=.52)))E`3JJG*0H"8P`/L8
MF1:(<KR4HP!E(L%A*]<:Y:7]PBX-^=W(4*SEIUM:JL))@I$6,];KEP28&^8L
MVA7I%ZU;8YXFX;BLV42=%[5!,!@+W.JRN-4IQ:,X[HZ@N',7T[8D,==%'7=7
M;*Z-<GE7+;+0ABPDVO'NR!<::I6[E7+<O9VT`_.]7IMG>4VR)*,)*//&V-C'
MQ<JX8=))FS]X3Y=--5B.$/*V536*)%#>O19594*S.+"<=PU!<$D/IV@Z'5*[
MJ[C:*Y.82VG0AB`"VO807&FJV?(U*M78W.N25OLE#9OU#VNI0E6L<]%*QTFV
M!I!W5S9F59DF[]TR1C)-M)O*;*(]6JRXHJLE"*@0W0!DE59&JNXQ^ZD2`7'&
M+.&XAMPX]>BBC=7*ZR@2^]A&)(8\);A$NS%S&7`GAJMHR-2IA$PB81,(M8KU
MQKEI?W"+@WYW<A0K.6G6UJJPDF"D18SUNN7!)@;YBS:%>D7K5MCGB;AN*S91
M)T7M4$P&`LDZK*XU2G%HSCNCJ"X<Q?3MB0QUT45=U=LKHUR>5<MLM"&+"3:\
M>[(%QIJMGR-2K$0L_#V)LZ>0C]&0;,I>;@'2J(*`5"8KDL\@YM@<%"$-YH^6
M8+(GZ`)1,01*(AT$>IPE60)AB0#YB''I!7$+(6`F$G`)'G!8CS$,LOG*[3")
MA$PBQLS,15>B)6?G9!I$PD'&OIB8E9!=-LPC(J,:JO9"0>N51*DW:,FB!U%#
MF$"D(41'T#.H0E.480B3,E@!Q)/`+F<X5PG99("$022>``U)/D5*]0UB5Y,V
MF*Y,[9BEDM>Q[PLKQ:U'.L3$2KT,4HDC][76,<&%%YLNZ-Q]U"I+)#]-1"R8
M(B#U=PJ76RK(\OKER_&E]^0UTP>)Z:XGZ$>$OIRXZ`+%PZI\SMAS/+A_AP7H
MK(X#HMD/IRXQ?V(LW>)*O-F.MQ,(J><W+/>:AJ>J3.O[M,T>96WGHJN.WD.A
M$KEE(6W[1K-6EXF3+(QSMT$<LSEC',#-=DNH9,I#+"B95-35Y173;DVPOI$X
M>#8=7T,8$@ACQTZ7'8[+'YW;?3B53Q[Y0GX]0<-J)3C$@N.&O00>UG"]\M7)
M;3T16JU.<D-A34?>-HV)[(.[>U86K<5I:RU5D'#/6&IB4JKQIHQG&R4>,JX4
M:1#ITQBT78('9I`1=IY&R.5.RR&!`2A6&VN(!B._/<2[@L'D`2SN=#[.N>'"
MJJ?,K)1G:2=S2LD\2T*]L0P!&XM$D1!9AJ(3TK9M[3FC>955IMOGY+9&M]Z;
M+UKI&0VW,0S^R1+8U$UO8JK7YNR+%E6,G*-YJX.$6+F1,]$#JH$<"<A!(%O+
MKPX9G*K+:HC'LIA.P0!`/>D)$#1@T0X#=+*EA6YT\'G-5-TCDUWSA4;""1W8
M&(,M02\BQ+]#J4N+6T(2U7+95-75W72+Y6X*D.[1HG>CZ0L4[3W*[BS@]O=1
MO3^9LJ-QJ%W6<HMBF8R*K!H>)*9-!K[D4S5N8X\ZZL>T"F=,I2:RL`"7#NRB
M`-LH\=0YW<2RM<KRH6W9-)-\+XQCNJM))C[3RC(F6Z,M!H6&W0!U=;,E;281
M4YWEK6UZ_L+KDUQ^A_<;#BFS8VW=8QQ`08\AZ!$E.9S&*MD^B"6VZPP,JM6I
M<$S.%3E^6N!4:KE!'5P\BN^L<OS9?<$]R9XU2/3^`3[<>'SAJ-<?.QK<>P\S
MY?!\@#[R`X70'1_>1'L2X_-+@Z66U_?*KM"DU?8=(E49JIW&%8ST%)(@)0<,
M7R0*D*LB?HJU>-CB9)P@H!54%R'3.!3E,`9]]-F/=91=%K8%B/)_33K6ECWU
M95%611/=5.((/8?Z^L=!T6X9$IDPB81,(F$3")A%_]'[^,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PBA.=W_`*\KNZ:CH>1=R9;S<ZQ8
M[/&`C$/UXM%&OR50CB,';U-$P%>3`6WS('(4[9))@X]PJ@?P%6MPPK[,2W-B
M!X,)`'4/J)%_,VO3J&!U:E9S#'KS:<"1/CSB9#0MH8AG[=SCHT+D:/Z[1R6X
MV4*?DZI=-_Z/I=IBE4BS%:M&U:%79^-7=-D'J(2</*SS.19JN6;A)4OE3*)T
ME"F#J4P"/M?+\^Z$;:L*Z=9X$0D0?(0&7EO,N6X]DJKN840M'&,IQ!'3J"7X
M+`_C&XB_Q3\<?VX:R_S/G?PKF?\`#;_W<_[%'\8Y1_%<;][#])/QC<1?XI^.
M/[<-9?YGQ\*YG_#;_P!W/^Q/C'*/XKC?O8?I*2-?[AU'MD)8VJ]I:YV86!%B
M$Z;7]WK-R"%&3!V,:$L-<DY((X9`(]?P>;L\O@4[.O8;I7OQ<K&V^\XUE>[A
MNB8NW%G`=G"LX^9B9>_W7*KMVL^R49,_!V)9V+>12-D"LIA$PB81,(F$3")A
M$PB81,(F$3"*!MUK.E+#QXA#$.>`L&^8Y&T=%B(I$:UC5^U-@U0[@%`,5<@;
M,IL$!"=.HKB02]#``A=Q`-F=/Y\:2WGG")_(E)4,TDV<NA_LY7C=^+"<X_EQ
MCYU65]-[$JERY6777-H:D>P?+[3,7(:]D(J&>15_C;=Q]XAU"1AE)-5$L_"6
M!9.6ZQ#EJY2;IOD.URBX24-XM`0HMJY;3?66.+81($O$QMOD"W`C3O`AVX$'
MCF2GD57<UNQK1NCF5@P(!$Q*K'B0_$'7ND%G&H(X9^KW.:KFQKS68IVG"M-E
M<UYVHS-E.V:N5(EFRXQ5:Y-&4<#\B\:C,6.6JS=@@HY263[%E"D(*YD<CLJA
M9139(.:\02`Z_O3'7I8`DZ?(ZDJNG7DWU0.T6YIB9=34QDP?1R8@!^OK99LN
M]YUG>R:GM]I1K#&3W#L+7E9W"1G`LBV%K5=9TC84=!LE)9E(4Y"[C+6Z1AUC
MG9G;N#5.1*FV1<'+X.?<H&GWFJO<15&1AKH\Y1)T:6UHB7%QOCJ1Q[]_L%_N
MEUNV)NG"-F@?;",P`X,=SR,>#'PY:`\(IL^U7NL=Z6QS+W5)Q&V32'#BI6WD
M*QB:^%/IB;K:7,1`EKGHDCN581Z=KE4DXE!QXE(:->/0</%4$4B)+6:\89&'
M6(4]Z-U\HU$G=+N4:`Z$[1WF]H@,`27%6W*EBYUIG=W948\96@#;'OY'>(U`
MW'N@^R"7)`#&?Y#9UT@>1<)2;`\E_N]L,LPJ5/EZVRI\U`/;<EK*?N4U3-HI
MF*C>ZA<W+=F6:C'K%(T$YC$2(*@BN<1/1CCU3P)W0`\>(W2!W`[=XB)0^;*/
MS2#W@=0X5^65=7S&%%A/N\B(Q($2#+89&,_G1E\Z)'=,="Q63OLQ<DN4.DJM
M&[$=5>GSFI=SV>:K:<=!.&MEF*1L/CM'1[-9Q*MEW)%9"+OKQN0S<2.$"]PI
M&`5#YS3&KX=EV2H$K1;6`7.@E&TGAU&(.NAZ5WD3N'-,*J.08TRILD0P[QC.
MD#CUB9&FHZ%'E$V/LV1HT3<;EM6*;J[!V19-40$'$T2*9R+.7KNR=LUQ-2CJ
MO'4FT>6>P0U?8`F6;%:+CDV"[E;S`)R&GNHQXW2JJQBT*Q,DR+,8P/>X:`D^
MSJ7`#*M1DY,J(7790!LL-8`B`01.P=WCWB`/:>(8DNL-1=O[2O=9XQIEO;9D
MYV3L#>=!NEBBZ[5G4I)LM=--HA`3<:`A,5:*G524%!5<46[J/47<',1$4`*D
M/=V+C4V<P^Y)%<*Y1!)8;MC@\"1WM-0=.+KBC,RKZN6??@&VRV$B!%R(;V(X
MQ![@=@0YX-HM?'?^UXRA:XM\]+/9"M1BVVHC:]EI4-2G-OCEZ=M]37=)O\Y1
M9P4"RNNG#*">A8TJX"4HW=ND#M2IH]0+W[EC2NR*H1`L.PP$C+:=T-THB0X2
MU&S=H0"^JC^(9<<?&NLF34/$%DHB.X;;-D9F)XP8'?L[P)#,%N<1:EZ[L'DO
M%LK*2LR-YY>5NGQJK5@QD+/)O3\%-#V1.-I*<X16J(65,E;,\%:8(>-3CVCH
M3E%3Q!D4ZQ.CE\C7NC#%,CJP'^(L#R;5M6[NKD*>%IKR.9QC;ME9F"(T!D3[
MK46B_=W:/WM&![%JU1VKLS8;7AU)+;3)72WEOME:[.(:'J_L[>YH<4]!FX>D
M=ED6#=-RP9JN%4F9B-R*',NF``DCXI;<;'H/-8C'W;-FUR>[N/F/'377HZWB
MIRLG(')Y'*V^)XFYA'O;0>/$<-=-.GH#;[3-P7^P6BHTR7G$&*5CW=R<J"EH
M;Q$6@Y7BM/3TVVI]'C$72#F+3L$O"MU'RS@Z*ZJS*#>B1,AC^9O!;BT0KMMC
M!S&FJ3.>,P-TCTL#HW7(>0STYF19;33.;"5]T=S#A63MB.AR-26.D9>48Z,V
M9MNSVW7-'^KTX!E-7[D=0).W0]:@'$K98S5+A1"L6>("8;RT!&S:"K=1E*![
M%9BO(-G)DFR"8IHI=2Q\:NJ^[PMQ$*I"))8&?$%F)'2-7`(<DZGF.3EVVXU'
MC;8RLN@9"(<BOV9!W`/1+1B06`&@GOCQ<K#?]-4:UVMTW?6.08OVTO(-6:4>
ME(NX::DX0TC[%N/MFBT@6-!91-("I$4.8"%*3H4*6=5"C+NJK#5@AAQ9P"WF
M=7^7769&'1;:7L(+G@[$AV[6=31E174PBISRO;GV/*Z3XT%5,2)W;=7\QLQ(
M@B0SW2NHV+6W7B&%0GZY-M;K&ZK\"Z[>G<SEEB"(`;-7EI\".7S!N]3!H?WD
M^[$_BC=(=L0L?FP]YGA<L?N7S)GVUUC=(?C'9$]DBKAI))HIIHHID212(1))
M)(A4TTDTR@4B:9"@!2$(4```````#,KCJ>*V```PX+SPB\>\G?X^XOD[>_L[
M@[^SKV]W;U[NWN].OV=<(HNVQI^H;HA(NNW8\Z>(B+#!6MJUA)Q_!":>K$NP
MGJ\_<+1RB2ZYH>9C47")!-X_(3XBF#TRSC95N).5E.W<8F.H!T(8C7K!95<O
M#IS81KOW;!(2T)&L2"#IU$.L?L/1M,V:UH061Y:T)W64\2R4JZ0%HE*]<X:5
M/%/8&34)/1*K99PUL$#).&<@W5*=!RBL/<3O*F<GM&9;CF[PQ'99%I1(!B0[
MC0]1`(/$+G(P:<H4>(9^)5)XR$B)`L0=1U@D$<"%KM?XPZIJ[#:$7"HW)K&[
M=GF-KMK8VQ+PX5"V,6,&S"VP\FO/*3,7:W:M;9.G$F1R+Y=TW*H=4>G3))\Q
MR;)8\IF&ZJ)C'NQ]DOW2&8QU(`9F/!1U\KQ*HY48"8C=(2EWY>T`!N!=Q+0$
MR=R1Q6[4O4M7I5AF[DDXGK+>+'$0]=F+I;I=6:L"];KKR8D(*NM3=C:-B86-
M>S[Q8$&;9N5==<RR_E6'R9#;DV70A41&-,22(Q#!RP)ZR2PXDMP#!34XE5%D
M[@92OD`#*1<L'('4`"26`#DN7*D_*ZM)A$PBIGHUL;4O(+>V@D>J5,L;>.Y*
M:J9%]4(9KL";EH?;]79%*5-%G'1FRH\LP@@0O:D6R"4.A2E#-7,/O.#AYI_6
MQ>J?;M`,#Y3`[2?J+&P1[IS#.P!^IDUT!U;R19$=@F-P'UU<S,I;*81,(F$3
M")A$PB__TOOXPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81>('()
MS)@<HJ%*0YB`8.\I%!.4AS%Z]P%.9,P`/V")1_F'"+RPB818]2)BUI1G.+1L
M>K-QT?)1,?,*,VYY1C%S+B)>3$:SD#)B[:Q\L[@6*KE$ARIKJ,D#'`QD4Q+U
MND(F`D=A()'02'8MUARW4YZUR80,XS,1O`(!;4`LX!ZBP<=+#J7$=UJN2#A1
MV_K\(]=K=GE=.XI@Y<*^,A4D_(NL@=0_8F0"AU$>A0`/L#/199$-&9`\I7AJ
MKD7E7$GR!<;Z-J'^%:W_`''&?U7/?%M_:R])7G@T_LH^@)]&U#_"M;_N.,_J
MN/%M_:R])3P:?V4?0%DH^&B(CS?*HJ-C/<>/S_+V+5EY_%W^+S>V23\GC\AN
MWNZ].X>GVCG,ISDVZ1/E*ZC"$'V0`\@99+.5TF$3")A$PB81,(L3.3+6OQ;B
M5>(R#E%N9LD5M%1[N4D'+EZ[08LVS5BQ26754</'*9.X0!-,#"=0Q$RF.7J$
M#.0B"`>TL%Q.8KB9D$CL#G70:#^G6M;UYL2O;-@%K!70DFY&,W.5F9B9N.7B
M9VOV2MR2\5.0<S&N.IVKUB\;CT$ICHKHF361441434-)?19CS$+&U`((+@@A
MP0>H^K@=5'CY%>36;*WTD8D$,006((ZP?,>(<$),;(J$#?:7K25DC-K=L"+M
M<M56/M'2B$@A3$XE>;04?))':,WH-)<%VZ*QR'<HMG)DN[VZG:C1;.FW(C'[
MJ!B#V;G;3S:]3CK2>337D4XTY-=8)&(Z]K/KUZN.MBW`K1I_D5K&JW*T4FQO
MIJ'?TMO0G=IEW-<F%:Q!,MG2,M$4>0E+"S:N8Z/C)J5@GC<SI8R;9FHW-[HZ
M)1(8TT,'(LJKNKB#&>Y@X<[`#(`<20""W$OHZ@LYCBU76T62D)0V;BQV@3)$
M23P`)!#G0-JRG/*:O)A%K5JJD5<8UM&2P."D8SE=LD>Z9JE0>,)JK3C"PPSU
MLJ=-4@"C(QJ8*)G*=)=`3HJE.DH<AI*[952,H]((/:""#ZCYN*BMJA=$1GT2
M!'6#$@@^D><:'18][$P,79XF5::_0D)FRRAVLM<(J(K)',($?7I5RSE[/)/7
ML?.+L52,BQ;<S--^N1P\1*9--N*JR70E.5<HF]H1&D23JY&@&H[2[!@>E@>9
M0KC;"8QWG(ZR`CHP.LB2"VFT,Y<C1G(RXU6L"A)-AKD"+:9=)OIAN,/'^"6>
MHJ)K)/))+V_C?.DE42&*HJ!SE,0!`>H!G'B6/$^))P--3IY%WX532'AQ:1<Z
M#4]O6M;;UZHW2E1L/:=;1C""D1!P.O;K!5*018NTG*[Q--W#Q[NPUDSPJB9G
M)1067[1$3]P&[NDALMJME.O()F/G1,@_G+'LU48KINHC"W&`K/S)");S!XOT
MZ$KE0T-7IME(/W^O&U?<R:4K4Y..GX:L'D9.O0<I(0C%%Z>&>33%[69EBT*\
M8-U%S"#%TD"R*"WD03\G.R!C&-YD`T@02P)`)XMJ#H2W$:$C5>PA7.,I2QQ$
MEXD$1<@$@.S@Q(U`?@0X!<+)MZE3V4NTF&M9K32>:1Q8YA*-X:+0EVT2T13:
M$8-'J;8CQ&.;-SE2!(A@2(00+T`!`,Y-MIB8&R1@2[.6?K;K70IIC,3%418`
MP+!VZGXLN&RCX>Z,*C:K)1"QTVR;)S,3&7*,K<A::3(2C(A'K7W<8^L,;&S*
M:!Q0<GCWRR9N@E!4Y?4?3*=4K:Z[G@="8D@2`\K$CI#CS+R,871IMLH:8#@2
M`,HDC7@2`>@L3Y5[G-#HSR'5KKNF51U7UWB4BO!N:[$+PZT@@Y*\0?*QBK,S
M)1XB[(54BHD$Y5``P#W!UP+KA,6"V0FS.Y=O*O3108&LTP-;NS!GZVX+VMZ7
M3F9T#M*G66IVLE)3+8[>!BT#MY>964<2\J@9)J449*5<+'4<KEZ*KG.)CF,(
MB.>&VTN]LCH!Q/`<!Y!T(*:0S51#$G@.)XGRGI/2M<M4-JRGUI_<++5Z@PK^
MNF$W=U9!6M12I:VA$-CSLS.1Y$V)U&;M-..\YU$`*J<Z0#U$P!DE<\FVR-5=
MDC.PB+.=7T`/I;51VPQ::I76U0%=8,GVC1M21IV/HOR)JU?MT&NZN6IZ_".Y
MJ<^>2E<GXZHV%RK)0\@H%?G9E>+"4AW<\1L@BX(H1=R=H<W818PD[A2LG5,"
MK)D0`P(,AH1J`[%NC@'ZDA57=63=B1B92<@B)U!T)9P_3Q+=:V`:)2#(QS8U
M-JIF\/.N+1$-QKT0*,79G;AV[=V*.2%GV,9UTZ?KJ*.T@*X.HLH83B)S",?C
M7/(^+)S%CJ=1U'LT&G!2>!0T1X,&$MPT&DNL=1U.O'5<HM2JI6:T>6LU\K!P
M_&478EAHX&:\F*GE&16;`V\*C\5?B\QBBIW>O7KGGBV.)>)+<S<3PZE[X53&
M/A1VN[,./7Y5Y_2]9_LL?IV"ZPC86<*/RB/_`+(9F2!`6D7_`$?^@-A0#L%-
M+L+V>G3ICQ+.]WSKQU.OEZT\*KN_=Q[H8:#3R=2YL9$Q4*T)'PT;'Q+!,QSI
MLHQFW8-"'5,)U#D;-4TD2F4.(B80+U$?4<\E*4SNG(F7;JNHPC`;81`CU`,L
MAG*Z3"*FEBE(^)YK&L,ZJ9M&T?AM;)=!8R:ZP>QE=KPCRW.&J9![`4CVM,CO
M*!2G44!=,`$H!T/JUQE+E&R`>4\N(]$#M].XK&LE&'.O$L+1AAR/F-@W>C:/
M2LU:>33^F4FM7BP:Z%%E==77;8U78L[<@\>"_IU%7V8%,L!A@D&L5*RM+8O%
MBN6IY%FDZ9+(BH8HH*K\U\OC;=93"_6%D8D[?I2V;AKJ!)M"Q8@]8'=O,Y4T
M57V8W=G5*<0)=,8[]ITT)B#J'#@CJ)DYOM*1@]76O:>SJNUIL568R8LZ;*$L
MA+>XDJ@PB$9AB_*JM$5A-K/229SH#'B!R)N2`4KE4IRGRL<:,\BK&Q[#.4B!
MJ-K2)8CB=!Q?JZ`K0RI0Q;<K*J$(1!DP.YX@.#PCJ>#=?256R1OTS0>2U[LM
MHI4"UGY_3G&ZF0457K2K)_/)R[[NV54(5.;FWU2@#QK>*DIGO<'*@]\;%(YT
M055$K<="-$+N7TUUW2V1MMD20S"-<)%@)%W`TU&O%AJLV61/'YG?9;3$62II
MB`).YE;.(<F(9B==#IP<Z*4;;R1=4:YFIMEHZ#4\;;=-1-GFVUI6=0T)4=\3
M-IINO[L1<:N@JX17V-4'<([:N",O;*G17\QD5.XM:K`%U7BUW.\;"`VIE6!*
M4>/T9"0(=]0SJU=S(T7>#;0S3K$CNT$;3*,)>S].)B06;0NRP-?Y6+VJHST_
M`T1@[F*G)[?3LM?7N#]D5I7=80K2P0]KCI-Q1RC(1FQ(.RUM_&D.W;J!'V%N
MO\8)+%+W/EHKMA"=Q$)"#':.,RQB1NT,2)@ZG6)'2%'7S4VTV65T`S@;-PW$
M:0#B0.W43$H$:#28/05XK\I+%$QLY)3^J`*1#2]7W=7&U5MDK;WKVM3TNA$2
MS>S,&M`82$$XJI7B;QT,8C/BHQ2<'2*=5(B*WHY;"4H1AD_[8UG=$1U`<,=Q
M!?@'VZL_%P/-+(1G*S$_V,;1MD9$Q)8[AL!&WB=N_1VU#'TP/)2ZVVV1"-1J
MNJ+31'>G[)M1:R5O;\G-$DFL7<9.M1Z5:?-=:!&2!E48HIED7)V9T'#I1%4R
M9V9BKI\OJJJD;;+(W"T08P`9X@E^^XX]#Z!^G3ROF5]UL!355*@TF;BPEVD8
MC:=C'AJ[,2QX:^N#Y27F?8UT(_2!GUAN6N(S;E5K\3?3R9G="EH.INV3B5?)
MTA(D-/N;'87,:1H*:K;^SC.#NTR+)$'V?+J82LW9C5PL,"3%N\#+@-VH8`OQ
MU9M%Y7S2^R->W!>R=8LB!)^Z1%G.W0N3%N&COJ%OQM\RZ>S:%0'=$91*-^=V
MN%9A+7N,"\PT]6JC(7)$T]1X:*FV3&KS49$K@@^"8.[*)D#&9=BW<2#W*/N]
MUXN),`#I$[2#(1TD2-03PVMQUT5CW^?O5&.:`!89`/(;@8Q,M8@$")`+'<_#
MNZJ-=?<I]B[(0U<M!Z8K#4-R:\OEVI)I3;SU!-I(:]G*_$S$#<#-=5/58=N_
M1L22K)ZP)+"<Y#)K((!T4&Q?RVC'.0)Y<CX4XQDT.B0)!CW]>&H.WL)5;'YK
MDY(Q37A1'C5RE%[#Q@0")=PL[Z$;NT!:[#;";;-WUP@V[$Q#ROK[5X[[_4E:
M^\.5Q)1D)(!H:UG923MKVHN$J[9&2+;R=A4E%793!VF,0HR3H./A<XQ92$A5
M?6QZ"1XD=/*"_F4<,@96?R/+A`Q-N/:XZ0#X4F/D(`\ZO[F(M],(F$3")A$P
MB81?_]/[^,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB@;96ZG&N+M#U-Y
M5"/FEHU_>[/5)KYZJU^=W*D*P';K4K$L"\*WG+.SL!5XU0%U!<%:.B@CW)%!
M2[CX@OIG:+6,9Q$@W",G[_'@&UTT<:ZJADYIQKX5&IQ*N4HE^,HMW&;C(%QK
MJQTT6AWC=*&LI_D%..=:,WEHUGHK2^R)QY%6U0?J^'L-@W5%M:TFL^KS4D:%
M/D:5+*(N3)',^3D"B9-`2]@34XAR(8,!D$5V761#Q]D@5E^.NX2CIT-TJ"_-
M&+9S"9Q@;:J*YEI>T";!MU&FTQDQZ7X!<W:^_KQI_6UGOEKU?6FSJGU^_7.5
MBUMM,VL;)56C/'CDK6IRZE.-*3U[L%09&DFT4>+:M$EC%:KR"1C%5'S&PJ<K
M(KIKR)-*48@[-09?2&YA$2T)<GI$>A>Y?,+\/&MOMQ8@PC.1'B!C&)^:=KF1
MB'$=H'09#BLI4VZ"/+W?"B*"*2COCMQ6<.E$TR$.Y7+L;E^U*NX,4H&66*V;
M)I@8W4033*7KT*`!Q:2>5X3GA?=^;0NZ@!S?/('''H_/R%J&P^4%FI5GW%$1
MFK(ZQ1&E%M.N+))*["-"RTK![9<K-??5Z%/29%BO)UH[90ZC1U(M$W*8`)'!
M3#V9-1RZNZO%E+),97;V&UP##K.X:'K`+=2AR.:6T6YD(XHE"CPW.]B19T@;
M2'CU$A^M1;R>VA/VCC[RVJEAJ3>J6W4(5`&CFO6EQ9(^9C+,6N3]?GH:9>UZ
MF/XV3,DX<LW;8[8"(*I&`KA9)3NRQR[&A7G<LMA;NJMW<0Q!#@@AY..!!?7J
M!57F>59;R_FU5E.RZG;PDX(DQ!!(B0>((;3K(6X<?ET;-OGDFUBXQ[KZ@5.-
MU]KV5X_V(6!U&MU%M.V.1VFVJ\:ZEJE7:K?:O.,&+(T4Y7;3)HI==P!'"8D+
M%G`UX6`92$[Y&4A8']G0"#EI$Q().X/'<`-"IN7D6Y_,A")KQX"$#46]K4F>
MT/$1G$@#:2);23J%'FJK',Z`A=<43<,@YNG&[=\%6OH2^V<32CC5VP;JQ;R;
MK4>Q)%R`D4H%EEI`Q:E*+B)F"Y@B7!^P&2F3Y-<,V>1=BQ$,^F1W1&F^,2V^
M(^D`.^!Q]H=*KXMD^7PQJ,R1GRV^,=LI:[)R#^',_0D3]W(\#W#\TK;]GLGE
MFXM:QU!6I6SUFP[!U/'2,?/4V"LLS+0*M1I<3.1<Z8M6B)M^1J.RWM?1?]Z!
MBNF;MP0P]3B;(L<BOF61E61C*N%I!$B`#ND01WB![&YNH@*7*B;>5XN'5.4;
M+*@08B1(VQ!![H)]LP?34$JS6@MGDW-IK76S!:'C7]IK3->P1"J9DEH*VQYE
M8>Y5Y=(X`=-Q7[7'O&2@"`"!T!S/S<?W3+OQW>,9:'KB=8GSQ(/G6G@97ON'
MC9+-*<=1U2&DAYI`CS*7\JJXJVW/2FU;!8YFS5?EAN.A&?N`&*J\;5-$SM(@
MH\K1(@,$8JR:EDI]^<[],5CN5Y4SD4SBD4Y0[3%OU9>-"N%=G+:IMQ)E8)$^
M43`&G0`W2LV["RK+)VU<VNK?A$1J,0.IC62=>DR?H492^S>1G'$BDSO%C7MY
M:59^16=VWJJK2=7V/KN,3`ZBT]?M2A(V1A::S'IB!GDE7GB3EJW3.L:+,0HC
MEB&/@9_<PY2IRSPA,@QD>J,V!!/0)!B=-RK3R>8\M[^=&-^$.-D(F,X#KG6Y
M$HCI,"X&NU7+A)N(LL-$V*OR;*:@9Z-93$++QKA)Y'2D5)-DWC"08ND3'1<M
M'C58BB9RB)3$,`AF5.$JYRKG$B<2Q!X@CB"MF$X6PA97(2KD`01P(/`A93.5
MTF$3")A%IM_MCJDU.5L;"K6.ZR#(B)&%8JK%1_,2CMRNFV13(1,A_;LT#*^5
MRN)3BBW(<Q2*J`1(\M%0NMC7*R,(GI)8#^G1VJ'(M-%4[(U2G(<(Q#D_TZ3U
M=?!0OK$ESDJ0[3HK!]K6<4N,M.VN8W1JQXY<6^;LJSJ?LCZ(JT%LBIR$='IR
M$DB@Q<.'KHJ+1N#3M5%'S!;R/"C</&D+(;``*Y^R!H')@02PU``U+Z.RI8OC
M2H/@1-4]Y,C9`]XRU)$1.)`<@`DE@&U9U$6[*QL"TN)C=%4C;>K9],[;U].:
M^I*=,.A,W&O4DCB`M[*+<.RH.%$+K6]BW)BW7[RI"DZ;*JF(0@`%K$LHK$<2
MR4?#MJD)2W:1,M8O^"8UD^0A5,VK(M,\VJ,_%IN@81VZR$=)`?A"=@![02LR
M.HR;+Y&[\<7*)M:>KKIK#C&V206B5XF`OCO7]BW-8)FM2[J1APDR-8AQ:8=5
MTU079'=`L9NJ*R17:`<>]>[X&$*I1]XA9;TN8[A6`0Q;5I,6+<="Q7?NGO/,
M<\W0G[K.JGH82V&PF)</INBX!#\"X<*[V9"VTPB810#M\;&EL;B^Z@D[DI&H
M[ELR=X^FT;0Z@B4]UQ\W:V;J7=O"$5A_DH7]2`!NK)%\:4@9`4C%.(CEW%\,
MT<Q$]F[PAM=GW>+7[+ZOMW.W0[JAF>(,GE9KW[?&EN;<VWPK/:;1M^QGZ695
MKU9!W>%EN/4\^)O961=[.Y&5_81[1([IG&Y-?>7:CF@C9HNRNY"/8QZBS"OF
MC'RZ*:IS"GXE1\JO?H9,Z9QSH#P=HKJ,6%8[W<W,0Q)UDX'G&BS,6%\)\OLE
MX^XVW">XV'N=_9N$G`&D-I(\AU*PE'K4^XG.'DOL-OO8J\="[X@YETO(;S:R
M"-G4ME8F:4G>RQ3M%\JG*0D:_.+B;`S1\V1$C@ZI"D+G=UD!#FL:#2Q-9&E;
M,Q$MK]1(TCJ#P7%%=AGR>>0+W$;0=;7W;HF.YM=0#K+0CBZ],J]NQM3.J9+Q
M?(AU-3]HYRH5E9/[X(X44HW>EGEM-JR<U`PSC93J=4H+MFM3$UI&/@G42B\,
MLN99NP!-&-/O(MC*C9&.._L'C6!8P)V-N?Q-#(29@QDO)RO]T-,XY!G*63M_
M6#A;(UN0-[[&\/41,=SEQ%;U4X]>;W7I>[W!+<??+<5H7L>ME-T1,.-T;3<0
MO8&=GAX%1E"1\NX;/B++-I9ND9T8A%.PYT"F3AMD(8F734:M,D_LR=K%F)U(
MTXQ.GG4]43/-PK[A=KBC7[P#<X?<`P!UX2&O'H7[IOZ]"$X]-]M([&)4T^/\
MTUGS60ES1DB;<1E*X17[R1?B2RJ6):OE7-!+O@-WO@="0_OCL>YE>!OSCC&O
MQ?'#-M;8Q]AM&?V@.AOFNF'[QLY>,L6>%[N7?<_B./;?O.S[2>E_G;5H*=3V
MM.1\@RO2N^'2B'%BW&ACQT]M^(55M3.[V%76GS4]/D8]@XV[]"FC#20!UDEG
MY#&6`5"!VS^+C0E$TBG_`#,7<0/=VC>VX$[-SMT-P4'A9<XRC>;R?=9,QL'>
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MPD%&QD6K.K1[9`?:JV:9LU@G3)K*J.!^92]Q?25F=KE.J(![Q8ZB90`@="E*
M4,:R4ISE*0CN[``/,(L/0MVJ$85QC`RVCZ1D3YS(F7I*SN<*1,(F$3")A$PB
MIONPR-(Y+\:=C2"2'TI?H_9'&6YJNRIJL!>;#0@+QK5-^@L/B,D^M&NW,2D)
MBG[G$R1+T!4>[5Q'NY?S"B)^\@8VQZ^Z\9MYI"7DB_0L;-:CF?+<F0^ZL$Z9
M=7?:4'\LH&/EDW2I:7X_:^=5AO3'99QW68RC3^MJ[%.9=19.LTJS1Z$+,0\.
MX.D+PRRU?;)QR3UVHZD&K(#)H+I^585*HS;Q8;0PL,Q,EN,@7!/GU8,">(T"
MMGE^.:A2=QJ$#`!_9C(,0/-HY<@<"'+[Y+T*M62A2NM+0R&QT^>K#^FSD9)G
M[!E:Y)QRT2]CG*T:6/43!6-7,EY$?$J4.A@,!P[LAC=97='(K.VV,A($=!!=
M]7Z58GCU68\\:V.ZF43$@]((8C1NA18TXRZW(+A69=WBVOW%9I]5^;6R[3TO
M*(,->VMS=J.^:O!<H'0GZO9G`.VL@`>\!=(BAU#J=QS63S#(T$!",=TBT8@!
MY1VR'D(T(X*J.68VIF9SD8QB\I$EH2W1/EC+4'BZY`T'4NV(+<U4?NGMR-9G
M9];;4D7B[N/G6[^!AVJ\;"LG31G#IP1JVTGTW\<I&)(HHO'9GJ9A<K*K'\\;
M)QIXEL0(;1O@.(8G4]+NS%^@-P`"]]WQ,NO-JD3/<=DSP+@:`:!MKN-K,3N&
MI)6Q%T=K=O);"EXV"+$/]GU"OT>W*Q:HMDW5?K,7)0<6W8MC%4:Q:Q8.2!FH
MH@0AE&[5L4?5ND)>/?,@QHC*;QKF91?K)!/EU#Z])/6I/<<82R)QK:5L!&3=
M400&ZM"VG0!U!<7[C:@1Q&/6S^T,7\-28&@1+^.FSL';"NUB986&"136:-T1
M679S$8@J<5?(1VF0R#DJS=15(_OOEI$HD1,3,R((=R00?4?-Q#'5>>XTO&0E
M(2C`0!!9A$@CT$#R\"X<+#Q?&[74)*ISD0>S1DNK%WF,F7K&>7:A9QV);%[U
M9W]A9()$C'CUS;'B[M($T$4$`7.@1(&W:B7J6??..R6TQ>)#CAMCM`'3[.G6
M>/'5<1Y;C0GOAN$VD"0?:WRW2)'!]SG@P=F;1<@_'JC$3UJ,9(7"OR&J:PM1
M*I-URRNH68-0'2$*W=4B;=LDTRSD"LG7&!BF<$.\0<-2.$5TW`G5-Y[]=_B-
MT8RC;+<00XW:]X=1U/#35B&T7OP^C_#;93C*J.V)$F.S3NEN(T''4$."#JO4
MTXY:^86>,MK%Y=6TG"7JQ[%@T`NDZXBHFS6^O2==LJZ$6\<N6CII+H2RJYT7
M17!$UQ$$O&B=1$_IS[Y5RJ(AM,!$]T.1$@C7L;H;MUU7@Y=CQMC=$S$HV&8[
MQ82D"):=KNQ?7AHX7-J6@:%1B:[3K(SL>35<!;JS2B#*`[+&Q-W=L'U@1<`\
M;+A**N'42U.F=SY3(^W`""`'5!3FW-NN\?Q-I\243+3B8N!Y.)X+JGE]%'N_
MA;AX491CKP$F)\O`<>KRJO.IJE`H\JG-5I@/5:!Q(X^1NI(SYB]/)BSNNY[#
M#7:5BDGJP*+.)*`H&O(#W"JA_<&2E4P5[A'O->R;9GEHLM;Q\J\S+:=VL&(/
MD,I2;H[NBSL2FL<U-5+^[XF.*PY?O6$2(?K$(0?I[P=7SS&6\F$3")A$PB81
M,(O_U/OXPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+2[=KVHWI[29"T1"
M,HZUY<&M\J2JACIFB[0RB)F$:R*9TC$.846,\X#LZ]AA$.X#`'09:K[:1=&N
M3"R&V7:'!;U!0W8]-\J)6P<USW1[)`$/Z"5JENTC2KN]V$^GOFZI]H4:M:XN
M"+9^1LB]J%1DK7+048V[&PK,#M7][F3F<)'*X5"0,4YQ*BV!"6K,NI%`@WW<
MS*.GSI``GMTC'3AIVEX;L&B^61*Q_O81A+7C&)D0.S64M>.O8&X&R-`43;'O
M/K-S;'(2VN;9JFQ$BK1)5]&RTFYIH!,QDNW@SL&W>==N54BK8C<XCU3.)T#&
M2'K'S;L9O"$0UD9AP"TH\"'?UOZ=5SD\OHRW\8S+URK+2(>,N(+-ZFZN&BW.
M$UY"0-PEKRU<R[FPSE-IE#E'4B_%\#ROT![:9*L$6%5+S'?LY&\3"ZKD3BLY
M/('!8QRI-RHPSOG.J-)`V1G*08=,F!]48Z=#:=+SPQX5W3O!)LE",2Y?2!D8
M^=Y2+\2^O`-I]BT%0;0\V0_E0FQ<;81IK:ZF;2@M@?-J`NLXJJ#7QH`:.+'*
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M_<`S23**"YU#.D#D(8BH&(02O>KADC+KELOW;GCIKUMP\O0GN=!Q3A61WXYC
MM:6NG4_'3H/$=:Y=?UE7JU-0TY&N9H7$!1HW7<4T=2/N8UI6(PS=5%%)F='L
M3?N7#5)1PZ*)5W(I)E4,9-)(A/)Y$[(3A(!I3,CIJY_JZAT><KJO&KJG"<3)
MXUB`UTVCLZ^L\3H^@"\=;:NK.JF%BBZHI+@PL]RM-^DFLI)JR**5HNTP[L-J
M>1:2I2IP[.7FWRSHS)L"3%%94XHHI=YP,R,BS)E"5C;HP$0P;2(8/UL-'.O6
M5YC8M6)&R-1.V4Y3+E^](O(CJ!)=AH.@!2-D"LIA%^"`&`2F`#%,`@8H@`@(
M"'00$!]!`0PBI5H!F72F[]M\8VO<C0G42SY`:.CB@(M:U4[=.O879E`C@#QI
M-(:H[$3(_8-4R=C5G84T0$")D*&MFGWO#Q>8']<#X5AZY1#PD>V4=">DQ=8O
M+Q[EG9?+!_ER/%J'T8R)$X#LC/4#H$P.A76S)6TF$3")A$PBKGR]N-FU[Q=W
MY>:9++P5KJFJ[E.UZ9;)MUG$9+1T.Y<,GJ*3M%PV.HW6(!@`Y#EZAZ@.7^5U
M5W\QPJ;8[JI61!'6"5G<WNMQ^5Y]],]ML*I$'J(&A5C,H+13")A$PB818MY.
M0L<]81LA+Q;&1E?<?*V#R0:-GLE[0A5'7L&JZI%WGMDS`93QE-V%$!'H&="$
MY"4HQ)B.);AY5R9PC*,93`D>`?4^1:\A:VTA8HA")GZ4_KCZKV.95,A/)N+$
MY<Q,Q`QR+^(:-O*P=U=@#MVC(NA5[F[PS5,`_6'Z=FLQKD90F+!(#AIJ"6/:
M=&'2'40M$K("%D#68D\=="`XZ-HU<]!8+S4V-KY*&E[$K>Z:G7X`[=*=G5+/
M"$AH11VU9OFJ<O)F?`RC3N64BW63!8Y!.DNF<.I3E$7@7F<:Q3/?+@&+GR#I
MX'T+WWG'$)V&^'AQXG<&'3J78:$>E:>_V%*([QUSKQC\D>U*]:=VWL(T@DDX
M5E$Y37EOT;!Q7L9)&2-&.(26C-L.#J$]J*GD;)'(MV&,098T1.'?>7%L+81;
MH:4;"7#.X,!T])T4,LB8SL;'CM--E-DWZ7A*H!B[,18>CH&JD26M58@%V[:=
ML<#"N7@%%HWEIB/C5W0'<(M""W2>.$5%P,[<)I!V@/50Y2_:(`,$:[)@F%<B
M!U`E6)VU5D"RR,2>L@+]-:*R64:09K%!%FY!D,DPAS2\>$H]CBD45-(-(\7'
MNW+($D3F%4A#)]I!'KT`<>'9M,]AV`L2Q9^IT\6K>(>)'>0X#AR.MNI<&*OE
M&G9<U?A+G5)B>)'!+GA(JQ1$A+DB16(W"4-&M'BSPL<+@Y4_.)/%WB!>[J/3
M.I4W0COG5(0=G((#]3]:\A?1.?APN@;&=@02W6W%NU>P+M3!0G'(6ZL"VK*P
M-[(X"?BO!7UQ4.D"$XK[OQQ*PJIF*!5Q3'N*(=.H9YX-KP'A2>7#0Z^3K\R>
M/2TSXT6CQU&GEZO.M<+L>*/=ZA6F[F-DH?8-2G[#4+#%O2/F;]Y5'</\W8>Y
M0%1DX*_B;$@Z8G14/WD9/!/T`J?=)X$O!ML((G"0$@>AW;T$$'RA1^\P\>FH
M$&%D"8D%P=K..K4$$-U%25E=64PB81,(F$3")A%%NZM5Q6ZM7V[6TL]=Q`6&
M/3-$6*-,)):IVF)=MYFHW"&5*=,Z4S4[-'M)!J8#%_7-R@(]!'+.)DRQ,BK(
MB`=IU!X2!TE$]D@2#Y55S<6&;BW8TY$;AH1QC(:QD.V,@".T*/N..Y)C8</-
MT39;-M7]^ZC<M*QMVM(_`T>OC(",-L:IE,DW.[H&R&"/S&,5!,/`)U6:GZYL
MIDV?BPHG"['.["MU@>SIC+ZT#H?,>!5?EN9/(A.C)`CGTG;9'K/1./U)C6/5
MJ.(5D\H+256-D;(V>MM:PZLUNO18*1JVGZ_M9M*7R9=QD7/.)RSW>NN&CU!M
M5;"X=U.HC46QYGVJ\:]*$TT%-VB`""FC1CXXQJ\G($S&5I@T0Y#")^D.]+<=
MKN.Z="LK)R<HY=F+C&N,H4BQY%@7E(:]T]V.T;F(/>&H4+P6P;;!;9V-K>GA
M$L9/:')790DGIB5+$$1-2]#:3F`@(9RM5;DR&PS"+M1VF"[!P06$6\`I2G$J
MR5N=%4\:B^US&O'AH`_M66!SK'0<.(U(\AIUY%U>7DXU+"5N3/4EO9JK+#NR
M#GCJ#I$^48W:>].1%1)O!NA:-6M9;2O#>F\CEOD-0E9V!L%T:2&Y$K=749"3
MLS9Y](3XZN!-$Q44GS5)T`%4\B1E%NL;#P;?<R:[#&[+E5K(`B+0VE@/:&_R
M%NW3C*SN8T^_`6U"=&'&[2)(,GLW!S+V3L\H?CIKN5TWAMG7FT[7JQ_)U2?"
M;D^.9J=:7C,]2:U)+>4QO&NR$5**(L[0@8B<QI9-G!JKMWJ@/YU`KH712>(T
M56'C7XU62(RBPMW#VMWABL@CAT6/+4:1+-Q4]V=EX^5;BRE"6XT[9'N[?%-H
M(/M=-;1<'60=^"VWZGWVOLG7^II&[:^@W=IU;R$M,E/UNNKVZ082.M=CZ9@*
M8H+V4<UN(5E!K6T2EETODZ+=1\W6.BFBFLBFTB\/"%%^3&F<A&RH`$[01.%A
MEP<L\.[WG8AW8O+XN><G'Q)7UQ,ZK9$@;B#"=8CJ6#[9][N@."P#AM4T'MC:
M^W+KJRP3-M@XFM6GB'H7=,U2(^L![9:S[0+9?GY6$NYFCOVJ2+^,0\`J%7!-
M``2`O>91527-QL;%IR80JD;(Y5E8D3T09G#-P)?AKKV*+`R\O+OQ;)W1%4\.
MJPQ$?G3W.Q=^(#<=-.TWMS&6ZH-W[NIEI2F(R+2(7N&P[;))U#4FMXY4J<QL
M/8,FBJ,/!-E#=21T2W\9G4K(J]&T9&HK.%1Z$`IKF%B'+M,3+91$;IS/",1Q
M/:>@#B2P5'/S8X5(D(;\B9VUP'&<SP'8.F1X1`)*\>.^I7VG]<I1%DET[+L6
MUS<OL+;-L1!8J%GV7;54W=C?L4EQ`S:$CBI(1L8CVD\,6P;$$O<4PBSLH95^
MZN.VB($81ZH1X`]IXGM)3EV)+#QA"R>[)G(SLE]*<N)'8-(QZH@*=,IJ\F$3
M")A$PB81,(O_U?OXPB81,(M%MEQ"`G*%66B*;F9OED<1;0BPG\+&(A(62LMC
MEW)4Q!7QHQT7[-`0Z@$@^;`</&)Q":JK?"ZPGN0B_G)``])?R`J"V[PYX]0#
MSLDWD`!D3Z`P[2%D&EWILI8I:E1%QJKZZPL>62E:JTG8I_8H=BLN=FWD9:O-
MGWS9G'J/2"D"BA$R'4*)`-W9R:;8UQNE5(4DL"Q`)Z@>#KH7TSLG3"Z!NB',
M7!('!R'=G5:=-;SO=ZD^.#>R$JQ&NV^-VSMK6CY3$R3!1G;J-;-#PS4L.L\G
MY(C2NNF.TWO>V6*NX(=!(WN3!W%'0R\.FF.>:]SU9$(!R#W91L.N@U[@UT&I
MT69AYU]\N6BS8UV-.R3`CO1E4--3HTSH7.@U5C2;'UXI'24NG?*8I$PT6A.2
M\H2T09HZ*A7/F]M,23TKX6S&+<>W4['"IBI'\9NAA[1Z4/`O$HQ-,]Q+`,7)
MZAV]BTO><<QE,7PV1#D[@P'62^@[5YJ;"H"(3!E;Q3TBUZ(C[!/F4LT*0(.`
MED3N(J;F!,]`(R(DT$S';N5NQ%8A1$AA`.N/`N.UJ9=XD#0ZD<0.LCI"'(QQ
MO>^'=`)[PT!X$ZZ`]!.A7*:W2G/I]>IL;;67EI:MA>NJTUGHMQ/MF946#@SM
M>&1='D46P-Y1J<5#)@7L<I&Z]%""/AJMC`6FJ0K/2Q;IZ>'0?05Z+J96&J-L
M3:`^UP_1T<>D>D+7U=O:M0OSW5KG8-/:[$CXAC/.::[L,6UL)8J0:S;]!TE%
MKNDW2X)QM>=NUBD*8[=HF"Z@$2.0YN_=<DTC)%$S02VYBSAAQ\I`[3IQ49S,
M49$L4Y$!D``[7#L7/#R`D]0U.B_`W'J(T+,V0NU-<&KM<*P/89\+Q6!A8(DK
M$-[!&'F94)3V,661@7:3U`5U"`LT5(L3JF8##[[KE;X5^[6>))V&TN6+%@VK
M'0]NB>^8FR=GO5?AQ9SNBP<.'+L'&H?HUX+WSFV-65EJV>V39>OZ^R>5\UM:
M.YRY5V):NJJ0[5,]F;.'\DW27KY5'R!1>E$6P"L0._J<O7R&-DV$BO'G(B6W
M2).O5H..ATXKV>7BU`2LR:XQ,=VL@.[]+4\-1KPU637OU%:NX)@YNM2;OK2@
MR<UADO8X=)W8VTD<J<<X@FZCPJTN@_4.4J)VX*%5$0`HB(YR*+B)R%,FCQT.
MC<7ZF[5V<B@&N)N@)3;:'&K\&UU?H915K[<[-2DWJX[9LU(IT74MN;:HWS^0
M>MZA74(6D7N>KD&J_>6*:<MTI%6)BB'<J"X*FJL!SD32(()ELWXA\:FK&KG.
M4JH28=XO*()9AP<Z:>E5,?-!HONR[80C"ZR+D[0T9$!R3Q8:Z\>I;S);CU3#
MVZLT.4V+3(^WW*&-/U6`=V.);R,_$^\81[9Y%H*NRF>%DG<B0C,I.IGG8J*`
M*`BJ)(8XN3.JRZ-$S5`L2Q8'4Z^1M>K1^(4\LS$A=51/(@+IQ>(<.0X&GE?3
MKU;@5YU^_P`!])UV:LU[URNK--WID9ROSS)O4YE6.,X,_/77,A*NS.V[!!`W
MGZ+JBD*9Q,(`'IY.B?BV0KIL8=!'>#\'8=*5Y%?A5SMOK>3Z@C:6XLYZ.G5>
MZP;9U74T4W-JV9K^M-UH1*RI+V"YUR&15KBYA(C/IJR,DV(>$6.40*[`10,(
M=`-B&-DVEJ\><B[:1)UZM!Q[.*]LR\6H`VY-<1MW:R`TZ]3P[>"WINX0=H(.
MFJZ+ELY13<-G+=0BR#A!8A5$5T%DS&35153,!BF*(@8!`0'ID)!!((U4X((!
M!<%>[/%ZF$3")A$PB81,(F$3")A$PB814^WLLE2^17$?9SGL:1,G8-D<?YV2
M`$RB13;E:CK)36KTP]#&:OKQJUDS1'_@=ODR%Z"J(&U,,>+@<SQQK(1A8!^`
M2)?DS)\@[%CYY%/,>491T@93J)_O(@Q?RR@`.T]JN#F6MA,(F$3")A%4WGA_
M]&7)[_P4OW_P%WFGR;_U;E_]]'Y5D\^_]&YG_<3^16RS,6LF$3")A$PB@'D%
MKJWW>%I,YK5W&1FS];;$KMNILI+E#Y>W:R!7E)OK9_T*8ZS-WKBV2PE1Z'*H
M[3;F$AC$+TNX-]5,[H9`)Q[*S&0''3O1;\>,?,ZH<PQ[KX43QB!E5V"42>&O
M=D_9LE+3K9:M;=0/PV)0'=<K*;^E53C+O73;CW#N(.LL[O,SHMW48MPC)/$7
M$@R&.UG)$=*J`*9%7*77N!58R<M65'P+Q98UTLBNSI^:+-QTX:S#>0]BANPY
M>\8YKJ>B&-;7T?.-6T:\0T"_E'66U>MZKMM'UOQWKT'JRMJ3->A(:O[1?1ZM
M0;3L9*,M4HT96SQII(RM:FT)!Q'I1[]\X3?R:4$H<C9FJ<XD3DLR:KLC.LGD
MRVR),'W,1OW,6U#.X`8;N)"CKQ;J,;EU<,6.^,0)D;7!%>W<'[I=F)+RV\(E
M<;0^I-BTP>'Q;/72QOW,\1+?I"[G3F(5^FVN3]SQO1C5&`LWZJDA$O$--22O
MF(7N3*Z:E,4#&6!#W,R:+?BGAV/XN5&R.A]D>*[Z:'[P>@]C\X&)D4_!_%K;
MP<.54M0>\?!9M=1]V?2.UM%Y!IS$KM/<R,+237^GDT%K:&W$PC+W7:A-L8R`
MM>U+Q%,DSW:.+$1J<C%2#LH/63KO6177*N9HLV8.DIL'9'&Q#.[9;X\S!XF0
M),81/LERQ`T(ZF<&04',-\\K-$*/$I]W@+`)")`$IR`[P8."=0>DNQ$2-VUC
M0)YU>+!9K1K&R2U>MUVA=UZ\L$I>5XF/J#*3U_6XQ*I6O6*]F\4;L6EJM%XY
MH+:+<L%8_P`157K=1,Y!AR+X"F%=>1$3C`UR`BYDTB=T9MK&6A+D%W8%3XN/
M8;[+;<61KG,60)DPB#"(VRANTG'4!HD,SR"P5)X_WN$@M!0J4*A4WE%A=]0]
MAFX=W`^:!4V6V?HP$C&%9OTU7PMW*R#A4J?02G1*/J)0SN[.IG/-GNW"9K(!
M?78S@]74HZ.7WPKP("&PUQM!(;3>[$:Z]!7#KVA[!(Z=AZU:]6V^M[!K,%K"
MKR%KK6XFLU/*/]9S\3882T:;=6Z<L4,QKT+9H=&791\\C%%4$#M%V1DS"<_M
MF;".5*RK)C*B4ID1,&#3!!%FT`DD':3'=U@KRO`LEAPJMQ9QR(QA$RC8Y>!!
M$J]Q(`$@)`2$>HQ4E5&L7]W8N.45L!=@ZN>NX_9NP[S*0C&/BF:Z\XSE*164
M9J.@4_D;6R6MK<'3]V5IT8*R,2_.W,9,I.Z"VR@5Y\J`15881B"YX-(L3JT=
MH`?5I1=6::L@V<NAD$&ZL3G(@`#5XQ<#1Y;B2VCQDRMWF6M=,(F$3")A$PB8
M1,(JX;QT&ML24@-FZZM!]8[]H3%XQI&Q&[,)&.D(5ZJ#F0U_L:`%1%*X:[F7
M)04.U.<CA@ZZ.V2J2Y3>2_AYHHC/'OK\3"F7E'@0>B43\V0Z^!&A!"S<[`.1
M*O)QK?"SZP1&?$$'C"8^=`]7$'6)!XZ]K;D\U=62.U'ORO%T;O5SWMX^NS#\
M'%#V<=MV@I,:7OJR;:,N+)R0Y531BGMYYAW"FX:=">8_>1RXBN65A3\;#Z2!
MWH=ED>,?+K$]!Z%'C<T!LCB9]?@9QX`GNS[:Y\)#ZNDATCI5@K'0*)<)"`E[
M;2:C:96J.E'U7D['6X:;D*V]6,@99Y`/9-DZ<P[I4S5(3*-S)G,*9>H_"'2E
M7?=5&<:KI1C(,0"0#Y6X^=:%F/1=*N=U$)S@7B2`2#V$C3S+@36JM7V-B^B[
M#K>A3T9*3C:SR<=-4^O2C&1LC(H$9V%\T?1R[=W.-"%`$G:A3.$P#H4X9[#)
MR*Y"5>1.,@&!$B"!U<>'9P7,\7%LC*-F-7*)EN(,002.!+CCV\5RW6N=?/@D
M@>T2FO`F(%I59<'58A'`2M8CQ$S"N27F8G]]`L3&$46:O<W2$?A(&>"^\;6N
MF&DXU.A/$CM[>*Z.-CRW;J('=':>Z-8C@#IJ!U<%Z9/66MIMM.,IG7U'EV=F
MB8R`LC23J<"_;6""A1$T/"SB#I@JE+1,28PBV;+@HB@(_`4N>QR,B!@87S!B
M20TB&)XD:Z$])'%>2QL:8G&>/`B0`+Q!<#@#IJ!T`\%RF5`H<;\K^74FHL/D
M<0_K\)[*MPS7Y/`RJB:LG"1?@9)_+XB152(9=LCV(K&*`G*(@&>&^Z6[==(N
M03J=2.!/61T%>QQZ([-M$!M!`8#0'B!IH#TC@O4QUQKR,D*]+1M#ID?*U*&7
MKM4DV-7@VDA6:^Z.FHY@J\\;L4W,+#.%$2&.U;&30.8@")1$`P;[Y1G&5TS&
M1<ARQ/6>L]I2.-CQE7.-$!.$6B1$/$=0+:#L&BAO;')NL4.P$UE1864W-O:0
M035C-1411NO(Q:#D030G]C6%41@=8TY)4Y/+(2RJ1SE-_1D7*G1,;>-R^RZ'
MO%TQ5ACC.7`]D!QG+L'G(5++YG519[M1`W9YX5QXCMF>$(]LO,"L?IW0UAC[
M>MO;?,[&WS?DI$K0[`T0BX1U]IZL/E`<.J-J>+?`+M%!R8I"R<V[ZRDP=,!.
M**':V+UE9L)5##PH&&$"Y?VID?.F?DB-(]IU7.'@61N.=GV"S/(8-[%<3\VL
M'\J1[TNP:*T^9JU4PB81,(F$3")A$PB__];[^,(F$3"*#MAQ+IMMC1EZ(1PK
M&1;R]T&9%,JAFT8EL*#CWT1-/A+^K31-9*.RB4S&]?<2Z90_2$0N42!QLRGY
MQ$9#MVD@CT2,O)%4<B!&7@W_`#090/9O`()\\1'RR"B#7^M]PQ>Y*'>K+5:C
M%5RH43D?0W4759Z+(S0'8>QM37.I2M6B"5B+=K,YB/UT<'XRDB9W\S=JJ&*F
MF'<M:OR,66+=379(V2G5)R#\V$XR!+G@9:,&8>BGCXV9',HOMJ@*X5W1:)#=
M^=<HF(VCB(:[B^XDZ=.C,.-&QWU$UG1'CI"LN(+AOR)X[3=HC9%NZ4@[CMUQ
MIOZ>L4*DBN@[>QL0EK5ZLHI^I7(JNT`I![ES-YCS#'C=D7`;@<JJT`CC&&]P
M>T[QZ^QX(\LR948U$CM,<.ZDR!X2L\-B.L#8>HZCM:>@U?(7>XU"?NE5AJY"
MU[2U[U99:U'/6SJ.LYMBN*$:5A8_V!$CA08)K3%BM/<`U>+F>D-[=MX3E6I>
M\1IJMA5893E;&8)XC;N8GZQW:LXTXE]+_NLK[J;+JHQA&F4)1!TEOV.`WS!M
M+.Q+\`VL`Z]XN[=KDWK24LUSC[`1M$N]-[7,Z>OG"]ETCK.492FC%R)&*FS?
MS[]Q6'!IU)8O8)+W,)"*X))'R[?S'%LAD1KJ,==\-!I9,-9Y`'&W^[AP=4,?
ME>77/&E;<),/#LU/>J@0:O*3M.[^]F-6"FBIZPOM<WU/6^*7<PFO+*YM<U=*
MR]G6%EJLU97B$''U"X4%DYC4K51[:XBV;A*RMQ7)#+CV';IN%EE%TZEN139A
M0JD'OBPB6((&IE&6NV47(V%MW6P#*[5BY%>?9=`F./(R,HDB43+01E`-NC)@
M=X?:>@$DD;6C4KA%<B;S?DX*/EZ/=M*:LIJSHLRW0EF$[K*V[VGG,>$([:@A
M()V%MM9F1!0SI!%/VSCRF+T3!2,VU2P::-Y%T+IRX:-.-8=^AMA?3I#*44W0
MYC?D>&#1.B$>.H,)6EFZ7\0-J.!?H>)J%J79.O-1<6Z=#TZF*6C6M*J-%V3-
MD>P;68:.Z_JMM35I^H3$C7;$R<Q,A,L01=K+LOF@Q"I@20!0QDLLW9./?E<Q
MMG;/P[)RE`:MK/<T@"-0.&K;N)Z54Q\3)Q\3E=,*8>+5",9EP^D-KQ)!#$AB
MXW;>`Z%ZM*Z9V!1"<2SVF!BU%]&\2;CH^VEB)=C)E<6R14X^)0Z\&J^)%&=1
MKMCIN1\QU"H"@I(MDP\A#.%4/<O+HN^)^',M=E1LBX([H\5W9]?O!Z#V/YA8
M611\)\6L/1B2JDQ![Q\)F=M&K/4SCM(U&B<>]LTN+XR$A#_35MUIJ+CCJG9<
MJRLD;+T6\5K5<@NE>:W;*C*QBZR_RJ/<O'U%FHD4)1&4E%0?>U;$,BO)=G8U
MLN8;^]59;;.`8B43,=TQD#TEA9&6C`;7.HBHY?ETPY9L[MU5--<R"#&48'O"
M42.@.:I1:6Z1W,-#LJ.IMO1;-VRAZW55#S^RN2DT\F7DQ$M[!`P6W)U_/U3Y
M<^>P%K9-XMSYTT;`FBU4?E.BB#45D@5[^/><61!G9+NUU!F+$P#2</'7Z.K<
M78LI!B9D08PJAWK;BY(<"PDQ8D2#=$V#\&<.LSK'6&T*5-<:Y61KD(X3I'&5
MUIN]HM;0F*L%/H.=6/F[N/%2+(G/-'B-,>)%\8I=CDR13&!(QER<9&1CW0SX
MQL/?R-\=.([_`!UT]H>9^G1=XN+E43Y;.5<>YC>'+O<#W#IIJ^T^=NC5>K3N
MG;_K!WK.>D8QI,?3.MMBZ]F8!A(1WOHMU8]B,;W$35<=/7#2-6C95JQ!I*I'
M5;K`JW9F(54B9Q+[EY5&0,B$9$;K(R!(.K1VD'I<.XX\3P3#P\C%.-9*(.VJ
M<"`0X>8D"'T8LTN!TCQ9<*EZ!MU+DJ@8[&-D6<%H+;]`<%8/6AFL98=DWZ`N
M\96J^5Z2-6/3JLSC5HIJJ=)N8K9-L`(E**GB]MS:K8VZD$WPEY1")B2>/>+N
M>.KZ]?-/+[J94]T$1Q[(:'@9S$A$.W=BQB.&C:=5D-,UF6I.H-64N>312FZ=
MKNF5.7*W6(Y:FDJW78Z%>JM'!/19FNX9&.B80(<R1BB8I#=2A0R[(W963;#V
M)V2(\A)*TL*J=&'BTV#OPKC$^4``_(I*RNK*818"=M=6JZ9%K-98"NI*=/&K
M.S,=$)J=3=H=AY!RW*;J;T]!^W.X566%JZY2/8"?D4=EM50>VV,1VD#Y5&?X
ME..G^ONE/VJ47_[=RQ[AG?Z*[[$O[%6^)<N_U]'VX_VK9(#<>HK6H"-7VIKB
MR+&4,B5*`O%8F%#+%*F8R0$CI1R85"E5((EZ=0`P?SAD<\7*K#V8UD1VQ(^4
M*2O,Q+2U657(]DHGY"I'R!64PB81,(F$3")A%&6X]5U[=6MK3K6RJO&;"QLT
M0:3$8IX)BMS\8\;2]9M<&X_]GG*M86#9^T./4H.&Y>X#%$Q1L8N3/$R*\BL`
MRB>!X$'0Q/802#V%5LS%KS<:W&M)$9#B.((+QD.V)`([0JXTODV_U6M':PYC
MJ1FM+P@L>*KVY'*81.CMS-6PF393D1;'"IX>BW)^V3`[^NRZ[19)P819&<('
M+V7[>7QR1+(Y4#93Q-?&ROL,>,H]4HOIQ8K-IYG+%,<7G!%5_`6<*K.HB7",
MCTPD07]EPM9VO^8OI30N\&>H=SMI>GU^T5J`MNO-OQP?5E`L\-,"NQ='DE(1
MNI)P+B/GF2[;JDE(-A0*1PJL@10"A)C<BR\W#.5B$3G&1C*![L@1U/H7&O0>
M@`J++_F+"P,X8>:#"N41*%@[T)`Z:MJ&((Z0VI(=77I=ZI>QZ\RME`M=>NE9
MD2@9E/5B883<4X'L34,F1['+N$`73(J7O3$04((]#``^F9%M-M$S5?7*%@Z"
M"#ZUMTWTY-<;<>V,ZCP,2"/2%M61J5,(JF\\/_HRY/?^"E^_^`N\T^3?^K<O
M_OH_*LGGW_HW,_[B?R*V69BUDPB81,(F$3")A$PB81:Y)T^I34K'SLQ5JY+3
MD2"814S)PD8_E8P$E_=)!'R+IJJ[9@FY_6%\9R]#_$'KZY)&VV$90A9(0/$`
MD`^4*.5-,YQLG5$S'`D`D>0]"V/(U(F$3")A$PB81,(F$3")A$PB81,(M+V!
MKBA;5K+VF;)J%?N]6D!*=S"62,:RC'SIE4(@];D<IG,SD6OE,*#E$4W"!A[D
MSE-ZY-1?=C6"W'ME"P=(+?T'9P4.1C4954J<FF,ZCT$./+Y>H\0JUM^/>Y-5
M>O'C?TL6MM^@M-1\@V#[;M+:HE\22<;7+V66A=N55DW:I]J!7$K.-4!#X6HE
M'H%\YV+D_P">PAXGTZCLEY3%C`]K")/6LP<OS,3_`-.Y@?#_`&=H-D?().+(
MCJ>4@.I<TFZ.2]1`$MC\392SH-BB5Y8N/FT:1>F+@0*(`Z:U?9B^G;8FFHI]
MJ":3Q5,H^AE!#U\]TY?;^HYF(GJMA*/KAXD?D77OO,Z=,GE)D!TU3C(?9GX<
MO-JO>7E[7$!%.8T;RTA7(>@MS<9=J60.XIC$5*#ZB0=LBC>(Y>G<#@2*`(&3
M$Y?BSSX78?8S,8C^]@/SC$^I>_%ZQI/!RXG^YF?7$2'K0W,"JJ!VQNE.6DJY
M'J(-2\6MS0@]H%,/?[VV5:O1(=3@!0*+CO$3`/;V@8Q7PNSYV7B@?WT#^:2?
M4GQBH^SA99/]Q8/7*('K7J-O;D!:/@UOQ!O#%(YC()SF]-B:YU;#IJ^G1R:*
MJ<MMJ\*-"$,!Q[HE`Y_T`Z&[A*]SPJ_U_-($]5<93/ID(1_*7GO_`#"W_+<H
MF!UVSA`>B)LE^2%P%-+\D-J$,3>&_4Z+7%N\J^N^+\>_I8NTA!+M0FMQVE65
MV$\3'JH0_P`F;UHQP$!$?^$.O>\#&_R>%OL^E<1+T0#1^T9KGW+F65_GL_PZ
M_H4`Q]-DGG]D05@-7Z?UEI>OC5]74J#ID.JX,]?$BFYC2$S(J=?++6*;=J.9
MNRS2_=^L>R#ARZ4_XE!RED961ES\3)N,Y]#\`.H#@!V``+0Q</%PJ_"Q:(PA
MQ+<2>LGC(]I)*DC*ZLIA$PB81,(F$3")A$PB_]?[^,(F$3")A%%5FM\/"[.I
M%?=O+C\ZEZ5LN9B8.';H.*Q.,JXYI"DRM+)BF9VK9(DS]JG%D3.F!B/G0"!^
MH"G9KJG/'NF!#8)P!)XA]S-V%B_D"JVW0AE45DSWF$R`/9(&UW[0XV^4K0*U
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M:?NX6;S$`'0R&NV/'S$L.`=>1YCCU8=-_P![.KPQ(DAY")TW2X><!Y<3M8%9
MFT;RBTK;M_6SBL;'8-M<ZU8V^P;`KK.*,W8L;#"W-^!X/SO3OQEF3:JJ>S/[
M18J[[J3L[4P,KS7AR\+%R!96399M$2_08\>AM==>"[MSH"[,QC58!74)&8;0
M$2.FKN-NFFI]>9;;NJ+:#7<Q[:Y6=O5]:5C8UH=,HMM(RL-5[!&/9")<RS=-
MVU6F+*^BH9V[4CHE)Z^[$0Z(=SEF1QP<.TS`D81,K#$:L"06+=0!(#R8=NA;
ML9U(@3$3D(U1G)@Y$2"0_7(@$M%SV:A\%9>4.OJXI:E"15RL,/2*_1;C:;-7
M8=@[KT72=A).UX*X(OGLQ'JS4,FBP6.X+').WA$TCF(@<I#B7NOEU]@K[T(S
MG*40"=3*/&+,6/4[#M4=O-,>LV]R<H0C&4I`!A&?"3DAQIJSGL4SW*XPE$@S
M3\\HX*U-)P4&S;,VYW;^3G;1-Q];KD-'-2"'F?S$[*MVR7<8B93*]RAR)E.<
MM2JJ=T]D.+$]@`!))[``2KMUT**_$L.C@!N),B(@#M)("KUN_?I:QK_8:4!$
M6AO?*M,ZKK\O7"M&A+#'Q&W;G%U6*M$.[:R#J%=(.VBTB5@Z3=G2+)L#H*]B
MB1R!>P\+Q+Z-\H^#(3(/03")D0='ZG#<"XXK/SL_PL?(%<)"^$H`CI`LD(B0
MU;K8O[08ZA6*I[%K&U6OLV3>R-&J42R,BTN$W+V2U,RK($7]I8)R>F;#,24L
MU,J*:ZB[YV<3E$/*<``<HVDRLF28DO\`-``\P```\@'D6C3$1JK$1(!A[1)E
MYR223UN3Y5LF1J1,(F$3"*G4YR/NFQ+!.47BC1HK8[ZNR;ROV[<MVDGL#HBC
MV!@KXG\(A(QC=Q8=IV>+,42NHZ"(1JV4,4CF1;'$2AJPP*:(0NYE<:XR#QA$
M/9(=;'2`/09:GHB5CSYE=D63HY50+)1+2LD2*HD<0XUG(=(CH.F06AVK65:9
MOHECR[YK3S^7M*J243KV+V/"<7*%+B)NWY;`5RFST-L6R(JN4S`(/K')G.)>
M@`7H(9-7D6$2/*^4Q$8\9&!ND.TF0,1YHA5[<:H2A'F_.I&<^$!,41/8!$B9
M\\Y+:J_HS\OZO5N4V)'T7C/(5N*650G=FV0*)=$6+EL0&[DDUL6W.9QPBZ(F
MH!%O</@4$!`#]?3(IYG.YV1HE=D"P\(#=%_)&+>H*:O!_E^NN61&C&-8XS.V
M3>6<G]94AD4X>_0IMF)J<:_NT14!N;8!#:O^A4E>\B)4#6LH_("*>0Y2`47`
M#W"`=.HAD/\`YKXWN_\`B/>/H]_=]GCZE8?D_@>\CW;W;Z?<V_:X>M:O=ZSP
M,>1M<=;%@^)*L7>`094Y];F&GRMK4*ZRR31"J/Y5,I9A8SHZ@(^R.H<%1'L^
M+KDE-G.A*P43RMT/:VF>GE;AYU%?5R&4:SD0Q-L](F0K[WX)/'L9:A6^,'&6
MP?-'''+95IUC(PC@L?)N...\Y8D+"/%&_P#16,MK\9NV:P2.FDF!TV[N$$!`
MH#VB`!TELYAS"&T9^/&R)U'BUASVB31GYQ)0U\KY99O/+LF=4HZ'P;2P/48/
M*'F,5E7,ORXT.07UB;1O+C6K/H>1D*?`1]!Y%0K(`.*SM.FM'">N-I^T32*(
MHQIJ](+"<01;+G`J9N!'EF;W:R<7(/`2)E4?QO;AY]PZR%V9\WP.]8!EXPXF
M($+@/P?8GYMAZ@59G6>SJ/N"G1E\UY/-[!6Y47**;E--PU=LG[%<[23AYB,>
MI-Y&%G(EZD=!VS=)).&ZQ1*<@#F?D8]V+;*F^&VP?)T$'@0>@C0K2QLJC,IC
M?CV;JSZB.((.H(.A!U"WW(583")A$PB818^5B8N=CGD1-QL?,1,@@9L_BY5F
MWD(Y\V/^FW>,G::S9R@?IZD.4Q1_FSJ,I0D)0D1(<"-"N9PA9$PG$&!X@AP?
M,NAGD_\`E.3_`"*Y&G<ZVK&K.,FA*Y"Q<<:4@(IBXE[Q//A^:6"QPFOZNNSB
MH]N@+I..*F\<Q1Q.Q,J":A%0-GV7+OYEA@X#9%EF1FR)+$EHC@`9'4]>@/%N
MA?!\T_E.SF/,7QJJL7`C$!P`\B=21"+`=6ICP=M5V#\0_P`O72G#D[N7HLM?
M['<95F5G-V*QVR10CWR?:8%$BTR!4B:B=N0Y^Y`SQJ^=MO\`@<`(F$V)S3GF
M7S5HW1A&H'0"(<?C%Y>5B`>I?0\H_E["Y.\Z)V2N(U)D6/XH:/D<$CK5[\QE
MNK@RC`DK&2,6HY?,TY)B[8*/(MZO&R;0CQNHW,YCI%J=-RP?(%4[D5DS%424
M`#%$!`,ZC+;*,F!8OKJ/..D+F4=\91)(<-H6/F/0>U4_LW"2F7*OS-4M>Z.4
M5AK5ACG43.0<MO:TO8R6C'J1D7;!^T6*9)RU<I&$IR&`0,`]!S4KYO;5.%M6
M)C1LB7!%8<'K"R+>24W5SJMS<J54@Q!MD00>@K:XGBS&14I&RGWZ<HY+Y;(,
MW_RZ6WO;GD6_]FX3<>RDFG>G[J/=>/QK)]Q>],PEZAUZY%+F,I1E'W/&#AG%
M8<>3M4L.5QA.,O?LHL06-LF/8>SK6W;YY&:QXU0=<MFWGTO7Z;8;*A5#VYG!
M2,[#5Z6>LGCV-^I"0R3V5CF,D#!1)-R5JJB18`*J9/N*(Q86!D<PG95BQ$K8
MQW;7`)'2SZ$A^#^139_,<7EM==N9(QIE+;N8D`D$AV<@%N+-UJ1:-L&B[.KS
M.VZZN%:O%9?A_19VJS,?.1BAP*4QT#.HY=PDDZ1[@!1$XE52-\)RE,`AD%U%
MV/8:KZI0L'000?6K%&11E5B['NC.H],2"/4MPR)3)A%!NWN0VN-,N(>#GEYN
MR7^T)K*4W5-`A75PV;<"MS&*NO"U:.'RHQ;82&\\D^49Q;;L'S.4^F7,7!OR
MQ.<`(T1]J<CMA'RD]/8')Z`J.9S'&PC"%AE+(E[-<!NG+R1'1UDM$=)45IR?
M-7:!#*QD%JKB[75S`5%2YBXWKM@S<`$_N%:_5YFI:UK3E8#E*4@S$^"8D,)R
MCU*`6=O*<?VIV9,_J_=P])$IG[,55W<ZRM8UU8M?UOO;/1$QA'[4USB<8KI-
M#[C8/+7DI9GB@@*K:K3E$U'`I^A@\;%CK2B0$VBB'4.GGDW*GP!U.(B<3\_$
M*H:4<LQXCM$IGSF<B/4%[\,NGKD<VR9'ZIC6/,(1!],BO=^"_4#GXIVR\BK0
MJ7T07G^6/)MPLU3'U,BW,SVPQ*5,YOB$#`8>O\N/BV4/8KHB.RFK]!>_!<,_
MK+<B1[;[O_J!>'X/ZPS`HU[=G*^M&2`"H>VY+;2LC=NFF)!;HI1M_G+C%`BV
M*3M*44!`Q1Z'[@Z='Q2P^WB8TO\`LH#UQ$2GP>H?J\W+C_VTSZIF0]2XRVG.
M45/)Y=;<K5KBBT((M:WR)U93K:W>&$W<+9Q<=4I:ALC4@]P]JRJ4@H3T#M,4
M``/1E<NMTR.6[">FJ<H_DSWCY%X</FE.N-S7>!T70C+\JOPSY]5CE>3.P]2]
MJ?*72TA1Z^D9-)UNS4TF[VMIEJ`]"&D+6FG$PNR=<L#+'*!EY"%<1C<#=59`
MH!USH<OHR?\`T[+$Y_LYC99Y!J82/DD">B*Y/,\C$TYIA&%?[2L^)7Y9:"<!
MVF)B.F2MU!SL)9X>-L-;EXR?@9EFA(Q$U#/FTG%2C!R0%&[V/D&2JS1XU73$
M!(HF<Q3!]@YESA.N<J[(F,P6((8@]H6M79"V$;*YB5<@X(+@CK!"RN<KM5EL
M7,GC'69M[6W>WZW,3\8;LE8BDH36Q)"'4`>@IS+:@1=E4B%"FZ`)7()&`P@`
MAU$.NA7RKF%D!8,60@>!DT0?)N(?S+,LYSRRJ<JSF1-@XB+S(\NP2;SK=M8\
MA=([F7>LM8[/J%NEXPICRE=8RJ3>UQ29?%U6E:G(@SLL8AU6*'>NU3()AZ=>
MH"`19&#F8@!R,>48G@2-#Y)#0^8J?%YA@YIE'%RH3F.(![P\L2TAYPIDRHKB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%__T/OXPB81
M,(F$49V/7JTYL>C[%;S2;%W1:W?*^QC5HLSUL]^NS5A1V[=+DDV2I?8*U-L*
M:9`#N*=4!-U,026*[Q"BZ@P<3E$N_P!%^SIW%5K,<SR:,D38UQD`&=]VWM'#
M:/6HMJ7&XE0B],Q;.XF=):8XZVCCI$J.J^'DF(*RHZK;FL4CXIHA4I9FGJ",
MZ)I`")S+NAZ%`Z0(6;<_Q99<C4QMO%IUX$;]!IP[Y]7:]6KEO@QPHQN<4XTJ
M1IQ$MFIUX_=Q])[&R=-T,^HLWK28@[N!B4'2L;I-\S?UI-P6P0U?<Q3R`F45
MTYEN>&DTE8P2/2]'23I%<X)`V4`BI>;<T70R(3I]NXV!CP)=QPU&NG!NW@NJ
M<"5$\:<+_P!70*R\>(#,>.ATUXN#HW%15.<2U)C7L=II+<*R4%%Z84UJ:)>U
M:.EU68C(K+PNQ(F+7G4F\58#J("R>KJI.@<LDC),SL%146&Q#F>R^66<7OFW
M>[D=&L26U'2!HQU.X:*I/E._'CAC,^[%.QC$'ITF`^AZ"=7&@VG53%,:5DY2
MU[,L9+J1JTVOJROZ[M$2-937%%_76]V9M+#$/_G2)VC5=I>7`JL5$US"LW1,
M5R4@*I*U8Y<8UX]?@ZU6&0+]!VZ$-]4:Z<3IP:[/"E*W)L\=A;4(2&WI&X."
M_P!8Z:Z@:\0>+$:%5KC6;0KEU<Q:ULUG4-;V=P>":O?)]$Q$C7H>W5])5\4L
M/9E(*4.@N#H9%@H9JT.#8OB7*Y]GF^(8&RIQ&R4QK](@F)ZPXT9CJ=>#<PP#
M6)BN\@SJC"6C^R"!(:Z28L7<:#30O@YGB_"OH+:-6B+":`KNQ]5Z^U$WCT(@
M7AZM6M=,[#'0QV#E>6(9\[48V18AQ5*!0%-(>@]#@?N',9B>/9*&Z==DIN_$
MR8E]-."XGRN$J\JJ%FVNRJ%;-[,8.`VNNA^13'L2@-=C59M`2,DYBW\;/U"W
MPTY%HH@K&6NC62)ML!($9/1=HN(_YS#I%<M5##[AF=1'R%$_D"K1>:+#.,7B
M8RB0>D2!B1Y6.AZ#JKF1CC)J%<I$2$HR!'1*)$@6/0XU'2'"CJX:$3NP7.0E
M[,1.SW9UI])_,LH'PLV5<TG='.P*A7&$4I,K*^$]IEI-=PX6=++'+)*D+VE(
MB"<]6;X/A1A7]W#>P?ILCMD26Z@``W1Y56NP/'\:4[?O9FMR!H!7+?$`/](R
M)+])[%80@'`A`4,4R@%*!S$(*9#'Z!W&(0QU#$*)OL`3&$`_E'[<HK17EA$P
MB8156YA2TXEJN%I,!-O:NZW-M75VE7]HBUBH3%?K>Q;='P]M>PBQB'\$VXJ_
MO&K-8.T[=PY(L40,F7-+E<8')G=.`D*JYV,>!,8DQ?L=B>L!EE<XG,8L**YF
M)NMA69#B!.0$B.W:X'42ZL+3ZA6*!5H"E4N$CZW5*O%M(6`@HM$$&,9&,4BH
MMVR!.IC&[2EZF.<3**'$3G,8QA$:-MME]D[K9F5DBY)Z2M&FFK'JKHI@(U1#
M`#@`%23GH<$7_"%QXCK&1YYZ7.!$2`HN<"T[:9S)(EZ@)CJ"0``O4.INF:W)
MM8\W'_\`96?G06)S[27)"W_CZ_S9K!K:HNJ.TN9/(-S".=>T"_<?24J-I[Q>
M."7OEGJ]?G7#W:=CBH=Z^9Q"[:/6)$QY7*AI%9J"AETVX`0AY!DTG'Y5@B>^
MZ%^XRU:()'<!/'7O%M'X.HSB7C*YSS`P->/9C[1'1Y2B"\R`2VG=#ZD<0%!G
M!/:E9VQ5-%\<=C-)*HHZYT%IZ[4BA6AFT0C>0`&KS:24OL>^!TY:6>LZ\E&A
M2HPQ``Z<@B+YT50[8B+&YSG&LQK,S/H(EXETXRD.->K;2.@R'SNK0<7E1Y%E
M59=6#RW)!@*\>N482X6Z/O!^=&!X1Z^\>#1L9^80NJU@.)SE!FYD5F_/#B\N
MC'LS,R/'ZJ-JD%$V;0\@[8,".71R@1,5UT40,8.]0A>I@H<C`,^9`EA[G=KU
M=T=3E:/\P$BOE)$22,^C0=/>.FK#TD+7]'.B[HYS;MW2S;N-;'TUKMEQKMFK
M)L6*.P[)8%K$E>X[8MP:0KN5K_T:K$']O6G+=Z^5?)>93R-TR>`_>8/=.3XF
M(3XGBV>+&8?:`VTQB['<^LP0&TX\5'@GWWGF;F@>'X-8IE`MO)?<)R9QM;2!
M!+ZEQP79%F"OI%2^3B6^J.9M$>5(H,8;D]2]B(;+K;83)Q[J]ZF8UJ6K&S$F
M1!,DA,NJ[)NH:3<%*F#L@,/*)E$D^NM&1R>57"W6>/..P].V9(,/(X$AU=YN
M*Q90&)SFB5.D,J$]XZ-U8B8S;K8F,CT]U^"NAF2MI09LC2;S8D^C.H;LWGKP
MB,8WC?D6M[;`P4`J9NX=KC)+,Y*I3;@\FX]UV**>8"F323`"AVB(W,?+%$#`
MXE-FKO.))\FA&BHY.%+(L%@S;Z]&:$@!Y=8G7SK0/PKR?\5'++]HU1_=UD_Q
M*/\`#L;[!_25?X5+^*Y?VX_H)^%>3_BHY9?M&J/[NL?$H_P[&^P?TD^%2_BN
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M-C6^MPD?4K':JS*TB&9Q3XED?VJXO`IU?80T>P"((W;K.)%F7WCI+U4(51,V
MQR/F6/#-\?(JQJ*:XDF0B1(OH!'O$DEW+`Z`K"_F'E65/`]WQ;LK(NLF`(F4
M3$,7,I':``&8.1J1Y%#7"?\`*)W+IZPQNQ]C\BK/J^6`&J[FDZ'FW#=Z_2#J
MM\IMULDVIH1ZU34`I'#-*,?MU0$WC<E$"GRWS?\`F?$RH2HHP(V1^E8.';&(
MU\A<'L5/DG\HYF'9')R>8RJG]&HZGLE(Z'M&TCJ*^@``$``!$3"```F'IU,(
M!]H]H%+U'_T``9\2OOU#?(/:#O3FGKKL&*BB3MAC&L7$5"#6.*3::O5QG8JE
MT.(>+%$IT&,E<;"Q174+\2:)S&#J(`&6\''&5E4T2EM@23(]48@RD?*(@LJ?
M,,HX>'?D0ANL``B.N4B(Q'D,B`>Q8316A8G4;&0L,X^"];KNY&[_`&SMZ4;)
MA8+G-]I#'9LQ$!^GZ1"F*5O#PK7QLV#-%,H$,KWJGZS,V65*,(1V8D-(0'"(
M_KD>,I'4GT*/!P(8D963EXF;/6RP\9'^J(X1B-`&Z=5!?YBCZ<@=#Q%IK%MO
M-.GXK;FG8MO)4B]6^E++QEKV75J]/1TF6K3<0E,,WT2\42\;HJP)=XF3[#"(
MC=Y%&$\V5=E4)P-4RTHQEJ($@AP6UZE1_F*4Z\"%M5TX6"ZL/&4HZ2G$$':0
MX(Z_,L7!R-G'F1+:EH%QNEXT/+Z3=S^V475^M=C3U9L7Z@*TJJ-:V2K..+76
M9ZV1`J'5@T90!(V3]XDBB3XAZG&OX5'*OJA#-%S0[L1OBVKP;:1$_.;CHY7,
M)6_&9XF/=.>`:'L[\CLF_=VS?=$R'S=W#4`*`>%.QI'=?&^#TE&;9N\YN*T(
M[+F-OW^7V[=)J_ZPH26YMA4VKR5;D)6T/;"SO,A!P"#:'2:&38L"IED9,%"G
M;,Y:[S:B.)GSRY8T!BQV"$1"(C.7AQD00`VT$O)]3[,>DQS^2Y,LWEL,*.7.
M69+>;)FR1G"'B3C$@F1.X@`1;0>U)]!.;^?,2YU%PMM,M1+WMBM35#G-4$A;
M:CN;:@VH$9_;NO*M/#.VEQ<3S-B1?P,FY2.217<I)>8QTRD/T,%/DLAE<VKC
M=35*$Q-X^'!M(2(8;6&H'`!7N?P.)R6V=%]L9URK:7B3W:V0B7EN<N">)/8O
M;#W&3>\S-;UWCQL"Q;(U(E2M@#RB;N-@3FT:'1I1.+CSZ@-$V&?F+(G6]AS4
MRFNFZB6;U$58LHNE6O416,G5$<JR+,ZB->5OCX/=$)2#G>X`#Q`X2(XZ/T)"
MZ4N<XU?+LB5F)LGX_?,XQ+#PV)):9+O$'V=2.E=B(@!@$I@`Q3`(&*(`("`A
MT$!`?00$,PE]$J(NZ@GQ/W519C791B]!\@KW]!WS6+;M)7=?;9LC%^^I>Q=?
MQ92E0KT=<YB.-$ST>V\;11T\:O")`<BPFV1;\2Q+H7ZYM$-T9],H`@2C(])B
M#NB3JP(ZEA&D<IS:)X^F!D6;90Z(6$$QG`=`D1MD!HY!;BLYMAO+\@]VK\;D
MIB4@]/46CP5\W\O7I!U$3EY=W>2G(_7^GDYMBX:2<+7I!E5W\K83M#@N[9>T
M9>1-)TOUXQC'!Q!GF`.5.9C6X<1V@&4V.A(<"+Z`N>("[RQ/F&:>6B9CAUP$
MK6+&6XD0K<:@$1,IMJ0T=`2I*M5@KO'5EIK7^M]9UAE$;&V$35U:@8-=I1X"
M!E/H6WW9!XX;Q5=DTO8'AJ`[1.=-$5O<&0`2F(911*O5"S..7?D9$C*NO>2>
M\2-T8])'3(>9_/9MLKY='#Q\;&B(66;(@=T`[92?0'1H$>5O-JLK0=/\RM;U
M^]NX"<JEH8/K&UIU^8>"L[BU+=J?89NGS1J_;85RZ5;N(.TPCI)1))R[AY,B
M("<CEN<O=+&[*Y5?92)B59`W1.L)QD!(/$]8(Z!(=A44\?#YSC5WFN4+03MF
M.[97*),2TAU2!Z3&7:%L_&/8MPO5&L$'LH6BVT-07ZR:>V))QS;V499)VJ)1
MK^+N<<QZ%]@VO-,G8J9%OVD*W4?F3('C(01CYA153=">._N]L!.(.I`DX,3U
M[9`Q?I92\LR+KZ+(9+>]4V&N9&@)BQ$@.C=$QDW0[*QF4%HIA$PB81,(F$3"
M)A$PBP-JLL13*Q8[A8%SM8&J0,Q99MTD@LZ4;1$%'N)2273;-R*.'!T6;4Y@
M3(4QSB'0H"(@&=UURMLKJ@'G*0`\I+!1VVPIJLNL+5PB9'R`.?4N3!33"QP<
M-88LYU8R>BHZ:CE54SHJ*,)1HB^9G414`#I'.W7*(E'U*/H.>3A*N<ZY>U$D
M'RA>USC9"%D/9D`1Y#JLKG*[3")A$PB81,(F$3")A$PB81,(O__1^_C")A$P
MB810'M;=;K55OJ,'(51N_KMSJVQWD39?J)1DX-?Z-`DM<7KWY)]/NR+.+E6V
MDFX:.DWAE2GBUD_:G$Q!&[C8@R:K9QL:R$HN&^;(L9._S2P(;I&JH9>:<6ZF
M$JGKG";2=N_$;A!F^<-Q!?YIT4<;'W0YU;)[TMSO5-4=7+5_%.#W%,R3&V+E
M?6:+K[_:LBMKHT\I1DWB$57WD%)+1[DR*A7*TD<3-FO4QAGHQ!DQPZADR%5F
M28`;>!(@-S;N)<..AN)5;)S3BRSKCB0-U6(+"1+60!F=C[>`8D'I)X!;%M'=
M.S-64.S6B;U]0BRT%$;$M;%DIM19.)FZ]23(R<;$,E!I/U2O=[)6A65.W;Q#
MF-CE$#&5>G`4R'XQ\3'R;JZX7SVR,8^QJ#+0GVFV@])D"7T"DRLW)Q:+;9X]
M>^(G(#?H1'4`=W=N,>@1(#:R7C4W+:2Y56J:0;%;FF>,.G)`_4J?G$CC8>WE
MD$UU2``JF035[0$>H!_)Z8M!CRVN!/#(F/R8)41+FMLP&W8M9_+L7,N6]+-!
MW2Q4^NTB-G)2OVC45<:0LG89"%F[3';4?I,7MXADFE;G/%3J%W+JOG`)./,E
M%2GJW,Q(5WY5AUSJKMLN,8RC,N`"`8?-.H[TN@:<8\7T]NSK8764UT"4HRK#
M$D&0F6,AH>[#5SJ^V?#;KQX#?%WM_P`[GZKJ%U(:Z8.MKP\?=)"YUF+:N)?5
MTI:*^#F0C47$G964+:++6%F28I1KAXP*9-=5$Y3J)M_9X5-6R%F4!>=A,1$G
M28!T.@<`OQ8\`>ORO/ONWV589.,#8!(RB-8&0U&L@)2BWLDC0D<0-#:\MYF*
M@(VUWG7L1&0MEX[,]]U=O6+JZGI58RTA38D:?,?.:C5(Z.=/9"_QI$'A5U&Z
M?Z\5NPB95#S'ED)3E53>3.-_AEXL.$CN#2D3I$N./!E`.;SA7&V_'`A+'\6.
MV3GC$;2\8@.9AB[<76U7'D!L#7527M&Q-0NJ1%)7>+KKNUOIUI9JO7:K*UR5
MECW^TH4$EKGHJ!A;$P1@W1E$")%5?-WRJK9F+D6L=6%1?:*Z,H3EL)8!B2"!
MM&[:"2#N'D(`)9Y;N89&-2;<C#,(;P-Q.Z(B03OELW$`$")TZ1(D!VV*"M#E
M3>5$.T/'+Q6Y>/<]=Y`U>DTK#5TI?6-GUFT82$/8T&S%":1G8O=ITD7Q44_?
MLHQ`_:0J29`CG6/<[G?=5>(APQ:8FX(U9C7PZ"2I*[3[]0S;+L<R+%XO"4&(
M.CN+.+:B(ZE8_*"TDPB81,(HNW/JR,W/K:QZ]DI)]`J2Q&#Z"M$2!/G-/MU>
MDV=AI]PA1.)2A*U>S1;5\@`F*4YT.PP]IARQB9,L3(KOC$2`=P>$HD-*)[""
M0JN;BQS<:S'E(Q)8B0XQD"#&0[8R`(\B@/7G)M[4Y>,U#RP;1NJ=MBH$7`W5
M<#1VE]W&2.HDWF=;7!Z<(N/GY%$A%7-9D56TNT65[$4W"717+M_+Q;&65RTF
MW%XF/&ROLG'B0.B8>)Z6*H8_,Y53CA\V`JR^`EPKM[82.@)Z8%I#H<:K;N1F
MA;;O&4TF\A-AURDL=-;CJ6ZD&DKKR3N3NP6&H,[!&LXM5^TV-3$8V%=,+&L"
MI0;KK^8A#E4`H&3-'@9M6''+$Z)3-M4J])"+"3%_9DY<=:EYC@79TL(PR(PC
M3=&S6!DYBX`??%@Q/03VJ8]B5BP7+7EHI\//PT#-6:MR-?//R5;>V"+9_-X]
M:.?.RUUK:*Z[7Z).#F23&2+V&Z=QC@`]:E%D*KZ[90,H1D"P+'0N-6/R*[D5
M678]M,+(QG*)#D$C4,=-P^55!><%V<UQNU%IB:V*#39G']K"&TIOZFTXU9L]
M(F:TV;-HF4"$?VRR_,FK])H0DPP&019R:8%Z$043143U!S@PS\K+A0^/>3XE
M<I.)`\0XB&;YI9QVZK'/(HSY;B84\ALG'`\.V,=LHF/`L92=_G!VEV:$;IN/
MCOMO<U7TE$SFY:&RL.HMMZYW(^L#?2DVHRM]FUH^/(Q#88$FZVWR"+DW*AA>
M$([<G,`]$3(ATR+%SL7$LRY0Q)F%M4H-X@[HF&.OAZD=&@[74^9R[+S:L*$\
MRL64W0L)\,M*4"XT\30'IU/8RR]ZXV3$ONVA\B=<;!CM;[3A:Z>C[)44I+BR
MT[;]&4#W*4)8JVA=*R_82,),`#F+D2R*[AH4`14!PD4@%XISXQQ+L'(H-F,9
M;H=YI0EU@[2""-"&8\0Q75_+9SS:.8XV0*\J,=L^[NC9'J(W1((.L2Y(X%PI
M)V[O_5FD6T>%ZL92V*>,*%0H$`U<639%Y?F$Q$8ZF46&(ZL5@<K+E\?>BA[=
M$P@*RB9>I@@Q<+)S#+P:_NX^U(Z0B.N4CH/EZE9R^88N"(^/9]Y+V8#6<CU1
MB-3Z&ZR%&6EJ/L6X;#D^26[(4:=9W]8<T75.I1D6DPKJ?73^383$XXLDG'&-
M%2&QMB2<,P<R?MA50C6K%LR265$BYSV,NZBJB.!B3WUB6Z<V;?(`@,#J(Q!(
M#\226&BK85&3=D2YEFPV6F.VNMW\.!()<C0SF0#)M(@"()U5L\S%K*#-W<EM
M%<<H8DUNC9E:HZ+A$Z\=&/G*CRR3*:9A(<T'58I)]8YDB:@=ISMFJA$S"'>8
MN7,3E^9GSV8F/*9Z2.`\I+`><JCG<RP>70WYN3&`/`'4GR1#D^8+JLBOSE:?
MM??-#U7JR&J^NM;R5A14NV[>0%GB*C&,JI$"K)6!*&@S3+&/8RDU&L3-(I=[
M*'/[QTD*C$0(8@_1R_E6W&PKLG)G*S($>[74#(N=`Y9R`=2`.`.J^5A_.5.7
MGT8N+"->,9=ZRV0B!$:E@X`)`:),N)'=79Q^,;B+_%/QQ_;AK+_,^?/_``KF
M?\-O_=S_`+%]-\8Y1_%<;][#])/QC<1?XI^./[<-9?YGQ\*YG_#;_P!W/^Q/
MC'*/XKC?O8?I)^,;B+_%/QQ_;AK+_,^/A7,_X;?^[G_8GQCE'\5QOWL/TD_&
M-Q%_BGXX_MPUE_F?'PKF?\-O_=S_`+$^,<H_BN-^]A^DGXQN(O\`%/QQ_;AK
M+_,^/A7,_P"&W_NY_P!B?&.4?Q7&_>P_23\8W$7^*?CC^W#67^9\?"N9_P`-
MO_=S_L3XQRC^*XW[V'Z2?C&XB_Q3\<?VX:R_S/CX5S/^&W_NY_V)\8Y1_%<;
M][#])/QC<1?XI^./[<-9?YGQ\*YG_#;_`-W/^Q/C'*/XKC?O8?I)^,;B+_%/
MQQ_;AK+_`#/CX5S/^&W_`+N?]B?&.4?Q7&_>P_23\8W$7^*?CC^W#67^9\?"
MN9_PV_\`=S_L3XQRC^*XW[V'Z2?C&XB_Q3\<?VX:R_S/CX5S/^&W_NY_V)\8
MY1_%<;][#])6"CI&/F(]C+1+YG*14HS:R,9)QSI!['R,>]0(Y9/F+UL=5L[9
MNVRI5$E4S&(H0P&*(@(#E&491E*,HD2!8@\0>HK0C*,XQG"0,"'!&H(/`@]2
MAWD=K&5W!I>[42O23>(M3M&$L-+DWA#'8LKU1++#7RC+R)""!S1A+=6F7N0+
M\7@[^@"/IEK`R(XN73=.+UAQ(=.V0,9-V[26[53YCBSS,*^BN36EC$]`E&0E
M%^S=$/V+C:&WS7=WUYX)6JM2V34'!(+:^J9I9,ELUQ;D2F3>QDDU'QJ/8-XN
MD=2*EDB>RE6?:LB;KWD3ZS<*S#F-=V//6$Q[,X]8[?I1XQ.A7F!GUYU<M-F3
M#2RL^U"72#UCZ,N$AJ%#_/.B[)V;I6.I.K]>3FP)]SLK6%G<(1,U0X-O&1-%
MOM<M<HH]<WFXU))19['QJJ;4C;W`F7``4\1![\M<ENQ\?+E=D7B$!7,:B1<R
MB0/9C+I.KMYU3Y]1DY6%&C%QY66&V$M#$,(S$B^Z4>(&C/KQ96S2<GC*V+^.
MI\DDX(T,^)3H_P"EVLP+I8?*K'D.,ZVJH2!E3CW'&1!N8W4?*/VCF-NLVRM#
M.VXNWEX.WF?L6N#MKW1I+L^T;7\G':_G;M74/J3A9N&)XW:SL=<KKG0?-714
MILQS3[%+3%-EZ_L"L6[:]SOX:SORU%L]H96"BSL/84T3%=F2<1<F)EF_ZL#F
M6^GR>;8LL_(KLL\;E-PAN`$@8F,(QWQW`-($=&A&A[/D,3DN9#EN-976<?G5
M!GM),2)QE9*>R>V4@8D%M=8RU';8/E5&;_Y#<,Y>E,N.=P@=O6^3UBO*40]Z
MTN\8P3FF[*HMVGW"=K-LUI#R$*Y95]TDP.4Q7BJO8"[9N4PF+1Y;+"P>:QM.
M?"6+$3:6VS7="41W=C@ZA^CJ)6AS6/,.8\FG1'ETXYDS!X[JR!MG&1[V]B&!
M;IZP%G]A:QVS1]\5/E3H:ARLLYV"QAZ1R?T>O/TB%FK76XU)1&I[!BG\E:D*
M,?86NDS&;B49;QOHXX-TU2#Y#&XHR,:[#MY;FW`"!,J;&D0"?:B0!NVRX^SH
M=64F1BY=&?5S7`H)-@$;JGB#(#V9@F6W?#A[6HT!5\VRJB[9NNJV79*K()*J
M,W)FQW+111,ISMG!F;AVT,N@81(<4E54Q,`]IS%Z".,0Q(!=;P+@$ABJ$;*&
MK\S=FUO3L1&1=ZT'IVYFMV^;2X12D:?9;W7HV285/1T.LJFJPLCYC*RY)BQB
M@"J#!%DW:**E7<BD&UC^)RG'LRI2,,VV&VL<)")(,K#U!AMB^I<D!@ZP<GPN
M<Y5>'"(LP*9[K9<8RD`1&H=!()W3;0,`2Y98F#K.M>$O(IT>(JM<UGH#DE7J
M35F4G!Q36%J5*WI2']G2CHF?5:I(,H9IM.M6<A&3E<?$>3B3(B)#N">3J=F1
MS?!&ZR5F;CRD6)>4JY`.1U["-1U2?H7$*L;DG,3LJC5R_)C&((#1C;$R8'H&
M^,M"?G1;I5C][ZMM&S)K0KJ`4A4HW6NXS[!M8R-BGJY*KP)]5[/UZ=I6'E?A
MI%T2<]UL!-P147#`42MA$BP*"42T,/)KQX9HF^ZRK;%@"'WPEJY&G=;@>/!:
M6?BVY,\`U[=M5V^3D@MLG#NL#KWWXCAQ4@3\_K/1&N7DW./:WKC6U&B1455.
M#:(A8A@AU\35FV2*0%7;QP<$T&Z)#N';E0I$RG54`#00AD9EXA`2LR)GRDG^
MG$\`.Q6++,;`QC.<HUXU8\@`_IP'$GM4,<2(2TA3]A[/N,)(569Y`[=LVY6U
M/EV_M)JJ5>1@JK2*)$SS7T,TGUZ+1(UX_0,`*-G;M1$X`=,P9;YG.OQ:,>J8
ME"BH5[APD03*1'9ND0#T@.J7*(6^#D95T#">1=*S:>,8D1C$'MVQ!(Z"2%:S
M,U:J81,(F$3")A$PB81,(JR\S[`>M<3>1<B@;M?N=/WJOP_3QB8\_;(%Y5:\
MD0JJ:J*BBTY,MRE*<O8<P@!A`!$0T.4P\3F>#$^SXL2?)$N?4"LSG-GA<IYC
M(>T:9`>60VCUD*?*K!I5BL5RMH"!D:]`P\&B8HG,4R43'MV"8@943*"`D;AZ
MF$3?S^N4K)FRRRP\92)])=7ZH"JJNL<(Q`]`99[.%(F$3")A$PB81,(F$3")
MA$PB81?_TOOXPB81,(F$6IVRC56\!6PM4.VEPJ-LA+S7?<=X#%VJNG6/#S#8
MR9B&*Y9&<J=O7J40.("`@(ADM5UE/B>'-MT3$]H/$**VBJ_P_%@#LF)#LD.!
M\RU:XZ4UM?EKPO:X-[)GV1KP^J;H5.T6V,1F:`H>9.I7O;Q,ZP;QR:@V%[W.
M&A4'9@<G`51`>@259>10*15,#P[-\=(EI::Z@OP&A<:<%%=A8V0;S;`GQ*_#
MEWI!X:Z:$-Q.H8Z\5Q[UHW7>QUFB]L93[Q1K4+;05?9W6Y1`2M-O)(X+/79X
M8F>9&G8^24AVJ@^Z%4Z9D0[#%*90I_:<R^@$5&(>49>S$M*+L0XT(<\%Y?@X
M^20;8R+0E#24@\9-N!8AP6''J6=KVKZ;5YY*T13.4^H4Z9`Z_&4D++9995>J
MUIS(/8:/<-I.7=L%EVKR5<JBY%'W2AUC=ZA@Z`'$\BVR!KD1LWF3``=XLYT#
M]`TX+NO%IJL%L`?$V"#F4CW8N0-2W2=>.O%5DOO'"XW&\;6L3*=LM-FKJ_@U
M:7L/7&\MKZ\3JS&(JD!"-)"V:IKKQ&C;#MD'+LW*R02J3]G+,`1:.#M$B`D&
MA3GU54XT#",X0!W1E7"3N26C,]Z((;@QB7(<K,R.6W77Y=D;)0G,C;.%MD-H
M$0'E6#MG(%_:<2#`L-%/\/H_7\#*6^2BF]B:(W>1L$S.0"5TMY*J2<MOF-:Y
MR'K1)LL/`R]C7<JKNEV:2!SN5UURB59PN=2E/,OG&J,C$F``!VQ=H\`2SD#H
M!Z&'`!:$,''KG=*`D!,DD;I;7E[1$78$\20VI)XDOP%N.^GG,2P@GE24?0T9
MJJ3TDTBY"RVV08AJ^82C$)&K.&SV>72>IKI0S4`=+`H^3\!!(L40ZYZ,[*$I
M3%K3-HL<"([X=CP[3IP[%R>789A&LTO`5&MC*1&PL\=3KP&IUTXK)M--U9I`
M1<!\WV$["'D22;*<DMF7N2M`+IPTG7DT'-A>SZ\D_CB0LPY2!JN=1OYE1=B3
MWO1R')RK#.4]L`X8@0B!Q!X,P+@:C7HX:+H8=0KC7OL+%P3.1EP(XDN0Q.AT
MZ?:U7NJ6JZ_39^.?PC)E&P52UK6M5:]K[0BWAJ=4A%E%W[9HLJH8_CER-(EN
M9,WD$B4*@8#B8YR@MR9VPD)DF<K#.1^D3P]'>/XQ7M.+739&4(@5PJC"`^C$
M<?3W1^*%*65E:3")A$PB81:]:ZC5;U`2-5NM;@K=69A`6TK7[)%,9N&D4!$!
M\3R-D4'#1P4#``AW$'M,`"'00SNNVRF<;*;)1L'`@L1YPH[::KZY57UQG4>(
M(!!\H*JRGP^9T@Q%./FZ]RZ#;(AT;4Z'L++9&JT@,?N53;ZZVW'71A!MU"CV
M@G#.(HB8?H`40`0TCS0W?Y[$JN/TB-D_M0,2?QA)90Y.*->7YMV./H@B</L6
M"0'XIBN>2"YQUW^CL]B\:=G-""'C=6;6VQ-7S:A1`P"5XYK5]O\`#*G()BCW
M),$`-V"'87R`*7._D]FIHR*SV3C,>N,3ZRNO#YY7H,C&M'UH3@?5*8]0_L]H
M3G.HH`4VL.)BQB@!3+!O?<+8%1`.@J`V'CF[%N!Q]>SRJ]G7IWFZ=1;.3?ZC
M)_=P_P#JKW?SW_2XG[VS_P"BOPR_.R2#M)&<2Z6)NH>8T[N+9H(?"8H*>U"N
MZD]UU.8#B3S(]`().X>_R$-R:/SLF?FA#^N:/SV7S<2'GLG_`%5KC*:'Y!7+
MN3VCRWM3.+7*0SJNZ!U[5=.M3F#U,@%JGW.T]AH(>HE$[.68+'_2`2#T`/1F
MX-7^7Y9$RZ[)&?J&R/IB5Y[AS"[_`#7-YB/55"-?Y1WS]$@I2U;QVTYIIW)2
M]#I;1G:)LO;8+U./Y:X;#L7<?RG">O\`;7\W;Y5-1?JIXEGAD2G$1*0N5LG.
MRLL1C=<37'A$`1B/)&($1Z%:Q>78>&93HI`MEQD293/EG(F1]*FO*BNIA%'&
MSM/ZMW17CU7:]`JNP($?*9%A:(9G*>Q67(":CN*=+IB\AY#L``!PU417+T#M
M.'3)\?*R<2?B8U\H3ZP6?R]8[#HJV5AXN;7X67CPLKZI!V\G2#VC5=:E=_*;
MUYI??U!WQQQM[ZJ-ZY8"GL^J;ZDK<ZA.U"7!2*L\+#SBZ@6"*<$@7JRC(TB$
MS_3TD3F.0`[B_06?S+?EX5V'GU"1E'2<>[(2&H)'`Z\6VZ.OFJ_Y3Q\+F&/G
M\NN,!&7>KGWHF)TD`>(T.C[M67:=]&U#_"M;_N.,_JN?.>+;^UEZ2OJO!I_9
M1]`5<>2N^>.'$^GM;GMZ'09L9-=PSA&,!KY2??S4BV3(J>.;+-8TL-'N3D4#
ML-(.V:)A'H!_MR_R_"S^9VFK%FY'$F3`#KXN?,"LWF6?RWE-(NS(-$\`(.2>
MK@P\Y"Z7$/S:";MWIKS7&OM?4'0&I9:V,/J_9%OK,;>;R%4B_++S8LHIK#O*
MU7',K&,E&A`.UF`054*L*Y"`;M^L/\M>Z8=]]]\[\D1.V,28QW'0:NY8Z\8]
M3+XL?S9[[G8^-CX]>/B&8W3E$2EM&I8-M#@-PDW%UW@4'='$G:3Q.,U[L/1=
MLF55$T2U^)F::K9"KJ_H(*UM11.=07,;J7L.W*8#E,7IW%,`?(7XG,\8&5]%
MT8=9$F]/#UK[C'S>4Y1$<?(HG/J!B_HX^I3C]&U#_"M;_N.,_JN4_%M_:R])
M5[P:?V4?0$^C:A_A6M_W'&?U7'BV_M9>DIX-/[*/H"?1M0_PK6_[CC/ZKCQ;
M?VLO24\&G]E'T!/HVH?X5K?]QQG]5QXMO[67I*>#3^RCZ`GT;4/\*UO^XXS^
MJX\6W]K+TE/!I_91]`3Z-J'^%:W_`''&?U7'BV_M9>DIX-/[*/H"?1M0_P`*
MUO\`N.,_JN/%M_:R])3P:?V4?0%L*22:*::**9$D4B$2222(5--)-,H%(FF0
MH`4A"%````````R/CJ>*D``##@O/"*O^V^-VOMLS$;=#N++K[:T`S.PK>X-9
M32E3V%$,3G%48IS(HI.(VTUPZAC">*F6DC&G[S#X`,839=QL^_&A*IHSQI%S
M"8W1)ZVX@]L2#VK/R^6X^7.-SRKRXAA9`[9@=3\)#ZL@8]BCM!YS3U@1-K(P
MNK^4L"AW)%F823#0^US)``'27D*[+(V/5UA>B!134.WDZXB8P@<J!"]2!.1R
MG(UC.S&GU$>)#S$-,><2\JKB7.L5A*%657U@^%9YP7@3Y)0'8N63EPSB0(78
M?'OE+KM5,I?F"ZVF)C9<0Q,4X%<*FF]'N]H,5&2)0,H"W4O<D7U*5003'SX8
M9?J,[&L'1]X($^:S8O?BXA_F.7Y59Z?NS,#SU;PR]P<X.-H!T7M=T8+`(@=I
M+:1WI#R"(@(AT<1LKK9F_;"8`[B^1,O<00,'4H@(O@^?T50([+*R/2)LO?CG
M+>FV8/;5:#Z#!U^&YJZ6=AV5>+WC?70]1(UI'&GD%.%5(4IN]4DF&MF\&*2:
MW:DH870`DH<`/V@!A*^$Y8_62I@/K6U#U;W]2?&L(_JHWV'ZM-I]>QO6N.;D
M#N^V"9'5G$;9(D,0H)V+>%JI&FZXFHJ`BDJ>,:2=^V,HBF40,<HP*1P$!(/:
M;IU]]RPZM<GF=?DK$K#Z6C'\I>?$,ZW3%Y19Y;91K'H><_R5B5N/V[-QAV\F
MMRHH4]<#`\TGQX3G]>TZ61-T3.PNFRWLBIM&Y1CAN)BK-F:M=:+]P@J@H3X,
MZ]]Q,7_T_$^]_:6M*0[8P;9$]IW'J*X/+\W,_P#4\S[G]G2\(GLE,G?(=@V`
M](5L:G4JO1*[$U&EUZ'JM7@FB;"&@("/:Q43&M$OT4&C%FFDW1*(B)C="]3&
M$3"(B(CF;;;9=9*VV9E9(N22Y*UJJ:J*X4TUQA5$,``P'F7G:*M6KM7Y:IW"
M`B+16)YFI'S5?GX]K*P\JR5Z"=L_CWJ2S5RB)B@(`8H]#``AT$`'/*[+*9QM
MJF8V1+@@L1Y"EM55]<ZKJQ*J08@AP1V@JK;7B"C54?EVIN1')/45:2*1%A2X
M&[UF\52%9@5-(S&`:[FI&S9:"9)(`?VZ#1ZBW;'/U(GVD(0-$\T-AW9.#CVV
M=,C$QD?+X<H`]I(<K+'*!4-N)S')IJZ(B491'8/$C,@=0!`'4LU6^(NO6=HB
M;QL6U;/W[;JX\"1J\KNZW)66+JLB`F$LG6J'`Q-5UI#2Z8B'8^1A2O4^TO8J
M7IG-G,[S7.FBNNBJ08BN+$CJ,B3,CLW-V+NOE&/&V%^3;;D71+Q-DMPB>L1`
MC`'MVOVJU&9JU4PB81,(F$3")A$PB81,(J><M%`MKWCWHI`".5]N;WIDO8(\
M_3L6UQI%T3<]S6<FZ@8C!R]J$7&*"`@)U)1-/KU.'75Y9]T,[,/"JF0!^O9]
MW'\XGS+'YM]]+E^"-3=?$D?4J^\EYGC&/XRN'F4MA,(F$3")A$PB81,(F$3"
M)A$PB81?_]/[^,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB818^5B8N=CGD1-QL?,1,@@9L_BY5FWD(Y\V/^FW>,G::
MS9R@?IZD.4Q1_FSJ,I0D)0D1(<"-"N9PA9$PG$&!X@AP?,NN^>_+!X]L-MTG
M>ND$Y'0.RJ1:8VSM@I1"NZ'->U7`)&)EJ*]72;,8R9BSJLEDHAS%)B@L?J0Q
MC".;D/YASI8MV'F-?CSB1WO:'41+I(.O>!U7SMG\L<OCET9V"^/DPF)=WV3U
M@Q/`$:=TQT*NGL+2VH=M,U6&SM84*_ME2"GTMM4A)U9'J0$P4:.Y!DN[9.$R
M%#L51.11,0`2F`0#,FC+RL8[L?(G`_5D1\BV\C"P\L&.5BUV#ZT0?E&BK=):
M/VYH%-6Q\6;9,6RK,?Z1(<8=JV=[/U638IF*==GJ78MC</K5J^=\7D]JT=NY
M"NJ*G`AFS4OZXE^.9BYK5\QJ$;#PN@&(_#B&$QUD`2[3P6;+!R\`&SE=LIU#
MC39(F)'^[F7E`]0),.P<59'4.VJCNNC1M\IRKY-DZ</XN6A)ID>*LU2L\*Z4
MCK%4+9"K"9Q#66O2:)T'2!Q$.I043,HBHFH>AE8UN)=*FUG#$$:B0.HE$]((
MU!_K6EAY=.;1&^DG:7!!#2C(:&,AT2!T(]&C%2;E=64PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(J7:C5)NKDGM/>Q1]U1]
M31K[CAJ-SU!1E*3+>8:3F][E'=PJ)G37M,9&5U%RB(`<(!R`")5!S6RA[I@8
MV'PNM/BSZP&:N)\Q,F^L%BXA]]YEE9W&BH&FOJ)=[9#\81@#]0JZ.9*VDPB8
M1,(F$3")A$PB81,(F$3")A%__]3[^,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%2]9JEI;F+$K1Q`8T?
MEO6)IK-,D@.5@AOW4\6C+1DV5,P`V:2-_P!4%?(NA3[1=*5E$YP%01,;6!.7
MRJ0EK=BR#=?AS+$>2,V;JWE8I`PN<0,=*,N)<='BUAP?+.MP>O8%=#,E;281
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(JE<BMF
MVI]*1/&_24B+?=>RXY1Q*V=J07"6CM6G5,QL&V9KL_5H2X=3,ZRT5,0TC,F*
M8.J#9P)=/!QZQ&6?EQ_PE9T'[2?$0'9TS/1'M(63S')ME*'+<*7^-M&LOV4.
M!L/;T0'3+L!4_:VUY5=34.J:VI$<$75:;"M(.&:";RK>W:D_6.WKCM*9Y)R+
MDQW#IP8.]PY5.H?J8XCE+(OLR;K<BZ3V3+G^G4.`'0%?QL>K$HJQJ(M5"+#_
M`*>T\2>DZK=\A4Z81,(F$3")A$PB81,(F$3")A$PB__5^_C")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M0/R.U)(;AUDZAJS)MJ_L:JS<'L74MH=)G40K6SJ4\"5J[YT5,>\T3)'*K&21
M``PJQ;]RGVCW],NX&5'%R!.R.ZB0,9CKA+0CRCB.T!4.98DLS&,*I".3"0G7
M+Z,XEXGR'V3]4E<K0FZ8[==+&65C5JK?*T^5JNU-<R2B?S[7=]C`!.8K\FB4
MYC*,UC]',:\#]3(QJR+E(1(IZ>9N)+$NVB6ZF0>$APE$\"/D(Z"X*]P,V.;3
MO,=E\3MG`\83'$'LZ0>D,0INRFKR81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A%Q7SYE&,W4C)/&L?'L6ZSMZ^?.$FC-FU;D,JNY=.ESI
MH-VZ"11,<YS`4I0$1$`ST`R(C$$R/0O)2C&)E(@1'$G@J9RW)2S;E=NZ7P\B
MX^[*>=:-L'(>PMG8:(H`D.=%XK`OB>W7W/;&@%ZMXZ$.:+!4Q/>2"!`,4=6/
M+Z\0"WFDC#I%0_62\O[./69:]42L:?,K<PFGD\!/H-Q_50\A_P!I+J$>[UR"
MG#2NDX#3$#)-VTI+7"[6R0)/[*V=:3HN;EL2S^`K?YK-ND4TT&L?'MB@VC(U
ML5-C%LBE003*'<8]3+RYY<XDQ$*8AH0'LQ'4.T\23J3J5=PL*O"KD!(SOF7G
M.7M3EUGL'"(&D1H%,V5%=3")A$PB81,(F$3")A$PB81,(F$3"+__UOOXPB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3"*L^U^.XV>VH[?U+;W&G=ZLF#>-4N<=&(3%:OT(S,46U3V_33K
ML6]XKZ!`$C5<'#26BQ-W,W:0`9,^AC9WAU'%R:O%PR7VDL8GZ4)?-/7H8GI!
M69E\N\6X9F)=X.<`VX!XS'T;(Z;AU%Q*/00M1:\@=UZ_$D7O?C5>G:B/ZH=B
M<<T!W+0Y;L,<#O`I[55EN*NF43`I_:FA)$A.HD*Z5,'493@XE_>P^80'U;?N
MY#\;V#Y=P\@40YAFX_=S^6V$_3I^\B?Q=+!Y-I\I6=C>:/'^3?L8E.8V*RF9
M%\SC6T+,:%WU"R_O'ZR+=!-1A*ZT:.$D`57#O<"'MDRE,<R@$(8P<2Y3FQC*
M>RLP`=Q961Z1/U<5W'G7+Y2C`3L$R0&-5H+GL,/7P5J<S5JKJ[YP?F9P'$!^
M>IM=,;*N=O<D($7-S<-(4C5;I51`%CEC[K),'"UI<,0.`JI1K55`1*8@N4S`
M/3Z+E'\OSYI'Q3EUPJZ0")3\\0=/.?,OE^>?S-7R>7A#"MG<>!(,8>:1'>;Z
MH;M50.!?YA^X-];-VEL;>1MES-5K$'#05/U5Q]T5LB\U"%D[,]>.WE@LR]&K
MMLF2OV["O@WCRS$BL5;W#HZ*112[@U.=<CQ<+'QJ,/PQ9(DRG;9&,B!T#<8C
MB7.T=`?BLCD/\PYF?DY63G>+*J,0(PJJG*(,B=9;1(NP8;B>)8:+M1_&)1?]
M)N67^T/D7^[G/G/A5W^IQOW]7Z2^I^,4?Z3+_P"'N_03\8E%_P!)N67^T/D7
M^[G'PJ[_`%.-^_J_23XQ1_I,O_A[OT$_&)1?])N67^T/D7^[G'PJ[_4XW[^K
M])/C%'^DR_\`A[OT$_&)1?\`2;EE_M#Y%_NYQ\*N_P!3C?OZOTD^,4?Z3+_X
M>[]!/QB47_2;EE_M#Y%_NYQ\*N_U.-^_J_23XQ1_I,O_`(>[]!/QB47_`$FY
M9?[0^1?[N<?"KO\`4XW[^K])/C%'^DR_^'N_03\8E%_TFY9?[0^1?[N<?"KO
M]3C?OZOTD^,4?Z3+_P"'N_03\8E%_P!)N67^T/D7^[G'PJ[_`%.-^_J_23XQ
M1_I,O_A[OT$_&)1?])N67^T/D7^[G'PJ[_4XW[^K])/C%'^DR_\`A[OT$_&)
M1?\`2;EE_M#Y%_NYQ\*N_P!3C?OZOTD^,4?Z3+_X>[]!9BN\J*=99Z%KS367
M)J/=3DHQB6[^Q<7M[UN!9+2#E-JF[FK!.41C#PD6W,J!UW3I9)!!(!.<P%`1
MSB?+;:X3F<C'(`)875DZ=0$G)Z@-2NZ^:TVV0K&+D@R(#FBT`/UDQ``ZR2P4
M]VJQLZC7)FS/V4[),X2/<2#B/K%?F+58'A$"]WMHBO0#.0F)9ZL/0I$D$3F$
M1ZCT*`F"E76;;(5Q,026<D`><E@%?ML%-<[91D1$.T09$^0`$D^1=!._OSUH
MZ!<R]:T/I*77FF#APP/8MS*'@D&#YJ8R"Y%J!`.U)=P!5RCT!>6CUB=O0Z0&
M$2E^UPOY.E,1LS<L;#JU>K_C'3\D^5?`\P_GJ-9G5@81WC1[-&/X`U],@>Q7
MPXW<Y]9JZ8I,GR"WS5'>W)Z.-8+='LJM+P,?5W,PJ=ZSJ#)@SKY3&)6H]5)J
MJNJJZ.X<D54*L=(R?3&S^3Y`R[HX.'(8L2T3N!);YSOTG7H8="WN6\]QCA42
MYAGP.7(/(")`B^NT!N@:/JY<NRG(>=G$4HE(??%)2<''HBP65DT95R4"B8ZK
M2)5CB2;QND!1[U$DCII_\0AE/X-S3_1S;KT;TNRO?'>4?Z^#]6K^AG0>='%#
MIT3W'#.5!$"IMV4);7[Q=0P@4B+5DRKZ[MVX5.(%(FD0YSF$``!''P?F7^E/
MIC_:GQWE/^LB3V"1]0"_/QLZ)=#XJZ7<ET=B;L39TKC;R'LJBQRD\JR2;F.U
M@I'>=LW_`%JB9EP4(G\7;T$.KX1F#6SPH#ZUM0^6;I\;P3I7XTS]6FZ7R0;U
MKU#RBMLR)6]#XE<GK.Z6*<S=Q8:U0]40Q>PA#]7[W:6P:K*-"F*8W0"L%E!,
M00`G42`9\.JAK=S/'B.PRF?R(D>M>?%+IZ4<IRI'MC&L><SG$^I>@TYSAO`$
M)$470>@HY</"K(W:W6G>-Q:D4Z=SQ&ITZ,UQ4472"9Q[$S6)XD*I.INX@],]
MV<GI]JZZ^75&(KC]J1E+\D+S?SR_V*,?'CURE*V7V8B$?RRO%OQ!B+BZ:2O)
M'95ZY)/6J[=ZC5;<HPJNF&<@U%$4'+;3--1C*M,>`4A\?U`:>4()S"!^X>[!
MYI*H&.!CPQP>F+FQO[R3D?B[4'*(7$3YEDV9,AKMDT:W_NXM$_C[E;ABQ91C
M-K'1K-K'Q[%NBT9,6+=)HS9M6Y"I(-FK5`B:#=N@D4"D(0H%*4````,S"3(F
M4B3(]*UXQC&(C$`1'`#@N5GB]3")A$PB81,(F$3")A$PB81,(F$3")A%_]?[
M^,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3"+1]C_=M]&3GWN_0_P!WGM#_`%+]X_R'Z,]C
MT_6?//J;^P_:=/M]Q\&34>\>+#W7?X[Z;7W/V-KZ%!D^[>#/WO9[NW>WMM;M
MW:>E=8W#3\#'XJ-C?@G^L?)]WKO[V?I;WWX?N[ZDC/D'L_JG^U_K'W_N/EGR
M;^Q/EWO^GKV9]#S7XQ\-H^+[&\3N.WB<"_#3;P?=WG9?,\F^!_%<GX)O?P_O
M-K^%Q#-NUW.^W;W6W+MQSYA?6IA$PB81,(F$3")A$PB81,(F$74/^93_`/UM
M_)WWXH/E?WL_+P^2_=5[/[^_^0'L?)[#^B_+_#U]M]3_`-E?I>/X^F?4<@^/
M[A\.?W9]=_ZO_P!O7LUZU\C_`#+_`/C>R7Q1O>VTV?K>SAT=6_N]2NQPJ^H/
MPHZ&^I/FWN_N\AOE7U!X_J+Z._6_0'U)XOU7U']"_+OF';\/O/)T],R.;;/B
M6;X;-XA=N&[YS=FYV[%M<E\3X5@>([^&&?CM^8_;M9^UU:#,Y:B81,(F$3")
>A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$7__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
